Enhancing the biocompatibility of coronary artery stents by Yu, Young
  
 
Enhancing the biocompatibility of coronary artery stents 
 
 
Young Yu 
 
MBBS (Hon 1) FRACP 
 
 
A thesis submitted in fulfilment of the requirements of the degree of 
 
Doctor of Philosophy 
 
Faculty of Medicine 
The University of Sydney 
 
December 2015 
 
ii 
Declaration 
This thesis presents experimental work undertaken between 2010 and 2014 at the Royal Prince 
Alfred Hospital (Camperdown, Sydney), the Heart Research Institute (Newtown, Sydney) and 
the School of Physics, University of Sydney (Sydney). Writing of this thesis was undertaken 
between 2014 to 2015, during my time as an interventional cardiology fellow in Boston, MA, 
USA. This work was primarily supervised by A/Prof. Martin K. C. Ng and co-supervised by 
Prof. Marcela M. M. Bilek, Prof. David S. Celermajer and Dr Steven G. Wise. 
The work contained herein was primarily performed and completed by me. This includes study 
design, execution of experiments, analysis of data, interpretation and presentation of the 
findings. Given the varied disciplines that this thesis covers and spans across, assistance and 
guidance was required in certain aspects of the work. 
In Chapter 2, Dr Louise Dunn provided experimental advice and assistance with the culturing 
and immunophenotyping of outgrowth endothelial cells. Flow cytometry analysis of outgrowth 
endothelial cells was performed predominantly by Gloria S. C. Yuen. Dr Steven Wise provided 
the tropoelastin for outgrowth endothelial cell experiments. 
Matti Hiob was responsible for the making of and gel electrophoresis analysis of tropoelastin 
constructs used in chapter 3. Dr Alexey Kondyurin was instrumental in assistance, theoretical 
guidance and experimental advice for the plasma physics and polymer focused chapters 4 and 
5. Specifically, optimization of the plasma polymerization chamber was performed under Dr 
Kondyurin’s guidance. FTIR transmission spectroscopy and ellipsometry of plasma 
polymerized samples and FTIR ATR spectroscopy of surface bound proteins was performed 
with the help of Dr Kondyurin. Recording of X-ray photoelectron spectra and raman spectra of 
the samples was done predominantly by Dr Kondyurin. Atomic force microscopy was 
performed by Dr Wojciech Chrzanowski. In Chapter 6, deposition of plasma polymers onto 
coronary stents was performed with the assistance of Miguel Santos. Scanning electron 
microscopy images of plasma polymerized samples after exposure to blood and coronary stents 
were taken by Dr Steven Wise. 
  
iii 
Acknowledgement 
In completing this thesis, I have walked a wonderful, thought provoking and at times 
challenging journey, spanning across disparate and diverse disciplines, ranging from cell 
biology to molecular chemistry to bioengineering to plasma physics. Along this journey I have 
found mentors, role models and lifelong friends. Below I will do my best to remember all those 
who have supported me over these years. 
Associate Professor Martin Ng – I first met Martin when I was coming to the end of my 
cardiology training. In our first meeting, I was offered the red or blue pill. When I accepted the 
red pill I embarked down the rabbit hole chasing the dream of a biocompatible coronary stent. 
Martin, you always kept the dream alive with your enthusiasm and never ending pursuit of 
‘better’. You made science fun for me and an integral part of my daily life. Thank you for 
giving me the overall direction and goal that formed the foundation of this thesis and the 
beginning of a dream to make a real difference. 
Professor Marcela Bilek – Applied physics and plasma physics were entirely foreign to me. 
When faced with the prospect of immersing myself in this area I was met with self-doubt and 
a sense of inadequacy. As a cardiologist the only physics I was equipped with was from high 
school. Marcela always approached each problem with elegant simplicity and practical 
reasoning that made the daunting seem achievable to me. She understood my background and 
gently wet my interest in plasma physics guiding my studies and research direction. Thank you 
for your patience and trust in me. 
Professor David Celermajer – I always considered David a sensei. His seniority, sheer 
experience and unparalleled professionalism always offered me a light at the end of some dark 
tunnels. Whenever I turned to David he never failed to be promptly available, responding 
despite a busy clinical load within hours of a question. David, your calm approach to every 
problem gave me hope that anything is achievable. 
Dr Steven Wise – Steven and I came from different backgrounds. He is foremost a dedicated 
and thorough scientist, believing in a systematic approach to experimentation. Over the years 
I have progressively become more reliant on his advice and guidance. He gave me directions 
for day to day experimental needs. He taught me that even mundane and boring data is 
iv 
important, for out of the rough a diamond can emerge. Steven, thank you for helping me 
become a basic scientist. 
Dr Alexey Kondyurin – Alexey is a great applied physicist. A large part of my PhD required an 
understanding of plasma physics and chemistry. For me this was completely uncharted territory 
and Alexey was my daily guide through this at times frustrating and foreign land. Alexey thank 
you for showing me the right path, the lunch time coffee breaks and telling me Russian jokes 
for which was I could never quite understand. 
Dr Daniel Bax – Daniel was there at the beginning of my PhD and to my disappointment I lost 
him to his home land of England. Nevertheless, Daniel was instrumental in teaching me the 
basics of cell assays and biological chemistry. From how to use a multi-pipette 101 to grappling 
with the concept of integrin mediated cell adhesion, he was always patient and understanding. 
I can only imagine his inner frustration at explaining such basic concepts to a clumsy clinician 
making a mess in his laboratory. Daniel my gratitude for giving me the tools to finish my PhD. 
Dr Louise Dunn – In many ways Louise was a mother hen for us young chickens. She has vast 
scientific experience coupled with an easy going and caring attitude. My project did not directly 
involve Louise, yet she was always available to give advice and provide psychological support 
for experimental failures. She was always my go to person to shot the breeze or bounce ideas 
off. Louise you are an amazing scientist but more importantly an even more amazing person, 
thank you. 
Professor Tony Weiss – Considered the ‘godfather’ of tropoelastin research, Tony was always 
happy to share his knowledge and experience with me. While not a supervisor for my PhD, 
Tony freely offered continued support. Thank you, god father Tony. 
The Gang – The rag tag gang of clinician researchers who accompanied me on this road. Jamie 
Morton, Edmund Lau, Chi-Jen (CJ) Hsu, Andy Yong and Kim Chan. We were a band of 
brothers embarking on a journey into an unknown land. Thank you for the laughs, whinge 
sessions and support. We all have gone on to bigger and better things and I am just glad to have 
been there at the beginning. 
I would like to thank the National Heart Foundation for providing me the financial assistance 
to undertake my PhD studies. 
v 
Finally, to my family … 
I would like to thank my family for your unyielding support and faith in me. When I presented 
to you a path of academia that would mean time away from home, possible financial ruin and 
uncertain future there was little hesitation. My mother and father – you gave me love and 
support without ever asking anything in return. 
To my Yingying, 5 years is a long time to ask you to follow me blindly along this path. We 
definitely went through up and downs, laughs and tears but we never gave up. I guess the most 
important part is that whatever we built we did it together, every step of the way. This thesis I 
dedicate to you (darling, yes it is finally done!). 
  
vi 
Publications and Presentations Arising from this Thesis and 
Collaborations 
Publications 
Published in peer-reviewed journals: 
Yu.Y, Wise.S, Celermajer.D, Bilek.M, Ng.M, Bioengineering Stents with Proactive 
Biocompatibility, Interventional cardiology, 2015, 7 (6) 
Yu.Y, Wise. S, Praveesuda.M, Bax.D, Yuen.G,, Hiob. M, Yeo.G, Filipe.E, Dunn.L, Chan. K, 
Hajian. H, Celermajer. D, Weiss. A, Ng. M, Characterization of Endothelial Progenitor Cell 
Interactions with Human Tropoelastin, PLOS ONE, June 26, 2015, 10 (6). 
Hamid. H, Wise. S, Bax. D, Kondyurin. A, Waterhouse. A, Dunn. L, Kielty. C, Yu. Y, Weiss. 
A, Bilek. M, Bannon. P, Ng. M, Immobilisation of a fibrillin-1 fragment enhances the 
biocompatibility of PTFE, Colloids and surfaces B: Biointerfaces, 2013. 
Chan. K, Simpson. P, Yong. A, Dunn. L, Chawantanpipat. C, Hsu. C, Yu. Y, Keech. A, 
Celermajer. D, Ng. M, The relationship between endothelial progenitor cell populations and 
epicardial and microvascular coronary disease – a cellular, angiographic and physiologic study, 
PLoS One, 2014. 
Submitted for peer-review: 
Nitrogen modulates the biocompatibility of plasma activated thin films for vascular 
applications. Y. Yu, A. Kondyurin, S. Wise, W. Chrzanowski, M. Santos, M. Hiob, D. 
Celermajer, Marcela. Bilek and Martin. Ng. 
Abstract presentations 
Yu.Y, Wise.S, Dunn.L, Weiss.A, Celermajer.D, Ng.M. Recombinant Human Elastin (rhELN)) 
Enhances Endothelial Progenitor Cell (EPC)-mediated Endothelialisation, poster presentation, 
Cardiac Society of Australia and New Zealand Annual Scientific Meeting 2011. 
vii 
Yu.Y, Wise.S, Mortada.A, Weiss.A, Celermajer.D, Ng.M. Endothelial Progenitor Cell (EPC) 
Interaction with Recombinant Human Elastin (rhELN) is Through Integrin alphaVbeta3. poster 
presentation, Cardiac Society of Australia and New Zealand Annual Scientific Meeting 2012. 
Y. Yu, S. Wise, A. Kondyurin, M. Bilek, M. Ng. Nitrogen Rich Plasma Activated Coatings for 
Enhancement of Endovascular Stent Biocompatibility, Poster presentation, AHA scientific 
sessions 2014. 
  
viii 
Table of Contents 
Declaration................................................................................................................................ ii 
Acknowledgement .................................................................................................................. iii 
Publications and Presentations Arising from this Thesis and Collaborations .................. vi 
Table of Contents ................................................................................................................. viii 
List of Figures ....................................................................................................................... xiii 
List of Tables ......................................................................................................................... xxi 
Abstract ............................................................................................................................... xxiii 
Abbreviations ....................................................................................................................... xxv 
Chapter 1: Introduction ........................................................................................................ 29 
1.1 Coronary artery disease .................................................................................................. 29 
1.2 Clinical management of coronary artery disease ........................................................... 31 
1.3 Biocompatibility – an evolving concept......................................................................... 34 
1.3.1 Balloon angioplasty ................................................................................................. 35 
1.3.2 Coronary artery stent ............................................................................................... 36 
1.3.3 Coronary stents – hemocompatibility ...................................................................... 38 
1.3.4 Coronary stents – in-stent restenosis ....................................................................... 40 
1.3.5 The Drug eluting stent (DES) – Clinical benefit ..................................................... 41 
1.3.6 Drug eluting stent – Biocompatibility issues ........................................................... 42 
1.3.7 Second generation drug eluting stents ..................................................................... 45 
1.4 Beyond drug eluting stents: Alternative approaches and strategies ............................... 48 
1.4.1 Polymer-free drug eluting stents.............................................................................. 48 
1.4.2 Biodegradable polymer DES ................................................................................... 52 
1.4.3 Biodegradable stents ................................................................................................ 56 
1.4.4 Stent surface treatment ............................................................................................ 60 
1.4.4.1 Inert surface coatings ....................................................................................... 61 
1.4.4.2 Antithrombotic surface coatings ....................................................................... 61 
1.4.4.3 Pro-healing surface coatings ............................................................................ 61 
1.5 Plasma modification of biomaterial surfaces ................................................................. 64 
1.6 Biomolecular functionalization of surfaces .................................................................... 67 
1.6.1 Elastin ...................................................................................................................... 67 
1.6.2 Tropoelastin ............................................................................................................. 68 
1.7 Thesis aims ..................................................................................................................... 69 
Chapter 2: Isolation of Outgrowth Endothelial Cells and Interaction with Recombinant 
Human Tropoelastin .............................................................................................................. 71 
2.1 Introduction .................................................................................................................... 71 
2.2 Methods and materials ................................................................................................... 81 
2.2.1 OEC isolation and culture ....................................................................................... 81 
2.2.2 Characterization of OECs ........................................................................................ 82 
2.2.3 Detection of CD31 ................................................................................................... 82 
2.2.4 Acetylated low density lipoprotein uptake (AcLDL), fluorescein isothiocyanate 
– Ulex europaeus agglutinin lectin (Ulex) binding and presence of Von 
Willebrand factor (vWF) .......................................................................................... 82 
ix 
2.2.5 Flow cytometry ........................................................................................................ 83 
2.2.6 Quantification of cell number .................................................................................. 83 
2.2.7 OEC adhesion in tissue culture plastic .................................................................... 84 
2.2.8 OEC cell spreading .................................................................................................. 85 
2.2.9 OEC proliferation .................................................................................................... 85 
2.3 Results ............................................................................................................................ 86 
2.3.1 OEC characterization ............................................................................................... 86 
2.3.2 Flow cytometry ........................................................................................................ 88 
2.3.3 OEC attachment to recombinant human tropoelastin .............................................. 89 
2.3.4 OEC attachment to recombinant human tropoelastin .............................................. 90 
2.3.5 Spreading of OECs on recombinant human tropoelastin ........................................ 91 
2.3.6 OEC proliferation on recombinant human tropoelastin .......................................... 93 
2.4 Discussion ...................................................................................................................... 93 
2.4.1 OEC culture and characterization ............................................................................ 94 
2.4.2 OEC attachment, spreading and proliferation is supported by rhTE in a dose 
dependent manner ..................................................................................................... 95 
2.5 Conclusion ...................................................................................................................... 97 
Chapter 3: Determination of the Mechanism of OEC Interaction with Recombinant 
Human Tropoelastin .............................................................................................................. 98 
3.1 Introduction .................................................................................................................... 98 
3.2 Methods and materials ................................................................................................. 101 
3.2.1 OEC isolation and culture ..................................................................................... 101 
3.2.2 Tropoelastin construct expression ......................................................................... 101 
3.2.3 Overexpression of constructs ................................................................................ 101 
3.2.4 Purification of constructs ....................................................................................... 102 
3.2.5 Reverse phase high performance liquid chromatography (RP-HPLC) ................. 102 
3.2.6 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) ........................................ 102 
3.2.7 Inhibition of OEC attachment to tropoelastin and constructs................................ 102 
3.2.8 OEC attachment to tropoelastin and constructs in cation free environment: 
Divalent cation add back assay ............................................................................... 103 
3.2.9 Anti-integrin blocking antibody inhibition of OEC attachment and spreading..... 103 
3.2.10 Attachment, spreading and proliferation on tropoelastin constructs ................... 104 
3.3 Results .......................................................................................................................... 104 
3.3.1 SDS Page ............................................................................................................... 104 
3.3.2 EDTA but not lactose or heparan sulfate inhibits OEC attachment to 
recombinant human tropoelastin ............................................................................ 105 
3.3.3 Recovery of OEC attachment is dependent on the divalent cation manganese..... 106 
3.3.4 OEC interaction with recombinant human tropoelastin is mediated by integrin 
αVβ3 ....................................................................................................................... 107 
3.3.5 N-terminal domains of tropoelastin support OEC attachment, spreading and 
proliferation ............................................................................................................ 110 
3.3.6 C-terminus of tropoelastin does not support OEC attachment .............................. 114 
3.3.7 N-terminus N25 and N18 support OEC spreading and proliferation to a 
comparable level ..................................................................................................... 115 
3.3.8 N25 and N18 terminus interactions are integrin-dependent .................................. 118 
3.4 Discussion .................................................................................................................... 123 
3.4.1 Integrin αVβ3 mediates OEC attachment and spreading on rhTE ........................ 123 
3.4.2 OEC binding region on rhTE can be mapped to a region between domain N10 
– N18 ...................................................................................................................... 124 
3.5 Conclusion .................................................................................................................... 125 
x 
Chapter 4: Optimization of Plasma Polymerization: Creation and Analysis of 
Nitrogenized Plasma Polymers ........................................................................................... 127 
4.1 Introduction .................................................................................................................. 127 
4.2 Methods and materials ................................................................................................. 133 
4.2.1 Plasma polymerization .......................................................................................... 133 
4.2.2 Attenuated total reflection fourier transform infrared spectroscopy ..................... 134 
4.2.3 X-Ray Photoelectron spectroscopy ....................................................................... 135 
4.2.4 Ellipsometry .......................................................................................................... 135 
4.2.5 Raman spectroscopy .............................................................................................. 135 
4.2.6 Atomic force microscopy ...................................................................................... 135 
4.2.7 Covalent bonding ................................................................................................... 136 
4.3 Results .......................................................................................................................... 136 
4.3.1 Optimizing plasma polymerization chamber for uniform polymer deposition ..... 136 
4.3.2 Rate of deposition .................................................................................................. 142 
4.3.3 Chemical and physical analysis of stable plasma polymer.................................... 144 
4.3.3.1 The elemental composition of plasma polymer ............................................... 145 
4.3.3.2 Surface topography of plasma polymers ......................................................... 146 
4.3.3.3 Carbon structure of plasma polymer .............................................................. 149 
4.3.3.4 Optical density of plasma polymer ................................................................. 150 
4.3.3.5 Covalent bonding capability of the plasma polymers ..................................... 150 
4.4 Discussion .................................................................................................................... 151 
4.4.1 Establishing uniformity of deposited plasma polymer film .................................. 151 
4.4.2 Evaluating deposition characteristics of plasma polymer ..................................... 152 
4.4.3 Elemental composition of plasma polymer: correlating Nitrogen content with 
deposition parameters ............................................................................................. 153 
4.4.4 Physical structure of plasma polymer and relevance for stent applications .......... 154 
4.4.5 Retention of covalent binding capacity of plasma polymer .................................. 157 
4.5 Conclusion .................................................................................................................... 158 
Chapter 5: Analysis of the Aging of Nitrogenized Plasma Polymers .............................. 160 
5.1 Introduction .................................................................................................................. 160 
5.2 Methods and materials ................................................................................................. 165 
5.2.1 Plasma polymerization .......................................................................................... 165 
5.2.2 Contact angle and wettability study....................................................................... 166 
5.2.3 Chemistry of plasma polymers .............................................................................. 166 
5.2.4 X-ray photoelectron spectroscopy ......................................................................... 166 
5.2.5 Free radical density in plasma polymers ............................................................... 167 
5.3 Results .......................................................................................................................... 167 
5.3.1 Water contact angle and hydrophilicity of plasma polymers ................................ 167 
5.3.2 Surface energy of plasma polymers....................................................................... 173 
5.3.3 Fitting of experimental data for surface energy ..................................................... 176 
5.3.4 Surface chemistry changes with time .................................................................... 179 
5.3.5 XPS curve fitting ................................................................................................... 199 
5.3.5.1 Curve fitting of PPolymer samples ................................................................. 202 
5.3.5.2 Curve fitting of NPolymer8 samples ............................................................... 203 
5.3.5.3 Curve fitting of NPolymer14 samples ............................................................. 204 
5.3.5.4 Curve fitting of NPolymer27 samples ............................................................. 205 
5.3.6 Elemental composition .......................................................................................... 206 
5.3.7 Free radical measurements – electron spin resonance spectroscopy ..................... 208 
5.4 Discussion .................................................................................................................... 210 
5.4.1 Contact angle and surface energy .......................................................................... 211 
xi 
5.4.2 Chemical and structural changes of plasma polymers........................................... 214 
5.5 Conclusion .................................................................................................................... 217 
Chapter 6: Biocompatibility of Nitrogenized Plasma Polymers: Thrombogenicity and 
Cell Interactions ................................................................................................................... 219 
6.1 Introduction .................................................................................................................. 219 
6.1.1 The hemostatic system .......................................................................................... 220 
6.1.2 Fibrinogen – role in physiological and biomaterial thrombosis ............................ 222 
6.1.3 Assessment of Fibrinogen structure ...................................................................... 225 
6.1.4 Biomaterial thrombogenicity ................................................................................. 225 
6.1.5 In vitro thrombogenicity assays ............................................................................. 226 
6.1.6 Endothelialization .................................................................................................. 228 
6.1.7 Mechanically stable coating platform.................................................................... 230 
6.2 Methods and materials ................................................................................................. 231 
6.2.1 Plasma polymerization (polymer deposition) ........................................................ 231 
6.2.2 Polymerization of stents ........................................................................................ 231 
6.2.3 Thrombogenicity studies ....................................................................................... 232 
6.2.4 Blood preparation .................................................................................................. 232 
6.2.5 Static blood assays ................................................................................................. 233 
6.2.5.1 Whole blood .................................................................................................... 233 
6.2.5.2 Scanning electron microscope ........................................................................ 234 
6.2.5.3 Platelet adhesion ............................................................................................. 234 
6.2.5.4 Platelet activation ........................................................................................... 234 
6.2.6 Dynamic flow experiments .................................................................................... 235 
6.2.6.1 Whole blood experiments ................................................................................ 235 
6.2.6.2 Platelet activation ........................................................................................... 235 
6.2.7 Cell culture ............................................................................................................ 235 
6.2.8 Cell adhesion to substrates .................................................................................... 236 
6.2.9 Cell proliferation ................................................................................................... 236 
6.2.10 Fibrinogen studies ............................................................................................... 237 
6.2.10.1 Fibrinogen attachment kinetics ..................................................................... 237 
6.2.10.2 Covalent immobilization of fibrinogen to plasma polymerized samples ...... 238 
6.2.10.3 Determination of fibrinogen conformation ................................................... 238 
6.3 Results .......................................................................................................................... 238 
6.3.1 Static blood assays ................................................................................................. 238 
6.3.1.1 Whole blood .................................................................................................... 238 
6.3.1.2 Scanning electron microscopy ........................................................................ 244 
6.3.1.3 Platelet attachment ......................................................................................... 247 
6.3.1.4 Platelet activation ........................................................................................... 247 
6.3.2 Dynamic flow assays ............................................................................................. 249 
6.3.2.1 Whole blood .................................................................................................... 249 
6.3.2.2 Platelet activation in Chandler loop ............................................................... 253 
6.3.3 Endothelialization on plasma polymers ................................................................. 254 
6.3.3.1 Human coronary artery endothelial cell attachment to plasma polymer 
samples ............................................................................................................ 254 
6.3.3.2 HCAEC attachment ......................................................................................... 255 
6.3.3.3 Out growth endothelial cell adhesion ............................................................. 259 
6.3.3.4 Cell proliferation ............................................................................................ 261 
6.3.4 Fibrinogen studies ................................................................................................. 264 
6.3.4.1 Fibrinogen binding kinetics ............................................................................ 264 
6.3.4.2 Robustness of fibrinogen attachment to plasma polymerized surfaces .......... 266 
xii 
6.3.4.3 Conformation of surface bound fibrinogen ..................................................... 267 
6.3.5 Integrity of NPolymer27 coating on stents ............................................................ 270 
6.4 Discussion .................................................................................................................... 271 
6.5 Conclusion .................................................................................................................... 278 
Chapter 7: General Discussion; Future Directions ........................................................... 279 
7.1 General discussion........................................................................................................ 279 
7.1.1 Isolation and characterization of outgrown endothelial progenitor cells with 
assessment of the interaction with recombinant human tropoelastin ..................... 279 
7.1.2 Outgrowth endothelial cells interact with tropoelastin via an integrin mediated 
mechanism with the binding region between N-terminal domains 10 and 18 ....... 280 
7.1.3 Optimization of the plasma polymerization process and creation of 
nitrogenized plasma polymers ................................................................................ 281 
7.1.4 Detailed study of the aging of plasma polymers ................................................... 281 
7.1.5 In vitro cell interaction and thrombogenicity assessment of nitrogenized plasma 
polymer ................................................................................................................... 282 
7.2 Future directions ........................................................................................................... 284 
7.3 Conclusion .................................................................................................................... 285 
References ............................................................................................................................. 286 
  
xiii 
List of Figures 
Figure 1.1. Schematic diagram showing the development of atherosclerosis. ........................ 30 
Figure 1.2. Diagram showing the clinical spectrum of acute coronary syndrome. ................. 31 
Figure 1.3. Diagram showing balloon angioplasty. ................................................................. 32 
Figure 1.4. Diagram showing stent deployment in a coronary vessel. .................................... 33 
Figure 1.5. Autopsy images of subacute coronary stent thrombosis. ...................................... 38 
Figure 1.6. SEM images of explanted stents 28 days after deployment in rabbit iliac 
artery. ...................................................................................................................... 44 
Figure 1.7. Scanning electron microscopy of the hydroxyapatite coating on the Vestasync 
stent. ........................................................................................................................ 49 
Figure 1.8A. SEM showing spray deposited paclitaxel on the surface of an Amazon PAX 
stent. ........................................................................................................................ 50 
Figure 1.8B. SEM of a Biofreedom stent showing microabrasions. ....................................... 50 
Figure 1.9. JACTAX stent. ...................................................................................................... 54 
Figure 1.10. Polymer filled reservoirs in the Costar star. ........................................................ 54 
Figure 1.11. Translucent polylactide struts of the Igaki-Tamai stent. ..................................... 57 
Figure 1.12. Abbot vascular BVS biodegradable stent. ........................................................... 58 
Figure 1.13. In vivo degradation of AMS-1 versus AMS-2 at 2 weeks. Stent integrity is 
noticeably improved in the AMS-2 stent. ............................................................... 59 
Figure 1.14. Schematic diagram representing the 4 states of matter (Top panel). Plasma 
glow discharge seen in a plasma chamber (bottom panel). .................................... 65 
Figure 1.15. Three-dimensional model of tropoelastin. ........................................................... 69 
Figure 2.1. Microscopy image of early EPCs isolated using the Hill method. ........................ 72 
Figure 2.2. Microscopy image of early EPCs as defined by the Vasa method. ....................... 73 
Figure 2.3. Light microscopy of outgrowth endothelial cells as described by Lin et al. ......... 74 
Figure 2.4. Diagram illustrating the role of EPCs in the cardiovascular system. .................... 75 
Figure 2.5A. Diagram highlighting endothelial denudation and thrombus formation after 
coronary stenting. .................................................................................................... 77 
Figure 2.5B. Recruitment of early and late endothelial progenitor cells to the site of stent-
induced vascular injury. .......................................................................................... 78 
Figure 2.6. Schematic diagram showing the deposited plasma activated thin carbon film 
(yellow) with covalent bonds anchoring surface immobilized proteins. ................ 79 
xiv 
Figure 2.7. Top panel shows OEC morphology under light microscopy as published by 
Yoder et al [333]. .................................................................................................... 86 
Figure 2.8. Immunofluorescent microscopy of OECs (right column) and HDF as control 
(left column) ........................................................................................................... 87 
Figure 2.9. Immunofluorescent microscopy of OECs labelled with anti-human vWF 
antibodies. ............................................................................................................... 88 
Figure 2.10. Flow cytometry characterization of OECs. ......................................................... 88 
Figure 2.11. Validation of the crystal violet cell staining method for quantification of 
OEC numbers. ......................................................................................................... 89 
Figure 2.12. Aggregated data from 3 donors of OEC attachment to a concentration 
gradient of recombinant human tropoelastin, collagen and fibronectin. ................ 91 
Figure 2.13A. Aggregated data from 3 donors of OEC spreading to a concentration 
gradient of recombinant human tropoelastin. ......................................................... 92 
Figure 2.13B. Phase contrast microscope of OECs spreading................................................. 92 
Figure 2.14. OEC proliferation was quantified after incubation for 3 days or 5 days on 
rhTE, Cn or Fn. ....................................................................................................... 93 
Figure 3.1. Schematic representation of the structure of tropoelastin. .................................... 98 
Figure 3.2. Schematic representation of N-terminal constructs and C-terminal peptide 36 
containing human dermal fibroblasts binding motif GRKRK. ............................. 101 
Figure 3.3. Gel electrophoresis of recombinant human tropoelastin and N-terminal 
constructs. ............................................................................................................. 105 
Figure 3.4. OEC attachment in the presence of the inhibitors heparan sulfate, lactose and 
EDTA. ................................................................................................................... 106 
Figure 3.5. OEC adhesion in cation-free buffer with repletion of cations. ............................ 107 
Figure 3.6. Inhibition of OEC attachment by anti-integrin antibodies. ................................. 108 
Figure 3.7. OEC spreading in the presence anti-integrin antibodies. .................................... 109 
Figure 3.8. Phase contrast microscopy of OECs spreading on full-length rhTE in the 
presence anti-integrin antibodies. ......................................................................... 110 
Figure 3.9. OEC adhesion as a function of increasing concentrations of N25 construct. ..... 111 
Figure 3.10. OEC attachment as a function of N18 concentration. ....................................... 112 
Figure 3.11. OEC attachment to N10. .................................................................................... 113 
Figure 3.12. OEC attachment to C-terminus peptide 36 fragment. ....................................... 114 
Figure 3.13. OEC spreading on N18 (top) and N25 (bottom) constructs with increasing 
protein concentration. ........................................................................................... 116 
xv 
Figure 3.14. Phase contrast microscopy of OECs spreading on N25 and N18 constructs. ... 117 
Figure 3.15. Phase contrast microscope of OEC spreading on N10 construct. ..................... 117 
Figure 3.16. OEC proliferation on N-terminal constructs and rhTE, over day 3 and 5. ........ 118 
Figure 3.17. OEC attachment on to N25 (top graph) and N18 (lower graph) in the 
presence of increasing heparan sulfate, lactose and EDTA concentration. .......... 119 
Figure 3.18. Divalent cation add back to OEC attaching to N25 construct. .......................... 120 
Figure 3.19. Divalent cation add back to OEC attaching to N18 construct. .......................... 121 
Figure 3.20. OEC spreading on N25 (Top) and N18 (Bottom) in the presence of anti-
integrin antibodies. ................................................................................................ 122 
Figure 3.21. Phase contrast microscopy of OECs spreading on N25 and N18 with anti-
integrin antibodies. ................................................................................................ 123 
Figure 4.1. Schematic representation of radiofrequency plasma chamber. ........................... 128 
Figure 4.2. Schematic representation of a plasma immersion ion implantation chamber. .... 129 
Figure 4.3. Schematic of covalent protein attachment using linker groups. .......................... 129 
Figure 4.4. Free radical mediated linker free covalent bonding. ........................................... 130 
Figure 4.5. Purpose designed plasma polymerization chamber. ............................................ 133 
Figure 4.6. Schematic representation of plasma deposition chamber. ................................... 137 
Figure 4.7. Subdivision of polymerized 316L SS for FTIR study. ........................................ 138 
Figure 4.8. FTIR analysis of chemical functional groups found in the plasma polymer at 
different distances from the gas inlet (position A). ............................................... 139 
Figure 4.9. Thickness of the plasma polymer at different distances away from the gas 
inlet (position A). .................................................................................................. 139 
Figures 4.10. FTIR analysis of plasma polymer chemical functional groups relative to the 
gas inlet (position B). ............................................................................................ 140 
Figures 4.11. FTIR analysis of plasma polymer chemical functional groups across the 
plasma polymer surface (position C). ................................................................... 141 
Figure 4.12. Thickness of plasma polymer across the plasma polymer surface (position 
C). ......................................................................................................................... 141 
Figure 4.13. Deposition rate for condition 1 (Nitrogen flow rate 0 sccm). ........................... 142 
Figure 4.14. Deposition rate for condition 2 (Nitrogen flow rate 1 sccm). ........................... 143 
Figure 4.15. Deposition rate for condition 3 (Nitrogen flow rate 5 sccm). ........................... 143 
Figure 4.16. Deposition rate for condition 4 (Nitrogen flow rate 10 sccm). ......................... 144 
Figure 4.17. XPS survey spectra of plasma polymers. .......................................................... 145 
Figure 4.18. Elemental composition of plasma polymers quantified using XPS. ................. 146 
xvi 
Figure 4.19. 2D and 3D AFM images of the plasma polymers. ............................................ 148 
Figure 4.20. Representative raman spectroscopy of the plasma polymers showing typical 
D and G peak. ....................................................................................................... 149 
Figure 4.21. Refractive index (n) as a function of wavelength. ............................................. 150 
Figure 4.22. Amount of protein retained on the polymer surfaces after SDS washing. ........ 151 
Figure 4.23. Schematic representation of carbon – carbon bonding configuration. .............. 155 
Figure 4.24. Representative raman spectra of pure graphite and diamond ............................ 156 
Figure 5.1. Schematic representation of the contact angle measured when a liquid is 
dropped onto a solid surface. ................................................................................ 161 
Figure 5.2. Schematic representation of intermolecular forces within a liquid. .................... 162 
Figure 5.3. Schematic diagram showing generation of free radicals from hydrocarbon 
monomers. ............................................................................................................. 164 
Figure 5.4. Contact angle change as a function of time. ........................................................ 165 
Figure 5.5. Images show a droplet formed from water on plasma polymer samples 15 min 
after removal from deposition chamber. ............................................................... 168 
Figure 5.6. Images show a droplet formed from water on plasma polymer samples 30 
days after removal from deposition chamber........................................................ 169 
Figure 5.7. Images show a droplet formed from water on PPolymer samples (lowest 
nitrogen content). .................................................................................................. 170 
Figure 5.8. Images show a droplet formed from water on NPolymer8 samples (nitrogen 
concentration of 8%). ............................................................................................ 171 
Figure 5.9. Images show a droplet formed from water on NPolymer14 samples (Nitrogen 
concentration of 14%). .......................................................................................... 171 
Figure 5.10. Images show a droplet formed from water on NPolymer27 samples (highest 
nitrogen concentration of 27%). ........................................................................... 172 
Figure 5.11. Water contact angle as a function of time for plasma polymers with varying 
nitrogen content. ................................................................................................... 173 
Figure 5.12. Contact angle at day 30 using diiodomethane for plasma polymers with 
varying nitrogen concentration. ............................................................................ 174 
Figure 5.13. Surface energy of plasma polymer samples plotted against time of exposure 
to atmosphere. ....................................................................................................... 175 
Figure 5.14. Polar energy of plasma polymer samples plotted against time of exposure to 
atmosphere. ........................................................................................................... 175 
xvii 
Figure 5.15. Dispersive energy of plasma polymer samples plotted against time of 
exposure to atmosphere. ....................................................................................... 176 
Figure 5.16. Polar energy plotted on semi logarithmic scale (time). Line represents 
theoretical fitting using one exponential function. ............................................... 177 
Figure 5.17. Polar energy plotted on semi logarithmic scale (time). ..................................... 177 
Figure 5.18. Polar component of surface energy plotted on semi logarithmic scale (time). . 178 
Figure 5.19. Dispersive component of surface energy of all plasma polymers plotted on a 
semi logarithmic scale (time). ............................................................................... 179 
Figure 5.20. Transmission FTIR spectra of deposited polymers 5 min (fresh sample) after 
exposure to atmosphere. ....................................................................................... 181 
Figure 5.21. Transmission FTIR spectra of deposited polymers 6 months after exposure 
to atmosphere. ....................................................................................................... 182 
Figure 5.22. Transmission FTIR spectra of PPolymer deposited on silicon wafer as a 
function of aging time in atmosphere. .................................................................. 183 
Figure 5.23. Transmission FTIR spectra of NPolymer8 deposited on silicon wafer as a 
function of aging time in atmosphere. .................................................................. 183 
Figure 5.24. Transmission FTIR spectra of NPolymer14 deposited on silicon wafer as a 
function of aging time in atmosphere. .................................................................. 184 
Figure 5.25. Transmission FTIR spectra of NPolymer27 deposited on silicon wafer as a 
function of aging time in atmosphere. .................................................................. 185 
Figure 5.26. Semi-log graph of absorbance of the 3525 cm-1 (NPolymer27) line as a 
function of aging time in atmosphere. .................................................................. 186 
Figure 5.27. Semi-log graph of absorbance of the 3525 cm-1 (NPolymer27) line as a 
function of aging time in atmosphere. .................................................................. 186 
Figure 5.28. Semi-log graph of absorbance of the 3525 cm-1 (NPolymer27) line as a 
function of aging time in atmosphere. .................................................................. 187 
Figure 5.29. Semi-log graph of absorbance at 3525 cm-1 as a function of aging time in 
atmosphere. ........................................................................................................... 188 
Figure 5.30. Semi-log graph of absorbance at 3380 cm-1 as a function of aging time in 
atmosphere. ........................................................................................................... 189 
Figure 5.31. Semi-log graph of absorbance at 3255 cm-1 as a function of aging time in 
atmosphere. ........................................................................................................... 191 
Figure 5.32. Semi-log graph of absorbance at 2945 cm-1 as a function of aging time in 
atmosphere. ........................................................................................................... 192 
xviii 
Figure 5.33. Semi-log graph of absorbance at 2888 cm-1 as a function of aging time in 
atmosphere. ........................................................................................................... 194 
Figure 5.34. Semi-log graph of absorbance at 2148 cm-1 as a function of aging time in 
atmosphere. ........................................................................................................... 195 
Figure 5.35. Semi-log graph of absorbance at 1715 cm-1 as a function of aging time in 
atmosphere. ........................................................................................................... 197 
Figure 5.36. Semi-log graph of absorbance at 1375 cm-1 as a function of aging time in 
atmosphere. ........................................................................................................... 198 
Figure 5.37. C1s spectra from XPS analysis fitted with 4 components. ................................ 200 
Figure 5.38. C1s spectra from XPS analysis fitted with 5 components. ................................ 200 
Figure 5.39. XPS spectra in the C1s region from PPolymer samples resolved into 5 
components. .......................................................................................................... 202 
Figure 5.40. XPS spectra in the C1s region from NPolymer8 samples resolved into 5 
components. .......................................................................................................... 203 
Figure 5.41. XPS spectra in the C1s region from NPolymer14 samples resolved into 5 
components. .......................................................................................................... 204 
Figure 5.42. XPS spectra in the C1s region from NPolymer27 samples resolved into 5 
components. .......................................................................................................... 205 
Figure 5.43. Top panel: Nitrogen / Carbon ratio (N/C) as a function of nitrogen gas flow. 
Lower panel: Oxygen / Carbon ratio (O/C) as a function of nitrogen gas flow. .. 207 
Figure 5.44. ESR spectra of PPolymer measured at two separate time points, within 3 
hours (fresh) and 28 days after deposition. ........................................................... 209 
Figure 5.45. ESR spectra of NPolymer27 measured at two separate time points, within 3 
hours (fresh) and 28 days after deposition. ........................................................... 209 
Figure 6.1. Schematic diagram of coagulation pathway. ....................................................... 222 
Figure 6.2. Structure of Fibrinogen. Adapted from Koh, Rodrigues and Venkatraman, 
2010 [502]. ............................................................................................................ 223 
Figure 6.3. Schematic diagram illustrating interaction of fibrinogen with platelet surface 
glycoprotein IIb/IIIa receptors. ............................................................................. 224 
Figure 6.4. Schematic diagram of roller pump set up for flow model of thrombogenicity. .. 227 
Figure 6.5. Schematic representation of the modified chandler loop. ................................... 228 
Figure 6.6. Optical microscopy of DES showing delamination of coated polymers after 
balloon expansion. ................................................................................................ 231 
xix 
Figure 6.7. Photograph of modified polymerization setup for adaptation of coating to 
three dimensional stents. ....................................................................................... 232 
Figure 6.8. Platelet rich plasma after centrifuging whole blood. ........................................... 233 
Figure 6.9. FTIR spectra of 316L SS and plasma polymers. ................................................. 237 
Figure 6.10. Photograph of 316L SS and plasma Polymerized samples after 60 min in 
whole heparinized blood. ...................................................................................... 239 
Figure 6.11. Weight of thrombus on samples exposed to heparinized whole blood for 60 
min in 37°C. .......................................................................................................... 240 
Figure 6.12. Photograph of 316L SS and Plasma Polymerized samples after 120 min in 
whole heparinized blood. ...................................................................................... 241 
Figure 6.13. Weight of thrombus on samples exposed to heparinized whole blood for 120 
min at 37°C ........................................................................................................... 242 
Figure 6.14. Photograph of 316L SS and Plasma Polymerized samples after 180 min in 
whole heparinized blood. ...................................................................................... 243 
Figure 6.15. Weight of thrombus on samples exposed to heparinized whole blood for 180 
min in 37°C. .......................................................................................................... 244 
Figure 6.16. SEM of 316L SS and plasma polymerized samples after a 60 min exposure 
to whole heparinized blood (x250 magnification). ............................................... 245 
Figure 6.17. Scanning electron microscopy of 316L SS and plasma polymerized samples 
after 180 min exposure to heparinized blood (x250 magnification). .................... 246 
Figure 6.18. Platelet adhesion measured by LDH release. .................................................... 247 
Figure 6.19. sP-selectin levels in PRP after 60 min exposure to 316L SS and plasma 
polymerized samples. ............................................................................................ 248 
Figure 6.20. sP-selectin levels in PRP after 180 min exposure to 316L SS and plasma 
polymerized samples. ............................................................................................ 249 
Figure 6.21. Photographic images of SS, PPolymer, NPolymer14 and NPolymer27 after 
120 min exposure to heparinized whole blood in chandler loops. ........................ 250 
Figure 6.22. Total thrombus weight developing on samples placed into a chandler loop 
for 120 min. ........................................................................................................... 251 
Figure 6.23. Photographic images of 316L SS, PPolymer, NPolymer14 and NPolymer27 
after 180 min exposure to heparinized whole blood in chandler loops. ............... 252 
Figure 6.24. Total thrombus weight developing on samples placed into a chandler loop 
for 180 min. ........................................................................................................... 253 
xx 
Figure 6.25. sP-selectin released from platelets after 180 min rotation in the chandler 
loop. ...................................................................................................................... 254 
Figure 6.26. Standard curve generated by correlating known cell numbers with measured 
absorbance............................................................................................................. 255 
Figure 6.27. HCAEC attachment to 316L SS and plasma polymerized sample in serum 
free media.............................................................................................................. 257 
Figure 6.28. HCAEC attachment to 316L SS and plasma polymerized sample in serum 
supplemented media. ............................................................................................ 258 
Figure 6.29. Reflective microscopy of HCAEC attachment in serum supplemented media 
on 316L SS and plasma polymerized samples. ..................................................... 259 
Figure 6.30. OEC attachment to SS and plasma polymerized samples in serum free 
media. .................................................................................................................... 260 
Figure 6.31. Reflective microscope of OEC attachment in serum supplemented media on 
316L SS and plasma polymerized samples. .......................................................... 261 
Figure 6.32. Proliferation of HCAEC on 316L SS and NPolymer27. ................................... 262 
Figure 6.33. HCAEC proliferation on 316L SS and NPolymer27. ....................................... 263 
Figure 6.34. Proliferation of OECs on 316L SS and NPolymer27. ....................................... 264 
Figure 6.35. Amount of Fg attached on to 316L SS and plasma polymerized samples as a 
function of time of incubation. ............................................................................. 265 
Figure 6.36. Amount of Fg attached to 316L SS and plasma polymers after 2880 min of 
incubation in Fg solution. ..................................................................................... 266 
Figure 6.37. Amount of Fg attached on surfaces before and after SDS washing, quantified 
using relative absorbance. ..................................................................................... 267 
Figure 6.38. Amide I spectra of Fg on 316L SS and plasma polymer samples measured 
using FTIR. ........................................................................................................... 268 
Figure 6.39. Secondary structure of surface bound Fg on 316L SS and plasma polymer 
samples. ................................................................................................................. 269 
Figure 6.40. Scanning electron microscopy of NPolymer27 coated coronary stents after 
crimping and expansion. ....................................................................................... 271 
  
xxi 
List of Tables 
Table 1.1. Summary of the ideal mechano-biological characteristics for a coronary stent. .... 37 
Table 1.2. Physical and drug elution properties of first generation DES. ............................... 42 
Table 1.3. Physical and drug elution properties of second generation DES. ........................... 46 
Table 1.4. Physical and drug elution properties of polymer free drug eluting stents. ............. 51 
Table 1.5. Physical and drug elution properties of biodegradable polymer drug eluting 
stents. ...................................................................................................................... 55 
Table 1.6. Physical and drug elution properties of biodegradable stents. ................................ 60 
Table 4.1. Deposition parameters for plasma polymers with different nitrogen content. ..... 134 
Table 4.2. Summary of the ratio of intensity of D and G peaks for plasma polymer with 
varying nitrogen content ....................................................................................... 149 
Table 5.1. Parameters of fitting for polar component of surface energy using two 
exponential functions. ........................................................................................... 178 
Table 5.2. Parameters of fitting for dispersive component of surface energy using two 
exponential functions. ........................................................................................... 179 
Table 5.3. Assignment of wavelength and chemical function groups on FTIR spectra. ....... 180 
Table 5.4. Parameters of fitted function of measured absorbance at 3525 cm-1 
wavelength. ........................................................................................................... 189 
Table 5.5. Parameters of fitted function of measured absorbance at 3380 cm-1 
wavelength. ........................................................................................................... 190 
Table 5.6. Parameters of fitted function of measured absorbance at 3255 cm-1 
wavelength. ........................................................................................................... 192 
Table 5.7. Parameters of fitted function of measured absorbance at 2945 cm-1 
wavelength. ........................................................................................................... 193 
Table 5.8. Parameters of fitted function of measured absorbance at 2888 cm-1 
wavelength. ........................................................................................................... 195 
Table 5.9. Parameters of fitted function of measured absorbance at 2148 cm-1 
wavelength. ........................................................................................................... 196 
Table 5.10. Parameters of fitted function of measured absorbance at 1715 cm-1 
wavelength. ........................................................................................................... 198 
Table 5.11. Parameters of fitted function of measured absorbance at 1375 cm-1 
wavelength. ........................................................................................................... 199 
xxii 
Table 5.12. Assignments of functional groups to binding energy. ........................................ 201 
Table 6.1. Secondary structure of fibrinogen as reported in the literature compared to our 
own findings. ........................................................................................................ 270 
  
xxiii 
Abstract 
Cardiovascular disease, in particular coronary artery disease is a leading cause of morbidity 
and mortality worldwide. Coronary artery disease occurs as a consequence of atherosclerosis. 
Impediment to coronary blood flow causes myocardial ischemia, manifesting clinically as 
angina. Plaque rupture can lead to rapid vessel occlusion and myocardial necrosis. 
Revascularization (restoration of normal blood flow) can be achieved percutaneously with 
balloon angioplasty and coronary stent placement. 
Coronary stents are the most commonly implanted medical prosthesis. To date the majority of 
commercially available stents are constructed from metallic alloys. Implantation of stents in 
the vasculature has two main biocompatibility issues 1) metals are thrombogenic, 2) stent 
deployment injures the vessel wall. Stent thrombosis and in stent restenosis are clinical 
consequences of stent thrombogenicity and vessel injury, respectively. Potent anti-platelet 
agents and use of anti-proliferative drug eluting stents reduce thrombogenicity and restenosis 
at the cost of increased bleeding and retardation of stent strut endothelialization leading to very 
late stent thrombosis. 
The interaction of biological systems with biomaterials is highly dependent on surface 
properties. Modification of the physical and chemical properties of the surface offers a simple 
and effective meanings to modulate the biological response to stents without altering the 
mechanical benefits that metallic alloys offer. Recently, plasma polymer deposition of thin 
films has been adapted for metallic substrates and three dimensional structures. These films 
reduce thrombogenicity and interesting can robustly attach biomolecules. One such molecule, 
recombinant human tropoelastin (rhTE) when attached to the films has been shown to enhance 
endothelial activity. Increasingly endothelial progenitor cells (EPCs) have been implicated in 
the maintenance of vascular health. Of particular interest is the capacity of these cells to 
participate in the healing of injured endothelium. Animal models demonstrate the ability of 
these cells to home in to sites of iatrogenic vessel injury and contribute to re-endothelialisation. 
The goal of this thesis is to design a reproducible and scalable biocompatible coating platform 
for coronary stents. We explored the capacity of rhTE to support EPC activity followed by a 
mechanistic study of the nature of this interaction. Following this, we purpose built a plasma 
polymer film deposition chamber, optimizing for consistent and predictable film production. 
xxiv 
Nitrogen content of the plasma polymer films were progressively increased. A detailed 
physical, chemical and biological characterization of these nitrogenized films was carried out. 
There were several key findings from this thesis. We found rhTE supported EPC attachment, 
spreading and proliferation via an integrin mediated process. Using truncated rhTE constructs 
we were able to narrow down the site of interaction on rhTE to a region between N-terminal 
domains 10 and 18. By increasing the flow of nitrogen during plasma film deposition we 
successfully created films with increasing concentration of nitrogen. Physical and chemical 
analyses demonstrated an amorphous carbon structure with smooth topography, containing 
nanoscale -conjugated graphite-like clusters, independent of nitrogen content. In contrast, 
nitrogen doping increased surface wettability and the amount of polar functional groups. In 
thrombogenicity assays lower thrombus formation, platelet adhesion and activation correlated 
with higher nitrogen concentration. Surprisingly, highly nitrogenized films also enhanced 
endothelial cell and EPC attachment and proliferation independent of rhTE functionalization. 
Nitrogenization of the plasma polymers did not impact on the capacity to covalently attach 
proteins. Nitrogenized plasma films is a promising platform to improve the biocompatibility of 
existing coronary stents.  
xxv 
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Chapter 1: Introduction 
A portion of chapter 1 has been published in the peer reviewed journal Interventional 
Cardiology 2015; vol 7: issue 6: 571-584 entitled Bioengineering stents with proactive 
biocompatibility, authored by Yu Y, Wise SG, Celermajer DS, Bilek MM and Ng MKC. 
1.1 Coronary artery disease 
Cardiovascular disease (CVD) has had a tremendous health impact across the globe. A rise in 
obesity levels, sedentary lifestyle and diabetes (in particular in developing countries) has led 
to CVD becoming the leading cause of mortality. Ischemic heart disease (IHD) is by far the 
single largest contributor to the burden of CVD. This is reflected in the Australian experience, 
with close to 600,000 people in 2011-2012 with IHD (Australian bureau of statistics). 
Coronary artery disease (CAD) is characterized by narrowing of the vessel lumen. Clinical 
presentation may be chronic and stable, with chest pain (stable angina) induced with physical 
exertion. In more acute clinical scenarios patients experience a rapid escalation or sudden onset 
of symptoms (acute coronary syndrome). 
In stable angina a progressive narrowing of the vessel occurs secondary to the development of 
atherosclerotic lesions. Atherosclerosis is considered an inflammatory process. Accumulation 
of low density lipoprotein (LDL) into the vascular wall leads to an inflammatory reaction [1]. 
Oxidation of LDL generates potent cellular stimulators [2], leading to activation of endothelial 
cells [3], smooth muscle cell proliferation with matrix deposition [4] and immune cell 
stimulation [5]. Oxidized LDL is internalized by the macrophage cell resulting in a lipid laden 
foam cell. Accumulation of these cells in the extracellular matrix leads to the development of 
atherosclerotic lesions [6]. As these lesions progress in size, reduction of the vessel lumen 
ensues with compromise to coronary blood flow and a reduction in myocardial oxygen 
delivery. During periods of physical activity an imbalance in oxygen demand and supply occurs 
causing the onset of ischemia and angina symptoms. 
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Figure 1.1. Schematic diagram showing the development of atherosclerosis. Adapted 
from Libby et al [7]. (A) Normal vessel showing three layers. Intima (monolayer of 
endothelial cells), media (smooth muscle cells and extracellular matrix) and adventitia. 
(B) Adhesion and migration of monocytes and subsequent maturation into macrophages 
with ingestion of lipids to form foam cells. (C) Migration, accumulation and 
proliferation of smooth muscle cells with deposition of extracellular matrix proteins. 
Apoptosis of lipid laden macrophages and smooth muscle cell leads to the formation of a 
necrotic/lipid core. 
Acute coronary syndrome encompasses a clinical spectrum of unstable angina (UAP), non-ST 
elevation myocardial infarction (NSTEMI) and ST elevation myocardial infarction (STEMI) 
(Figure 1.2). While varying in degrees of myocardial injury and clinical severity, the syndrome 
is highlighted by the rapid or sudden worsening of coronary flow obstruction, ranging from 
ischemia without cell death (UAP) to transmural myocardial cell necrosis (STEMI). The 
underlying mechanism is disruption of the atherosclerotic plaque with exposure of 
subendothelial collagen and tissue factor. Activation of platelets and the coagulation pathway 
leads to thrombus formation [8]. Acute coronary syndrome is responsible for the morbidity and 
mortality attributed to CAD [9]. 
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Figure 1.2. Diagram showing the clinical spectrum of acute coronary syndrome. 
Characterized by acute destabilization of the atherosclerotic plaque with varying 
degrees of luminal compromise. 
1.2 Clinical management of coronary artery disease 
Management of CAD can be broadly divided into medical and revascularization therapy. 
Medical treatment encompasses anti-angina and cardio-protective agents, achieving 
symptomatic and/or prognostic benefits through reductions in cardiac work load, myocardial 
oxygen demand, coronary and peripheral vasodilation [10, 11]. Secondary prevention with the 
use of antiplatelet agents, medical optimization of CVD risk factors - hypertension, diabetes 
and dyslipidaemia are designed to prevent future cardiovascular events [12]. 
The goal of revascularization therapy is to restore sufficient blood flow to ischemic 
myocardium supplied by chronically or acutely narrowed coronary vessels. This was initially 
achieved through coronary artery bypass surgery (CABG) using autologous conduits (veins or 
arteries) anastomosed to proximal and distal points across the stenosed segments of coronary 
vessel [13]. In the late 1970’s percutaneous treatment of ischemic heart disease (PCI) was 
introduced with the development of coronary angioplasty using expandable balloons [14]. A 
wire was inserted via a peripherally placed arterial sheath in a retrograde fashion along the 
aorta into the coronary vessel. A balloon was passed along the wire to the stenosed segment of 
coronary vessel and expanded (Figure 1.3). The improvement in coronary blood flow 
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following balloon angioplasty is largely a mechanical effect in part due to compression of the 
atherosclerotic plaque but as shown with intravascular ultrasound (IVUS) largely secondary to 
vessel stretch [15]. 
A high re-narrowing (restenosis) rate of around 30% in the treated vessel segment was reported 
following balloon angioplasty [16]. Recoil of the vessel and negative remodelling were the 
predominant reasons for loss of luminal diameter. Percutaneous treatment was improved with 
the introduction of coronary artery stents, metallic scaffolds capable of optimizing vessel 
patency following balloon expansion by eliminating the effect of acute vessel recoil [17] 
(Figure 1.4). This minimally invasive approach has seen a significant uptake over the past 30 
years, as reflected by declining rates of CABG [18]. In the United States alone over one million 
patients under go coronary stenting a year [19]. 
 
Figure 1.3. Diagram showing balloon angioplasty. Improvement in coronary vessel 
lumen size is from compression of the atherosclerotic plaque and stretching of the 
vessel. 
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Figure 1.4. Diagram showing stent deployment in a coronary vessel. The stent acts as a 
scaffold propping up the vessel preventing recoil. 
Recent trials in stable coronary artery disease have brought into question the value of PCI in 
reducing mortality in patients with stable angina, emphasizing the efficacy of optimal medical 
therapy [20, 21]. Furthermore, in patients with complex coronary artery disease or those with 
diabetes mellitus CABG may deliver more durable clinical outcomes [22, 23]. These studies 
have led to a more judicious approach in patients with stable ischemic heart disease or complex 
coronary anatomy as reflected by a modest decline in the total volume of interventions 
performed [24]. 
PCI still has a role in patients with stable coronary artery disease. Freedom from angina was 
significantly higher in patients who underwent PCI in contrast to those on medical therapy, 
showing the benefit of PCI in patients with refractory symptoms [20, 25]. The prognostic 
benefits derived from revascularization may be related to the degree of ischemic burden. A 
large amount of ischemic myocardium correlates with an increased mortality [26]. PCI in stable 
patients with a significant ischemic burden may be of value, with earlier PCI in these patients 
offering greater reduction in ischemia [27]. 
The evidence for PCI in patients with acute coronary syndrome is robust. Early PCI compared 
to conservative medical therapy in patients with UAP or NSTEMI leads to an improvement in 
mortality, reduced myocardial infarction and hospital readmissions [28, 29]. Patients with 
STEMI from coronary vessel occlusion have the highest mortality. During the first hour of 
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oxygen deprivation ischemic necrosis is largely confined to the subendocardial layer. However, 
this soon evolves over the next few hours into transmural necrosis. A critical window of 3 to 6 
hours following coronary artery occlusion is available to salvage ischemic but still viable 
myocardium [30]. The goal in STEMI is to restore flow to the occluded vessel as rapidly as 
possible. Pharmacotherapy with fibrinolytic agents (“clot busting”) have been reasonably 
effective [31]. However, fibrinolysis is limited by a rapid decrease in clinical efficacy 4 hours 
after symptom onset, relatively lower rates of restored normal coronary flow (TIMI 3 flow), 
higher rates of bleeding and recurrence of ischemia [32-34]. Trials comparing fibrinolysis to 
PCI in STEMI clearly demonstrated superior clinical benefits in patients receiving PCI [35, 
36]. 
Coronary stents have evolved over the past 3 decades to become one of the most implanted 
prosthetic devices worldwide. The prognostic benefit of coronary stenting is not as well 
established in the stable angina cohort. However, there remains a role for symptom relief in 
refractory angina and in patients not tolerating medical therapy. PCI confers the greatest 
survival benefit in the setting of acute coronary syndrome with clear reductions in mortality 
and myocardial re-infarction. Taken together the clinical utility of coronary stenting remains 
robust. For the foreseeable future this treatment modality for CAD will remain the dominant 
strategy for the majority of patients indicated for revascularization. 
1.3 Biocompatibility – an evolving concept 
Biocompatibility is a broad term used to describe the interaction of an implanted prosthesis 
with the human body. A key requirement of a biomaterial is to elicit the minimal amount of 
harm to the host environment. 316L stainless steel (316L SS), titanium and cobalt chromium 
(CoCr) alloys used extensively in clinical applications are highly corrosion resistant [37], 
thereby reducing tissue toxicity from material deterioration following in vivo implantation. 
Bio-stable synthetic polymers such as polytetrafluoroethylene (PTFE), silicones and poly-
methyl-methacrylate (PMMA) have gained prominence in a variety of ophthalmological, 
orthopaedic and vascular applications [38]. 
Our concept of biocompatibility has evolved with a better understanding of the tissue and 
cellular responses to biomaterials. Implanted prosthesis can be more than just a passive entity 
but can be designed to actively modulate the host response. Biocompatibility has been 
redefined to reflect this realization, incorporating three important tenets. A biomaterial 1) has 
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an active functional role in local tissue 2) elicit an appropriate biological response 3) the 
response needs to be tissue appropriate and will depend on the intended role [38]. This 
represented a shift from the limited goal of ‘do no harm’ to one of active regulation of the 
biological response specific to the clinical application and local environment of the implanted 
bio-device. The concept of biocompatibility will be explored in the context of percutaneous 
coronary intervention, from balloon angioplasty to coronary stents. 
1.3.1 Balloon angioplasty 
The expansion of a balloon (POBA) inside a stenosed segment of coronary artery was the first 
form of percutaneous treatment for CAD. Luminal enlargement of the vessel was achieved in 
part through the mechanical distortion of the atherosclerotic plaque either by compression 
and/or plaque fracturing. A larger contribution was due to stretching of the entire arterial wall 
[39]. Mechanical disruption of the atherosclerotic plaque resulted in arterial injury complicated 
by acute vessel closure [40]. This acute and catastrophic complication occurred with an 
incidence of 2 – 14% [41]. Angioscopic evaluation (using fiber-optical catheters) with direct 
vessel visualization demonstrated intimal dissection, endothelial disruption, thrombus 
development and plaque rupture [42, 43]. Trauma to the vessel wall appeared to be inevitable, 
where the act of restoring vessel patency is predicated on the mechanical alteration of the vessel 
architecture. 
The durability of vessel patency was suboptimal with a discouragingly high incidence of 
restenosis [44]. Clinically significant restenosis following POBA occurs in approximately 30-
40% of patients [45]. The loss of luminal size stems from a complex interplay of mechanical 
and biological factors. Elastic recoil occurs secondary to overstretching of the vessel and leads 
to a reduction in luminal diameter shortly after balloon angioplasty [46]. Chronic negative 
vessel remodelling from fibrosis and adventitial thickening further contributes to restenosis 
[47]. 
Balloon expansion and the resultant vessel injury stimulate a healing response to re-establish 
the integrity of the endothelium. Intimal hyperplasia represents an over exuberant form of this 
healing process. Initiation of this response is due to disruption of the endothelium, internal 
elastic lamina, tunica media and the mechanical stretching of myocytes [16]. The biological 
response can be categorized into three main phases. An initial inflammatory phase 
characterized by platelet activation and influx of monocytes with release of multiple growth 
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factors. A second phase involves endothelial migration and the change of smooth muscle cells 
from a contractile state into a proliferative and synthetic phenotype. The final phase is marked 
by myocytes depositing proteoglycan rich extracellular matrix (ECM), which constitutes the 
bulk of the neointimal volume [48]. The degree of intimal hyperplasia is proportional to the 
severity of vessel wall injury [49]. Re-endothelialization of the injured vessel segment appears 
to play a vital role in the termination and retardation of further intimal growth [50]. 
Numerous strategies were tried to treat restenosis with limited success. Debulking of the 
neointimal tissue using directional atherectomy and excimer laser were found to paradoxically 
precipitate restenosis due to further arterial injury [51]. Pharmacological approaches attempted 
to target a broad range of biological pathways in the neointimal process with antiplatelet agents, 
anti-inflammatory drugs, novel growth factor antagonists, anti-proliferative agents and lipid 
lowering medications, all with poor clinical results [52]. The coronary stent, a tubular metallic 
scaffold was introduced in 1986 [53] to address the shortcomings of balloon angioplasty. 
1.3.2 Coronary artery stent 
The coronary stent was introduced to address both acute complications and restenosis after 
POBA. It was a purely mechanical solution to a complex biomechanical issue. The choice of 
material for the coronary stent was predominantly influenced by engineering considerations. 
A stent needs to be deformable allowing it to be crimped on to an angioplasty balloon and still 
retain structural integrity upon expansion and deployment. Once implanted, sufficient radial 
force is essential to counter act vessel recoil. Stent radio-opacity facilitates operator 
visualization during stent positioning [54]. The ideal characteristics for a coronary stent are 
summarized in Table 1.1. 
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Table 1.1. Summary of the ideal mechano-biological characteristics for a coronary 
stent. 
Flexibility Facilitates the delivery of the stent through vessel 
tortuosity 
Low Profile 
 
Stent can be crimped on to a balloon and passed across 
tight coronary lesions 
Expandability Can be expanded to a sufficient size and conform to the 
vessel wall 
Radial strength Overcome compressive forces from the artery 
Adequate radio-opacity Allows determination of stent position 
Biocompatibility Thromboresistant. Stent material should limit the 
activation of platelets and coagulation components. 
Promote endothelialization – Promote the 
endothelialization of stent struts 
Limit intimal hyperplasia – inhibit neointima formation 
to prevent coronary restenosis 
 
To satisfy mechano-physical requirements, the main material used for coronary stents have 
been metallic alloys. 316L SS was the material of choice for 1st generation stents. Stent 
biocompatibility was centred on corrosion resistance and material stability in vivo. Focusing 
on passitivity, material inertness and limited inflammatory response were the key 
characteristics desired [55]. 316L SS was however not entirely free from adverse host 
reactions. Release of surface nickel, chromate and molybdenum ions can induce allergic and 
inflammatory responses [56, 57]. 
Coronary stents addressed some of the inadequacies of angioplasty. Acute vessel closure was 
complicated by a high incidence of myocardial infarction and mortality with emergent CABG 
used as a bail out strategy [40]. Angiographic evidence of intimal dissection strongly predicted 
this acute complication [58]. Coronary stents initially found clinical relevance as an alternative 
to urgent CAGB in abrupt vessel closure. Scaffolding of the vessel by the stent splinted the 
vessel open, preventing vessel recoil/spasm and sealing the dissection flap. High procedural 
success rates, reduced myocardial infarction and the need for CABG [59] gave credibility to 
this new technology. 
Soon after establishing a role in the emergent setting the clinical indications for stents were 
broadened by demonstrating utility in elective interventions. The landmark Benestent and 
STRESS studies reported high rates of procedural success, larger immediate and long-term 
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vessel diameters combined with a reduced need for repeat coronary intervention [17, 60, 61]. 
A meta-analysis of 29 randomized stent versus POBA trials in routine patients showed an 
overall reduction in restenosis and repeated angioplasty rates [62]. On the basis of these studies 
coronary stents saw a rapid adoption in clinical practice. 
Despite modest improvements in clinical outcomes coronary stents were not entirely 
biocompatible. The drawback of coronary stents centred around two main issues, intimal 
hyperplasia and the thrombogenicity of the metallic material. Clinical consequences 
manifested as stent thrombosis and restenosis. These shortcomings highlight the inadequacy of 
an inert bio-prosthesis leading to a re-think of how an implant can actively modulate the host 
response. 
1.3.3 Coronary stents – hemocompatibility 
A high incidence of subacute stent thrombosis (within 30 days of stent deployment) was 
reported during initial clinical experience [63] (Figure 1.5). Clinical factors contributing to 
stent thrombosis include i) patient characteristics; including diabetes, female sex, lesion and 
anatomical complexity. ii) clinical context: acute bail out in threatened or abrupt vessel closure, 
acute coronary syndromes iii) operator technique; inadequate stent expansion and stent under 
sizing [64]. 
 
Figure 1.5. Autopsy images of subacute coronary stent thrombosis. 
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A pro-thrombotic microenvironment develops following endothelial disruption. Intact and 
normal functioning endothelium is vital in maintaining hemostatic balance. As much as it is a 
physical barrier separating blood components from the pro-thrombotic subendothelial matrix 
the endothelium has important paracrine function. Production and release of nitric oxide (NO), 
prostacyclin and tissue plasminogen activator inhibits platelet aggregation and promotes 
fibrinolysis [65]. 
In response to injury the quiescent endothelium switches to a pro-coagulant state with up-
regulation and expression of tissue factor (TF) leading to the activation of factors X and IX in 
the coagulation pathway [55]. Exposure of the sub-endothelial space rich in collagen, TF and 
Von Willebrand Factor (vWF) is a powerful stimulus for the activation of the extrinsic pathway 
and platelets [64]. Platelet glycoprotein Ib/IX interacts with vWF, while glycoproteins Ia/IIa 
and IV is activated through collagen [66] leading to a rapid deposition of peri-stent thrombi in 
the first few days post implantation. [67] 
Thrombogenicity of a metallic stent can be in part considered a surface phenomenon. Within 
minutes of exposure to blood, rapid adsorption of plasma proteins to the surface occurs [68]. 
The composition, protein orientation and conformation of this protein layer mediate the 
interaction between the material surface and molecular-cellular components in the blood. 
Fibrinogen (Fg), the precursor to fibrin has been studied in relation to biomaterial thrombosis 
due to its pivotal role in platelet aggregation [69]. In physiological clotting the binding of Fg 
and integrin GPIIb/IIIa on activated platelets is critical in platelet aggregation [70]. This 
interaction is dependent on initial platelet activation by stimulators (thrombin, thromboxane, 
and ADP). Following activation, a conformational change in the platelet GPIIb/IIIa receptor 
occurs facilitating Fg binding [71]. In normal physiological conditions circulating plasma Fg 
does not bind and activate resting platelets. 
Immobilization of soluble Fg onto a stent surface can lead to unfolding of the tertiary structure 
with exposure of platelet adhesion sites located at the carboxy terminus [72]. Structurally 
altered Fg can bind to the GPIIb/IIIa receptor and activate quiescent platelets [73]. In vitro and 
ex vivo studies have shown the amount and conformation of surface adsorbed Fg correlates 
with the number and activation state of adhered platelets on biomaterials [68, 69, 74-76]. Using 
infrared reflection-absorption spectroscopy Desroches et al [77] found a rapid and extensive 
conformational change when Fg was adsorbed on to 316L SS. 
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Stainless steel can activate the coagulation system [74, 76]. Both the extrinsic and intrinsic 
pathways participate in this process. Surface adsorption of Factor XII results in a low grade 
production of thrombin [78]. Monocyte activation followed by increased TF expression can 
occur following blood-biomaterial contact with subsequent initiation of the extrinsic cascade 
[79]. Surface adsorption of complement components, C3b and C5a can induce leukocyte 
activation and TF up-regulation [80]. 
Early subacute stent thrombosis rates were reported to be 16-24 % [81, 82]. Aggressive 
antithrombotic regimes combining antiplatelet agents and heparin/warfarin were used [17, 61]. 
Meaningful reductions in stent thrombosis were offset by a high incidence of bleeding. The use 
of high pressure stent deployment to ensure vessel wall apposition combined with dual 
antiplatelet therapy (DAPT) of aspirin and a thienopyridine saw thrombosis rates decline to 
<1% [83]. A minimum of one month of DAPT is currently recommended following 
implantation of bare metal stents [84]. Nonetheless, combination antiplatelet therapy is 
associated with a significant increase in major bleeding compared to aspirin alone [85]. 
Reducing the inherent thrombogenicity of stents along with encouraging the rapid healing of 
the vascular wall may reduce stent thrombosis and the need for DAPT. 
1.3.4 Coronary stents – in-stent restenosis 
Expansion of coronary stenting into diabetic patients and complex coronary lesions saw a 
disappointingly high rate of in stent restenosis (ISR) [86]. While the majority of patients report 
recurrent angina symptoms, restenosis can present more acutely as myocardial infarction [87]. 
There are differences in the pathophysiology of restenosis occurring after angioplasty and 
coronary stenting. Serial IVUS show that post-angioplasty restenosis is characterized by a loss 
of arterial cross sectional area due to chronic arterial remodelling. In contrast, stenting virtually 
eliminates acute recoil and chronic remodelling, with development of neointima accounting 
almost exclusively for restenosis [88]. 
ISR is an inflammatory fibro-cellular healing response to arterial injury. In order to expand a 
stent against a stenotic arterial segment sufficient outward force is required, leading to 
inevitable injury to the vasculature [89]. Histological studies reveal an initial acute 
inflammatory response surrounding the stent struts consisting of neutrophils. Chronic 
inflammatory cells (macrophages and lymphocytes) increased in presence after 12 days. The 
degree of inflammation correlates with the severity and depth of vessel injury [67]. Vascular 
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smooth muscle cells (VSMCs) migrate towards areas of injury, proliferate and deposit ECM 
rich in proteoglycan, forming the neointima. The neointima becomes more hypocellular with 
time, mirroring features found in wound healing [90]. An increase in neointimal thickness and 
restenosis is seen when stent struts penetrate the lipid plaque core and causes tunica media 
fracture [89], suggesting the healing response is proportional to the degree of vessel disruption. 
Chemical properties of metal alloys can contribute to ISR. Release of metallic ions in to the 
vessel wall can induce free radicals exacerbating inflammation and stimulating the fibro-
proliferative process [91]. Allergy and hypersensitivity to the leeched nickel and molybdenum 
found in 316L SS can further contribute to restenosis [92]. 
Mechanically based and systemic cyto-inhibitory strategies have been adopted to treat ISR. 
Repeat angioplasty with compression of the neointimal tissue was initially attempted. 
However, the limited improvement in luminal diameter [93] prompted investigators to explore 
debulking techniques. Coronary atherectomy did successfully remove neointimal tissue, but 
concerns over damage to stent struts limited the uptake of this approach [94]. Laser and cutting 
balloons did not gain significant traction due to limited clinical efficacy. Focal brachytherapy 
at the site of stent deployment was designed to induce DNA damage in proliferating VSMCs 
[95]. Unintentionally radiation therapy also damaged the endothelium. Injury to the 
endothelium at the stent edge can manifest as edge restenosis [96]. Delayed restenosis some 
years after brachytherapy has been reported [97]. More concerning were reports of late stent 
thrombosis (LST) (>30 days after stent deployment) presenting as acute myocardial infarction 
[98]. Histological sections in LST cases revealed impaired stent endothelialization and thrombi 
formation [99]. 
Systemically delivered anti-proliferative drugs were promising in theory but failed to offer real 
clinical benefit, hampered by dose limitations from toxicity, short half-life and low local 
vascular concentrations [100]. However, the use of these agents inspired the next paradigm 
shift in stent technology, the drug eluting stent. To date this approach has been the most 
effective in reducing ISR but also introduced additional biocompatibility issues. 
1.3.5 The Drug eluting stent (DES) – Clinical benefit 
By using the stent as a drug carrying vehicle, sufficient levels of cyto-toxic agents can be 
delivered to the site of interest without risk of systemic contamination. DES consists of a 
metallic alloy backbone coated with a drug-impregnated permanent polymer. Serving as a 
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reservoir, the polymer controls the release of the drug. The sirolimus eluting Cypher stent 
(Cordis, Johnson and Johnson), followed soon after by the paclitaxel eluting Taxus stent 
(Boston Scientific) were shown to be markedly superior to bare metal stents (BMS) at reducing 
restenosis (Table 1.2) [101, 102]. Sirolimus was originally used in organ transplant patients as 
an immunosuppressant agent. In vitro studies demonstrated potent inhibition of VSMCs [103]. 
Sirolimus binds to the intracellular protein FKBP12. The Sirolimus-FKBP12 complex inhibits 
the mammalian target of rapamycin (mTor) leading to arrest of the cell cycle in the G1 phase 
[104]. Paclitaxel is an anti-neoplastic agent, inhibiting microtubule function, halting the cell 
cycle in the G0/G1 and G2/M phase [105]. Both drugs non-specifically target the proliferation 
of VSMCs. This non-specificity is one of the key contributors to the biocompatibility 
limitations of the DES platform. 
Table 1.2. Physical and drug elution properties of first generation DES. 
Stent FDA 
Approval 
Metal 
platform 
Strut 
thickness 
Polymer Polymer 
thickness 
Drug Release 
kinetic 
28 days 
Cypher 
(Cordis, 
Johnson and 
Johnson) 
2003 SS  140 µm 
PEVA 
PBMA 
Parylene  
12.6 µm Sirolimus 80% 
Taxus 
Express 
(Boston 
Scientific) 
2004 SS 132 µm SIBS 16 µm Paclitaxel <10% 
Adapted from Garg and Serruys, JACC 2010, [106] 
1.3.6 Drug eluting stent – Biocompatibility issues 
Anecdotal reports of DES thrombosis emerged soon after widespread clinical adoption [107, 
108]. Unlike the acute and subacute thrombosis seen in BMS, these reports detailed a 
phenomenon of stent thrombosis occurring years after stenting. Large studies showed that with 
the use of DAPT early stent thrombosis was less than 1% for BMS and DES [109]. A closer 
analysis of randomized DES trials revealed an increase in very late (>1 year) stent thrombosis 
(VLST) in both Taxus and Sirolimus eluting stents [110]. More worrying was that this risk 
appeared to persist at a rate of 0.35-0.6% annually [111-113]. 
The devastating clinical outcomes of DES thrombosis (mortality of 20-40% and myocardial 
infarction of 50-70% [114]) necessitated an urgent examination of DES hemocompatibility. 
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Premature cessation of DAPT, stent under-sizing, vessel dissection and complex coronary 
anatomy were clinical and procedural predictors of DES stent thrombosis [115]. 
The host reaction to the non-erodible polymer coatings and the detrimental impact of the cyto-
toxic agents on endothelial healing were found to be the critical biological reasons for DES 
stent thrombosis. Endothelialization of BMS struts occurs more rapidly than DES, reaching 
completion by 3 months [67]. In contrast, angioscopic studies of DES found incomplete stent 
endothelialization associated with thrombus [116, 117]. This was further support by high-
resolution optical coherence tomography (OCT) showing uncovered stent struts 2 years after 
implantation [118, 119]. 
Post mortem studies of patients with DES thrombosis found exposed struts surrounded by an 
abundance of fibrin clot [120]. Animal models have allowed the comparison of 
endothelialization between DES and BMS. Scanning electron microscopy (SEM) images of 
explanted rabbit iliac stents (day 28 post-implant) shows poorly endothelialized struts in 
sirolimus and paclitaxel eluting stents, with struts clearly visible. On the other hand BMS 
showed a complete and smooth layer of neo-intima with no visible uncovered struts (Figure 
1.6) [121]. Sirolimus and paclitaxel increase endothelial apoptosis, inhibiting endothelial 
migration and proliferation [122] thereby retarding the endothelialization of stent struts. 
Moreover, the endothelium adjacent to stented segments is dysfunctional, with an exaggerated 
vaso-constrictive tone secondary to reduced NO production [123]. Up regulation of TF is also 
evident [124]. 
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Figure 1.6. SEM images of explanted stents 28 days after deployment in rabbit iliac 
artery. Neointima can be seen covering all stents, however endothelialization above the 
stents in SES and PES remains poor with visible stent struts. Insets (x 200 
magnification) shows proximal and distal regions of stents. Thrombi and inflammatory 
cells can be seen. In contrast, BMS show very little clot and ongoing inflammation. 
Adapted from Joner et al, 2008 [121]. (SES = sirolimus DES, PES = paclitaxel DES, 
BMS = bare metal stents). 
Taxus and Cypher stents are coated with permanent poly(styrene-b-isobutylene-b-styrene) 
polymer and poly(ethylene co-vinyl acetate) + poly(n-butyl methacrylate) co-polymer, 
respectively, which are susceptible to damage under mechanical strain [106]. The expansion 
of a coronary stent exerts significant mechanical stress on the polymer coating. SEM images 
show that post expansion there is polymer peeling, flaking and cracking with exposure of the 
thrombogenic metal. Moreover, heterogeneity and roughness of the polymeric surface is seen 
with wrinkling and irregularities [125]. Loss of polymer integrity is an additional factor 
contributing to stent thrombosis. 
A range of adverse biological responses have been attributed to the polymer coating on DES; 
including hypersensitivity reactions, medial necrosis, vascular inflammation and 
hypereosinophilia [106]. Collectively these reactions contribute to stent thrombosis. 
Interestingly, long term follow up out to 5 years after DES implantation demonstrates a process 
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of delayed intimal hyperplasia. Progressive loss of luminal diameter is noted between 8 months 
and 5 years [126], a time frame longer than expected for restenosis. Continued inflammation 
to the permanent polymers may in fact stimulate ongoing neointima formation. 
Recommended duration of DAPT following stenting (BMS or DES) for acute coronary 
syndrome is one year based on data showing that prolonged thienopyridine treatment reduces 
major cardiovascular events, including death and myocardial infarction [127]. The optimal 
duration of DAPT to prevent stent thrombosis remains controversial. Finding the right balance 
between higher bleeding with DAPT and risk of stent thrombosis has proven challenging. A 
minimum one month duration of DAPT in BMS is based on the time for endothelial recovery 
from histological studies. Accordingly, with a more prolonged time noted for 
endothelialization after DES deployment an extended duration of DAPT is intuitive. Multiple 
studies have shown that discontinuation of DAPT less than one year is the most important 
contributor to stent thrombosis [115, 128]. These findings underpin current guidelines of one 
year of DAPT for DES [84]. However, the recently published 10,000+ patient DAPT 
randomised clinical trial suggests ongoing risk of stent thrombosis up to 30 months after 
implantation. Not surprisingly continuation of DAPT beyond one year to offset this continued 
risk was penalized by increased major bleeding [129]. 
The negative consequences of DAPT have been extensively reported in the context of studies 
and clinical experience. Randomized trials have demonstrated repeatedly that stretching DAPT 
beyond one year is associated with increased major and clinically significant haemorrhagic 
events [130]. Non-cardiac surgery presents a particularly challenging scenario. When aspirin 
alone versus DAPT was evaluated during the peri-operative period a much higher incidence of 
severe bleeding in DAPT patients was found [131]. On this basis, thienopyridines are typically 
terminated up to a week before surgery. Cessation of DAPT coupled with the hyper-coagulable 
peri-operative period has seen higher rates of stent thrombosis events occurring in the early 
post-operative period [132]. Bleeding and thrombosis remains an ever present challenge that 
continues to be unresolved in the current stent era. Underlying these issues are the 
biocompatibility shortcomings of the DES platform. 
1.3.7 Second generation drug eluting stents 
Everolimus (EES) and zotarolimus (ZES) DES have largely replaced Taxus and Cypher stents 
in contemporary clinical practice. Improvements in the stent material/design, polymer 
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composition and the eluted drug were made. The key physical and drug elution properties of 
EES and ZES eluting stents are summarized in Table 1.3. 
Globally, the composition of coronary stents has shifted away from stainless steel in favour of 
CoCr alloy. Used in the Xience (Abbott Vascular), Endeavor (Medtronic) and Resolute 
(Medtronic) stents, CoCr has the characteristics of exceptional radial strength and high elastic 
modulus [37], physical attributes which allowed for the development of thinner stent struts. 
Procedural benefits of thinner struts included enhanced deliverability and vessel 
conformability. Limited evidence suggests that a reduced stent footprint may in fact decrease 
vessel injury and intimal hyperplasia [133]. Thin struts may also confer a lower 
thrombogenicity profile; however reported studies are too small to be conclusive [134]. 
Purported biocompatibility improvements from the change in alloy and stent design remains 
largely theoretical. 
More recently, further evolution of 2nd generation DES has seen the adoption of platinum-
chromium (Pt-Cr) in the Promus element platform (Boston Scientific). Pt-Cr has robust radial 
strength, excellent corrosion resistant and endothelial adhesion along with superior radio-
opacity [135]. 
Table 1.3. Physical and drug elution properties of second generation DES. 
Stent FDA 
Approval 
Metal 
platform 
Strut 
thickness 
Polymer Polymer 
thickness 
Drug Release 
kinetic 
Xience V 
(Abbott) 
2008 CoCr 81 µm Fluoropolymer 7.6 µm Everolimus 
80% 
(28 
days) 
Endeavor 
(Medtronic) 
2008 CoCr 91 µm Phosphorylcholine 4.1 µm Zotarolimus 
95% 
(within 
14 days) 
Endeavor 
Resolute 
(Medtronic) 
2012 CoCr 91 µm 
Co-blend C10, 
C19, pyrrolidone 
4.1 µm Zotarolimus 
85% (60 
days) 
Adapted from Garg and Serruys, JACC 2010, [106] 
Efforts were made to design more biocompatible polymers in the 2nd generation DES, although 
polymers remained permanent i.e. not biodegradable. The Xience EES has a primer polymer 
and a top layer drug-polymer mix consisting of polyvinylidene fluoride-co-
hexafluoropropylene (PVDF-HFP). PVDF-HFP is highly hydrophobic due to fluorination of 
the carbon backbone. Preclinical testing found incorporation of fluorine reduced polymer 
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degradation, improved biocompatibility and limited platelet adhesion by increasing the ratio of 
adsorbed albumin/fibrinogen [136-138]. 
Using a biomimetic approach, the Endeavor stent is coated with a hydrophilic 
phosphorylcholine polymer. This lipid analogue mimics cellular membranes and conceptually 
enhances biocompatibility by cloaking the metallic alloy. Drug retention was however poor 
with 95% of the drug dispersed within 14 days [106]. Insufficient attenuation of intimal 
hyperplasia was reported in clinical trials [139]. Rectifying this, the Endeavor Resolute ZES 
incorporated a blend of hydrophilic and hydrophobic polymers, consisting of C-10 
(hydrophobic butyl Methacrylate), C-19 (methacrylate, pyrrolidone, and acetate monomer) and 
hydrophilic polyvinyl pyrrolidone [140]. The hydrophobic component extended drug release 
over a longer 180 days. Pyrrolidone was used to maintain a hydrophilic interface to the blood 
stream [141]. Hydrophilic surfaces are resistant to protein adsorption and the adsorbed proteins 
retain a more native conformation. [142, 143]. In vitro monocyte adhesion and activation were 
reduced on this combination polymer platform [144]. 
Improvements to the eluted drug were also made. Zotarolimus and everolimus are analogues 
of sirolimus and work similarly to target the mTor. These new analogues were designed to 
enhance elution characteristics by increasing lipophilicity. Movement of the drugs across the 
cell membranes was more efficient and helped to reduce systemic contamination [145, 146]. 
Pre-clinical studies of 2nd generation DES suggested that the enhancements in stent design 
improved biocompatibility. Reductions in inflammation and thrombogenicity, better 
endothelial adhesion and more complete strut endothelialization [147] were described. EES 
and ZES yielded similar levels of endothelialization in a 13 month OCT study with 92.6 to 94.2 
% of stent struts covered with endothelium [148]. Despite more complete endothelial healing, 
a small percentage of stent struts remained exposed. 
The clinical efficacy of 2nd generation DES in the prevention of ISR has being well established. 
Multiple trials corroborated an unequivocal advantage over BMS [149, 150], superiority over 
Taxus stents [151, 152], a similar effectiveness to Cypher stents [153, 154] and comparable 
competence between EES and ZES [155, 156]. 
Demonstrating that pre-clinical improvements in biocompatibility translated into clinically 
meaningful reductions in stent thrombosis, myocardial infarction and mortality has been 
challenging. In fact, an advantage over 1st generation DES has not been definitively established 
48 
in individual studies. What can be gleaned from the data is that in randomized studies of 2nd 
generation DES, the incidence of stent thrombosis was very low and numerically better than 
the 1st generation [157-159]. A major limitation to these studies is that they were not powered 
by sufficient patient numbers to determine statistical superiority [160]. Using meta-analysis 
investigators have attempted to draw more convincing conclusions from aggregated trial data. 
Among all DES the EES (Xience) platform has consistently shown a lower incidence of stent 
thrombosis [161, 162]. 
DAPT has significantly reduced the incidence of stent thrombosis across all stent types [129] 
making statistically meaningful comparisons of stent thrombosis on DAPT problematic. The 
thrombogenicity potential of various stent platforms may be masked by broad DAPT use in 
stent trials. As an alternative, shifting the ‘goal post’ by shortening the duration of DAPT helps 
to evaluate stent thrombogenicity in a more stringent manner. Clinical trials with mandated 
DAPT use of 3 to 6 months have taken this new approach in assessing stent thrombosis [163, 
164]. Ultimately, the goal of hemocompatibility advancements is to have a stent platform 
needing a very short period of DAPT or none at all. 
1.4 Beyond drug eluting stents: Alternative approaches and strategies 
1.4.1 Polymer-free drug eluting stents 
Following stent implantation, the fibro-cellular response leading to intimal hyperplasia is 
largely complete by 6 months [165]. Theoretically drug elution needs only to cover this period, 
beyond which the ongoing presence of a polymer/drug delivery system serves no function. 
Observations that permanent polymers may induce inflammation and hypersensitivity 
reactions has led to innovative designs with polymer free drug delivery (Table 1.4). 
The VESTA-sync stent is constructed from stainless steel and uses a microporous 
hydroxyapatite coating to elute sirolimus (Figure 1.7). Hydroxyapatite undergoes complete 
dissolution in 9 to 12 months, while elution of sirolimus is complete within 4 weeks [166]. 
Preliminary results from the Vestasync II trial comparing Vestasync to BMS reported an 8 
month in-stent late loss of 0.39 mm for VESTA-sync compared with 0.74 mm with BMS [167]. 
These promising results will need to be examined in larger studies. 
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Figure 1.7. Scanning electron microscopy of the hydroxyapatite coating on the 
Vestasync stent. 
The CoCr Amazonia PAX stent (Figure 1.8A) employs a micro spray crystallization process 
to deposit paclitaxel onto the abluminal surface. A relatively rapid drug elution occurs within 
45 days [168]. The PAX A trial randomizing 30 patients to the Amazonia stent or Taxus stent 
reported 4 month results showing similar in-stent late loss between the two stent groups [169]. 
The abluminal surface of the stainless steel Biofreedom stent (Figure 1.8B) is treated with a 
microabrasion method to create a textured surface [168]. Biolimus A9, a highly lipophilic 
rapamycin analogue is then coated onto the surface [170]. 12 months angiographic follow up 
from the BIOFREEDOM First In Man (FIM) trial found non-inferiority in in-stent late loss 
between the Biofreedom stent and the Taxus stent [171]. Recently announced data from the 
LEADERS FREE trial comparing Biofreedom to a BMS in high bleeding risk patients with 
one month of DAPT found the Biofreedom stent to be both more effective (reduction in target 
lesion revascularization) and safer (lower cardiac death, myocardial infarction or stent 
thrombosis events) [172]. 
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Figure 1.8A. SEM showing spray deposited paclitaxel on the surface of an Amazon PAX 
stent. Figure 1.8B. SEM of a Biofreedom stent showing microabrasions. 
The Yukon DES also has a microporous surface created by mechanical treatment of the 
stainless steel stent [173]. Sirolimus is sprayed on in the catheterization suite, using a 
proprietary coating methodology. The majority of the drug is eluted in the first 6 days followed 
by a prolonged release over 21 days [174]. Results from the ISAR-TEST 3 comparing the 
Yukon and Cypher stent found inferior late loss results [175]. Inadequate control of restenosis 
was likely due to the short drug elution time. 
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Table 1.4. Physical and drug elution properties of polymer free drug eluting stents. 
Stent CE Approval Metal Surface Modification Strut Thickness Drug Release Kinetic 
VESTASYNC 
(MIV THERAPEUTICS) 
Pending SS Hydroxyapatite coating 65 µm Sirolimus 100% (90 days) 
AMAZONIA PAX 
(MINVASYS) 
Yes CoCr Microdrop spray crystallization 73 µm Paclitaxel 98% (30 days) 
YUKON 
(TRANSLUMINA) 
Yes SS Abluminal microporous surface 87 µm Sirolimus 100% (25 days) 
BIOFREEDOM 
(BIOSENSORS) 
Yes SS Abluminal microporous surface 119 µm Biolimus 90% (50 hours) 
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1.4.2 Biodegradable polymer DES 
An alternative to polymer free drug elution is to use a biodegradable polymer, delivering more 
controlled drug release while leaving behind a bare metallic scaffold. These polymers are 
primarily composed of lactic acid/lactide analogues. Differences between stents in this 
category include the eluted drug, kinetics of elution and the degradation time for the polymers. 
Key properties of these stents are summarized in Table 1.5. 
The Biomatrix Stent is a stainless steel platform coated with polylactic acid eluting biolimus, 
a sirolimus analogue. By applying the coating only to the stent’s abluminal surface (as opposed 
to the entire stent surface), drug release is more localized towards the vessel wall [176]. Full 
degradation of the polymer occurs over 9 months. In the randomized LEADERS trial 
comparing Biomatrix stent to the Cypher stent at 12 month follow-up, the composite primary 
endpoint (cardiac death, myocardial infarction and target vessel revascularization) was non-
inferior in the Biomatrix group versus the Cypher group [177]. Clinical follow up to 3 years 
reveal a trend towards lower MACE (major adverse cardiac events) in Biomatrix stent group 
(Biomatrix 15.7% vs 19% Cypher; P for superiority = 0.09) with cumulative VLST rates 
remaining low at 0.2% [177]. 
Using a similar strategy to the Biomatrix stent, the Nobori stent adds an ultra-thin non-
degradable parylene coating between the stent and polylactic acid to improve polymer 
attachment. One year clinical data from a 3068 patient all-comers registry reported excellent 
efficacy and safety results with target lesion failure of 3.6% and MACE of 4.8% [178]. The 
Nobori stent will be further evaluated in the SORT-OUT V trial (vs Cypher), COMPARE II 
(vs Xience), SECURITY (vs Resolute with 6 month DAPT arm and 2 month DAPT arm) and 
BASKET PROVE 2 (vs ProKinectic and Xience) clinical trials. 
The Supralimus sirolimus eluting stent utilizes two biodegradable coatings on a stainless steel 
stent platform. The undercoat consists of a matrix of poly-L-Lactic acid, poly-DL-lactide-co-
glycolide and polyvinyl pyrrolidone intermixed with 1.4 mcg/mm2 of sirolimus. A top coat of 
polyvinyl pyrrolidone prevents early release of the drug. Complete polymer degradation occurs 
over 7 months. Two year data from the acute coronary syndrome E-Series registry reported 
reassuringly low stent thrombosis rates of 0.6% [179]. The Series III trial, currently in progress, 
will evaluate the Supralimus against the Xience stent. Supralimus and Supralimus–Core using 
a thinner CoCr platform have recently received European CE Mark. 
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Eluting paclitaxel, the Infinnium stent utilizes the same platform as the Supralimus stent. The 
polymers are mixed with paclitaxel in various ratios to form three layers with distinct fast, 
medium and slow release kinetics. A good safety and efficacy profile was shown in the non-
randomized SIMPLE II registry [180]. The Supralimus stent had superior angiographic but 
equivalent clinical results to the Infinnium stent [181]. 
The Yukon Choice PC stent is a biodegradable polymer stent which has been compared against 
2nd generation DES. The stent platform is based on the Yukon stent. A proprietary 
biodegradable matrix (degrades in 6-9 weeks) eluting sirolimus is applied prior to deployment 
in the catheterization suite. ISAR-4 was a clinically driven randomized study evaluating the 
Yukon Choice against Cypher and Xience stents. MACE at 1 year was comparable between 
the 3 stents. Cardiac death, myocardial infarction, target lesion revascularization (TLR), and 
stent thrombosis was not significantly different [182]. Efficacy and safety remained similar 
between the stents in a recent report of 3-year results [183]. 
Unique to the JACTAX stent, a polylactide coating is deposited in a microdot fashion (Figure 
1.9) to minimize the amount of polymer. Paclitaxel is eluted over a period of 90 days, with 
polymer degradation over 6 months. Non-inferiority in MACE, TLR compared to historical 
data from the Taxus Atlas trial was reported in the FIM JACTAX HD trial (HD = higher dose, 
9.2 μg each of drug and polymer per 16-mm stent) [184]. The OCTDESI OCT study examined 
the degree of stent strut coverage at 6 months in 60 patients randomized to JACTAX HD, 
JACTAX LD (LD= lower dose 5 μg of drug), and Taxus Liberte stents. No increase in 
endothelialization was reported in either dosing of the JACTAX stent over Taxus [185]. 
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Figure 1.9. JACTAX stent. SEM showing microdot polymer deposits on the stent 
surface. 
The Costar stent has struts with reservoirs filled with polylactide-co-glycolide eluting 
paclitaxel over 30 days [186] (Figure 1.10). Placement of the polymer within the reservoirs 
helps to minimize polymer contact with the vessel wall. Initial trials showed promising efficacy 
and safety data [187-189]. However, disappointing results from the pivotal Costar II trial [190] 
against the Taxus stent spelt the end of the platform. Suboptimal performance was likely due 
to the lower dose of paclitaxel used and the short-release kinetics. 
 
Figure 1.10. Polymer filled reservoirs in the Costar star. 
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Table 1.5. Physical and drug elution properties of biodegradable polymer drug eluting stents. 
Stent CE Approval Metal Polymer Strut thickness Drug Release kinetic 
Biomatrix 
(Biosensors) 
Yes SS Abluminal PLA 112 µm Biolimus 45% (30 days) 
Nobori 
(Terumo) 
Yes SS Abluminal PLA 112 µm Biolimus 45% (30 days) 
Supralimus 
(Sahajanand Medical) 
Yes SS PLLA-PLGA-PVP 80 µm Sirolimus 100% (48 days) 
Infinnium 
(Sahajanand Medical) 
Yes SS PLLA-PLGA-PVP 80 µm Paclitaxel 50% (9-11 days) 
 Yukon Choice PC 
(transluminal) 
Yes SS PLA - Shellac 87 µm Sirolimus 90% (30 days) 
Jactax 
(Boston Scientific) 
Yes SS Microdot Abluminal PLA 97 µm Paclitaxel 100% (60 days) 
Costar 
(Conor Medsystem) 
Yes CoCr PLGA in reservoir 127 µm Paclitaxel >90 % (30 days) 
PLA (Polylactic acid), PLLA (Poly-L-Lactic acid), PLGA (Poly-lactide-co-glycolide), PVP (polyvinylpyrrolidone). 
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To date, the potential biocompatibility advantages of degradable polymer stents have not been 
conclusively demonstrated in clinical trials. Most studies have been relatively small and based 
on surrogate angiographic endpoints as opposed to hard clinical end points. While the ISAR-
TEST 3 and ISAR-TEST 4 demonstrated comparable efficacy and safety to 1st and 2nd 
generation DES, superiority in safety was not shown. In an attempt to address inadequately 
powered individual trials a recent meta-analysis by Bryne et al [191] of pooled 3 year data from 
the LEADERS, ISAR-TEST 3 and ISAR-TEST 4 trials encompassing 4000 patients found a 
significant reduction in stent thrombosis in the biodegradable polymer group compared to the 
non-erodible polymer group. A reduction in the composite clinical end points (cardiac death, 
myocardial infarction, TLR) was also noted in the biodegradable polymer group (18.2% vs 
20.1%, P=0.04). This was largely due to a reduction in TLR. While the findings from this meta-
analysis is encouraging, data from single large-scale randomized studies are needed to consider 
this platform as a replacement for the current generation of DES. 
1.4.3 Biodegradable stents 
Recent efforts have sought to construct the entire stent from biodegradable material. The aim 
is to deliver a temporary scaffold supporting the vessel when needed and then to have the 
scaffold degrade to leave a healed and remodelled vessel. LST although rare can occur with 
BMS especially with discontinuation of aspirin [192] reflecting the persistent thrombotic risk 
of a permanently present metallic prosthesis. One key attraction of a biodegradable scaffold is 
the potential to eliminate the risk of VLST. 
A biodegradable stent (BDS) has a number of theoretical benefits including: 1) removal of the 
reliance on long-term anti-platelet therapy 2) elimination of the negative impact of a rigid 
metallic scaffold on vasomotor tone 3) maintenance of future bypass surgery targets and 4) 
ensuring safety for MRI imaging [193]. Challenges in the development of this platform include 
having sufficient structural strength to resist vessel recoil, maintaining structural integrity as 
the stent starts to degrade [194], developing an appropriate time frame of degradation, having 
sufficient radio-opacity and minimizing inflammatory response to the polymer. Table 1.6, 
summarizes the key properties of some BDS in development. 
Polylactide (PLA), the main polymer used in BDS undergoes hydrolysis, breaking down into 
carbon dioxide, lactic acid and water. [193]. In animal models reasonable short term (1 month) 
radial strength was demonstrated. As degradation occurred, favorable vascular 
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biocompatibility and low toxicity was shown [195]. The Igaki-Tamai PLA stent (Figure 1.11) 
was the first polymeric BDS. In a 15 patient FIM study over a 6 month period, acute recoil was 
absent, comparable restenosis rates to BMS was observed and satisfactory safety with no 
MACE or stent thrombosis was reported [196]. A larger 50 patient trial demonstrated complete 
resorption of the stent, a low subacute and LST rate and TLR of 12.7% at 1 year. The main 
impediment to the Igaki-Tamai stent has been over its method of deployment. Prior to 
deployment, heating to 65-75 °C is necessary for stent expansion leading to concerns of arterial 
wall necrosis and acceleration of neointimal hyperplasia [197]. 
 
Figure 1.11. Translucent polylactide struts of the Igaki-Tamai stent. 
To date the most investigated BDS stent is the Abbot Vascular biodegradable stent (BVS) 
(Figure 1.12). Consisting of a PLLA backbone, the BVS elutes a sirolimus analogue, 
everolimus. To achieve sufficient radial strength thicker 150 μm stent struts are needed. At 1 
year no TLR and a MACE of 3.3% was reported [198]. The 6 month late loss [198] was higher 
than the metallic equivalent Xience stent [151], due to a progressive loss of radial strength with 
breakdown of PLLA. [198] Encouragingly at 2 years there was no further late catch up in late 
loss and full stent strut resorption was noted [199]. 
A redesigned stent geometry (in-phase zig zag hoops linked by bridges, BVS version 1.1) was 
used to provide more uniform and sustained radial support. Angiographic follow up at 6 months 
of 45 patients reported a more reassuring late loss of 0.19 mm. A larger 1000 patient Absorb 
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Extended trial is currently in progress to further evaluate the BVS in patients with more 
complex coronary lesions. 
 
Figure 1.12. Abbot vascular BVS biodegradable stent. 
A competing biodegradable scaffold technology is the Reva stent, composed of tyrosine 
polycarbonate which degrades into water, carbon dioxide and ethanol in approximately 2 years 
[200]. Unique features include radio-opacity from incorporation of iodine and a slide and lock 
stent design. The FIM RESORB study found disappointingly high rates of TLR at 4 – 6 months 
[201]. Improvement in polymer strength, stent geometry and incorporation of sirolimus elution 
was made for the next generation ReZolve stent. Preliminary data from the FIM experience 
reported a respectable 12 month late loss of 0.2 ± 0.19 mm [202]. Moving ahead the company 
has made rapid refinements with the ReZolve2 stent (lower profile with improved radial 
strength) and the Fantom stent (thinner stent struts and improved deliverability) is currently 
undergoing clinical evaluation. 
A number of unresolved issues remain for BDS. Mechanical requirements confine strut 
thickness to that thicker than contemporary CoCr or Pt-Cr alloy stents. Deliverability of the 
stents in more tortuous, narrow and calcified vessels may be a challenge. The ostia of side 
branches appear to be at greater risk of being obstructed by the struts (jailed) of biodegradable 
scaffolds [203]. Furthermore, balloon dilatation through the cells of BDS to optimize side 
branch patency is contraindicated due to risk of disruption to scaffold integrity. Full resorption 
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of current polymeric BDS requires years, delaying the benefits of a stent free artery [204]. In 
addition, the dependence on sirolimus analogues to curb intimal hyperplasia can still impair 
endothelialization. More concerning, is recently released results from the large GHOST-EU 
registry (Abbot BVS stent) in real world patients showing a cumulative stent thrombosis rate 
of 2.1% at 6 months. The majority of the stent thrombosis events occurred in the first 30 days, 
bringing into question the biocompatibility of PLLA before full resorption [205]. 
Clinical studies for metallic bioresorbable stents are relatively limited compared to polymer 
based stents. The most progress has been made with the magnesium alloy, Absorbable Metal 
Stent (AMS, Biotronik), which degrades through biocorrosion with minimal inflammation 
[206, 207]. Radial strength is comparable to that of stainless steel stents with low initial elastic 
recoil. Unlike polymeric scaffolds, the magnesium alloy stent has the added advantage of 
expanding beyond nominal size. The first clinical experience in 63 patients was less than 
impressive with high rates of clinically driven TLR of 26.7% at 12 months [208]. These 
suboptimal results can be attributed to the rapid loss of radial strength with faster than expected 
in vivo degradation of the alloy [209]. Undeterred by this, revisions to the strut thickness and 
stent geometry have been made in the 2nd AMS stent with improved radial support [210] 
(Figure 1.13). 
 
Figure 1.13. In vivo degradation of AMS-1 versus AMS-2 at 2 weeks. Stent integrity is 
noticeably improved in the AMS-2 stent. 
Recently this new platform was combined with paclitaxel drug elution via a biosorbable 
polylactic-coglycolic acid polymer in the DREAMS stent. The FIM study (BIOSOLVE-1 
trial), found a high procedural success rate coupled with a target lesion failure rate of 7% at 12 
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months. However, a late lumen loss higher than contemporary DES was reported [211]. The 
second generation of the DREAMS stent with sirolimus elution is currently been evaluated in 
the BIOSOLVE-2 trial. 
Table 1.6. Physical and drug elution properties of biodegradable stents. 
Stent CE Approval Polymer Strut thickness Drug 
Resorption 
time 
Igaki-Tamai 
(Kyoto Medical) 
Yes PLLA 170 µm None 24 months 
BVS 1.0 
(Abbott Vascular) 
NO 
PLLA 
Horizontally 
linked 
circumferential 
out of phase 
zigzag hoops  
157 µm Everolimus 24 months 
BVS 1.1 
(Abbott Vascular) 
Yes 
PLLA 
Horizontally 
linked in phase 
zigzag hoops 
157 µm Everolimus 24 months 
REVA 
(REVA Medical) 
No 
Poly-tyrosine 
polycarbonate  
200 µm None 24 months 
ReZolve 
(REVA Medical) 
No 
Poly-tyrosine 
polycarbonate 
114 - 228 µm Sirolimus 24 months 
(Fantom) 
(Reva Medical) 
Pending 
Poly-tyrosine 
polycarbonate 
Next generation 
ReZolve stent 
Approximately 
50% reduction in 
strut thickness of 
ReZolve stent. 
Sirolimus 24 months 
AMS –1 
(Biotronik) 
Pending Mg 165 µm No < 4 months 
Dreams 
(Biotronik) 
Pending  Mg 125 µm 
Paclitaxel 
(1st 
generation) 
Sirolimus 
(2nd 
generation) 
> 4 months 
 
1.4.4 Stent surface treatment 
Stent biocompatibility can be viewed as a surface phenomenon. The surface of the stent is the 
interface between the body and the implant. Corrosion resistance and chemical stability of the 
surface in the in vivo aqueous environment prevents inflammation and adverse host reactions 
[212]. Even more important, the chemical-physical properties of the surface determine the 
composition and structural orientation of physisorbed plasma proteins. This surface protein 
layer determines how a biomaterial interacts with in vivo protein–cellular systems [213]. 
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Modifying the surface chemistry can modulate the process of protein physisorption potentially 
leading to improved biocompatibility. Alternatively, the surface can be functionalized with 
bioactive molecules or chemical functional groups that could direct cellular and protein 
reactions. Importantly, surface modification alone has the added advantage of preserving the 
mechanical properties of the stent body material. 
1.4.4.1 Inert surface coatings 
High cellular concentrations of chlorides found in vivo is corrosive for metals [214]. 316L SS 
has a chromium oxide film which is susceptible to chemical reduction reactions leading to 
pockets of corrosion [215]. Inert coatings have been used in an attempt to enhance corrosion 
resistance and hemocompatibility of the bulk material. Gold was initially used due to its 
chemical inertness and good in vitro biocompatibility [216]. However, the lack of effect on 
restenosis meant this coating was soon abandoned [217, 218]. 
1.4.4.2 Antithrombotic surface coatings 
Heparin, a polysaccharide which exerts anti-coagulant effects through binding to anti-
thrombin, has been coated onto a variety of materials. Once bound to heparin, anti-thrombin 
undergoes a conformational change greatly increasing the efficiency of factor Xa inhibition. 
Heparin-bound surfaces have seen commercial success in vascular grafts and tubing for 
extracorporeal circulations [219, 220]. Registry studies of heparin-coated stents reported low 
rates of stent thrombosis with single-agent antiplatelet therapy [221]. Nonetheless in 
randomized studies heparin-coated stents performed poorly in regulating intimal hyperplasia 
[222, 223]. 
1.4.4.3 Pro-healing surface coatings 
Current explorations in new stent designs have not departed from the use of cytotoxic agents 
to curb restenosis. A fundamental short coming of this approach is the impediment of 
endothelial recovery. Endothelialization appear to be more rapid with 2nd generation DES 
however slower than BMS. Histological studies show stent thrombus is strongly associated 
with non-endothelialized struts [120]. Increasingly, attention has turned to novel proactive 
strategies that encourage healing of the endothelium. 
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A completely endothelialized stent is shielded from platelets, white cells, complement and the 
coagulation system rendering it an integral part of the vascular wall. Sirolimus and paclitaxel 
inhibit endothelial cell mTor and microtubules, respectively, impacting on cell viability and 
function [224, 225]. Critically, reconstituted endothelium following DES implantation remains 
dysfunctional with reduced vascular endothelial growth factor (VEGF) and NO release and 
have inadequately formed cell-to-cell junctions [226]. Preclinical models demonstrate 
endothelial function and recovery have been improved with 2nd generation DES [121]. Despite 
this some residual dysfunction may still be present with 2nd generation DES. Following 
acetylcholine stimulation EES were found to have a numerical higher, although statistically 
non-significant degree of vasoconstriction compared to BMS [227]. Pathology studies, have 
shown improved endothelialization and total stent coverage with EES over 1st generation DES. 
However, 2.6% of the stent struts were not covered by endothelium and [228] could 
conceivably still present a thrombogenic nidus. 
Confluent and functionally normal endothelium is important for modulation of intimal 
hyperplasia. A number of studies highlight the importance of the endothelium in the regulation 
of VSMCs. The degree of neo-intima formation correlates with the amount endothelial 
denudation, with increasing thickness the more pronounced the damage [229]. Moreover, 
endothelial regeneration over the injured vasculature retards VSMC proliferation and 
extracellular deposition [230]. Secretion of NO maintains VSMC in a quiescent phenotype 
[231]. Taken together the endothelium plays a vital role in the modulation of VSMCs. 
Persistent endothelial dysfunction may be causally related to the phenomenon of accelerated 
atherosclerosis associated with neo-intima. Suspicion of a different restenosis process arose 
when a constant rate of repeat target vessel revascularization following DES implantation was 
seen out to 5 years [232]. Virtual histology IVUS showed the presence of both calcification 
and necrotic core in the neo-intima [233]. Pathological assessment of sirolimus eluting stents 
and BMS found foamy lipid rich macrophages and neo-atherosclerotic changes more prevalent 
in DES. [234]. ‘Leaky’ poorly formed endothelial junctions may lead to lipoprotein 
extravasation into the subendothelial space [226]. OCT studies show some VLST events may 
be caused by ruptured neo-atheroma [235]. 
Reconstitution of the endothelium was once thought to be solely from the migration and 
proliferation of adjacent healthy endothelium. It is now believed to be at least in part from 
circulating endothelial progenitor cells (EPCs) [236]. Asahara et al [237] first proposed the 
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existence of bone marrow-derived circulating EPCs which can be mobilized to the site of 
vascular injury contributing to endothelial healing. High levels of circulating EPCs have been 
correlated with vascular health and associated with reduced cardiovascular events [238]. 
Elevation in circulating EPCs is seen in response to ischemia [239] and following PCI [240]. 
A reduction in intimal hyperplasia is observed when a robust number of circulating EPCs are 
present [241]. Collectively, these findings implicate EPCs in the maintenance and repair of the 
vasculature. 
Two broad populations of EPCs have been identified based on the time of emergence from ex-
vivo culture. The ‘early’ EPC, a monocyte-derived cell, modulates angiogenesis and 
vasculogenesis through paracrine function. The ‘late’ EPC or outgrowth endothelial cell (OEC) 
is derived from a primitive endothelial lineage and is characterized by high proliferative 
capacity and integrates directly into the reconstituting endothelium [242]. Efforts to exploit late 
outgrowth EPCs in vascular medicine have yielded some promising preclinical findings. 
Infusion of autologous OECs following iatrogenic endothelial injury decreased intimal 
hyperplasia, enhanced endothelial vaso-reactivity with integration into the repairing 
endothelium [243, 244] When OECs were seeded onto de-cellularized arterial segments and 
grafted on to sheep carotid artery, accelerated development of a complete endothelial 
monolayer was noted with high long term patency rates [245]. 
Recently investigators have attempted to leverage EPCs to speed up endothelial coverage of 
stents. Initial attempts at seeding autologous EPCs on to stents in vitro were not fruitful. This 
approach was limited by poor cell adhesion and damage following balloon expansion [246]. 
The Genous EPC capture stent (OrbusNeich Medical) employs murine monoclonal anti-human 
CD-34 antibodies coupled to a polysaccharide coating to capture EPCs. Preclinical studies 
showed promising results with reduced thrombogenicity, enhanced surface EPC localization 
and increased endothelialization when compared to BMS [247]. Registry data demonstrated a 
satisfactory safety profile, with absence of stent thrombosis with only 1 month of DAPT. 
However, in a randomized head-to-head clinical trial versus the Taxus stent, the Genous stent 
had significantly higher rates of TLR [248]. These disappointing results were further mirrored 
by a larger study against a broad range of DES. This later trial was terminated early due to 
unacceptably high target lesion failure [249]. 
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Following on from these disappointing results, a revised Genous stent (Combo stent) has been 
released, combining EPC capture with sirolimus drug elution from a biodegradable polymer. 
Recent results from a randomized trial against the Taxus stent demonstrated non-inferior rates 
of angiographic restenosis, low rates of complications and no stent thrombosis [250]. These 
findings will need to be validated across a broader population of patients. 
Failure of the Genous stent to make a meaningful reduction in restenosis does not necessarily 
invalidate the pro-healing strategy. Anti-CD34 is non-specific for EPCs. EPCs are a 
heterogeneous group of cells with overlapping surface markers. To date, no unique set of 
surface markers can definitive identify an EPC [251]. Furthermore, the CD34 marker can be 
found on a variety of cells including primitive hematopoietic cells [252] and mature endothelial 
cells [253]. Therefore, EPCs only represent a small fraction of the cells bearing CD34+. Taken 
together, the effectiveness and specificity of CD34+ based EPC capture is uncertain. It is likely 
that a rather heterogeneous group of cells is captured on to the stent surface, with varying 
contributions to endothelialization and modulation of VSMC activity. 
1.5 Plasma modification of biomaterial surfaces 
The physical and engineering requirements of coronary stents have largely confined material 
choice to metallic alloys. Even though biodegradable materials are currently under 
investigation, widespread adoption of polymer scaffolds as a replacement for metal is some 
time away. Metallic alloys while mechanically sound are hampered by their inherent 
thrombogenicity. 
Chemically tailored and/or functionalized surface coatings can be designed to have low 
thrombogenicity coupled with biological and cellular modulation. Previously used inert 
coatings such as gold have largely been directed towards improving corrosion resistance and 
in part thrombogenicity. A coating platform that aims to improve thrombogenicity along with 
enhancing endothelialization would provide a more complete approach to stent 
biocompatibility. 
Plasma (ionized gas) treatment of biomaterials can be broadly divided into two approaches, 1) 
The use of plasma bombardment to alter polymer surfaces 2) The use of plasma to deposit thin 
‘plasma polymer’ films on to substrates. Both approaches promote the chemical-physical 
modification of the biomaterial surface without altering the mechanical properties of the bulk 
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material. Advantages of plasma treatment over physically abrasive and wet chemical processes 
include the ability to treat substrates of varying three-dimensional geometry, relative simplicity 
of the process, applicability to a wide range of materials and targeted modification of 
chemical/physical characteristics of the surface. 
Plasma is considered the 4th state of matter (Figure 1.14). It is generated when energy is applied 
to a gas displacing electrons from atoms, leading to formation of charged ions and radical 
species. These energized ions and electrons initiate a cascade, colliding with more atoms 
resulting in an ionized gas (plasma). 
 
Figure 1.14. Schematic diagram representing the 4 states of matter (Top panel). Plasma 
glow discharge seen in a plasma chamber (bottom panel). 
An electrical potential (between two electrodes) is commonly used to provide energy for 
creation of gaseous plasmas. The gas pressure (low versus atmospheric) and the power of the 
electric field can be changed to generate different plasmas. Atmospheric systems (the pressure 
of gasses are atmospheric) have the advantage of not requiring expensive and complex vacuum 
pump systems but is limited by the non-uniformity of the plasma produced and the substantially 
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higher voltages required for plasma generation [254]. Corona discharge, dielectric barrier 
discharge and plasma jet are some examples of atmospheric systems. 
Low-pressure plasmas, require less electric potential to generate a plasma. The plasma is 
uniform with consistent electron density [255]. This technique has been found to have a broad 
role in biomaterial applications and will be the focus of discussion herein. One of the most 
common sources of low-pressure plasma is radiofrequency glow discharge plasma. Here the 
current discharge by the electrodes is within the radiofrequency range, typically 13.56 MHz 
Uniformity and stability of the plasma are the main advantages of these systems [255]. 
When a material is exposed to plasma the energetic particles impact the surface leading to 
changes in the chemical and physical properties [256]. The type of ions and radicals present 
will depend on the gases used in the plasma; this in turn will govern how the surface is 
modified. The effect of plasma treatment with inert or non-organic gases on the material surface 
can be grouped into four main categories 1) introduction of chemical functional groups 2) cross 
linking of polymer chains 3) alteration of surface roughness and 4) surface graft polymerization 
[257]. Together these changes can affect surface wettability, chemical constitution, charge and 
structural make up. Furthermore, reactive functional groups and/or radicals on the surface can 
act as anchor points for covalent attachment of ECM proteins [258] or anticoagulant molecules 
[259]. 
Introducing chemical functional groups into the surface layer of a biomaterial can effectively 
transform an otherwise inert surface into a bioactive one. When polymers are exposed to 
oxygen plasma an increase in surface oxygen moieties such as carbonyl, carboxyl and hydroxyl 
groups [260] occurs. Oxygen functionalized polystyrene polymer show improved epithelial 
adhesion [261]. PTFE, a very hydrophobic polymer commonly used in vascular grafts has poor 
cell adhesion. Ammonia gas plasma treatment leads to a significant increase in wettability 
(water loving) of PTFE with an increase in endothelial attachment and proliferation [262]. 
Additional chemical and structural changes from plasma treatment include cross-linking of the 
polymer. Free radicals and polymer chain scission can occur in the polymer surface when 
exposed to ionic bombardment. Crosslinking bonds developing between these active sites leads 
to formation of a denser three-dimensional network and an increase in surface mechanical 
strength [257]. A more precise but complex method of tailoring surface chemistry is using graft 
polymerization. The first step uses plasma treatment to activate the surface with reactive 
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radicals, subsequently a spacer molecule like acrylamide is attached covalently to the surface 
via radical reactions. The free end of the spacer molecule can be functionalized with cell 
adhesive molecules/fragments such as collagen or RGD (Arg-Gly-Asp) [263]. 
Biomedical applications of plasma treated polymers have been confined to vascular grafts, 
conduits and dialysis tubing [264, 265]. In contrast metallic materials are not easily modified 
with plasma treatment. The technique of plasma polymerization uses plasma assisted 
deposition of thin organic films to achieve a unique surface chemistry distinct from the metallic 
substrate. This method helps to circumvent the otherwise difficult task of surface modification 
of metals with plasma bombardment alone. Key to plasma polymerization is the use of carbon 
donor gases in the plasma. Ethylene, acetylene, benzene and methane are commonly used. 
These monomer gases are fractured into free radical fragments, which subsequently recombine 
on the substrate surface into rearranged and highly crossed linked units. The thin films can be 
deposited onto both two and three dimensional geometries with robust adhesion [266]. Similar 
to plasma treatment of polymers the use of different gas combinations can introduce distinct 
surface chemical functional groups [267]. Additionally, the deposited thin films can be 
produced with a high concentration of free radicals, resulting in a bioactive surface, radically 
different physically and chemically from the underlying substrate [268]. 
1.6 Biomolecular functionalization of surfaces 
1.6.1 Elastin 
Plasma treatment of polymers and plasma polymerization can generate surfaces that are rich in 
free radicals. These surfaces can be used to bind directly or via spacer groups a range of 
bioactive molecules that can regulate local cellular activity. One such molecule is tropoelastin, 
a precursor of elastin. Elastin is the dominant component in elastic tissue providing mechanical 
and cell signalling function [269]. Elastin has a critical role in regulating VSMC function as 
evidenced by the premature death of elastin null mice from uninhibited smooth muscle cell 
proliferation and occlusive arterial disease [270]. Elastin appears to modulate VSMC activity 
by maintaining the cells in a quiescent state [271]. Collagen and fibronectin are abundant ECM 
proteins with strong cellular adhesion. However their use as vascular biomaterials are limited 
by high thrombogenicity [272] [273]. In contrast, evidence points to elastin having low 
thrombogenicity. Various forms of elastin, including decellularized elastin fibers [274], elastin 
scaffolds [275] and elastin based peptides [276] decrease platelet adhesion, aggregation and Fg 
68 
adsorption. Extracting elastin for study and biomedical application has been challenging. 
Historically elastin was harvested using complex chemical techniques from bovine, porcine 
and equine ligaments and aorta [277]. 
1.6.2 Tropoelastin 
Tropoelastin, the soluble monomer of elastin, is a 60 Kda protein (Figure 1.15). Structurally, 
hydrophobic and hydrophilic domains characterize tropoelastin. The high lysine and alanine 
content of the hydrophilic domains are responsible for crosslinking to form elastin. Obtaining 
tropoelastin from animal sources was an inefficient endeavor requiring the use of lysyl oxidase 
enzymes to break the cross linking bonds [277]. Advancements in bacterial expression systems 
have facilitated the large quantity production of recombinant human tropoelastin (rhTE). rhTE 
has a similar physiological profile to native tropoelastin, undergoing self-assembly in vivo 
[278]. rhTE is a cell adhesive protein able to support human dermal fibroblasts [269] and 
human endothelial cells [279]. For biomaterial application rhTE has been successfully 
immobilized on both plasma modified polymeric surfaces and plasma polymers. Importantly 
the biological activity of immobilized rhTE remains intact with enhancement in cell attachment 
over bare metallic and polymer surfaces [280, 281]. Furthermore, surface attached rhTE is non-
thrombogenic [258]. The combination of non-thrombogenicity and potential to enhance 
endothelial function marks tropoelastin as a promising protein for functionalization of 
biomaterials. 
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Figure 1.15. Three-dimensional model of tropoelastin. Adapted from Yeo et al PNAS, 
2012. [282] 
1.7 Thesis aims 
In contemporary cardiovascular medicine, a truly biocompatible stent platform remains 
elusive. Driven by this reality a diverse range of strategies are being explored including 
biodegradable polymer drug eluting stents, polymer free drug eluting stents, biodegradable 
stents and endothelial capture stents. The multitude of approaches reflects a lack of a definitive 
solution to the issue of stent biocompatibility. Elution of cyto-toxic drugs is an effective means 
of inhibiting intimal hyperplasia and remains the predominant strategy employed in new stent 
designs. The non-specificity of inhibition of these agents has consequences as evidenced by 
delayed and dysfunctional endothelial recovery and persistence of exposed thrombogenic stent 
struts years after implantation. Recognition of the role of the endothelium as a natural in vivo 
regulator of VSMCs offers a new direction in combating stent restenosis. Focusing on the 
acceleration of healthy endothelial recovery may in fact retard intimal hyperplasia. 
For now, and the immediate future the main material of choice for stents remain metallic alloys. 
Unfortunately, metallic alloys are inherently thrombogenic. Complete endothelial coverage 
remains the definitive anti-thrombotic surface. However, there is a time window prior to 
endothelialization where stent struts are exposed to the blood stream. Our goal of designing a 
more biocompatible stent platform through leveraging plasma polymerization technology is 
twofold - improving stent hemocompatibility and enhancing endothelialization. We will 
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examine this in the context of modulation of the chemical and structural make up of plasma 
deposited thin carbon films and the potential role of rhTE bio-functionalization. 
The interaction of rhTE with fibroblasts, smooth muscle cells and more recently endothelial 
cells in native or surface immobilized forms have been well documented in the literature. EPCs 
have an important role in vascular healing and studies suggest a contribution to the recovering 
endothelium after stent injury. The first part of this thesis will explore the interaction of rhTE 
with EPCs, delving into the mechanism of the interaction. The second part of this thesis will 
focus on the optimization of plasma polymerization as a coating platform to improve 
hemocompatibility and endothelialization. 
The aims in detail are 
1. To assess the interaction of rhTE and EPCs 
2. To elucidate the mechanism of interaction of rhTE and EPCs. 
3. To develop a bioactive plasma polymer surface with increasing nitrogen content 
a. To design a plasma polymerization chamber and optimize for uniform and 
reproducible thin film deposition. 
b. To modulate the surface chemistry and structural composition of plasma films 
using nitrogen doping with detailed chemical-physical characterization 
c. To assess thrombogenicity and endothelialization of nitrogenized plasma 
polymers 
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Chapter 2: Isolation of Outgrowth Endothelial Cells and 
Interaction with Recombinant Human Tropoelastin 
A portion of chapter 2 has been published in the peer reviewed journal PLoS One; 2015 June 
26;10 entitled Characterization of Endothelial Progenitor Cell Interactions with Human 
Tropoelastin, authored by Yu Y, et al. 
2.1 Introduction 
Since the first description of endothelial progenitor cells (EPCs) by Asahara in 1997 [237], the 
idea of vasculogenesis in adulthood has excited the imagination of researchers around the 
world. Once thought to only occur via proliferation of local mature endothelial cells, Asahara 
proposed that bone marrow derived EPCs are recruited to ischemic sites where they can 
actively participate in postnatal neovascularization. 
Asahara purified CD34+ cells from peripheral mononuclear cells (MNC) and when plated onto 
fibronectin (Fn)-coated tissue culture plates (TCP), these cells attached, proliferated and 
became spindle shaped. Co-culturing with CD34- MNCs facilitated the differentiation of these 
cells into tube-like structures. Over time, expression of endothelial markers increased on these 
attached cells. In mouse and rabbit models of hindlimb ischemia it was found that injected 
CD34+ cells incorporated into capillaries. 
Attempts have been made to define EPCs using different combinations of simultaneously 
expressed cell surface markers. A commonly used set of markers is CD34+, VEGFR-2+ and 
CD133+. CD34+ is found on hematopoietic stem cells (HSC) and has been adopted for EPCs 
based on the idea of a shared common ancestor between HSC and angioblasts. However, 
CD34+ is not a specific marker of cellular naivety as it is also found on mature endothelial 
cells [283]. VEGFR-2 (vascular endothelial growth factor receptor) is found on endothelial 
cells but it is by no means limited to this cell line. Found also in the central nervous, 
cardiovascular and hematopoietic systems VEGFR-2 is therefore not a unique identifier of 
endothelial lineage [284]. CD133 (AC133) is a large transmembrane protein with an unclear 
function. Notably absent on mature endothelial cells, CD133 has been used to reflect stemness. 
Overlapping of these surface markers between a diverse range of cell lines leads to a lack of 
specificity in the currently accepted flow cytometry-based definitions of an EPC. Moreover, 
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there is a paucity of evidence showing that CD34+ AC133+ VEGFR-2+ cells actually give rise 
to endothelial colonies [285]. Case et al [285] examined CD34+ AC133+ VEGFR-2+ cells 
isolated from cord and peripheral blood for colony forming capacity with established 
endothelial culture protocols. Finding that these cells did not give rise to colony forming units, 
failed to form vessels in matrigel and were positive for the hematopoietic specific antigen 
CD45, the authors concluded that cells bearing CD34+ AC133+ VEGFR-2+ were in fact not 
endothelial but hematopoietic in origin [285]. To date, no combination of surface markers 
unequivocally defines an EPC. 
In vitro culture of MNCs has been used to isolate EPCs from peripheral or cord blood. It is 
thought that rare populations of EPCs exist within the mononuclear cell fraction in blood. An 
array of culture conditions on differing substrates, fibronectin (Fn) or collagen (Cn) have been 
employed to select out EPCs. Complicating the field, different conditions have yielded diverse 
populations of cells with markedly distinct morphological and functional characteristics. 
Broadly speaking two distinct populations of EPCs have been cited in the literature depending 
on the time of appearance in culture. Early outgrowth EPCs typically appear within a week in 
culture. MNCs are plated onto Fn-coated TCP. Variations in culture conditions exist between 
investigators. Hill et al [286] initially plated peripheral MNC onto TCP to preselect a non-
adherent population of cells which was replated onto new TCP. Emerging colonies of EPCs 
were identified as thin flat cells in the periphery radiating from a central cluster (Figure 2.1). 
 
Figure 2.1. Microscopy image of early EPCs isolated using the Hill method. 
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Alternatively, a simpler method advocated by Vasa et al takes MNCs and plates the cells on to 
Fn plates without replating. After 4 days those cells which remain adherent are considered 
EPCs. Morphologically these are different to those described by Hill et al as they do not form 
clusters [287] Figure 2.2. 
 
Figure 2.2. Microscopy image of early EPCs as defined by the Vasa method. 
While morphologically different these two types of early EPCs exhibit overlapping functional 
and surface maker characteristics. Early EPCs have endothelial features including VEGFR-2+, 
AcLDL (acetylated low density lipoprotein) uptake and UEA-1 Lectin binding [251]. These 
cells are in fact hematopoietic in nature, participating in angiogenesis through paracrine release 
of cytokines, such as VEGF (vascular endothelial growth factor) [288]. Using a novel 
angiogenesis assay Sieveking et al demonstrated that early EPCs augmented tubulogenesis in 
a concentration dependent and paracrine manner but did not integrate into the newly forming 
blood vessels [242]. Taken together both early outgrowth cells and original flow cytometry 
defined EPCs described a heterogeneous group of hematopoietic like cells aiding 
vasculogenesis through cytokine release. 
Given a deficiency of unique phenotypic identifiers of a true EPC a functional definition is 
necessary. Hirschi et al [288] proposed a functional definition which is summarized below 
1. EPCs can differentiate into endothelial cells 
2. Differentiated cells can form in vitro tubular structures 
3. In vivo, incorporate into injured endothelium or newly forming vascular structures 
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Highly proliferative endothelial-like late outgrowth cells (OECs), also known as endothelial 
colony forming cell (ECFC), have garnered significant interest and have been purported to be 
true EPCs. OECs typically arise from MNC plated on type 1 Cn coated TCP. Emerging later 
than early EPCs, these cells appear 2-to-4 weeks in culture. Using gender-mismatched bone 
marrow transplant recipients Lin et al [289] showed that OECs were derived from the donor, 
exhibited vigorous proliferative capacity, were cobblestone-like in appearance (Figure 2.3) 
and displayed endothelial surface markers. Importantly they noted that circulating endothelial 
cells were a distinct population derived from the transplant recipient and did not proliferate 
with exuberance dispelling the possibility that OECs were shed endothelial cells from the 
vessel wall. 
 
Figure 2.3. Light microscopy of outgrowth endothelial cells as described by Lin et al. 
Ingram et al successfully [290] cultured OECs from both cord and peripheral MNC 
populations. Consistent with Lin et al, a robust proliferative potential was demonstrated. 
Crucially these cells exhibited endothelial markers but lacked the hematopoietic marker CD45 
noted on early EPCs. In vitro and in vivo studies confirmed OECs behaved functionally like 
true EPCs. Using their angiogenesis model Sieveking et al [242] demonstrated OECs co-
cultured with fibroblasts formed interconnecting vascular structures and incorporated into pre-
existing vascular structures. When cord blood-derived OECs were implanted in nude mice, 
new vascular networks formed [291]. To date this homogenous cell type most closely aligns 
with the functional definition of an EPC and is chosen as the study cell line for this thesis. 
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EPCs are thought to play an integral role in maintaining the health of the cardiovascular system. 
EPCs represent a small fraction of the cells in the bone marrow (Figure 2.4), mobilizing in 
response to tissue ischemia and/ or endothelial injury [292]. Released EPCs circulate in the 
peripheral blood system localizing to sites of endothelial disruption and ischemia, guided by a 
hypoxic gradient generated by up regulation of hypoxia inducible factor-1. This in turn 
increases the expression of stromal cell derived factor-1 which enhances the adhesion, 
migration and homing of progenitor cells to areas of ischemia [293]. Stabilization and adhesion 
occurs through a host of adhesion molecules and integrins. True EPCs incorporate into the 
developing vessel or contribute to endothelialization at areas of injury while hematopoietic-
like cells facilitate this process through the paracrine release of growth factors [294]. 
Extracellular matrix (ECM) molecules such as Fn interact with integrins on EPCs to promote 
EPC localization and initiate differentiation into mature endothelial cells [295]. 
 
Figure 2.4. Diagram illustrating the role of EPCs in the cardiovascular system. 
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Multiple human studies show an association between circulating EPC levels and the incidence 
of ischemic events and cardiovascular risk factors [296-298], reinforcing the idea that EPCs 
are closely linked to the health of the cardiovascular system. A caveat to these findings is that 
the definition of an EPC varies greatly in these studies, relying on both surface marker and 
culture-based methods. CD34+ and VEGFR-2+ cells appear to be reduced in patients who are 
smokers [299] and diabetics [300]. Patients with coronary artery disease (CAD) not only have 
decreased EPC numbers but also impaired EPC function [301]. Conversely high levels of EPCs 
appear to be protective against cardiovascular death and major cardiovascular events [302]. 
Associations between CVS disease and late outgrowth endothelial cells (OECs) have also been 
reported. Patients with newly diagnosed CAD were noted to have OECs which displayed 
impaired endothelial phenotype expression and function [303]. Notably, in acute myocardial 
infarction mobilization of OECs from the bone marrow is suggested by a rapid and sizable 
increase in the number of these cells [304]. This mobilization may in fact be clinically 
beneficial. In a small study Meneveau et al demonstrated decreased infarct size and improved 
left ventricular ejection fraction in acute myocardial infarct patients who have detectable OEC 
colonies from their peripheral blood [305]. 
Coronary angioplasty and stenting causes unavoidable injury to the vessel wall with disruption 
to the endothelium stimulating a robust vascular smooth muscle cell (VSMC) response. A 
continuous and functional endothelium not only maintains a physical barrier 
compartmentalizing the subendothelial matrix and VSMCs but also modulates vascular 
homeostasis through secretion of vasodilators and cytokines. Endothelial nitric oxide (NO) is 
known to preserve VSMC in a quiescent state [306]. Contemporary commercially available 
coronary stents rely on cytotoxic anti-proliferative drugs to restrict VSMC activity which limits 
intimal hyperplasia and in-stent restenosis (ISR). Non-specific inhibition of cellular 
proliferation also perturbs endothelial function culminating in delayed endothelial coverage of 
stent struts and recovery of function, manifesting clinically in stent thrombosis [120]. Evidence 
points to a detrimental effect of sirolimus, a common agent used in drug eluting stents (DES), 
on EPCs [307]. Given the role of the endothelium in regulating VSMC activity, belated 
endothelial recovery may in fact contribute to intimal hyperplasia. Animal studies show that 
the greater the area of endothelial disruption the more prominent the neo-intimal formation 
[308, 309]. Furthermore, after intimal injury, only areas not covered with endothelium 
developed significant neointima [230]. Intuitively, the more rapid a confluent endothelial layer 
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can be re-established the faster the thrombogenic potential of a stent can be reduced and VSMC 
regulation restored. 
EPCs may play a role in mitigating stent-induced vascular injury. When patients with acute 
myocardial infarction were assessed for early EPC levels pre-and post-percutaneous coronary 
intervention (PCI) a significant rise in EPC colonies was noted 24 hours after the procedure 
[310]. Even in stable patients who go on to PCI a noticeable elevation in early EPC colonies 
within a day post procedure occurs. Importantly, patients who only had a diagnostic 
angiography (where by no iatrogenic vessel injury occurred) did not have a similar increase in 
EPCs [311]. Taken together these studies show PCI-related vessel injury induces an elevation 
of circulating early EPCs which may contribute to endothelial healing. Using a combination of 
CD34+ and CD45- surface markers to isolate OECs Padfield et al showed a transient 
circulatory increase just 6 hours after PCI, a finding not present when diagnostic angiography 
alone was performed [312]. While these are only association studies we can infer a potential 
role for early and late EPCs in endothelial healing after iatrogenic injury. 
Figure 2.5A and 2.5B illustrates the proposed functional role of early and late EPCs after PCI 
[313]. Figure 2.5A shows the damage to the vessel wall upon implantation of a coronary stent 
with injury to the endothelium and the tunica media. Thrombus formation with platelet and 
leukocyte complexes are seen early. 
 
Figure 2.5A. Diagram highlighting endothelial denudation and thrombus formation 
after coronary stenting. 
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Figure 2.5B depicts the proposed role of EPCs following stenting. Early EPCs (named CFU 
cells in the diagram) are recruited rapidly to the site of trauma where an abundance of cytokines 
is secreted stimulating endothelialization through recruitment of EPCs and increased 
proliferation of adjacent healthy endothelium. Occurring in a more delayed fashion OECs (true 
EPCs) home to sites of denuded endothelium, localize and proliferate to contribute to the 
growing endothelial layer [313]. 
 
Figure 2.5B. Recruitment of early and late endothelial progenitor cells to the site of 
stent-induced vascular injury. The CFU (colony forming units) or outgrowth 
endothelial cells incorporate into the healing endothelium. Early EPCs support 
vasculogenesis through release of paracrine factors [313]. 
Experimental evidence supports the notion that OECs directly contribute to endothelial 
regeneration. When ex-vivo expanded OECs were injected into mice following wire injury to 
femoral arteries, rapid re-endothelialization was seen along with a reduction in neo-intimal 
development. A similar study cultivated bone marrow-derived autologous OECs and infused 
them into rabbits following wire injury to the central ear artery. Localization of OECs to areas 
of injury and attenuation of neo-intima formation with preserved vessel lumen size was 
observed [314]. OEC-conditioned media was found to strongly inhibit VSMC migration and 
proliferation. This was attributed to high levels of pigment epithelium-derived factor [315]. 
Pislaru et al adopted a novel method of tagging ex vivo expanded OECs with magnetic spheres. 
When these OECs were injected into pigs with magnetized coronary stents, successful 
localization of these cells to the stented areas was described [316]. In a follow-up study the 
authors found delivery of OECs to stented segments promoted stent re-endothelialization [317]. 
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Transitioning of OECs from the circulation into the tissue space to participate in endothelial 
healing requires anchoring of the cells to the vascular substratum. The ECM has a pivotal role 
in both structural support for cells and in delivering molecular cues to maintain cellular health 
and survival. Bridging the interactions between cells and ECM are the integrins which are 
transmembrane cellular adhesion molecules. EPCs may in fact alter surface expression of 
various integrins depending on which stage of its transition from bone marrow to local tissue 
[318]. Fn an abundant ECM protein appears to be instrumental in facilitating EPC attachment 
and differentiation [318]. 
The surface of a coronary stent should ideally be favorable for EPC attachment, spreading and 
proliferation, thereby encouraging endothelial coverage of struts. Functionalizing stent 
surfaces with covalently attached ECM proteins have recently been achieved using a novel 
plasma activated polymer coating [319]. Plasma-assisted deposition of thin free radical active 
films will be discussed in more detail in subsequent chapters. In brief a novel purpose-designed 
vacuum chamber was used to coat thin carbon films on to substrate surfaces. Characteristics of 
this plasma film are robust substrate attachment and the capacity to covalently couple with 
proteins in solution. Importantly bound proteins retain full biological function. 
Figure 2.6 shows a schematic representation of covalently linked proteins to the plasma 
polymer. 
 
Figure 2.6. Schematic diagram showing the deposited plasma activated thin carbon film 
(yellow) with covalent bonds anchoring surface immobilized proteins. 
Proteins attach to plasma polymers in a non-specific manner therefore the biological 
functionalization of the surface is dependent on the protein incubated with the polymer prior 
to clinical use. An ideal candidate protein should aid OEC attachment to the stent surface. Once 
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anchored the surface should further promote the proliferation of OECs. Potential candidate 
proteins include Fn and Cn which are abundant ECM proteins strongly adhesive for vascular 
endothelial cells [320, 321]. Potential use of these proteins for bio-functionalization is however 
constrained by pro-thrombogenic tendencies, in particular platelet activation [322, 323]. 
Moreover, Fn promotes smooth muscle cell migration [324, 325]. 
Elastin, the structural protein found in elastic tissues, is located in the external elastic lamina 
and interspersed among VSMCs in the tunica media. A thin layer of elastin is also found in the 
internal elastic lamina supporting intimal endothelial cells [326]. More than a bio-mechanical 
protein, elastin is involved in cell signalling and bioregulation. Particularly relevant to the 
vascular system is the modulation of VSMC activity. In elastin knockout mice aberrant 
vasculogenesis occurs with complete obliteration of the vascular lumen, indicating the 
importance of elastin regulation of VSMC proliferation [270]. Furthermore, elastin has been 
implicated in the chemo-attraction of endothelial cells and in regulating angiogenesis [327, 
328]. Especially pertinent to bio-engineering applications is the finding that elastin is not 
thrombogenic [274]. Exploitation of elastin for bio-functionalization has been hindered by 
difficulty in the purification process due to the insolubility of this protein. By using 
recombinant E.coli expression systems, large quantities of the monomeric precursor to human 
elastin, tropoelastin can be made [329]. Recombinant human tropoelastin (rhTE) behaves in 
vivo similarly to endogenous tropoelastin, undergoing self-assembly [278]. Biologically rhTE 
displays a duality of action, inhibiting smooth muscle cell proliferation but supporting 
endothelial activity [330]. 
Earlier work by our group successfully bonded rhTE covalently to plasma polymerized 316L 
stainless steel (316L SS). When coupled in this fashion rhTE remained attached in vivo and did 
not illicit an immunogenic response [319]. In in vitro assays endothelial cell attachment and 
proliferation on stainless steel was augmented by immobilized rhTE without an impact on 
thrombogenicity [258, 281]. Taken together these preliminary findings show that rhTE is a 
promising candidate protein for enhancing endothelialization of biomaterial surfaces. While 
the biological activity of rhTE has been evaluated for a range of cells, the capacity to support 
OECs has not been. This is a critical question to explore given the purported role of OECs in 
endothelial repair. A hostile local environment to OECs would be detrimental to stent 
endothelialization. In this chapter we cultured OECs from healthy volunteers and characterize 
them using complimentary methods. We then explored the capacity of rhTE to support OEC 
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attachment, adhesion and proliferation across a number of donors to ensure consistent 
biological activity. 
2.2 Methods and materials 
2.2.1 OEC isolation and culture 
Blood was drawn from healthy young male volunteers who were not on any medications. 
Approval was obtained from the ethics committee in accordance with the Declaration of 
Helsinki and Good Clinical Practice Guidelines (Sydney South West Area Health Service 
Ethics Approval #X06-0191). All donors provided informed consent. Blood was collected into 
12 EDTA vacutainer tubes totalling approximately 120 ml of blood. This was divided into 6 
large Falcon tubes with 20 ml of blood in each. The tubes were centrifuged at 2000 RPM for 
10 min. Serum was aspirated carefully with a pipette and discarded. The remaining volume of 
cells was diluted in a 1:1 ratio (v:v) with PBS (phosphate buffer solution) following which an 
equal volume of lymphoprep was added. Further centrifugation at 740 g for 30 min allowed 
density gradient separation of the MNC fraction from other blood components. A buffy coat 
containing MNC was visualized as a thin dense white interface between the serum and red 
blood cells. Using careful aspiration, the buffy coats were collected and placed into a single 
new falcon tube and consolidated into a cell pellet after a further 5 min of centrifugation at 515 
g. Following removal of all residual liquid from around the pellet, 20 ml of EGM-2 media was 
used to resuspend the cells in solution. The total number of MNCs was counted using a 
haemocytometer after staining a small representative volume of cells with trypan blue (1:2 
dilution with 0.4% (w/v) trypan blue). 
Cell density was adjusted to a concentration of 1 – 2 x107 cells / ml using EGM-2 media. 
Approximately 1 ml of cells was added into each well of a 6 well type I rat tail Cn pre-coated 
TCP. Non adherent cells were removed with gentle washing and exchange of EGM-2 media, 
daily for the first 7 days following which this was extended to every second day. OECs emerged 
typically between days 14 – 21 as clusters of cobblestone-shaped cells. Clusters of OECs 
expanded outwards from the periphery and were extracted for passaging when the wells 
reached approximately 80% confluence. 
OECs were lifted from culture wells by incubation with trypsin/EDTA (0.025% (v/v) trypsin, 
0.02% (v/v) EDTA) for 2 – 3 min at 37 °C. The trypsin/EDTA was neutralized with the addition 
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of 2 ml of EGM-2 media in to each well. Extracted cells from each well were combined and 
centrifuged for 5 min at 1500 rpm following which the cells were resuspended in EGM-2 media 
and transferred into 25 cm2 size cell culture flask. At approximately 80 – 90% confluence the 
cells were further expanded into 175 cm2 flasks. To prevent senescence of OECs with each 
expansion, the cells were split in a more conservative 1:2 or 1:3 ratio. OECs were noted to 
exhibit robust and rapid proliferation. All OECs used for experiments were between passages 
5 – 10. 
2.2.2 Characterization of OECs 
We probed OECs for endothelial characteristics using established methodologies. Specialized 
cell chambers with glass cover slip bottoms were seeded with OECs at a density of 2 – 3 x 104 
cells / chamber. The cells were allowed to grow to confluence before imaging and 
immunostaining. Gross morphological appearance of OECs was obtained using light 
microscopy. Immunophenotyping methods are described in detail below. Human dermal 
fibroblasts (HDF) were used as the control cell type. 
2.2.3 Detection of CD31 
Platelet endothelial cell adhesion molecule (PECAM-1) as known as CD31 is found on 
endothelial cells. We probed its presence on OECs using immunostaining. OECs grown in 
glass cover slip chambers were fixed using formaldehyde followed by aspiration and washing 
with PBS. 1% Triton-X-100 in PBS (v/v) was added for 5 min in order to permeablize the cell 
membrane. OECs were exposed to peroxidase for 30 min and then goat serum for 1 hour to 
block non-specific antibody interactions. Anti-CD31/PECAM-1 antibody (1:100 antibody 
dilution) was added for 1 hour at 37°C. Excess unbound antibody was washed away with PBS. 
The detection of CD31 antibodies was achieved using horseradish peroxidase conjugated 
antibody anti-mouse kit, also incubated for 1 hour at 37°C. Haematoxylin was used to 
counterstain the cell nuclei. 
2.2.4 Acetylated low density lipoprotein uptake (AcLDL), fluorescein isothiocyanate – 
Ulex europaeus agglutinin lectin (Ulex) binding and presence of Von Willebrand factor 
(vWF) 
Endothelial cells have the capacity to uptake AcLDL and bind to Ulex [331], properties we 
explored in OECs. OECs were brought to confluence in glass slip bottom chambers. Media 
83 
was aspirated and cells washed gently three times with PBS. Dil-AcLDL solution was made 
by combining 3 ml of serum free EBM-2 media and 6 μl of 1mg/ml of Dil-AcLDL. 200 μl of 
solution was added to each chamber. Using foil, each chamber was isolated from light and 
incubated for 2 hours at 37°C. Ulex lectin solution was prepared by adding 40 μl of Ulex lectin 
to 4 ml of PBS. 200 μl of the solution was added to each chamber and incubated for 30 min in 
room temperature with foil wrapping to protect from light. vWF is a large glycoprotein with a 
multimeric structure expressed on endothelial cells, functioning as an anchorage protein for 
circulating platelets [332]. Using immunofluorescent labelled rabbit anti-human vWF antibody 
(1:200 dilution) added to OECs for 2 hours, we probed for presence of vWF rich granules in 
OECs. At the end of incubation for Ulex binding, AcLDL update and vWF staining the 
solutions were aspirated and excess washed with PBS. In order to identify cellular nuclei in the 
vWF assays the cells were further stained using DAPI 0.15 μg/ml in PBS for 10 min. The cells 
where then visualized using a Nikon Eclipse fluorescent microscope and representative images 
taken. 
2.2.5 Flow cytometry 
We probed OECs for the presence of characteristic endothelial surface markers and more 
importantly for the absence of the hematopoietic cell specific makers CD45 and CD14. OECs 
were detached from TCP using trypsin in keeping with methodology described above. 
Following liberation from culture, the cells were washed thoroughly with PBS buffer and 
resuspended in 0.5% BSA (bovine serum albumin) to prevent non-specific receptor binding. 
FcR blocking reagent was subsequently added followed by staining with CD34-PerCP-Cy5.5, 
CD45-APC-Cy7, CD31-PE, CD14-APC, CD309 (VEGFR2)-PE and CD54-PE for 30 min at 
4°C. Excess reagent was removed using PBS washing with the cells then stained with Zombie 
Aqua Viability dye for 30 min at room temperature. Prior to reading on the FACSVerse flow 
cytometer (BD Biosciences, USA) the cells were given a final PBS wash and resuspended in 
0.5% BSA. For negative controls unstained OECs and fluorescence minus one (FMO) analyses 
were used. 
2.2.6 Quantification of cell number 
The number of cells in adhesion and proliferation assays were quantified using crystal violet 
staining. While this methodology has been validated for other cell lines it has not been applied 
for quantification of OECs. Assessment of cell number is based on correlation of cell number 
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with colorimetric intensity from the release of crystal violet. It is important to ensure a linear 
correlation between the color intensity and increasing cell number. Known quantities of 
increasing concentrations of OECs were seeded on to 24 well TCP and allowed to attach for 
60 min or 120 min at 37°C. The cells were directly fixed using 3.3 % formaldehyde for 20 min. 
Formaldehyde was thoroughly washed using PBS and then stained using crystal violet (0.1% 
w/v) in room temperature for 1 hour. Excess crystal violet was then aspirated and the TCP 
wells were washed 6 times using RO or distilled water. Using gentle upside down tapping of 
the TCP plate, residual water was removed and the samples were allowed to air dry briefly 
before solubilizing the crystal violet stain with acetic acid 10% (v/v). 100 μl of crystal violet 
solution from each well was transferred to a 96 well TCP and placed into a plate reader to 
determine the absorbance at 580 nm. The absorbance was then correlated with the known 
number of cells. 
2.2.7 OEC adhesion in tissue culture plastic 
OEC attachment to rhTE was assessed on protein pre-coated TCP. Fn and Cn were used as 
positive controls. Using serial dilution with PBS a gradient concentration of Fn, Cn and rhTE 
protein solutions were made. 96 well plates were coated with 100 μl of protein solution 
overnight at 4°C. Next day, the protein solution was aspirated from the wells and washed three 
times with PBS. To prevent nonspecific interaction of cells with TCP the wells were blocked 
using 150 μl of heat denatured (85°C for 10 min, then cooled on ice) BSA (1% w/v) for 1 hour 
after which excess BSA was removed and washed three times with PBS. Near confluent flasks 
of OECs in 175 cm2 flasks were liberated using 5 ml of trypsin/EDTA with incubation at 37°C 
for 4 min. Neutralization of trypsin was done by adding 10 ml of EGM-2 with 10% fetal calf 
serum. Using the centrifuge set at 1500 rpm for 5 min, the cell suspension was consolidated 
into a cell pellet which was resuspended in serum free EGM-2. Serum free media was used to 
prevent confounding of cell attachment by pre-existing ECM proteins in serum. A cell density 
of 2 – 3 x 105 cells/ml was made with 100 μl aliquots of cells placed in each well. Triplicate 
wells for each concentration of Fn, Cn and rhTE were made. OECs were allowed to attach for 
60 min in an incubator with 5% CO2 at 37°C. Non-adherent cells were then washed gently 
away with three 100 μl PBS washes, with adherent cells fixed using 3.3% formaldehyde. 
Crystal violet staining for determination of cell numbers proceeded as described above. A 
standard curve was generated using pre-prepared known concentrations of cells. 
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2.2.8 OEC cell spreading 
96 well TCP was pre-coated with rhTE, Cn and Fn in triplicate wells and blocked with heat-
denatured BSA as described above. OECs were prepared in a similar fashion to attachment 
assays, with resuspension of the cells using serum free media. The density of cells was reduced 
to 1x105 cells/ml to provide enough space for the cells to spread. 100 μl aliquot of cells were 
added to each well and incubated in 37°C in 5% CO2 for 120 min. To preserve cell morphology 
10 μl of 37% formaldehyde was added directly into each well without any pre-washing for 20 
min at room temperature. The formaldehyde was aspirated and wells washed extensively. To 
image the cells each well was filled with distilled water and a glass cover placed across the 
plate. 
Cell were imaged using phase contrast microscopy (Zeiss Axiovert microscope) and images 
taken using a Pixelink camera. OECs with phase dark nuclei and abundant cytoplasmic 
projections were considered spread. Non-spread cells were small and rounded with phase bright 
nuclei. 
2.2.9 OEC proliferation 
Solutions of Fn, Cn and rhTE, were made using PBS to a concentration of 5 µg/ml, 5 µg/ml 
and 40 µg/ml, respectively. Protein solutions were sterile filtered using 0.22 µm size filters to 
remove bacterial contamination. 24 well TCP was chosen in order to give adequate room for 
cell growth. All steps were conducted in a sterilized tissue culture hood. 500 μl of protein 
solution was added to each well and coated overnight at 4°C. On the next day, residual protein 
solution was aspirated and the wells washed three times with 500 μl of PBS. Heat denatured 
1% (w/v) BSA pre-sterilized (using 0.22 µm filters) was added (600 μl) into each well for 1 
hour at room temperature to prevent non-specific cell interaction with polystyrene. Excess BSA 
was subsequently removed and washed three times with PBS. 
OECs were prepared as before with the exception of resuspending the cells in EBM-2 media 
supplemented with 10% fetal calf serum. Addition of serum was to provide nutrients for cell 
growth. A lower cell density of 6 x 103 cells/ml was made and 1 ml aliquot of the cell 
suspension was added into each well. Two proliferation time points were used, day 3 and 5. 
For the 5 day proliferation, media was exchanged on day 3 by gentle aspiration and replacement 
with 1 ml of EBM-2 media with 10% fetal calf serum. At the conclusion of each time point, 
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non-viable cells were gently washed away with PBS. Adherent cells were then fixed with 3.3% 
formaldehyde for 20 min with quantification of cell number using crystal violet. 
2.3 Results 
2.3.1 OEC characterization 
 
Figure 2.7. Top panel shows OEC morphology under light microscopy as published by 
Yoder et al [333]. Bottom panel shows appearance of isolated OECs from our donors. 
Light microscopic images of cultured OECs are shown in Figure 2.7. Comparable morphology 
is noted between microscopy images of OECs in the literature and our enumerated OECs. The 
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typical appearance is one of densely packed cells with cuboidal nuclei resembling 
cobblestones. 
Using immunofluorescence microscopy, we assessed OEC binding and uptake of Ulex and 
AcLDL, respectively. The left column of Figure 2.8 shows HDFs used as negative control. 
Ulex binding and AcLDL uptake was absent for HDFs. In contrast green fluorescent Ulex 
staining of OECs and red fluorescence of AcLDL uptake can be discerned in the right column 
(OECs). Merging of Ulex binding and AcLDL uptake showed overlap of staining. Similarly, 
CD31 was absent from fibroblasts but clearly present as light brown staining throughout the 
cytoplasm of OECs. Separately we probed for the presence of vWF in OECs. Figure 2.9, shows 
green fluorescent vWF granules distributed in the cytoplasm of OECs. Our enumeration 
technique along with morphology and immunofluorescent staining characteristics are 
consistent with the OEC phenotype reported by other authors. 
 
Figure 2.8. Immunofluorescent microscopy of OECs (right column) and HDF as control 
(left column) 
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Figure 2.9. Immunofluorescent microscopy of OECs labelled with anti-human vWF 
antibodies. Cell nuclei stained using DAPI appear blue with vWF as green. 
2.3.2 Flow cytometry 
Results from the flow cytometry analysis (Figure 2.10) were congruent with 
immunofluorescence findings. Immunophenotyping revealed OECs expressed endothelial cell 
surface antigens CD31 99.7±0.1%; CD54 (ICAM-1) 95.4±0.1%; VEGFR2 96.3±0.1% without 
antigens specific for hematopoietic cells present (CD45 0.43±0.03%; CD14 0.20±0.03% 
negative). The progenitor cell marker CD34 was notably present in a subset of cells 
(25.2±0.5%). 
 
Figure 2.10. Flow cytometry characterization of OECs. Stained cells are represented by 
blue histograms with unstained controls shown in black. OECs are 
CD34/31/54/VEGFR2 positive and CD45/14 negative. 
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2.3.3 OEC attachment to recombinant human tropoelastin 
We explored the interaction between rhTE and OECs, starting with the capacity of rhTE to 
support OEC adhesion. Cn and Fn, highly cell adhesive ECM proteins, were used as positive 
comparators for rhTE. The number of cells were quantified using a colorimetric method by 
staining with crystal violet. In order to determine if this method can accurately detect rising 
cell numbers in a linear fashion we correlated increasing OEC concentrations with absorbance 
measurements after attachment to TCP alone for 60 or 120 min. 
 
Figure 2.11. Validation of the crystal violet cell staining method for quantification of 
OEC numbers. Known OEC numbers were correlated and plotted with measured 
absorbance values. 
The plot in Figure 2.11 shows that over the cell numbers tested, a linear relationship is seen 
between the absorbance measured and increasing cell numbers. A strong association for 60 min 
and 120 min OEC attachment is seen, R2 = 0.9936 and R2 = 0.997, respectively. Determination 
of an appropriate time point of attachment was done by choosing two time points, 60 min and 
120 min. Over the typical density of 20,000 – 30,000 cells per well used for attachment assays, 
a slightly higher absorbance was noted with 120 min attachment, inferring an incremental 
improvement in attachment. However, the use of 60 min attachment did not impact on the 
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strength or linearity of the association between absorbance and cell number. A time point of 1 
hour was chosen so that assays could proceed in a more time-efficient manner. 
2.3.4 OEC attachment to recombinant human tropoelastin 
OEC attachment to rhTE was compared to Cn and Fn after 60 min of attachment to TCP pre-
coated with increasing concentrations of rhTE to a maximal of 50 μg/ml. Assays were 
performed with OECs isolated from three different donors to ensure overall findings were 
consistent for the cell type and not donor dependent. 
Aggregated data from all three donors are presented below (Figure 2.12). A concentration-
dependent effect on augmentation of OEC attachment is seen for rhTE, Cn and Fn. Cn and Fn 
had similar adhesion curves, characterized by a more rapid increase in OEC adhesion with 
initial small increments in protein concentration. Compared to the rhTE curve, a plateau in the 
curve is reached sooner and at lower concentrations of Cn and FN. Cn and Fn supported a 
maximal adhesion of 76.3 ± 4.7 % and 74.7 ± 6.5 %, respectively, at a concentration of 5 μg/ml. 
While a numerical increase in OEC adhesion level is seen with Cn and Fn concentrations up to 
50 μg/ml, this was not statistically significant (P >0.05). 
OEC adhesion on rhTE differs from Cn and Fn in that the slope of the adhesion curve is less 
steep and maximal attachment is achieved at higher coating concentrations. Above a 
concentration of 10 μg/ml (up to 50 μg/ml), attachment levels were numerically higher with 
progressively higher protein concentrations but statistically not significant (P>0.05). The 
maximal level of OEC attachment for rhTE reached was 65.1 ± 6.6 %. This was lower than 
both Fn (P = 0.027) and Cn (P = 0.014). 
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Figure 2.12. Aggregated data from 3 donors of OEC attachment to a concentration 
gradient of recombinant human tropoelastin, collagen and fibronectin. 
2.3.5 Spreading of OECs on recombinant human tropoelastin 
For cell spreading assays we incubated OECs on protein-coated TCP for 120 min and used Cn 
and Fn as positive controls. Coating concentrations for Cn and Fn were extrapolated from 
attachment assays. Maximal OEC adhesion for Cn and Fn occurred at a concentration of 5 
μg/ml. This concentration was chosen to coat TCP. Morphological appearance of the cells as 
seen with phase contrast microscopy was used to determine spreading. The aggregated cell 
spreading data for 3 separate donors is shown in Figure 2.13A. 
We found that spreading of OECs on rhTE followed a similar concentration-dependent trend 
as for attachment, reaching a plateau of 58.6 ± 3.8 % at 25 μg/ml. While OEC spreading at 40 
μg/ml was numerically higher than for 25 μg/ml at 60.8 ± 2.8%, this was not statistically 
significant (P = 0.46). At concentrations of 5 μg/ml OEC spreading was greater on Cn and Fn 
at 82.2 ± 5.7 % (vs. rhTE P = 0.001) and 76.8 ± 3.3 % (vs. rhTE P = 0.006), respectively. The 
level of spreading on Cn and Fn were comparable (P = 0.41). 
Figure 2.13B shows representative phase contrast microscopy images of OECs spreading on 
TCP alone (BSA blocked – A), rhTE (40 μg/ml – B), Fn (5 μg/ml – C) and Cn (5 μg/ml – D). 
On BSA-blocked TCP, OECs appeared as poorly spread small phase bright cells with minimal 
92 
cytoplasm. As cells begin to spread the nuclei become darker and irregular cytoplasmic 
projections become more prominent. 
 
Figure 2.13A. Aggregated data from 3 donors of OEC spreading to a concentration 
gradient of recombinant human tropoelastin. 
 
Figure 2.13B. Phase contrast microscope of OECs spreading. A) TCP. B) rhTE (40 
μg/ml). C) Fn (5 μg/ml). D) Cn (5 μg/ml). Representative images. 
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2.3.6 OEC proliferation on recombinant human tropoelastin 
We examined the potential for rhTE to encourage OEC proliferation by comparing cell 
densities after 3 and 5 days of incubation on rhTE coated TCP. Cell numbers were quantified 
using crystal violet. Fn and Cn were used as positive controls. The assays were performed 
across three donors, with the aggregated data presented below. 
Cell density in OEC proliferation assays was expressed as absorbance measured at 580 nm 
wavelength. After 3 days the measured absorbance for rhTE, Cn and Fn was 0.71 ± 0.16, 0.85 
± 0.09 and 0.85 ± 0.12 respectively (Figure 2.14). Proliferation on Cn and Fn was numerically 
higher however there was no statistically significant difference between the three proteins 
(P>0.05). After 5 days in culture absorbance for rhTE, Cn and Fn was comparable, at 1.17 ± 
0.1, 1.34 ± 0.14 and 1.29 ± 0.18, respectively (P>0.05). rhTE increased OEC density 1.65 ± 
0.18 fold from day 3 to day 5 (P = 0.02). 
 
Figure 2.14. OEC proliferation was quantified after incubation for 3 days or 5 days on 
rhTE, Cn or Fn. Aggregated data from 3 donors. 
2.4 Discussion 
In this chapter our goals were two fold. First, to successfully culture and comprehensively 
characterize OECs from the MNC fraction of peripheral blood. Second, to examine 
systematically across three donors the capacity of rhTE to support OEC activity - attachment, 
spreading and proliferation. 
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2.4.1 OEC culture and characterization 
Isolation of OECs from peripheral MNCs proved to be a challenging task with initially low 
yield from donors. 6 healthy donors were recruited with successful isolation of small colonies 
of OECs in Cn coated 6 well TCP. Attempts to expand OECs into larger tissue culture flasks 
were unsuccessful for the first 3 donors. Cells became senescent after the second to third 
passage with loss of shape and enlargement of the cytoplasm. It became apparent that OECs 
needed to be in close proximity to one another to maintain cellular health and proliferative 
capacity in particular during the first 2 passages. Surprisingly, cells become more hardy and 
robust after the third passage. For subsequent donors, OECs were brought to at least 80% 
confluence of wells / flasks before passaging. For the first 2 passages, cells were split in a 
gentler 1:1.5 to 1:2 ratio to maintain cell to cell contact resulting in successful expansion of 
OECs. By the third and fourth passages cells could be split in a 1:3 to 1:4 ratio for rapid 
expansion of cell numbers. 
Despite intensive research in the field of EPCs there remains no universally agreed definition 
of a true EPC. Asahara’s seminal paper used minimally enriched CD34+ peripheral MNCs to 
isolate putative EPCs [237]. Doubt however has been cast on the assertions made by Asahara, 
notably due to the limited homogeneity of the enriched cells (only 15% were CD34+) and 
failure to functionally exclude a possible hematopoietic origin [334]. Further efforts to refine 
the definition by adding additional cell markers CD133 and VEGFR-2 was popularized by 
Case et al [285]. The current understanding is that cells with CD34+ CD133+ VEGFR-2+ 
surface antigens are in fact hematopoietic in nature and are now considered pro-angiogenic 
hematopoietic cells rather than true EPCs [333]. 
We adopted a widely used method for isolating OECs through emergence of colony forming 
units from MNCs plated on Cn coated TCP [335]. As proposed by Lin et al [289] in their 
milestone paper, OECs from sex mismatched bone marrow transplant recipients displayed 
characteristics closely resembling that of an EPC. These outgrowth cells were characterized by 
endothelial phenotype and robust proliferative capacity, in stark contrast to circulating 
endothelial cells. Additional studies have demonstrated that OECs conform to the functional 
definition of an EPC, with incorporation into and formation of blood vessels [242, 336, 337]. 
Phenotypic characteristics of OECs are not unique to this cell line and as yet there are no 
exclusive set of features which define these cells. However, it is widely agreed that OECs 
display endothelial attributes and lack hematopoietic specific surfaces antigens [251]. 
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OECs are largely defined by the method of isolation from MNCs and late emergence of highly 
proliferative colonies from culture. Our methodology of OEC isolation closely followed that 
used by Lin et al [337]. Typical endothelial-like cells appeared 2 to 3 weeks in culture with 
cobblestone-like arrangement. OECs from our 3 donors exhibited rapid proliferation reaching 
near confluence in 24–48 hours after passaging in a 1:3 – 1:4 ratio. Moreover, the OECs could 
be expanded beyond passage 16 without senescence. 
Our expanded OECs exhibited classic endothelial features of Ulex binding and AcLDL 
endocytosis [290]. In difference, HDFs showed no evidence of AcLDL uptake or Ulex binding. 
Endothelial surface marker CD31 [338] stained positive on OECs but was absent for HDFs. 
Separately, we interrogated for the presence of vWF in the cells. Glycoprotein vWF is produced 
almost exclusively by endothelial and megakaryocytes and has a central role in haemostasis. 
Immunofluorescent staining of OECs found an abundant distribution of vWF throughout the 
cytoplasm. Cell surface immunophenotyping yielded results consistent with the literature 
[251]. We found OECs expressed endothelial markers CD31, CD54 and VEGFR2 and crucially 
did not express CD45 and CD14 hematopoietic markers. Progenitor cell marker CD34 was 
present in a subset of cells. Taken together our method of OEC isolation, the emergence of 
typical outgrowth colonies with high proliferative potential and endothelial phenotype is 
consistent with late outgrowth endothelial progenitor cells (also known as endothelial colony 
forming cells (ECFC)), considered to represent a true EPC [333]. 
2.4.2 OEC attachment, spreading and proliferation is supported by rhTE in a dose 
dependent manner 
Interaction between ECM proteins and cells is important for providing vital signalling cues for 
maintenance of cellular health [339]. OECs are thought to be recruited to sites of endothelial 
injury, transitioning from the bone marrow into the circulation and localizing to the tissue 
compartment [313]. Anchoring of migrating cells is predicated on the interaction between cell 
and the substratum [340]. Cellular proliferation is dependent on robust anchorage onto an 
appropriate substrate, this has been termed anchorage dependence [341]. 
Elastin is an abundant protein found in elastic tissue, imparting elasticity to arteries [342]. 
Beyond mechanical support, crucial cell signalling cues are provided by elastin as evidenced 
by uncontrolled proliferation of VSMCs during embryogenesis in elastin knock out mice [270]. 
Tropoelastin is the monomer precursor of elastin and can be readily produced using an E. Coli 
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expression system. A wide range of cell types have been noted to interact with rhTE [269, 343]. 
Of particular relevance to vascular medicine is the capacity of rhTE to both support endothelial 
attachment and proliferation [344] while controlling VSMC activity [345]. 
Combining the potential to facilitate endothelialization with attenuation of intimal hyperplasia, 
rhTE is a particular attractive biomolecule for enhancing stent biocompatibility. Our group has 
previously demonstrated that rhTE can be covalently attached to metallic substrates via a 
deposited thin plasma polymer interface [346]. When surface bound, rhTE still retains 
biological function and can support endothelial activity [347]. Given the important role EPCs 
have in endothelial regeneration we explored the interaction between rhTE with OECs. To date 
there has been no detailed characterization of this interaction. 
Cn and Fn are highly cell adhesive ECM proteins [348, 349]. Despite this biological attribute, 
Fn and Cn can stimulate platelets [322, 350] limiting application in vascular medicine. 
Nevertheless, we used Cn and Fn as positive controls for rhTE, benchmarking the attachment, 
spreading and proliferation of OECs on rhTE against them. Proteins were coated overnight to 
ensure adequate physisorption on to TCP. To quantify cell numbers, we employed a well-
established crystal violet staining technique [269]. Correlating known OEC numbers with 
measured absorbance we found a linear relationship between cell numbers and absorbance, 
validating this approach for detection of OEC numbers. 
rhTE supported OEC attachment to moderate levels (65.1 ± 6.6%). Attachment however was 
lower than for Cn and Fn. Similar degrees of attachment on rhTE have been reported for HDFs 
[269] and human umbilical vein endothelial cells (HUVEC) [344]. Although lower than Fn and 
Cn, cell attachment to rhTE is in keeping with other elastic fiber proteins, namely fibrillin, 
microfibrils [351] and fibulin-5 [352]. A dose-dependent effect can be seen with attachment of 
OECs on rhTE (and Cn and Fn). The adhesion curve as a function of rhTE concentration 
follows a gradual rise reaching a plateau at higher concentrations than Fn and Cn. Taken 
together, rhTE can support OEC attachment to moderate levels. 
Spreading of OECs on rhTE was compared to Cn and Fn (5 µg/ml). rhTE enhanced OEC 
spreading in a concentration-dependent manner reaching a plateau of 58.6 ± 3.8% at 25 μg/ml 
rhTE. Similar levels of cell spreading on rhTE has been reported for HDFs [269]. By 
comparison to rhTE, Cn and Fn consistently displayed greater spreading – a finding consistent 
with our data for cell attachment. We found that the spreading curve for rhTE mirrored that of 
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the attachment curve, typified by a steady ascent towards a plateau at modest concentrations of 
rhTE. Overall, OEC spreading to rhTE was comparable to attachment, reaching moderate 
levels. 
Finally, we interrogated the interaction of OEC and rhTE over a more prolonged time frame, 
assessing cell proliferation over 3 and 5 days. The concentrations for rhTE (40 µg/ml), Cn (5 
µg/ml) and Fn (5 µg/ml) chosen for proliferation assays were based on supra-physiological 
levels. Cn is typically used for isolation of OECs from MNC. This affinity for Cn can be seen 
in Cn supporting (numerically) the highest level of proliferation. Proliferation on rhTE was not 
statistically different from that observed with Cn or Fn. In fact, rhTE promoted OEC 
proliferation to a respectable level, with a 1.65 fold increase between day 3 to day 5. rhTE can 
adequately stimulate OEC proliferation at a rate comparable to and to levels similar to that of 
Fn and Cn. 
2.5 Conclusion 
Using established methods OECs were successfully cultured from peripheral MNC of healthy 
donors. These cells were characterized by high proliferative capacity and endothelial 
phenotype, consistent with descriptions in the literature. We demonstrated that rhTE supported 
a moderate level of OEC attachment and spreading in a concentration dependent fashion. 
Proliferation was enhanced by rhTE to levels comparable to that seen on Cn and Fn. Taken 
together rhTE is a promising biomolecule that has the potential to stimulate endothelialization 
by supporting both endothelial and OEC activity. 
In the following chapter we will delve into the mechanistic basis OEC and rhTE interactions, 
examining integrin mediate processes. 
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Chapter 3: Determination of the Mechanism of OEC Interaction 
with Recombinant Human Tropoelastin 
A portion of chapter 3 has been published in the peer reviewed journal PLoS One; 2015 June 
26;10 entitled Characterization of Endothelial Progenitor Cell Interactions with Human 
Tropoelastin, authored by Yu Y, et al. 
3.1 Introduction 
The elasticity in arteries, skin and cartilage is attributed to the presence of interspersed elastic 
fibres, made up of two proteins, microfibril and elastin. Elastin is the main component of elastic 
fibres and responsible for the physical properties of elastic tissue. Highly insoluble, elastin is 
formed through the cross-linking of its precursor tropoelastin. This monomer is produced by 
smooth muscle cells, endothelial cells and fibroblasts. Released on the surface of these cells, 
tropoelastin coacervates, followed by deposition on to microfibrils. Lysyl oxidase promotes the 
cross linking of tropoelastin side chains found in alanine rich (KA) and proline rich domains 
(KP) [277]. In arteries elastin is found in both the internal elastin lamina and intimal media, 
providing support for longitudinal loading and the sustained mechanical stress of arterial 
pulsation [353]. 
Tropoelastin has a molecular weight of approximately 60 – 70 kDa with the human gene 
encoding it spanning 34 exons. Structurally, tropoelastin consists of glycine, valine and proline 
rich hydrophobic domains alternating with hydrophilic domains consisting of lysine and 
alanine. Schematic representation of tropoelastin domains is shown in Figure 3.1. 
 
Figure 3.1. Schematic representation of the structure of tropoelastin. 
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Beyond mechanical and physical function elastin has critical biological signalling roles. In 
elastin knock out mice, premature death resulted from unchecked vascular smooth muscle cell 
(VSMC) proliferation culminating in the occlusive obliteration of arteries [270]. In vitro studies 
demonstrate VSMC proliferation is suppressed by elastin and at lower concentrations elastin 
stimulates endothelial proliferation [354]. A diverse range of cells can interact with elastin, 
including support for fibroblast attachment and spreading, chemoattraction of endothelial cells 
and monocytes [355] [356]. 
The insolubility of elastin creates challenges for in vitro studies. Previously, in vitro work relied 
on the purification from elastin rich tissues using complicated chemical and/or heat-based 
approaches. Recombinant human tropoelastin (rhTE) can be produced using bacterial 
expression systems (Escherichia coli) [329]. rhTE has properties similar to native tropoelastin, 
whereby under physiological conditions it undergoes coacervation and can be cross linked in 
vitro to form elastin fibers [277]. Studies demonstrate that the biological function of native 
tropoelastin is preserved with rhTE. rhTE has been noted to support endothelial [357] and 
fibroblast [269] activity and inhibit VSMC proliferation [330]. The advent of rhTE has greatly 
facilitated the study of tropoelastin structure and biological function. 
Our knowledge of the nature of interaction between cell receptors and cell binding motifs on 
tropoelastin is continually evolving. The site of cell binding appears to vary depending on the 
cell line. The C-terminus of tropoelastin is one of the most conserved regions across different 
species and has been a focus of multiple studies. Broekelmann et al [343] reported binding of 
bovine chondrocytes to the last 17 amino acids at the carboxyl terminus of bovine tropoelastin. 
The cell surface heparan (predominant) and chondroitin sulfate containing glycosaminoglycans 
(GAG) were found to be responsible for this interaction. In contrast human tropoelastin does 
not exhibit this type of interaction, due to the absence of exons 34 and 35 [269]. 
Another mechanism of cell adhesion is via elastin binding protein (EBP). EBP, a 67 Kda 
protein combines with sialidase and carboxypeptidase A to form a transmembrane elastin 
receptor [358]. Located in the mid portion of elastin the hexapeptide VGVAPG motif acts as 
the recognition site for this receptor complex. [359] This interaction accounts for the 
chemotactic properties of elastin but the lack of cellular adhesion to VGVAPG fragments in 
contrast to full length tropoelastin suggests alternative binding sites in human tropoelastin 
[269]. 
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Interaction between extracellular matrix (ECM) protein and cells are crucial for cellular 
adhesion, migration and differentiation [360]. The main cell receptor for binding to extra 
cellular matrix are integrins. Integrins are transmembrane heterodimers consisting of two non-
covalently linked transmembrane glycoproteins subunits, α and β [361]. At least 18 α and 8 β 
subunits are known in humans, with different combinations of these subunits giving rise to 
specificity of ligand binding. Once bound to ligands, integrins transduce vital signals into the 
cell interior. Arginine-glycine-aspartic acid (RGD) has been identified as the predominant 
integrin binding motif in ECM proteins [362]. 
Tropoelastin does not have a RGD sequence and was once thought to lack the ability to interact 
with integrins [343]. Rogers and Weiss discovered using solid phase assays that αVβ3 bound 
in a divalent cation dependent fashion to the C-terminal 16 residues of tropoelastin, a region 
encoded by exon 36. Integrin αVβ3 can bind to a range of non-RGD motifs [363]. Leading on 
from this work Bax et al showed for the first time human dermal fibroblasts (HDFs) can bind 
to the C-terminus of rhTE. The binding site was localized to a GRKRK motif with the 
interaction mediated by integrin αVβ3 [269]. More recently the central and N-terminus regions 
of tropoelastin have been probed for cell binding capacity. Hiob et al, using N-terminal 
constructs found human umbilical vein endothelial cells (HUVECs) bound to the first 10 (N10) 
and 18 (N18) domains (Figure 3.2). Remarkably, attachment to peptide 36 (containing the 
GRKRK) was greatly diminished for endothelial cells [357], a stark contrast to findings for 
HDFs. The mechanism for endothelial cell binding to the N-terminal was not explored. Taken 
together, cell interaction sites on tropoelastin appear to span from the N-terminus to the C-
terminus with distinct cell type dependent binding patterns. Three main cell surface receptors 
1) integrin 2) EBP and 3) GAGs have been identified. 
In the previous chapter we demonstrated that full length rhTE can support late outgrowth 
endothelial cell (OEC) attachment, spreading and proliferation. Here we investigate the 
mechanism of interaction between rhTE and OECs followed by mapping of the site of 
attachment using rhTE constructs. 
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Figure 3.2. Schematic representation of N-terminal constructs and C-terminal peptide 
36 containing human dermal fibroblasts binding motif GRKRK. 
3.2 Methods and materials 
3.2.1 OEC isolation and culture 
OEC isolation and culture was carried out as described in chapter 2. The same donors were 
used. 
3.2.2 Tropoelastin construct expression 
Expression of tropoelastin N-terminal constructs representing the first 25 (N25), 18 (N18), and 
10 (N10) domains was completed with the help of PhD candidate, Matti Hiob from the School 
of Molecular Bioscience, University of Sydney. Expression of full-length human tropoelastin 
through an E.coli system has been described in detail elsewhere [364]. The method for 
expression of rhTE constructs is described in brief below. 
3.2.3 Overexpression of constructs 
An E.coli overexpression system was utilized for production of truncated tropoelastin 
constructs. Transformed E.coli were streaked on to agar plates and incubated at 37 °C 
overnight. A single E.coli colony was used to inoculate lysogeny broth as a starter culture and 
allowed to grow overnight at 37 °C. 2-TY medium was inoculated with 5% starter culture (v/v) 
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with addition of 1mM IPTG (isopropyl β-D-1-thiogalactopyranoside) to stimulate protein 
overexpression. 
3.2.4 Purification of constructs 
Induced cultures were centrifuged into cell pellets and resuspended in lysis buffer. Suspensions 
were lysed by repeated freeze thaw cycles using liquid nitrogen. Cell debris was removed from 
the lysate using centrifugation with the supernatant collected. Using rotary evaporation, 
tropoelastin constructs were isolated from the supernatant. Chloroform was used to wash lipids 
from the residue followed by air drying and dissolving in ammonium acetate buffer. Dissolved 
constructs were removed using dialysis followed by further centrifugation and finally freeze 
drying. 
3.2.5 Reverse phase high performance liquid chromatography (RP-HPLC) 
Concentrated constructs were purified using RP-HPLC (Agilent Technologies). A Zorbax 
StableBond 200SB-C18 5 mm analytical column was used at a flow rate of 1 mL/min. A 0-
100% acetonitrile, 0.1% TFA gradient over 1 h was used to elute protein fractions. 
3.2.6 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
The purity of the expressed protein constructs was confirmed using SDS-PAGE. Constructs 
were resuspended in loading buffer and heat denatured at 70°C for 5 min. Each construct as 
well as standards (Invitrogen, USA) were loaded on a 12% NuPAGE Bis-Tris gradient gel 
(Invitrogen, USA) and run at 200V for 37 min. Gels were fixed with 50% (v/v) methanol for 
20 min and stained with Coomassie stain solution for 2 hours. Coomassie was removed by 
destaining overnight in 25% (v/v) methanol and 10% (v/v) acetic acid. 
3.2.7 Inhibition of OEC attachment to tropoelastin and constructs 
Inhibition of OEC attachment to rhTE with the addition of lactose, heparan sulfate and EDTA 
(Ethylenediaminetetraacetic acid) was performed in 96 well tissue culture plastic (TCP). The 
experiments were performed in triplicate. Protein coating of TCP proceeded as described for 
adhesion assays in chapter 2. In brief, 100 µl of 40 µg/ml concentration of rhTE was added to 
each well and left overnight at 4 °C. The next day each well was washed and blocked with heat 
denatured BSA (bovine serum albumin) followed by PBS (phosphate buffer solution) washing 
to remove residual BSA. Cells were prepared as before but reconstituted with serum free EBM-
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2 buffer from pellet to double the cell density of attachment assays (4 – 6 x105 cells /ml). 50 µl 
aliquots of cell suspension were added to each well. Lactose, heparan sulfate and EDTA were 
diluted to appropriate concentrations using serum-free media. 50 µl aliquots of each inhibitor 
solution were added at double the concentration to each well. OECs were allowed to attach for 
60 min at 37°C. The media solution was aspirated followed by gentle washing with PBS to 
remove non-adherent cells. Quantification of cell numbers was performed using the crystal 
violet staining method as described in chapter 2. 
3.2.8 OEC attachment to tropoelastin and constructs in cation free environment: Divalent 
cation add back assay 
Integrin-mediated interactions are dependent on divalent cations. We investigate this process 
by assessing OEC adhesion in a cation-free environment with incremental replenishment of 
select cations. Coating of TCP with rhTE and constructs followed the same methodology as 
above. Increasing concentrations of cations Ca2+, Mg2+ and Mn2+ were prepared using cation 
free HEPES buffer. OECs were lifted from near-confluent flasks and resuspended in cation 
free HEPES to a density of 4 – 6 x105 cells /ml. 50 µl aliquots of divalent cations and OECs 
were mixed and added to 96 well TCP. Adhesion assay proceeded for 60 min at 37 º C and cell 
numbers were quantified using crystal violet. 
3.2.9 Anti-integrin blocking antibody inhibition of OEC attachment and spreading 
We used a panel of anti-integrin blocking antibodies (α2β1, α5β1, αVβ3) to determine which 
integrin contributed to the interaction between OECs and tropoelastin / constructs. OECs were 
harvested and resuspended using serum free EBM-2 media to a density of 2 – 3 x 105 cells/ml. 
1 ml of cells were placed into Eppendorf tubes. Integrin blocking antibodies were added to the 
tubes to a concentration of 30 μg/ml and left in the incubator at 37 °C for 1 hour. 100 μl of each 
antibody and cell mix was added to BSA blocked TCP coated with protein/fragments. After 60 
min of adhesion cells were quantified using crystal violet. For spreading assays, the cell density 
used was reduced to 1 x 105 cells/ml with incubation for 2 hours on protein coated TCP before 
fixing and imaging. Determination of cell spreading followed the same method as described in 
chapter 2. 
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3.2.10 Attachment, spreading and proliferation on tropoelastin constructs 
Attachment, spreading and proliferation of OECs on N10, N18, N25 and Peptide 36 (containing 
fibroblast adhesion motif GRKRK) was performed in order to map the binding site responsible 
for the interaction observed between rhTE and OECs. Assays proceeded as described for full-
length rhTE in chapter 2 and will be briefly described here. Increasing concentrations of 
constructs were coated on 96 well TCP overnight and blocked with heat denatured BSA the 
following morning. OECs were trypsinized and resuspended in serum free media. Adhesion 
and spreading proceeded in 37°C incubators for 60 min and 120 min, respectively. 
Quantification of adherent cells was done using crystal violet staining and cell spreading was 
determined using morphological appearance of the cells seen with microscopy. Proliferative 
studies were conducted over 3 and 5 days in larger 24 well TCP pre-coated with constructs. All 
solutions and proteins were sterile filtered. Crystal violet staining was used to quantify the 
amount of cells present at the end of each time point. 
3.3 Results 
3.3.1 SDS Page 
Electrophoresis gel results are shown below in Figure 3.3. Sizes of N25, N18 and N10 domains 
are shown relative to full length rhTE. 
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Figure 3.3. Gel electrophoresis of recombinant human tropoelastin and N-terminal 
constructs. 
3.3.2 EDTA but not lactose or heparan sulfate inhibits OEC attachment to recombinant 
human tropoelastin 
OEC attachment to rhTE proceeded in the presence of increasing concentrations of inhibitors 
(Figure 3.4). The inclusion of heparan sulfate up to a concentration of 10 g/ml had no impact 
on the adhesion of OECs to rhTE. Similarly, when lactose α or β up to a concentration of 10 
mM was added to OECs it did not lead to a disturbance in attachment. Incorporation of EDTA 
had an entirely different effect. A dose dependent inhibition of OEC attachment can be seen 
with increasing EDTA concentration. At a concentration of 10 mM OEC attachment was 10.9 
± 1.6%, representing an 81.3 ± 2.7 % decrease in adhesion compared to no EDTA addition (P 
< 0.0001). 
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Figure 3.4. OEC attachment in the presence of the inhibitors heparan sulfate, lactose 
and EDTA. 
3.3.3 Recovery of OEC attachment is dependent on the divalent cation manganese 
Integrin mediated interactions are dependent on divalent cations [365]. OECs were suspended 
in divalent cation free HEPES buffer and added to rhTE coated TCP for 60 min. A 
concentration gradient of Ca2+, Mn2+ and Mg2+ was added back to the buffer (Figure 3.5). In 
the absence of cations OEC attachment was greatly impaired, reaching only baseline levels of 
14.9 ± 0.4 %. With rising Mn2+ concentrations in the cell solution complete recovery of OEC 
attachment was achieved (67.9 ± 3.7 %, P <0.0001). Mg2+ on the other hand promoted a modest 
level of adhesion of 37.4 ± 2.8%. In contrast the addition of Ca2+ gave the lowest level of cell 
adhesion, 24.6 ± 2.8 %. Taken together both the loss of cell attachment in the absence of cations 
and subsequent full recovery with the addition of Mn2+ points to a cation dependent process of 
OEC and rhTE interaction. 
107 
 
Figure 3.5. OEC adhesion in cation-free buffer with repletion of cations. 
3.3.4 OEC interaction with recombinant human tropoelastin is mediated by integrin 
αVβ3 
Inhibition of OEC adhesion to rhTE by EDTA (a divalent cation chelator) and restoration to 
full levels of attachment with divalent cations (Mn2+) strongly suggested an integrin-mediated 
process. Anti-integrin blocking antibodies αVβ3, α2β1 and α5β1 were separately incubated 
with OECs for 60 min to allow adequate antibody to integrin binding before proceeding with 
adhesion or spreading assays. 
Adhesion levels for OECs incubated with α2β1 and α5β1 anti-integrin antibodies were 62.8 ± 
2.9 % and 62.6 ± 2.5 %, respectively (Figure 3.6). This was not dissimilar to control values 
(no antibody) of 59.5 ± 4.6%, P = NS, >0.05). In contrast the addition of αVβ3 led to a 
pronounced decrease in cell adhesion to 34.2 ± 1.9 %, P < 0.0001). 
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Figure 3.6. Inhibition of OEC attachment by anti-integrin antibodies. 
Next we examined the effect of anti-integrin antibodies on OEC spreading. Anti-integrin 
blocking antibodies αVβ3, α2β1 and α5β1 were incubated with OECs for 60 min before the 
cell suspension was added to rhTE coated wells and allowed to incubate for 120 min. OEC 
spreading in the presence of each anti-integrin antibody is shown below (Figure 3.7). 
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Figure 3.7. OEC spreading in the presence anti-integrin antibodies. 
α2β1 and α5β1 anti-integrin antibodies did not blunt the spreading of OECs on rhTE, with 
levels of 61.2 ± 5.6% and 62.6 ± 6.9%, respectively, NS, P = 0.9. OEC spreading in the absence 
of any blocking antibodies was similar at 60.3 ± 10.4 %, NS, P = 0.9. In contrast the inclusion 
of αVβ3 led to a significant inhibition of OEC spreading to 26.5 ± 5.9%, P = 0.002. This 
represented a 2.27-fold decrease in spreading when compared to the absence of anti-integrin 
antibody. 
Microscopy images of the OECs are shown below (Figure 3.8). Comparable numbers of spread 
(phase dark) and unspread (phase bright) OECs are seen for no antibody, α2β1 and α5β1 panels. 
A different appearance for cells incubated with αVβ3 is evident with the majority of OECs 
unspread with bright nuclei and minimal cytoplasmic projection. Taken together αVβ3 inhibits 
both OEC attachment and spreading on rhTE. 
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Figure 3.8. Phase contrast microscopy of OECs spreading on full-length rhTE in the 
presence anti-integrin antibodies. 
3.3.5 N-terminal domains of tropoelastin support OEC attachment, spreading and 
proliferation 
Sites of cell interaction on rhTE appear to differ between cells. Fibroblasts were originally 
shown to bind to the C-terminus via an integrin-mediated mechanism [269]. Recently the same 
group demonstrated that the central domains of rhTE can also support fibroblast adhesion 
[366]. Endothelial cells appear to interact with the first 10 N-terminal domains but poorly 
adhere to the C-terminus [357]. We sought to determine the region of interaction between 
OECs and rhTE through the use of N-terminal and C-terminal constructs. 
We began with N-terminal domains starting with the longest N25 construct and moving to 
successive shorter N18 and N10. Adhesion assays proceeded as for full-length rhTE with 
preincubation of TCP with increasing concentrations of N25 and cell adhesion for 60 min. 
Figure 3.9 shows the percentage of OEC cells attached as a function of the concentration of 
N25. A characteristic curve is noted which mirrors that of full-length rhTE (chapter 2). 
Attachment is dose-dependent and rises gradually towards a plateau. Adhesion reached 39 ± 
0.7 % (10 μg/ml) to 48.7 ± 2.3% (40 μg/ml). While numerically higher at 40 μg/ml this was 
not statistically significant, P >0.05) 
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Figure 3.9. OEC adhesion as a function of increasing concentrations of N25 construct. 
Having established that N25 can support OEC adhesion, we examined if this was maintained 
with the shorter N18 construct. The attachment curve is shown below in Figure 3.10. A 
comparable graph to N25 is noted, represented by a dose-dependent attachment profile. 
Attachment levels ranged from 42.4 ± 3.3 % (10 μg/ml) to 47.56 ± 5.1% (40 μg/ml), there was 
no statistical difference between these values. Notably OECs adhered to N18 just as well as the 
N25. 
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Figure 3.10. OEC attachment as a function of N18 concentration. 
Our findings prompted us to proceed to the even shorter N10 construct to determine if the 
interaction site maybe encapsulated within this region (Figure 3.11). We initially coated up to 
40 μg/ml of N10 construct on to TCP. Surprisingly attachment of OECs were significantly less 
than N25 and N18, reaching approximately 19.2 ± 2.9% (10 μg/ml) to 23 ± 1.2 % (40 μg/ml), 
no statistically significance between the concentrations were noted. Given the shorter length of 
the construct we hypothesized that the diminished adherence may reflect the need for a higher 
concentration of protein/binding sites for biological effect. Using concentrations up to 100 
μg/ml we found adhesion was not improved, reaching a peak of 25.9 ± 2.9% at 100 μg/ml. This 
was not significantly different from 40 μg/ml, P = 0.19. In light of these findings the first 10 
domains of the N-terminus do not appear to contain a robust adhesion site for OECs and does 
not account for attachment to rhTE. 
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Figure 3.11. OEC attachment to N10. Top graph shows initial concentrations up to 40 
μg/ml. Lower graph OEC adhesion with protein concentration increased to 100 μg/ml. 
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3.3.6 C-terminus of tropoelastin does not support OEC attachment 
The tropoelastin C-terminus has been extensively studied for the ability to support cell binding. 
An integrin-mediated mechanism was discovered for HDFs and the last 36 peptides from the 
C-terminal region (Pep36), more specifically the GRKRK motif [269]. Recently it was found 
that the Pep36 did not universally support cell adhesion, with limited affinity of human 
umbilical vein endothelial cells (HUVECs) for this region [357]. We sought to determine the 
interaction between Pep36 and OECs. Increasing concentrations of Pep36 was coated on to 
TCP. The attachment curve is shown in Figure 3.12. Poor adhesion to Pep36 is seen without 
any relationship to protein concentration. Even at the highest concentration of Pep 36, 
attachment reached only 5.7 ± 0.34%, not dissimilar from background (Pep 36 concentration 0 
μg/ml). In stark contrast to fibroblasts, the C-terminus does not support OEC adhesion in a 
meaningful way. 
 
Figure 3.12. OEC attachment to C-terminus peptide 36 fragment. 
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3.3.7 N-terminus N25 and N18 support OEC spreading and proliferation to a comparable 
level 
Having established that OECs can adhere to N25 and N18 we next assessed the capacity of 
these domains to support OEC spreading and proliferation. For spreading assays N25 and N18 
were coated on to 96 well TCP and OECs incubated for 120 min at 37 °C. We found OECs 
spread on N25 and N18 in a dose dependent manner to equivalent levels of 55.9 ± 3.7% and 
56.7 ± 1.9 %, P = 0.95. The uptake of the spreading curve is reminiscent of cell adhesion, with 
a slower upstroke and reaching a plateau at approximately 10 – 20 μg / ml of protein 
concentration (Figure 3.13). Microscopy images of OEC are shown in Figure 3.14. 
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Figure 3.13. OEC spreading on N18 (top) and N25 (bottom) constructs with increasing 
protein concentration. 
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Figure 3.14. Phase contrast microscopy of OECs spreading on N25 and N18 constructs. 
Unspread cells are seen as small phase bright structures. Spread cells display darker 
nuclei with developing cytoplasmic projections. 
In striking difference, microscopy images of OEC spreading on N10 (100 μg / ml) is shown in 
Figure 3.15. Here the cells are poorly spread as seen by the phase bright nature of the nucleus 
and the lack of cytoplasmic projections. This finding is not surprising given the absence of 
OEC adhesion on N10. 
 
Figure 3.15. Phase contrast microscope of OEC spreading on N10 construct. 
OEC proliferation on N25 and N18 was quantified with rhTE as a comparator and allowed to 
proceed for day 3 and 5. Despite lower adhesion and spreading than full-length rhTE we found 
comparable amount of proliferation between the constructs and rhTE (Figure 3.16). 
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Figure 3.16. OEC proliferation on N-terminal constructs and rhTE, over day 3 and 5. 
On day 3 absorbance values were 0.26, 0.22 and 0.2 for rhTE, N18 and N25, respectively, P > 
0.05, non-significant). By day 5 all three proteins were able to augment proliferation, by 1.76, 
1.77 and 1.9 fold, for rhTE, N18 and N25 respectively. Absorbance values for day 5 were non 
significantly different from each other, p > 0.05. 
3.3.8 N25 and N18 terminus interactions are integrin-dependent 
We established OEC interactions with rhTE is independent of the C-terminus but is centred on 
the N-terminus. We showed that the nature of interaction between full-length tropoelastin and 
OECs is divalent cation dependent and mediated through the integrin αVβ3. Here we explore 
this phenomenon with N25 and N18 constructs. 
40 μg/ml concentration of N25 and N18 were coated on TCP and cells were prepared in serum 
free media as for adhesion assays. Increasing concentrations of lactose, heparan sulfate and 
EDTA were made. Double concentrations of inhibitors and cell suspension were added in a 
one to one ratio to a total volume of 100 μg/ml with OECs allowed to attach for 60 min in 37 
°C. 
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Incorporation of lactose α, β and heparan sulfate up to a concentration of 10 mM and μg/ml, 
respectively for both N25 and N18 did not impact on the level of OEC attachment. Similar to 
our findings for full-length rhTE we noted that a concentration-dependent effect was observed 
with the addition of EDTA, a progressive reduction in OEC adhesion. At 10 mM EDTA 
concentration OEC attachment was 11.7 ± 0.06% and 11.9 ± 0.9% for N25 and N18 constructs 
respectively (Figure 3.17). 
 
 
Figure 3.17. OEC attachment on to N25 (top graph) and N18 (lower graph) in the 
presence of increasing heparan sulfate, lactose and EDTA concentration. 
120 
EDTA inhibition of attachment suggested an integrin-mediated mechanism of interaction 
between OECs and N25/N18 constructs. We further assessed this by attaching OECs in 
divalent cation depleted HEPES Buffer and then incrementally adding back the cations. The 
attachment curve is shown below in Figure 3.18 and 3.19. Adhesion curve of N25 was 
analogous to that of N18, defined by a complete restoration of OEC attachment with escalating 
concentrations of Manganese. Magnesium addition into the cell suspension resulted in a modest 
increase in adhesion. On the other hand, calcium repletion produced only minimal 
improvement in cell attachment. These findings mirror the results seen with full-length rhTE, 
further supporting the interaction between OEC and N-terminal domains is mediated by 
integrins. 
 
Figure 3.18. Divalent cation add back to OEC attaching to N25 construct. 
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Figure 3.19. Divalent cation add back to OEC attaching to N18 construct. 
Using anti-integrin blocking antibodies we implicated the integrin αVβ3 in the mediation of 
OEC adhesion to full-length rhTE. Allowing time for antibody blocking of integrin receptors 
we preincubated OECs suspended in serum free media with antibodies for 1 hour prior to 
placing the cells in TCP wells. Effect of the blocking antibodies on OEC spreading is 
represented graphically in Figure 3.20. 
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Figure 3.20. OEC spreading on N25 (Top) and N18 (Bottom) in the presence of anti-
integrin antibodies. 
Inclusion of α5β1 anti-integrin antibody did not impact spreading of OECs on both N25 and 
N18 which was similar to control (58.4 ± 2.8 % and 55.5 ± 6.2%, N25 and N18, respectively, 
P >0.05). Inhibition of OEC spreading on N25 and N18 by αVβ3 was significant, with a 
reduction in spreading to 33 ± 4.5 % and 35.2 ± 7.9 %, for N25 and N18, respectively. This is 
consistent with the results seen with full-length rhTE. Images of OECs taken with phase 
contrast microscope is shown in Figure 3.21. Without the addition of antibodies the cells can 
be seen as a mixture of both spread and unspread states. When αVβ3 is included during 
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spreading, the cells were predominantly in un-spread states, characterized by bright small cells 
with minimal cytoplasm. 
 
Figure 3.21. Phase contrast microscopy of OECs spreading on N25 and N18 with anti-
integrin antibodies. 
3.4 Discussion 
In chapter 2 we established that recombinant human tropoelastin can support OEC attachment, 
spreading and proliferation in a concentration-dependent manner. Using well validated 
methods [269, 351] we explore in this chapter the mechanism underlying this interaction and 
aimed to determine the region on rhTE responsible for OEC adhesion. 
3.4.1 Integrin αVβ3 mediates OEC attachment and spreading on rhTE 
Tropoelastin interaction with cells is mediated via three main mechanisms 1) integrin, 2) elastin 
bind protein (EBP) and 3) cell surface glycosaminoglycans (GAGs). The addition of lactose is 
known to block EBP mediated binding of cells to tropoelastin [358]. Similarly, heparan sulfate 
can be used to the same effect with GAG mediated adhesion [269]. We added increasing 
concentrations of heparan sulfate and lactose during cell adhesion in an attempt to inhibit 
possible EBP or GAG mediated attachment. However, despite going to 10 mM or 10 μg / ml 
of lactose or heparan sulfate, respectively, we were unable to reduce adhesion of OECs to rhTE. 
Collectively, these results exclude EBP and GAG as potential mediators of OEC and rhTE 
interactions. 
We next exploited the fact that integrin function is modulated by divalent cations. Ligand 
binding to integrins is facilitated by divalent cation binding at the metal ion-dependent adhesion 
site on α or β domains [365]. In the absence of cations, ligand binding is impaired [367]. EDTA 
is a cation chelator and has been used to reduce the cation levels in solution [368]. We 
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introduced increasing amount of EDTA with the goal of progressively depleting cation levels 
in the cell suspension. We noted a concentration dependent negative effect on OEC adhesion 
with EDTA addition. To confirm these results we performed the converse assay in which OECs 
were suspended in divalent cation free HEPES buffer and then determined cell adhesion when 
individual cations were reintroduced. The findings were consistent with a divalent cation-
dependent cell attachment process. More specifically we found Manganese alone was able to 
fully recover cell adhesion. Manganese has being implicated in integrin to ligand binding, in 
particular the integrin αVβ3 [369]. Manganese has been reported to induce strong ligand 
affinity in αVβ3 [370]. 
Using a panel of anti-integrin blocking antibodies we sought to ascertain the integrin involved 
in OEC adhesion. Antibodies to α2β1 and α5β1 had no effect on either OEC attachment or 
spreading. α2β1 typically interacts with collagen via the GFOGER motif [371] and α5β1 binds 
to fibronectin through an RGD motif [372]. rhTE on the other hand does not contain either of 
these motifs [373]. In contrast, αVβ3 significantly inhibits both adhesion and spreading of 
OECs on rhTE, reflecting the findings reported by Bax et al for HDFs [269]. The extent of 
inhibition was however lower than for fibroblasts. Other authors have observed similar levels 
of inhibition with mature endothelial cells and attributed this to multiple redundant integrins 
on endothelial cells contributing to adhesion [374]. Extrapolating from our findings an integrin 
but not a GAG or EBP mechanism mediates OEC interaction with rhTE, with αVβ3 being a 
major integrin involved in this process. 
3.4.2 OEC binding region on rhTE can be mapped to a region between domain N10 – N18 
Conflicting information exists for the capacity of the N-terminus to support cell attachment. 
Early studies examined exclusively the C-terminus as a site for cell adhesion. Recently, 2 
studies have interrogated the N-terminus as a potential region for cell attachment. However, it 
is interesting to note that the actual region responsible for adhesion varies between cells. 
HUVECs preferentially attached to N18 and N10 regions to comparative levels with lower 
attachment to N25. The C-terminus did not support HUVEC adhesion in difference to HDFs 
[357]. HDF adhesion was found to be independent of the N10 domain, with very low affinity 
for this region. The authors mapped the adhesion site to the N-terminal domain 16-17 mediated 
by integrin αVβ5, although αVβ3 inhibition was not assessed [366]. 
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Using Pep36, the last 36 peptides of the C-terminus containing the integrin mediated fibroblast 
attachment site GRKRK we discovered a lack OEC attachment to this region, despite using 
supra-maximal concentrations. We then started with the longest N-terminal construct N25, 
finding modest support for OEC adhesion and spreading. Using the N18 construct we 
discovered comparable levels of OEC activity, this suggested that the cell active site was 
contained within the N18 with N18-N25 region redundant. Further truncating the constructs 
we examined if cell activity could be preserved with N10. Surprisingly, in contrast to HUVEC 
we discovered strikingly lower OEC affinity for N10, despite using concentrations up to 100 
μg/ml. Extrapolating from these results the N10 domain lacks cell binding capacity. Taken 
together the OEC attachment pattern points to a region between N10 – N18 domains of rhTE 
as the site of adhesion. 
Following a similar approach to full-length tropoelastin we sought to identify the cell receptor 
responsible for OEC and N-terminus domain interactions. To ensure consistency and 
reproducibility of results we examined N25 and N18 constructs together with results 
unsurprisingly consistent with that of full-length tropoelastin. The combination of EDTA 
modulation of OEC attachment and manganese dependent recovery of OEC interaction in 
divalent cation free buffer was indicative of an integrin-mediated process. More specifically 
using αVβ3 OEC spreading was significantly reduced on both N25 and N18 fragments, 
confirming the important role of this integrin in mediating rhTE and OEC interactions. 
3.5 Conclusion 
In this chapter we determined that the binding site for rhTE did not reside in the C-terminus 
consistent with reported findings for HUVECs. An integrin binding mechanism was 
established and attributed to the integrin αVβ3. However, we note that inhibition of OEC 
activity was not absolute, pointing to additional integrins compensating for this receptor 
blockade. Indeed, published work after completion of this study showed a role for integrin 
αVβ5 in fibroblast attachment to the central region of tropoelastin. As suggested by Wilson et 
al, the blockade of one integrin receptor is unlikely to completely abolish cellular interaction 
with rhTE [279]. 
Utilizing progressively shorter N-terminus constructs we were able to isolate OEC binding to 
a region lying between N10-N18. However, the level of adhesion was lower than that seen on 
full length tropoelastin implicating the possibility of additional binding sites lying between 
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N25 and the C-terminus, offering scope for future exploration of tropoelastin and OEC 
interactions. 
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Chapter 4: Optimization of Plasma Polymerization: Creation and 
Analysis of Nitrogenized Plasma Polymers 
4.1 Introduction 
The aim of this chapter is to optimize a purpose built plasma polymer deposition chamber for 
uniformity of thin film coating and consistency of deposition rate. Furthermore, we created 
nitrogenized plasma polymers by increasing nitrogen gas flow during the polymerization 
process. Using complimentary methods including attenuated total reflection (ATR) fourier 
transform infrared spectroscopy (FTIR), x-ray photoelectron spectroscopy (XPS), 
ellipsometry, raman spectroscopy and atomic force microscopy (AFM) analysis, we 
comprehensively characterize the physical and chemical properties of nitrogenized plasma 
polymers. 
Plasma modification of biomaterials can alter the chemical and surface properties of materials 
without changing the physical bulk characteristics. Radiofrequency (RF) is a widely used 
method for plasma generation, where an electrical field is applied to a gas/gases. When 
sufficient energy is applied to gas atoms, electrons are ejected leading to the creation of charged 
particles. Electrons accelerated by the electrical field collide with and ionize additional gas 
atoms creating an ionization avalanche that results in a quasi-neutral cloud of positive ions, 
electrons and radicals. Polymers have become increasingly used in biomedical applications 
such as vascular grafts and catheters [375]. The benefits of elasticity, chemical inertness and 
ease of construction are offered by these materials [376]. Plasma technology has been 
employed to enhance the surface properties of these polymers for biocompatibility by altering 
a range of physical and chemical properties including surface energy-wettability, hardness, 
wear resistance and surface functional groups [255]. A typical RF plasma chamber is shown in 
Figure 4.1 
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Figure 4.1. Schematic representation of radiofrequency plasma chamber. A substrate 
(a) is immersed in the plasma (b) generated by applying a voltage between electrodes (e) 
to provide an electric field across injected gases (c). The chamber pressure is regulated 
by inflow of gases and the extraction pump (d). 
When a material is placed in plasma the surface is exposed to highly reactive and energetic 
species. The energetic collisions between these species and the polymer leads to dissociation 
of bonding between polymer components with fragmentation, free radical generation and cross 
linking of reactive fragments [377]. The degree of free radical generation, fragmentation and 
depth of collisions depends on the energy of the ions. A limitation of RF plasmas is the 
relatively low energy of ion bombardment. 
Plasma immersion ion implantation (PIII) represented an important advancement to circumvent 
this limitation (Figure 4.2). A pulse generator is used to apply a significant pulsed negative 
bias (ranging from 1 to 300 kV) to the substrate [378]. The use of negative bias creates a high 
voltage sheath, electrons are repelled from the substrate surface while the positive ions are 
accelerated towards the substrate [379]. The ions gain energy in the sheath and in turn impact 
the substrate with more energy and penetrate to a greater depth. PIII has been used in a wide 
range of medical applications, for example enhancing wear resistance of titanium oxide films 
[380], functionalizing titanium alloy with hydroxyl moieties for improved osteointegration 
[381] and fabrication of diamond like carbon (DLC) thin films [382]. 
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Figure 4.2. Schematic representation of a plasma immersion ion implantation chamber. 
The lower electrode is connected to a pulse generator which can bias the substrate with 
a large negative voltage. Ions (positive charged species) are accelerated towards the 
substrate gaining much higher energies than in conventional plasma chambers. 
More recently, work on PIII has expanded the use of this technique for linker free covalent 
bonding of molecules on to polymer surfaces. The linking of biomolecules to surfaces has been 
used to enhance the bioactivity of substrates. The range of medical applications include 
biosensors exploiting immobilized antibodies for rapid detection of diseases and attachment of 
biocompatibility enhancing molecules such as heparin, albumin and cell adhesion proteins 
[383-386]. A key requirement for robust surface immobilization of molecules is covalent 
attachment. This coupling has been previously achieved with the use of complicated chemical 
linkers groups (Figure 4.3) such as carbodiimide and glutaraldehyde, which covalently 
conjugate proteins onto carboxylated and amino containing polymers, respectively [387]. 
 
Figure 4.3. Schematic of covalent protein attachment using linker groups. (adapted 
from J. Am. Chem. Soc, 2010, 132 [388]) 
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Chemical linker-based covalent bonding can be a cumbersome process prompting the 
development of linker free methods. PIII treatment of polymers can create highly crossed 
linked surfaces containing a large reservoir of free radicals [389]. Covalent bonding (Figure 
4.4) occurs between these highly reactive free radicals and protein terminal groups or side 
chains [268]. PIII treated polymers demonstrated remarkable resistance to sodium dodecyl 
sulfate (SDS) removal of surface bound proteins. When compared to plasma treatment, the use 
of PIII extended the covalent binding capability of the surface along with preservation of 
biomolecule function [390]. Polytetrafluoroethylene (PTFE) which typically has poor cell 
adhesive qualities can be covalently functionalized with collagen following PIII treatment 
resulting in enhanced dermal fibroblast attachment [391]. 
 
Figure 4.4. Free radical mediated linker free covalent bonding. Initially proteins are 
physisorbed on to the polymer surface. Surface located free radicals which have 
migrated from the polymer bulk form covalent bonds with the protein. 
Linker free covalent bonding has important biocompatibility implications beyond the 
immobilization of biomolecules. When a coronary stent is exposed to the in vivo environment, 
rapid physisorption of plasma proteins on to the stent surface occurs [143]. In fact, this protein 
layer acts as the real interface between the stent surface and the cellular/protein systems in 
plasma. The composition and more importantly the conformation of this protein layer 
determines if the surface is seen as foreign or native [392]. Soluble fibrinogen (Fg) does not 
usually activate platelets, however when Fg is adsorbed on to unfavorable biomaterial surfaces 
denaturing occurs leading to activation of platelets [68, 77]. Generally, hydrophobic surfaces 
induce a greater protein unfolding and loss of native conformation. In contrast, hydrophilic 
surfaces tend to promote the preservation of protein structure [393]. Hydrophilic surfaces do 
not retain adsorbed proteins well and a dynamic exchange of initially adsorbed proteins and 
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plasma proteins occur altering the composition of this layer [394]. Control of this process is 
crucial and can be facilitated by covalent bonding. Firstly, covalent attachment of molecules 
could result in a more consistent protein layer less susceptible to competing adsorption kinetics 
of plasma proteins. Secondly, the plasma treated surface is highly oxidized by reactions of 
radicals with atmospheric oxygen, making it hydrophilic and ensuring retention of native-like 
protein confirmation. This phenomenon is illustrated by the preservation of the bioactivity of 
enzymes covalently attached to PIII treatment surfaces [395]. 
Initial work done with PIII and covalent attachment of proteins paved the way for adaptation 
of this method for plasma polymerization. Plasma polymerization occurs when an organic low 
molecular weight gas such as benzene is used in plasma. Through energetic collisions the 
organic gas is broken into carbon radicals which deposit on to the substrate in the form of 
highly cross linked non repeating units with free radicals within the network. This cross linked 
carbon based film is called plasma polymer. Plasma polymers can be deposited onto a variety 
of substrates independent of the geometry, have good substrate adhesion and physical-chemical 
stability [396]. These advantages give plasma polymerization particular relevance for vascular 
applications. The vast majority of coronary stents are constructed from metallic alloys. Metals 
offer the advantage of durability and mechanical strength but have limited biocompatibility 
due to inherent thrombogenicity. Plasma polymerization can deposit a thin carbon film on to 
the stent surface, enhancing the biocompatibility while retaining the key mechanical strengths 
of the bulk material. As in PIII, negative bias pulses can also be applied to the substrate during 
plasma polymerization to provide more energetic ion bombardment. A combination of 
polymerization, cross linking and free radical generation occurs on the surface [268]. Plasma 
polymer deposited with bias had significantly better retention of protein activity than plasma 
polymer without bias [397]. 
Using plasma polymerization with bias a plasma activated coating (PAC) capable of covalent 
bonding of recombinant human tropoelastin (rhTE) has previously been reported [281]. An 
improvement in thrombogenicity was demonstrated with PAC when compared to 316L 
stainless steel (316L SS) [258]. Functionalization of rhTE on to PAC enhanced the 
endothelialization of this platform. Importantly this polymerization method was adapted for 
robust coating of the complex three-dimensional structure of a coronary stent [319]. 
Tropoelastin is a good candidate molecule for bio-functionalization of PAC due to its capacity 
for pro-endothelialization and low thrombogenicity [258]. In contrast, the highly cell adhesive 
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proteins collagen and fibronectin have limited vascular application due to activation of platelets 
[398]. However, one crucial limitation of using tropoelastin is the risk of enzymatic 
degradation. In vivo tropoelastin is cleaved by serine proteases such as kallikrein and thrombin 
reducing its biological activity [399]. The durability of immobilized tropoelastin in storage and 
the possibility of allergic reactions to tropoelastin in the human environment are as yet 
unanswered concerns which can hamper the clinical translation of the tropoelastin-PAC 
platform for coronary stents. 
The goal of this work is to develop a new plasma polymer platform that addresses the 
limitations of PAC while preserving and extending its core qualities. The first objective is to 
provide the surface with the capacity to inherently enhance endothelialization independent of 
the need for biomolecule functionalization. Surfaces that can accelerate endothelialization have 
been shown to be less thrombogenic while simultaneously reducing neointimal hyperplasia 
[400]. The second goal of the new platform is to further enhance the thrombo-resistance seen 
with PAC. Finally, retention of covalent bonding in the new platform is critical. This has 
important implications for in vivo protein and surface interactions (as previous described) and 
broadens the clinical utility of this surface. For example, attachment of antimicrobial molecules 
[401] can reduce bacterial colonization or anti-mitotic agents to limit intimal hyperplasia. 
Changing the chemistry of the surface can change the way it interacts with proteins and cells. 
Plasma treatment is an excellent tool to tailor specific chemical functional groups on to the 
surface, allowing control over surface wettability, charge and the composition and state of 
proteins attached [402]. Compared to chemical graft modification and self-assembled 
monolayers, plasma based functionalization is simple, dry, controllable and can uniformly treat 
three dimensional structures [402]. In a broad sense hydrophilic surfaces are generally more 
biocompatible owing to better preservation of native protein structure [403]. Evidence for this 
can be seen with reduced platelet adhesion on more hydrophilic polymers [404]. Plasma 
polymerization can be used to coat hydrophilic films on to hydrophobic substrates improving 
biocompatibility [405]. Surface functional groups have direct impact on the cell activity [406]. 
Surfaces rich in amine (-NH2), carboxyl (-COOH) and hydroxyl (-OH) functional groups 
display enhanced cell adhesion attributed to favorable conformation of bound fibronectin with 
exposed cell binding epitopes [402]. 
Nitrogen has been used to improve biocompatibility of surfaces. Ammonia plasmas have been 
used to treat polymers, successfully functionalizing the surface with amino groups, increasing 
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wettability and hemocompatibility [407]. Yasuda et al, found plasma polymers deposited using 
ethylene and N2 gas led to significant prolongation of coagulation time [408]. Cell adhesion of 
surfaces can also be improved with the use of nitrogen gas. PTFE when modified with nitrogen 
plasma becomes more hydrophilic and an increase in endothelial attachment is seen [409]. 
These findings are also mirrored in nitrogen doped plasma polymers with benefits in improved 
cell adhesion across varying cell lines [410, 411]. Moreover, nitrogen rich plasma polymers 
appear to favorably support cell viability and metabolism [412]. 
4.2 Methods and materials 
4.2.1 Plasma polymerization 
A purpose built plasma polymerization chamber was constructed with the assistance of Dr 
Yongbai Yin (Applied Physics, University of Sydney). The chamber was not optimized prior 
to commencement of the project. Figure 4.5 shows a photorealistic representation outlining 
the key components of the system. Substrates used for deposition were 316L SS (25 μm 
thickness) or silicon wafers (p-type double side polished). 316L SS samples were cleaned with 
acetone, 80% ethanol and finally distilled water prior to use. 
 
Figure 4.5. Purpose designed plasma polymerization chamber. 
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The system consists of two electrodes spaced 10 cm apart. The top electrode is RF capacitively 
coupled at 13.56 MHz and powered using an ENI-6B RF generator through an ENI Matchwork 
matching system. The lower electrode is a negatively pulse biased electrode driven by a RUP-
6 (GBS Elektronik GmbH, Dresden, Germany) power supply. Samples were placed and 
clamped on to the flat square substrate holder (connected to the lower electrode). Samples were 
cleaned using argon plasma at a RF power of 75 W (80W transmitted and 5W reflected, with 
optimal matching) and a negative pulse bias of 750 V at 3kHz with 10 µs pulses for 10 min. 
The gas mixture during deposition consisted of acetylene (C2H2 - carbon donor gas), argon and 
nitrogen. The ratio of the gases was varied using mass flow controllers (MKS, Andover, MA), 
in order to produce samples of different nitrogen content. Total gas flow rate was kept at 15 
sccm. The chamber was modified with a variable gate between the chamber and the rotary 
pump. This allowed deposition pressures to be kept constant at 150 mTorr. The deposition 
conditions for plasma polymers with different nitrogen flow rates are shown in Table 4.1. 
Table 4.1. Deposition parameters for plasma polymers with different nitrogen content. 
 
4.2.2 Attenuated total reflection fourier transform infrared spectroscopy 
ATR-FTIR was used to determine the chemical bonding states of plasma polymer films. The 
FTIR spectra were recorded using a Digilab FTS7000 FTIR spectrometer fitted with an ATR 
accessory with a trapezium germanium crystal and incidence angle of 45°C. Samples were 
analysed with 500 scans using a resolution of 1 cm-1 in order to enhance the signal to noise 
ratio and spectral resolution. Analysis of spectra was done using GRAMS software. 
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4.2.3 X-Ray Photoelectron spectroscopy 
XPS (Specs-XPS, mode XP-50 High Performance Twin Anode with Focus 500 Ellipsoidal 
Crystal Monochromator and PHOIBOS 150 MCD-9 analyser) was utilized to provide data on 
the elemental composition of the samples. CASA XPS analytical software was used to calculate 
areas of elemental peaks with the concentration of each element expressed as an atomic 
percentage. 
4.2.4 Ellipsometry 
Ellipsometry measurements were done on plasma polymer deposited on to silicon wafers using 
a Woollam M2000D ellipsometer (J.A. Woollam). The thickness of the plasma polymers and 
optical constants including refractive index were determined using a Cauchy layer model with 
the WVASE32 software. 
4.2.5 Raman spectroscopy 
Raman spectroscopy was used to characterize the bonding of carbon in the plasma polymers. 
The raman spectra were measured using a Renishaw raman spectrometer equipped with Leica 
microscope (objective x50, 1800 geometry of illumination, notch filter for excitation beam, 
CCD matrix detector of 2400 l/mm) and Kr-Ar mixture laser (413 nm) as the excitation source. 
The resolution of the instrument was 2 cm-1 in the scan range from 1000 to 3000 cm-1. The 
spectra were analysed using GRAMS software. 
4.2.6 Atomic force microscopy 
To analyse changes to morphology and roughness three-dimensional images of plasma 
polymer surface were obtained using AFM (MFP-3D-Bio, Asylum Research). Each sample 
was placed on a magnetic stub and scanned in AC mode using a medium-soft silicon cantilever 
(OMCL-AC240, Olympus) with nominal spring constant 2N/m. Scan sizes of 2×2 µm were 
used for image analysis. 
XPS, FITR, raman measurements and data analysis were done with guidance and support from 
Dr Alexey Kondyurin (Applied Physics, University of Sydney). 
AFM images were taken by Dr Wojciech Chrzanowski, analysis of data was performed with 
his guidance (Pharmacy, University of Sydney). 
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4.2.7 Covalent bonding 
Triplicate 316L SS and plasma polymerized 316L SS samples (1.2 x 0.8 cm) were incubated 
overnight at 4°C in 24 well plates coated with 40 µg/ ml of rhTE. Unbound protein was 
aspirated and washed 3 times with PBS (phosphate buffer solution). Control samples with 
attached protein were left in PBS and not exposed to SDS. Test samples were placed in 5% 
SDS (w/v) in PBS and incubated at 90°C for 10 min, following which the samples were washed 
extensively with PBS to remove any residual SDS. The control samples were similarly washed 
with PBS. The samples were returned to new 24 well plates and blocked for 1 hour with 3% 
(w/v) bovine serum albumin (BSA) to prevent non-specific antibody binding. After blocking 
with BSA, anti-elastin antibody (1:2000, mouse) was added and allowed to incubate for 1 hour 
following which samples were incubated with anti-mouse IgG-HRP conjugated secondary 
antibody (1:250) for 1 hour. After each step the samples were washed 3 times with PBS. The 
samples were moved into new 24 well plates and ABTS solution (40 mM ABTS in 0.1 M 
NaOAc, 0.05 M NaH2PO4, containing 0.01% (v/v) H2O2) was added at 37 °C for 30 min. 100 
μl volume of solution from each well was transferred to a 96 well plate for reading of the 
absorbance at 405 nm on a plate reader. 
4.3 Results 
4.3.1 Optimizing plasma polymerization chamber for uniform polymer deposition 
The chamber configuration was optimized to ensure a uniform coating of the plasma polymer 
on to the samples. Figure 4.6 is a schematic of the different configurations of the gas inlet. 
Position A, the gas inlet is positioned to the right side above the substrate holder. In Position 
B, the inlet was moved to below the substrate holder. Position C, a rubber conduit with evenly 
spaced holes was connected to the gas inlet and fashion into a circular shower head 
configuration and placed circumferentially around the top most edge of the chamber. 
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Figure 4.6. Schematic representation of plasma deposition chamber. Position A, gas 
inlet is positioned above the substrate. Position B, gas inlet is placed below the substrate. 
Position C, gas inlet with shower head configuration. Red arrows represent general 
direction of gas inflow into the chamber. 
The uniformity of the chemical composition and thickness of the coating was determined using 
a combination of visual examination, FTIR and ellipsometry analysis. For uniformity analysis, 
plasma polymers were deposited using argon, acetylene and nitrogen gas (gas flow at 5 sccm 
for each gas) on to 316L SS pieces measuring 6 cm x 5 cm or silicon wafers. On each piece the 
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side closest to the gas inlet was marked. After deposition the polymerized steel pieces were cut 
into 5 strips of 1 cm x 6 cm and interrogated with FTIR (Figure 4.7). The FTIR spectral lines 
at wave lengths 1702 cm-1, 1530 cm-1, 1452 cm-1 and 1378 cm-1, corresponding to vibrations 
of C=O, NH, CH2 and CH3 functional groups respectively, were used to get an overview of the 
chemical composition of the surface. Coating thickness was determined using ellipsometry 
study of plasma polymerized silicon wafers. Measurements across the surface were made at 1 
cm intervals. 
 
Figure 4.7. Subdivision of polymerized 316L SS for FTIR study. 5 strips of 1 cm x 6 cm 
dimensions were cut for FTIR analysis. Position of gas inlet is shown. This however 
applies to position A and position B. In position C the gas inlet is above the substrate. 
Gas inlet at position A resulted in a non-uniform plasma polymer coating. This was evident 
(not shown) on gross appearance where a color gradient from dark yellow (side closest to gas 
inlet) to light yellow could be seen. Not unexpectedly a decline in the amount of functional 
groups present in the plasma polymer occurred the further away from the (Figure 4.8) gas inlet. 
Mirroring these findings, a gradient of polymer thickness is also evident (Figure 4.9). Taken 
together, with the gas inlet at position A thickness of the deposited plasma polymer was not 
uniform with greater thickness the closer to the gas inlet. 
139 
 
Figure 4.8. FTIR analysis of chemical functional groups found in the plasma polymer at 
different distances from the gas inlet (position A). 
 
Figure 4.9. Thickness of the plasma polymer at different distances away from the gas 
inlet (position A). 
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In position B, the gas inlet was placed well below the substrate holder, conceivably producing 
a more uniform distribution of plasma density superiorly. Disappointingly visual inspection 
readily demonstrated a color gradient on the surface (dark yellow to light yellow). This was 
confirmed by FTIR analysis (Figure 4.10) where a gradient in surface chemical functional 
groups persisted. 
 
Figures 4.10. FTIR analysis of plasma polymer chemical functional groups relative to 
the gas inlet (position B). 
Using a shower head configuration in position C ensured that the gases did not enter the 
chamber from a single point. A significant improvement in uniformity was achieved, with a 
more consistent intensity of functional groups (Figure 4.11) and polymer thickness (Figure 
4.12) across the coating surface. The color of the coating reflect this with a consistent light 
yellow from edge to edge of the sample. 
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Figures 4.11. FTIR analysis of plasma polymer chemical functional groups across the 
plasma polymer surface (position C). 
 
Figure 4.12. Thickness of plasma polymer across the plasma polymer surface (position 
C). 
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4.3.2 Rate of deposition 
The relationship between thickness of the deposited plasma polymer and time of treatment in 
the chamber was assessed. 2 cm x 2 cm pieces of silicon wafer was placed centrally on the 
substrate holder and treated for a define time. Thickness of the deposited plasma polymer was 
determined using ellipsometry measurements. The deposition was performed with 
progressively longer time points for each gas mixture. Different deposition time points were 
done over 4-5 days to ensure there were no significant day-to-day variations in the gas flow 
controllers, power source generator and vacuum pump that could affect consistency of 
polymerization. 
Figure 4.13 shows the polymer thickness as a function of time generated under gas mixture 
condition 1 (refer to Table 4.1). The data points showed a linear relationship between polymer 
thickness and time. Linear regression was applied to the data points with a R2 = 0.9908 
reflecting a good fit. 
 
Figure 4.13. Deposition rate for condition 1 (Nitrogen flow rate 0 sccm). 
Figure 4.14 and 4.15, shows a similar data representation for gas mixture conditions 2 and 3. 
The introduction of nitrogen gas did not affect the linear nature of the relationship between 
polymer thickness and time of deposition. The slope of the fitted line decreased with increasing 
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nitrogen flow - 20, 18.38 and 17.06 for a nitrogen flow of 0, 1 and 5 sccm, respectively. The 
color of the plasma polymer became darker and yellow-brownish as the thickness increased. 
This provided a visual guide to the thickness for future depositions. 
 
Figure 4.14. Deposition rate for condition 2 (Nitrogen flow rate 1 sccm). 
 
Figure 4.15. Deposition rate for condition 3 (Nitrogen flow rate 5 sccm). 
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For condition 4, nitrogen was increased to 10 sccm and acetylene decreased to 1. Two time 
points, 10 minutes and 20 minutes of deposition were used as initial starting points to assess if 
deposition would occur. Thickness measurements were 7.8 and 7.4 nm for 10 and 20 min 
respectively. This was much lower than predicted. The acetylene to nitrogen ratio decreased 
from 1:1 for condition 3 to 1:10 for condition 4. We estimated a decrease in the deposition rate 
of a factor of ten which should result in a thickness of approximately 20-30 nm (10-20 min 
deposition time). Moreover, an increase in polymer thickness was not seen from 10 minutes to 
20 minutes, suggesting a failure of deposition. We hypothesized the low density of acetylene 
gas with condition 4 substantially reduced polymer deposition rate and favored the removal of 
deposited polymer by bombarding energized ions. In order to decrease the energy of 
bombarding ions to retard the ablative process the RF power was reduced from 75w to 50W. 
Linear deposition kinetics for condition 4 with reduced power at 50W, linear regression fitting 
showed a good R2 value of 0.987 (Figure 4.16). The slope of the line was decreased to 1.42, 
an approximately 12-fold reduction when compared to condition 3 (nitrogen flow 5 sccm). 
 
Figure 4.16. Deposition rate for condition 4 (Nitrogen flow rate 10 sccm). 
4.3.3 Chemical and physical analysis of stable plasma polymer 
Analysis of the structure and elemental composition of the plasma polymers were performed 
after stabilization of the surface in atmosphere one month following deposition. 
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4.3.3.1 The elemental composition of plasma polymer 
Plasma polymers were successfully deposited under four distinct conditions in which the flow 
of nitrogen was increased. In order to determine the elemental composition of the films, 2 cm 
x 2 cm silicon wafers were used for substrates. The films were analyzed using XPS. From 
herein onwards the plasma polymers will be designated as PPolymer for a nitrogen flow of 0 
sccm, with nitrogen doped polymers named according to nitrogen content; NPolymer8 
(nitrogen flow 1 sccm), NPolymer14 (nitrogen flow 5 sccm) and NPolymer27 (nitrogen flow 
10 sccm). 
The XPS survey spectra of the deposited polymers is shown in Figure 4.17. The spectra are 
characterized by distinct peaks at 532 eV (O1s), 400 eV (N1s) and 285 eV (C1s) regions. With 
an increase in nitrogen flow from 0 sccm to 10 sccm, an increase in the prominence of the N1s 
peak is seen with a relative decrease in C1s peak. The O1s peak remained stable. 
 
Figure 4.17. XPS survey spectra of plasma polymers. 
The quantitative elemental composition of the polymers is shown in Figure 4.18. The 
percentage of nitrogen in the PPolymer was 3.75±1.06%. The highest nitrogen concentration 
146 
achieved was 26.7±0.3% (nitrogen flow 10 sccm). In contrast, a relative decrease in carbon 
levels was seen from 79.0±2.9% to 58.9±1.5%. Oxygen levels remained relatively stable across 
different nitrogen flow rates. 
 
Figure 4.18. Elemental composition of plasma polymers quantified using XPS. 
4.3.3.2 Surface topography of plasma polymers 
AFM was used to determine the topography and roughness of the deposited polymers. Silicon 
wafers were cut to 1 cm x 1cm in size, placed centrally on the substrate holder and treated 
under varying nitrogen gas flow conditions. Scans were initially performed using a scan size 
of 10 µm x 10 µm to identify a representative area free from particulate contamination. A more 
detailed study was then performed using 2 µm x 2 µm scan sizes. 
AFM images in two dimensions and three dimensions for the plasma polymers, PPolymer, 
NPolymer8, NPolymer14 and NPolymer27 are shown for Figure 4.19. The surfaces of the 
plasma polymers appear to be smooth. The root mean square (RMS) roughness ranged from 
0.26-0.52 nm. A minor increase in RMS was seen with increasing nitrogen content in the 
plasma polymer.
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RMS=0.39 nm 
PPolymer 
 
 
RMS=0.4 nm 
NPolymer8 
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RMS=0.26 nm 
NPolymer14 
  
RMS=0.52 nm 
NPolymer27 
  
Figure 4.19. 2D and 3D AFM images of the plasma polymers. From top to bottom PPolymer, NPolymer8, NPolymer14, Npolymer27. 
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4.3.3.3 Carbon structure of plasma polymer 
The vibrational frequencies of carbon molecules in the plasma polymers were assessed using 
highly sensitive raman spectroscopy. The representative raman spectra between the 
wavelengths of 1300 and 1700 cm-1 are shown in Figure 4.20. A prominent peak is seen at 
1596 cm-1 (G peak) attributed to bond stretching of sp2 carbon atoms [413]. A number of 
theories have been proposed to explain the presence of the peak at 1367 cm-1 (D peak). Current 
thought is that this is from LO phonons and active double resonance representing disorder in 
the polymer structure [414]. The ratio of the intensity of D and G peaks for each of the polymers 
is given in Table 4.2. No trend can be seen between the ID/IG ratio with increasing nitrogen 
flow. 
 
Figure 4.20. Representative raman spectroscopy of the plasma polymers showing typical 
D and G peak. 
Table 4.2. Summary of the ratio of intensity of D and G peaks for plasma polymer with 
varying nitrogen content 
 PPolymer NPPolymer8 NPPoymer14 NPPolyme27 
ID/IG Ratio 0.523 0.5 0.58 0.57 
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4.3.3.4 Optical density of plasma polymer 
The refractive indices of PPolymer and NPolymers were obtained from optical analysis using 
ellipsometry. Silicon wafers cut into 2 cm x 2 cm sizes were used as the substrate. The n value 
(refractive index) as a function of the wavelength of light is shown in Figure 4.21. PPolymer 
and NPolymer8 had similar refractive indices. As nitrogen content in the polymers 
(NPolymer14 and NPolymer27) increase a decrease in refractive index is seen. 
 
Figure 4.21. Refractive index (n) as a function of wavelength. 
4.3.3.5 Covalent bonding capability of the plasma polymers 
Protein attachment (recombinant human tropoelastin) to plasma polymer surfaces was assessed 
using ELISA, following SDS washing. Control (with no SDS washing) samples were compared 
with SDS treated samples. Figure 4.22 shows the amount of protein retained on the surfaces 
expressed as a percentage of controls. SS samples had the lowest protein retention of 
24.1±2.6%. In contrast all polymer coated samples had significantly more protein retention, 
PPolymer: 50.9±1.1%, NPolymer8: 66.23±2.4%, NPolymer14: 71.7±3.9%, NPolymer27: 
67.17±1.1%. NPolymer samples had significantly higher protein attachment than PPolymer 
samples, however they were not statistically different from each other (P>0.05). 
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Figure 4.22. Amount of protein retained on the polymer surfaces after SDS washing. 
4.4 Discussion 
4.4.1 Establishing uniformity of deposited plasma polymer film 
A new purpose-built plasma polymerization chamber was used for this project. The deposition 
characteristics of this chamber were unknown. The first priority was to ensure plasma polymer 
coatings were homogenous in chemical composition and thickness. This is of vital importance 
for clinical applications where robustness of the coating needs to be maintained. The adhesion 
of polymer films to the substrate is strongly influenced by internal stresses in the polymer 
[415]. Thickness of the deposited polymer is an important determinant of internal stress and 
therefore likelihood of delamination [416]. An inconsistency in thickness could result in 
variations in internal stress leading to weak areas at risk of peeling and cracking. 
FTIR is a sensitive tool for evaluating the vibrational modes of molecules in the polymer which 
in turn helps to identify the type of chemical bonds and functional groups present. Infrared 
radiation is passed through the polymer coating, some of the energy is passed through and some 
adsorbed. The resulting spectra are unique fingerprints of the chemical bonds in the material. 
ATR-FTIR was used for analysis of plasma polymers deposited on stainless steel. C=O, NH, 
CH2 and CH3 bond vibrations in the deposited polymer were assessed using FTIR. Gas inlet 
positions 1 and 2 resulted in non-uniform coatings. C=O function groups appear to show the 
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most significant variation across the polymer surface. A more gradual decrease in NH, CH2 
and CH3 functional groups is seen going from region 1 (closest to the gas inlet)  to region 5. 
Ellipsometry analysis helped to determine the thickness of polymer and showed a decrease in 
thickness moving away from the gas inlet. These findings can be explained by an 
inhomogeneous distribution of gas when the gas inlet is placed towards one side of the substrate 
independent of the vertical position (above or below the substrate holder). A higher 
concentration of radical species and monomers is concentrated closest to the gas inlet, resulting 
in a faster rate of deposition and increased thickness. 
The flaws in the chamber setup (gas inlet position 1 and 2) were rectified by moving the gas 
inlet to the most superior position of the chamber. To avoid a single point of gas discharge we 
fashioned a circular tube with evenly spaced holes. While a gas concentration gradient is 
expected from top to bottom of the chamber, we anticipated at any particular vertical level in 
the chamber the gas concentration should be roughly uniform along the X and Y axes i.e. lateral 
uniformity. The improvement in uniformity was significant. C=O groups appear to be most 
sensitive to uniformity and can be shown to remain largely steady across the surface. This is 
also true for NH, CH2 and CH3 groups. The thickness of the polymer mirrors the consistency 
of the chemical groups with generally uniform thickness from edge to edge. One caveat to these 
findings is that there appears to an edge effect, i.e. a slight increase in thickness and intensity 
of chemical functional groups at the edges of the sample. In order to account for the minor edge 
variation all samples used in subsequent chapters for protein and biological assays had 1 cm 
removed from all four edges. 
4.4.2 Evaluating deposition characteristics of plasma polymer 
The deposition rate of the chamber was examined next. A predictable thickness for polymer 
coatings is important to ensure consistent coatings are produced for assays. Yin et al reported 
that a minimum thickness of 70 nm is necessary for a sufficient repository of free radical for 
covalent binding [397]. The deposition parameters and chamber setup were different but none 
the less provides a rough guide for thickness. For the four deposition conditions with increasing 
nitrogen flow a linear relationship is seen with polymer thickness and time of deposition. The 
introduction of nitrogen resulted in a progressive decrease in the rate of polymer deposition as 
can be seen by the decrease in the slope of the linear regression line. Similar findings were also 
reported by Silva et al with nitrogen doping of amorphous carbon films [417]. 
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When the RF power was kept at 75W, deposition essentially stopped with a nitrogen flow of 
10 sccm. Yasuda and Hsu proposed a competitive ablation and polymerization model of plasma 
polymerization [418]. The formation of a plasma polymer is a balance between polymer 
forming reactive intermediates which form polymers and the etching or ablation effect caused 
by non-polymer forming gases (Argon, Nitrogen) which remove the plasma polymer. At a 
nitrogen flow of 10 sccm and acetylene flow of 1 sccm, the concentration of polymer forming 
species derived from acetylene was too low, resulting in conditions favouring ablation than 
polymer growth. The discharge power can also impact the etching and deposition balance. 
Yasuda demonstrated when power is increased there is an initial increase in deposition 
followed by a higher rate of etching as power is increased further [419]. The discharge power 
coupled to the chamber was decreased from 75W to 50W to facilitate polymerization resulting 
in deposition at a rate considerably lower than the previous conditions but retaining a similar 
linear correlation with time. 
4.4.3 Elemental composition of plasma polymer: correlating Nitrogen content with 
deposition parameters 
XPS is a surface sensitive technique which can be used to determine the elemental and chemical 
constituents in materials. X-ray photons are used to bombard the surface of the material 
resulting in electrons being ejected. The kinetic energy of the ejected electrons is analysed by 
the spectrometer. From this the binding energy, i.e. the energy needed to eject the electron can 
be determined. Each element has unique binding energies for its electrons, a fingerprint, which 
can be compared to the XPS spectra of a material with unknown elemental composition [420]. 
As the ratio of nitrogen to acetylene increases the amount of nitrogen incorporated into the film 
rises. XPS survey spectra shows semi-quantitatively increasing prominence of the nitrogen 
peak as nitrogen is bonded to carbon during polymerization. The maximal nitrogen that could 
be incorporated was 26.7±0.3%. Attempts to increase the nitrogen flow rate above 10 sccm did 
not result in polymeric deposition. Potentially the power could have been decreased below 50W 
to encourage polymerization however the goal was to maintain parameters between the 
conditions as close as possible. One of the highest nitrogen contents achieved in plasma 
polymerised films was 36.3% using an atmospheric dielectric barrier discharge system [421]. 
The difference in maximal nitrogen amount may reflect differences in deposition methods. In 
our approach chamber pressures were substantially lower than atmosphere (~150 mTorr) and 
substrates were biased with pulses of negative voltage of 500V. Together these two factors 
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increase ionic bombardment energy of the surface, rate of etching and removal of polymer 
coating [422]. 
4.4.4 Physical structure of plasma polymer and relevance for stent applications 
The surface and structure of the polymer coatings were analyzed using a combination of AFM, 
ellipsometry and raman spectroscopy. AFM is a high resolution scanning probe microscope 
with vertical resolutions of up to 0.1 nm [423]. Using scans of 2 µm x 2 µm the topography of 
the deposited plasma polymer was found to be very smooth. Changes in nitrogen content did 
not affect the surface smoothness significantly. Surface topography has important implications 
for biocompatibility. Virchow’s triad describes the three main components contributing to 
vessel thrombosis – vessel wall disruption, hypercoagulability and blood flow [424]. A rough 
surface can cause turbulent blood flow [425] leading to increased shear forces and varying 
velocities of flow. Such flow characteristics can generate more contact between cellular 
components and the material surface and create stagnant regions susceptible to clot formation 
[426]. Smoother polymer surfaces are noted to reduce thrombus development [427]. 
Raman spectroscopy is a form of vibrational spectroscopy. A laser is directed towards a 
material. The energy leads to excitement of the raman active vibrational modes of the material. 
These modes are complementary to those observed in infra-red spectroscopy. The inelastically 
scattered light is then frequency shifted accordingly. The pattern of the frequency shifts of the 
emitted photons provides information about the vibrational states excited. Raman spectroscopy 
is very sensitive to local microstructure in carbon-based materials allowing the determination 
of carbon bond configurations [428]. 
Carbon is unique in the versatility of its structural configuration. Graphite and diamond are 
naturally occurring carbon allotropes (different structural forms of an element) with 
distinctively different structural properties. Carbon can form two different bond geometries 
planar (graphite) and tetrahedral (diamond) Figure 4.23. The carbon – carbon bonds are termed 
sp2 and sp3 bonds for graphite and diamond, respectively. sp3 bonds are characterized by one 
carbon bound to four other carbons in a three dimensional tetrahedral structure resulting in a 
rigid and extremely hard material whilst in sp2 bonding each carbon atom is linked to only three 
others in a planar structure. 
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Figure 4.23. Schematic representation of carbon – carbon bonding configuration. Top 
image shows sp2 bonding in graphite with carbon atoms in planar arrangement. Bottom 
image shows sp3 bonding in diamond with carbon atoms in tetrahedral arrangement. 
The typical raman spectra of pure graphite and diamond is shown in Figure 4.24. Pure graphite 
is composed only of sp2 bonds characterized by a sharp peak at 1575 cm-1 (G peak). The 
distinguishing feature of pure diamond (only sp3 bonds) is a single sharp line at 1332 cm-1. 
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Figure 4.24. Representative raman spectra of pure graphite and diamond (top and 
bottom images respectively). 
The spectra of our deposited plasma polymer (Figure 4.20) shows a prominent G peak which 
is consistent with a predominantly sp2 carbon structure. The smaller D peak also known as the 
disorder peak, indicates the presence of crystalline structure in the plasma polymer. In these 
clusters of disorder, the carbon atoms are bonded more strongly in covalent tetrahedral sp3 
formation [429]. The ratio of the intensity of the D peak to G peak ID/IG gives additional 
information on this structure. This ratio for our plasma polymer remained similar irrespective 
of the nitrogen content reflecting a consistency of carbon structure. The low ratio suggests a 
structure lying between graphite and nano-crystalline graphite [414]. These findings have 
important ramifications for suitability of our plasma polymer as a coating for coronary stents. 
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In contrast to our plasma polymer, coating films with a high proportion of sp3 carbon bonds 
are called DLC and can be deposited using ion beam deposition, cathodic arc, pulsed laser 
deposition and plasma enhanced chemical vapour deposition. Mechanically, DLC is attractive 
for biomedical purposes due to its inertness, smoothness and wear resistance [430]. While these 
attributes may be attractive for orthopaedic and prosthetic valves, the application to coronary 
stents is less appealing. Coronary stents are deployed by expansion of a balloon from a crimped 
configuration, undergoing significant deformation. The hardness of DLC and the high internal 
stress causes brittleness [431] which can result in peeling and cracking of the coating during 
stent expansion. In contrast carbon films deposited with a higher content of sp2 carbon bonds 
display lower stress and improved substrate adhesion [432]. Interestingly, investigators have 
utilized nitrogen incorporation into hard carbon films during deposition to reduce internal stress 
[433]. A purely graphitic carbon film coating consisting only of sp2 bonds may also be 
inadequate for stent use. Within graphite the strong covalent bonds between carbon atoms are 
in hexagonal arrays like a sheet. Inter-sheet bonds are much weaker van der Waals forces [434]. 
Creating covalent bonds between the sheets of graphite can increase mechanical stability while 
maintaining the low stress and adhesion benefits of a high sp2 structure. The disorder or clusters 
of sp3 bonding within our plasma polymer indicate focal points of stronger covalent bonding 
between carbon atoms in different planes of the graphitic matrix. 
The refractive index of a material is a reflection of the density of a material. Denser and in 
general harder materials have higher refractive indices (if similar chemical composition). 
Nitrogen incorporation can prevent significant sp3 bonding from developing between carbon 
atoms [435], reducing hardness and brittleness. The refractive index of the plasma polymers 
was similar for PPolymer and NPolymer8 surfaces but a decrease was seen with NPolymer14 
and NPolymer27. Collectively the surfaces all had refractive indices lower than typically 
observed for DLC films [436]. These findings corroborate the results of raman spectroscopy. 
4.4.5 Retention of covalent binding capacity of plasma polymer 
Linker free covalent binding of molecules is a unique characteristic of the plasma polymers 
deposited by Yin et al [437]. It was found surface immobilized enzymes and extracellular 
matrix proteins were extremely resistant to SDS removal consistent with covalent bonding and 
crucially remained biologically active. Waterhouse and Yin et al covalently attached 
tropoelastin to plasma polymers leading to improved endothelial adhesion and proliferation 
compared to 316L SS [281]. Bio-functionalization offers an exciting approach to enhancing 
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the bioactivity of an otherwise inert surface. However, enthusiasm using this strategy needs to 
be tempered by the possible enzymatic degradation of proteins in vivo. Tropoelastin can be 
attacked by a number of blood serine proteases raising concerns regarding the durability of in 
vivo biological activity. Nonetheless, the importance of covalent bonding for improving 
biocompatibility cannot be disregarded. Linker free anchorage of proteins provides an 
opportunity to impart a wide range of biological activity to surfaces. Careful selection or use 
of enzyme resistant proteins may mitigate the issue of in vivo degradation. Furthermore, in vivo 
proteins once adsorbed onto the surface may also become covalently anchored locking them 
into more biocompatible conformations. Indeed, the authors reported improved 
hemocompatibility of plasma polymers [258]. 
Our goal was to preserve covalent bonding for the deposited surfaces as nitrogen content is 
increased. Covalent bonding was established by comparing protein amount on surfaces after 
SDS treatment. We found that all the plasma polymer surfaces retained much higher amounts 
of protein than 316L SS. SDS is used to remove protein adsorbed on to surfaces [438] by 
disruption of weaker adsorption forces such as Van der Waals and ionic interactions but does 
not affect covalent bonds. The bound tropoelastin before and after SDS washing was detected 
using ELISA. SDS is known to damage the conformation of proteins. The BA-4 anti-elastin 
primary antibody binds to tropoelastin in a conformationally independent manner [439] 
detecting tropoelastin even after SDS treatment. PPolymer had significantly less protein 
retention than the nitrogen doped surfaces. Covalent bonding has been attributed to the 
presence of free radicals in the plasma polymer forming bonds with side chain groups on 
proteins [268]. The increased covalent bonding may be attributed to a higher density of free 
radicals in NPolymers. This hypothesis will be examined in the following chapter. Importantly 
the incorporation of nitrogen did not lead to a reduction in covalent bonding. In contrast oxygen 
or hydrogen doping of plasma polymer films resulted in a loss of binding capacity despite the 
presence of free radicals [440]. It has been suggested that the mobility of free radicals within 
the polymer structure is equally important [435]. Free radicals need to be able to move to the 
surface to be able to form bonds with proteins. 
4.5 Conclusion 
Plasma polymers with varying nitrogen concentrations were successfully created. 
Modifications of the gas inlet position ensured that the coatings were uniform. As the nitrogen 
flow was increased more nitrogen was incorporated into the plasma polymer structure. A 
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maximal nitrogen concentration of approximately 27% was achieved. Detailed analysis of the 
plasma polymer revealed a graphitic structure with low refractive index and smooth surface 
topography that remained largely consistent across the different nitrogen plasma polymers. The 
structural characteristics of the plasma polymer coatings are well suited to stent applications. 
Importantly the unique covalent binding capacity of the surfaces was preserved with increasing 
nitrogen. 
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Chapter 5: Analysis of the Aging of Nitrogenized Plasma 
Polymers 
5.1 Introduction 
Stability and predictability of the chemical properties of plasma polymers is important for 
clinical application. The aim of this chapter is to explore the physical-chemical changes of 
nitrogenized plasma polymers when exposed to the atmosphere. Using contact angle 
measurements, electron spin resonance (ESR), transmission fourier transform infrared 
spectroscopy (FTIR) and X-ray photoelectron spectroscopy (XPS), the wettability, surface 
energy, surface chemistry and free radical changes with time will be examined. Additionally, 
we develop mathematical models to predict and explain the observed changes. 
Increasingly the study and modification of biomaterials has become divided into two areas, the 
surface and the bulk of the material. This approach stems from the realization that in creating 
a material that retains physical attributes suitable to meet mechanical demands, 
biocompatibility is often sacrificed. Examples include small diameter prosthetic vascular grafts 
fashioned from Dacron or Polytetrafluoroethylene (PTFE). These materials were chosen due 
to chemical inertness, flexibility and ease of manipulation. However, clinical use has been 
limited by poor biocompatibility resulting in graft thrombosis and intimal hyperplasia [441]. 
Similarly, coronary stents are primarily fashioned from metallic alloys largely due to a need 
for mechanical deformability and high radial forces to resist vessel recoil. The dependence on 
metals compromises biocompatibility due to the inherent thrombogenicity of the material. 
Modification of the surface of a biomaterial has become an important area of research. The 
surface is a key determinant of biocompatibility. A variety of coating strategies have been 
employed to separate the physio-chemical properties of the surface from the bulk material. 
These include organic coatings such as carbon thin films [442], polymer-based surface layers 
such as polyethylene glycol [443] and self-assembling monolayers [444]. While these 
approaches seem to differ there is a common thread in which they modulate key surface 
compositional parameters [445, 446]. 
Wettability, surface energy and surface tension are interrelated parameters. When a liquid is 
dropped on to a solid surface, the spread of the liquid over the surface reflects the wettability 
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of the surface by that liquid [447], in other words how easily the liquid can spread across a 
surface [448]. The wettability with respect to water can be measured using the contact angle 
made by a water droplet on the material surface. The contact angle is obtained when a sessile 
drop of liquid is placed on a solid surface. The angle that is formed by the liquid-air interface 
and the liquid-solid interface on a flat surface is measured (Figure 5.1). It should be noted that 
this approach is not valid for rough or shaped (non-flat) surfaces. Generally speaking a surface 
with a contact angle less than 90 degrees is considered hydrophilic (high wettability) and an 
angle more than 90 degrees is considered hydrophobic (low wettability) [449]. 
 
Figure 5.1. Schematic representation of the contact angle measured when a liquid is 
dropped onto a solid surface. Adapted from Yuan Y, Surface Science Techniques, 2013 
[449]. 
The interaction of a liquid with a solid surface is dependent on two inter-related phenomena: 
the surface tension and surface energy. The surface tension is responsible for shape of the 
liquid. Intermolecular interactions within the liquid provide mutually attracting forces between 
the molecules helping maintain the shape of the liquid. At the surface of the liquid the 
intermolecular forces contract the surface and are responsible for the surface tension (Figure 
5.2) [449]. 
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Figure 5.2. Schematic representation of intermolecular forces within a liquid. Adapted 
from Yuan Y, Surface Science Techniques, 2013 [449]. 
When a liquid comes in contact with a surface three interfacial tensions 1) liquid-air, 2) solid- 
air 3) solid-liquid are at play and determine the wettability of the liquid on the solid. The term 
surface energy is often used interchangeably with surface tension and is defined as the amount 
of energy required to form a unit area of a new surface at an interface. In order for a liquid to 
spread over a surface, the surface energy (intermolecular energies of the surface molecules) 
must be high enough to overcome the surface tension (intermolecular forces) holding the liquid 
in shape. Surfaces with higher surface energy are therefore more hydrophilic (water loving). 
Consideration of these interactions introduces an additional concept – the interfacial free 
energy. This free energy incorporates the surface energy and tension contributions from the 
solid and liquid at the solid-liquid interface. For biomaterial surfaces exposed to the in vivo 
aqueous environment this parameter has important implications. It represents the driving force 
for protein adsorption on to the surface and affects the structural conformation of adsorbed 
plasma proteins [450]. The interaction between a blood contacting material and blood cellular 
components is conveyed through a rapidly adsorbed protein layer [392]. 
The interfacial free energy can be expressed as: 
γSL = {(γPL)1/2 – (γPS)1/2}2 + {(γdL)1/2 – (γdS)1/2}2 
γSL = interfacial free energy 
γS = surface free energy of the solid 
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γL = surface tension of the liquid 
p = polar component 
d = dispersive component 
The lower the interfacial free energy the lower the driving force for protein adsorption and 
denaturing and the more biocompatible a material is in the aqueous blood environment [451]. 
From the above equation a material with high surface energy will have lower interfacial free 
energy and potentially improved hemocompatibility. 
The surface free energy model of material-blood interaction can be extended to cell adhesion. 
The cell membrane can be seen as an interface which also interacts with solid and liquid 
interfaces. A driving force for cell attachment to surfaces can be expressed as an equation 
(below). 
[256] 
Δ Fadh = interfacial free energy of cell adhesion 
γCS = cell-solid interfacial free energy 
γCL = cell-liquid interfacial free energy 
γSL = surface-liquid interfacial free energy 
A Δ Fadh is considered energetically favorable if it is less than 0 and less favorable if greater 
than 0 [256]. It can be deduced from this equation that a surface higher in energy enhances cell 
adhesion. 
Plasma technology has been employed to enhance surface energy and wettability of a material. 
Donnet et al used plasma to treat a variety of carbon-based surfaces [452]. They found a 
significant increase in surface energy in particular the polar component of surface energy. 
PTFE is a highly hydrophobic material with poor cell adhesion characteristics. Plasma 
treatment with O2, N2 and NH3 gases led to a significant increase in surface energy and 
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wettability [453]. Similar findings were reported when polyurethane was exposed to helium 
plasma. The authors also noted markedly improved cell adhesion [454]. Plasma modification 
of polyethylene produced superior hemocompatibility with reduced fibrinogen (Fg) and 
platelet adhesion [265]. 
Plasma polymerization is different from plasma modification as it does not alter the surface 
energy of the polymer but rather coats it with a carbon-based thin film that is cross linked with 
non-repeating units. When a hydrocarbon gas such as acetylene (C2H2) is placed in a plasma 
chamber, ionized and fragmented species and free radicals are produced. The free radicals are 
generated from energetic collisions in which there is breaking of the carbon to hydrogen and 
carbon to carbon bonds [455] (Figure 5.3). 
 
Figure 5.3. Schematic diagram showing generation of free radicals from hydrocarbon 
monomers. 
The highly reactive fragmented species deposit onto the substrate surface and grow 
progressively from cross linking of the fragments via radical reactions. Additional gases added 
into the plasma such as oxygen and nitrogen incorporate into the growing film. The outcome 
of these processes is the creation of plasma polymer films rich in radicals and polar chemical 
groups [456] with high surface energy and wettability [457, 458]. 
Surface energy and wettability of plasma treated surfaces change with time. A reduction in 
surface energy and wettability is seen when the surfaces are exposed to atmosphere (Figure 
5.4). Similar findings are reported for plasma polymerized surfaces with a reduction of 
wettability with time [459]. This phenomenon has been termed hydrophobic recovery [460] or 
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film aging [461] and has important implications for practical applications of plasma 
polymerized films. 
 
Figure 5.4. Contact angle change as a function of time. Contact angle for plasma 
treatment of polyamide with either air, N2 or H2O plasma [462]. 
As discussed above the surface energy / wettability of a surface is an important determinant of 
its biocompatibility. Surfaces with higher surface energy appear to promote hemocompatibility 
and cell adhesion. Logistical challenges make the utilization a plasma polymer-coated vascular 
device soon after deposition challenging. Determination of how our plasma polymer surface 
transforms with time, in particular finding a time point of stable surface chemistry has 
implications for reproducibility of biological response. 
5.2 Methods and materials 
5.2.1 Plasma polymerization 
All plasma polymers were deposited in the purpose-built chamber. Substrates used for contact 
angle and FTIR measurements were silicon wafers (low doped p-type one side polished). 
Silicon wafers were used to ensure a completely flat surface for contact angle measurement 
and a translucent material enabling transmission FTIR analysis. Conditions for generation of 
nitrogen containing plasma polymers were as described in chapter 4. For the aging study all 
samples were exposed to atmosphere and stored under cover in a temperature regulated 
laboratory (22-25º C). 
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5.2.2 Contact angle and wettability study 
Contact angles on the plasma polymers were measured with two liquids: distilled water and 
diiodomethane, using the sessile drop method, with a Kruss contact angle DS10 instrument. 
For each time point three separate measurements were made and the averaged contact angle 
recorded. The surface energy was calculated using the Owens-Wendt-Rabel-Kaelble method. 
For each plasma polymerization condition a single 6 cm x 6 cm piece of silicon was used for 
contact angle measurements over time. 
5.2.3 Chemistry of plasma polymers 
The surface chemistry of the deposited plasma polymers was assessed using transmission FTIR 
spectra, recorded using a Bomem FTIR spectrometer. The difference in spectra between those 
taken from the silicon wafers with and without the polymer coating were calculated. The peak 
absorbance of spectral lines associated with particular bond vibrations were used to quantify 
chemical changes in the coating. GRAMS software was used for spectral analysis. 3 cm x 3 cm 
silicon wafers were used as substrates. The wafers were secured onto rectangular shaped 
cardboard cards with a central cut out to allow transmission of the infrared beam. The cardboard 
cards were placed in the sample holder of the spectrometer for determination of absorbance 
spectra at the same position of the sample at each different time point. The same sample was 
used for the aging studies for each of the deposition conditions. All samples were stored in 
atmosphere under cover in a temperature regulated laboratory (22-25º C, 50-70% humidity). 
Experimental data of surface energy and FTIR spectra were fitted with theoretical curves using 
OriginLab 9 software (OriginLab, USA). 
FTIR data was analyzed using DigiLab software (DigiLab, USA) and GRAMS spectroscopy 
software (Thermo Scientific, USA) 
5.2.4 X-ray photoelectron spectroscopy 
XPS (Specs-XPS, mode XP-50 High Performance Twin Anode with Focus 500 Ellipsoidal 
Crystal Monochromator and PHOIBOS 150 MCD-9 analyser) was utilized to provide data on 
the elemental composition of the samples. CASA XPS software was used to calculate areas of 
elemental peaks with the concentration of each element expressed as an atomic percentage. 
High-resolution spectra of the C1s peak were used to resolve the main spectra into individual 
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components associated with bonding to different chemical species. The binding energy of the 
main C1s peak was assigned 285 eV and used to correct for the effect of surface charging of 
the plasma polymers on the peak positions [463]. 
5.2.5 Free radical density in plasma polymers 
ESR spectrometry is commonly utilized in the detection of unpaired electrons (free radicals) 
and has been successfully applied to plasma treated and deposited materials [464]. ESR 
measurements were made using Bruker ESR spectrometer with a sweep width of 250 G. 
Samples were measured using a sweep time of 83.89 seconds, 100kHz modulation frequency 
and 2 G modulation amplitude. Each sample was analysed using 8 scans, with the signal 
averaged to increase sensitivity. 
The choice of deposition substrate required special consideration. Samples for measurement 
needed to be placed in elongated ESR tubes measuring 3 – 4 mm in inner diameter. The 
background free radical density of the substrate should be a minimum considering the thickness 
of the deposited plasma polymer (~100 nm). Borosilicate glass capillaries measuring 2 mm 
outer diameter was used as substrates due to a low background level of free radicals. 
Two deposition conditions were used 1) PPolymer (no nitrogen gas during plasma 
polymerization) 2) NPolymer27 (nitrogen of 10 sccm). In order to remove possible contribution 
of free radicals induced in the glass capillaries during polymerization, controls were produced. 
For deposition condition 1 – a separate glass capillary was placed in argon plasma alone 
(without a carbon monomer – acetylene) and treated for the same time. For deposition condition 
2 – a separate glass capillary was treated with argon and nitrogen (10 sccm) for the same time 
as polymerization. The measured ESR spectra of control glass capillaries acted as background 
and were subtracted from the ESR spectra of the polymerized glass capillaries. 
Weak pitch provided by Bruker with known free radical concentration and type was used as a 
standard for comparing the amount of free radicals between the two conditions. 
5.3 Results 
5.3.1 Water contact angle and hydrophilicity of plasma polymers 
The contact angle of plasma polymers deposited on silicon wafer was measured as soon as 
possible after deposition. The minimal time to calibrate the Kruss contact angle system and 
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transport the samples from the plasma deposition system was 15 min and represented the first 
measurement, samples at this time point were considered fresh. Photographic images obtained 
from the Kruss contact angle system of water droplets on the plasma polymer surface at 15 min 
are shown in Figure 5.5. As specified in the previous chapter plasma polymers were named 
according to nitrogen content (PPolymer – no nitrogen used in deposition, NPolymer8 – 8% 
nitrogen, NPolymer14 – 14% nitrogen, NPolymer27 – 27% nitrogen). The images show that 
the water droplet becomes more spread across the surface with rising nitrogen content in the 
plasma polymer. The contact angle is depicted by the red arrows and can be seen to become 
more acute with increasing nitrogen. 
 
Figure 5.5. Images show a droplet formed from water on plasma polymer samples 15 
min after removal from deposition chamber. Intersecting red lines represents the 
contact angle. 
The images for water droplets on plasma polymers after storage in atmosphere for 30 days is 
shown in Figure 5.6. Two features are apparent. Firstly, NPolymer27 sample displays the 
greatest water spreading and the lowest contact angle at 55 degrees. A progressive decrease in 
contact angle is seen which correlates with increasing nitrogen content. Secondly, in 
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comparison with the contact angle at the earliest time point (15 min) the contact angle for each 
respective nitrogen content has increased with less water spreading. 
 
Figure 5.6. Images show a droplet formed from water on plasma polymer samples 30 
days after removal from deposition chamber. Intersecting red lines represents the 
contact angle. 
To highlight this phenomenon of “hydrophobic recovery”, where there is a loss of wettability 
(increase in contact angle) with time we show serial water droplet images at key time points 
for each plasma polymer according to nitrogen concentration. 
Contact angle of PPolymer shows a progressive loss of spreading of the water droplet with time 
exposed to atmosphere (Figure 5.7). The contact angle increases from 15 min to 30 days 
reflecting a loss of wettability. A more rapid change in wettability is seen between 15 min and 
day 1 while a slower evolution occurs between 1 day and 30 days. 
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Figure 5.7. Images show a droplet formed from water on PPolymer samples (lowest 
nitrogen content). Each image is a time point from deposition. Intersecting red lines 
represents the contact angle. 
Images of water droplets at representative time points are demonstrated in Figure 5.8, 5.9 and 
5.10 for NPolymer8, NPolymer14 and NPolymer27, respectively. Similarities are evident 
between these nitrogen doped samples and PPolymer (Figure 5.7). With increasing time, the 
contact angle becomes less acute and the water droplet more rounded. The surface becomes 
less wettable and more hydrophobic with time. Further mirroring the changes seen in PPolymer 
samples, a rapid change in contact angle occurs in the first day after exposure to the atmosphere. 
A much more gradual increase in contact angle is seen between day 1 and day 30. 
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Figure 5.8. Images show a droplet formed from water on NPolymer8 samples (nitrogen 
concentration of 8%). Each image is a time point since deposition. Intersecting red lines 
represent the contact angle. 
 
Figure 5.9. Images show a droplet formed from water on NPolymer14 samples 
(Nitrogen concentration of 14%). Each image is a time point since deposition. 
Intersecting red lines represent the contact angle. 
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Figure 5.10. Images show a droplet formed from water on NPolymer27 samples (highest 
nitrogen concentration of 27%). Each image is a time point since deposition. 
Intersecting red lines represent the contact angle. 
Water contact angle as a function of time showing all measured time points generates a curve 
of contact angle kinetics (Figure 5.11). The gradient of the slope for each of the samples is 
very steep in the first three hours after deposition reflecting the rapidity of chemical reactions 
in the polymers during this time. By the end of day 1 hydrophobic recovery enters a slower 
phase moving towards a plateau by day 30. It can be seen at any time point NPolymer27 had 
the lowest contact angle. 
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Figure 5.11. Water contact angle as a function of time for plasma polymers with varying 
nitrogen content. 
5.3.2 Surface energy of plasma polymers 
The surface energy of a surface can be calculated from the contact angles made by two liquids 
using the Owens-Wendt-Rabel-Kaelble model [465]. This model divides surface energy into 
two components, polar and dispersive, which relate to polar and dispersive interactions 
between the liquid and surface. This is expressed in the equation below: 
γs = γps + γds 
γs = surface energy 
γps = polar component 
γds = dispersive component 
Water is a highly polar liquid with the contact angle on a surface giving a reflection of the polar 
interactions and component. Diiodomethane is a liquid with low polarity. Using diiodomethane 
the non-polar and dispersive interactions between the liquid/solid interphase can be examined 
[466]. Similar to the studies detailed above for water, the contact angles for diiodomethane on 
plasma polymer samples were measured over a series of time points from 15 min to 30 days. 
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For illustration the image of diiodomethane droplets on plasma polymer surfaces on day 30 is 
shown in (Figure 5.12). 
 
Figure 5.12. Contact angle at day 30 using diiodomethane for plasma polymers with 
varying nitrogen concentration. 
The relationship between contact angle and nitrogen concentration is subtler for diiodomethane 
droplets than for water. As nitrogen concentration rises a small increase in the contact angle is 
seen indicating a reduction in non-polar interactions with higher nitrogen. Contact angle 
measurements for water and diiodomethane were used with the Owens-Wendt-Rabel-Kaelble 
model to calculate the surface energy, dispersive and polar components for the plasma 
polymers. 
Mirroring the time related changes with contact angle, the surface energy (Figure 5.13) for 
deposited polymers shows a rapid change in the first few hours followed by a much more 
gradual change after 1 day. NPolymer27 and PPolymer samples had the highest and lowest 
surface energy at 30 days of 55.7 mN/m and 47.4 mN/m, respectively. The surface energy of 
NPolymer14 and NPolymer8 was intermediate at 51.1 mN/m and 50.9 mN/m, respectively. 
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Figure 5.13. Surface energy of plasma polymer samples plotted against time of exposure 
to atmosphere. 
The polar and dispersive components of the surface energy are graphed separately to allow 
more detailed analysis of the relative contributions of each component. The changes with time 
seen with the polar component (Figure 5.14) follows those seen with the total surface energy. 
A rapid initial decrease in polar energy in the first day followed by a more gradual change to 
day 30. The NPolymer27 sample had the highest polar energy at any time point. In contrast, 
dispersive energy (Figure 5.15) remains similar between different nitrogen concentrations and 
the changes with time are only gradual. 
 
Figure 5.14. Polar energy of plasma polymer samples plotted against time of exposure to 
atmosphere. 
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Figure 5.15. Dispersive energy of plasma polymer samples plotted against time of 
exposure to atmosphere. 
5.3.3 Fitting of experimental data for surface energy 
The experimental data for polar energy and dispersive energy were fitted with theoretical 
curves in order to estimate the values for time zero and after infinite storage. Contact angles 
and surface energy immediately after deposition is impossible to measure given the time 
required to transport the sample to the analyser. Compositional changes in the chemical 
makeup of the plasma polymer surfaces underscores the observed evolution of surface energy 
[467]. A detailed analysis of this is found in subsequent sections of this chapter. Given the 
kinetics of chemical transformation in the polymer surface can be described by first order 
kinetics we can approximate the experimental data using models based on exponential 
functions [468]. 
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Figure 5.16. Polar energy plotted on semi logarithmic scale (time). Line represents 
theoretical fitting using one exponential function. 
Figure 5.16 shows the polar energy on a semi logarithmic scale fitted with one exponential 
function. A poorly fitting curve indicates a need for an additional exponential function. 
 
Figure 5.17. Polar energy plotted on semi logarithmic scale (time). Line represents 
theoretical fitting using a function composed of two exponential functions. 
178 
The theoretical fitting improved significantly using a function with two exponential 
components. An adjusted R square value for the fitting was 0.98. The parameters of the 
equation are labelled in the Figure 5.17. The function is shown below. 
y = y0 + A1 Exp (-t/t1) + A2 Exp (-t/t2) 
Figure 5.18 shows the polar constituent of surface energy of all polymers fitted with two 
exponential component functions. A consistency of fitting is seen. The parameters of the fitting 
are shown below (Table 5.1). 
 
Figure 5.18. Polar component of surface energy plotted on semi logarithmic scale (time). 
The line represents theoretical fitting using a function composed of two exponential 
functions. 
Table 5.1. Parameters of fitting for polar component of surface energy using two 
exponential functions. 
Polar energy y0, a.u t1 (min) t2 (min) A1, a.u A2, a.u 
PPolymer 5.59 7397 85 3.8 5.44 
NPolymer8 8.81 2513 58 3.28 7.37 
NPolymer14 10.59 2849 40 2.82 8.52 
NPolymer27 15.46 2224 61 4.36 6.54 
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Figure 5.19. Dispersive component of surface energy of all plasma polymers plotted on a 
semi logarithmic scale (time). The line represents theoretical fitting using a function 
composed of two exponential functions. 
The dispersive component of the surface energy is shown in Figure 5.19. The fitted lines using 
two exponential component functions show good consistent fitting across polymers with 
varying nitrogen concentrations. The parameters from the fitted curves are shown below (Table 
5.2). 
Table 5.2. Parameters of fitting for dispersive component of surface energy using two 
exponential functions. 
Dispersive energy y0, a.u t1 (min) t2 (min) A1, a.u A2, a.u 
PPolymer 41.86 6824 205 2.04 1.47 
NPolymer8 40.41 10208 66 2.54 3.04 
NPolymer14 40.33 4187 53 3.66 2.87 
NPolymer27 38.33 8109 93 2.66 4.27 
 
5.3.4 Surface chemistry changes with time 
The chemical function groups in the plasma polymers deposited on silicon wafers were 
measured using transmission FTIR spectra over a wavelength range of 700 – 4000 cm-1. Lines 
found in the wavelength range of 3600 – 3100 cm-1 represent stretch vibrations of NH groups 
in amines and amides [469] and hydroxyl groups [470]. The region between 3000 – 2800 cm-1 
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is assigned to asymmetrical and symmetrical stretch vibrations of methyl (CH3) and methylene 
(CH2) groups, the 2250 – 2100 cm-1 region is attributed to C ≡ N stretch vibrations in nitrile or 
iso-nitrile groups. The region between 1800 – 1500 cm-1 consists of overlapping contributions 
from C = O in carboxyl, carbonyl groups, hydroxyl, peroxide and amide groups, C = C in 
ketones and alkenes, C = N stretch vibrations from amines and N – H bending vibrations in 
amides [469]. The broad background with a maximum at 1500-1100 cm-1 is attributed to C– C 
vibrations of carbonized structures. 
More specific line assignments of the FTIR spectra of the deposited polymers are shown in the 
Table 5.3 below. 
Table 5.3. Assignment of wavelength and chemical function groups on FTIR spectra. 
Wavenumber (cm-1) Chemical group assignment 
3525 OH 
3380 OH/NH 
3255 NH 
2945 CH 
2888 CH 
2148 Nitrile (C ≡ N) 
1715 C = O 
1550 NH 
1375 C – C/CH 
 
Polymers deposited on silicon wafers were measured within 5 min (fresh sample) of removal 
from the plasma polymerization chamber and exposure to the atmosphere. FTIR spectra of the 
plasma polymers are shown in Figure 5.20. Nitrogen dependent variations in FTIR spectra can 
be gleaned from this semi-quantitative comparison. 
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Figure 5.20. Transmission FTIR spectra of deposited polymers 5 min (fresh sample) 
after exposure to atmosphere. 
The spectra of PPolymer (no nitrogen doping during deposition) shows the lowest 
concentration of NH and OH groups with the lowest absorbance in the 3600 – 3100 cm-1 region. 
In contrast, lines from the stretch vibrations of methyl groups are prominent (3000 – 2800 cm-
1). PPolymer was deposited with no nitrogen gas and not surprisingly there is an absence of 
nitrile lines (2250 – 2100 cm-1). Towards lower wavelengths we see reduced intensities of lines 
in the 1800 – 1500 cm-1 and 1500 – 1100 cm-1 regions. 
Patterns can be observed in the spectra as the nitrogen concentration increases. There is an 
increase in the hydroxyl (OH) lines at 3525 cm-1. A more pronounced rise and broadening of 
the OH and NH lines at 3380 cm-1 and 3255 cm-1. A subtle nitrile line is seen with NPolymer8 
and as anticipated this line becomes more obvious in NPolymer27. A dominant peak in the 
1800 – 1500 cm-1 region with high nitrogen samples indicates an abundance of C = O, C = N 
and C = C species. Expansion of the NH shoulder (1550 cm-1) is in keeping with more 
nitrogenous species. Moderate increases in the C – C region are also noted. Intriguingly an 
apparent rightward shift of the peak in the 1800 – 1500 cm-1 region towards lower wavelengths 
correlating with nitrogen concentration is found. The peak for PPolymer is centered at a 
wavelength of 1700 cm-1, shifting to 1630 cm-1 for NPolymer27. Conceivably the peak shift is 
secondary to strong influences of emerging C = N species on the contour of this region. 
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Figure 5.21. Transmission FTIR spectra of deposited polymers 6 months after exposure 
to atmosphere. 
The spectra of the deposited polymers after a prolonged exposure to the atmosphere (6 months) 
is presented in Figure 5.21. With increasing nitrogen, NH, OH, Nitrile, C = O, C = N, C = C, 
NH and C – C groups are seen to increase while CH groups decrease. The rightward shift in 
the peak in the 1800 – 1500 cm-1 region with increasing nitrogen is unchanged at 6 months, 
with the wavelengths of the peaks for a particular nitrogen concentration remaining consistent 
with that seen at 5 min. 
Scrutinizing the spectral differences for a particular plasma polymer for different time points 
between 5 min and 6 months sheds light on the effect of aging on the overall spectral shape. 
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Figure 5.22. Transmission FTIR spectra of PPolymer deposited on silicon wafer as a 
function of aging time in atmosphere. 
Representative FTIR Spectra for each plasma polymer at 5 min, 1 day, 1 week, 1 month and 6 
months are graphed together. Time related transformation of the PPolymer spectra is evident 
(Figure 5.22). Rising OH, NH, C = O, C = N and C = C moieties as evidenced by increasing 
spectral intensity in the 3600 – 3100 cm-1 and 1800 – 1500 cm-1 regions. Subtler increases in 
CH and C – C groups are seen. Absence of spectral lines in the nitrile region is noted. 
 
Figure 5.23. Transmission FTIR spectra of NPolymer8 deposited on silicon wafer as a 
function of aging time in atmosphere. 
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The evolution of the FTIR spectra for NPolymer8 samples (Figure 5.23) is similar to that seen 
with PPolymer samples. With exposure to the atmosphere the intensity of all functional groups 
increases. The increases in the 2250 – 2100 cm-1 region are most prominent, followed by those 
in the 3600 – 3100 cm-1 region. Very subtle spectral lines in the nitrile region are noted. 
 
Figure 5.24. Transmission FTIR spectra of NPolymer14 deposited on silicon wafer as a 
function of aging time in atmosphere. 
Distinct characteristics in the spectra can be seen as the nitrogen concentration is increased to 
14% (Figure 5.24). A modest but clearly visible line at 2250 – 2100 cm-1 representing C ≡ N 
(nitrile) groups appears. With exposure to the atmosphere this line decreases in intensity. CH 
groups are less of a feature in the spectra and their increase with time is only minor. When 
compared to lower nitrogen (PPolymer and NPolymer8) samples the signal intensity in the 
3600 – 3100 cm-1 and 1800 – 1500 cm-1 regions undergo considerable increase and the 
shoulders broaden. 
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Figure 5.25. Transmission FTIR spectra of NPolymer27 deposited on silicon wafer as a 
function of aging time in atmosphere. 
In the FTIR spectra for NPolymer27 (Figure 5.25) OH and OH/NH lines increase with time in 
the atmosphere. The NH line at 3255 cm-1 is a dominant feature in these spectra. Not only is 
there substantial increase in intensity but it is coupled with widening of the shoulder. CH 
groups have the lowest intensity and only subtle variations are noted with aging. Nitrile lines 
are seen to decrease. The 1800 – 1500 cm-1 region stands out in these spectra not only with a 
sharp and tall peak but also a considerable shoulder in the 1550 cm-1 region. This shoulder is 
likely secondary to rising nitrogenous species. The C – C carbonized structures (1500 – 1100 
cm-1) are more prominent when compared to other spectra with higher intensities at base line 
(5 min time point) and more obvious changes with time. 
To understand quantitatively how aging impacts each chemical functional group and its relation 
to nitrogen concentration a detailed exploration was made. The intensity of absorbance for each 
chemical functional group was graphed as a function of time of exposure to the atmosphere. 
Approximately 16-19 time points were recorded for each of the plasma polymers. A theoretical 
fitting function was generated to model the kinetics of the experimental data. 
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Figure 5.26. Semi-log graph of absorbance of the 3525 cm-1 (NPolymer27) line as a 
function of aging time in atmosphere. The solid line represents a theoretical fit using 
one exponential function. 
The intensity of the absorbance at the wavelength 3525 cm-1 (hydroxyl vibrations) for 
NPolymer27 is shown as an example of the fitting process (Figure 5.26). The blue solid line 
represents an initial attempt to fit the data with a single exponential function. The adjusted R 
square value for the fitted line is 0.93. The fitting is suboptimal using one exponential function. 
 
Figure 5.27. Semi-log graph of absorbance of the 3525 cm-1 (NPolymer27) line as a 
function of aging time in atmosphere. The solid line represents a theoretical fit using a 
function with two exponential components. 
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The same graph was fitted with a two exponential component function (Figure 5.27). An 
improved fitting of the theoretical line and the experimental points can be seen and the adjusted 
R value increases to 0.95. 
 
Figure 5.28. Semi-log graph of absorbance of the 3525 cm-1 (NPolymer27) line as a 
function of aging time in atmosphere. The solid line represents a theoretical fit using a 
function with three exponential components. The parameters of the fitted equations are 
shown on the graph. 
The use of a three component exponential function resulted in the best fit of the experimental 
data (as can be seen in Figure 5.28). The adjusted R square value increased to 0.98 
The three component exponential function used is shown below. 
y = y0 + A1 (1 – exp (- t/t1)) + A2 (1 – exp (- t/t2)) + A3(1 – exp (- t/t3)) 
Chemical functional groups at specific wavelengths were graphed as a function of time aged. 
Each panel represent a functional group graphed according to nitrogen concentration in the 
plasma polymer giving a more expanded view of the curve fitting. The final panel shows all 
the plasma polymers plotted together providing a relative view of intensity of the functional 
group and variations with time. All experimental data were fitted with the above equation. 
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Figure 5.29. Semi-log graph of absorbance at 3525 cm-1 as a function of aging time in 
atmosphere. The solid lines represent theoretical fits using functions with three 
exponential components. A – PPolymer, B – NPolymer8, C – NPolymer14, D – 
NPolymer27, E – All polymers combined. 
The intensity of the hydroxyl group vibration line at 3525 cm-1 was plotted and fitted with the 
3 exponential component function (Figure 5.29). Each polymer was plotted individually (A-
D) in order to show the integrity of the fitting and the phases of change with time. To allow 
comparison between the spectra, a combined plot (E) is shown at the bottom of the panel. The 
intensity of the line is greatest for NPolymer27 and lowest for PPolymer. After an initial 
separation in the lines between PPolymer and NPolymer8, the intensity levels become similar 
towards 6 months. The slope of the increase for nitrogen doped samples are similar, 
characterized by an initial slower phase followed by a more rapid middle phase and then a 
slower phase towards maximal intensity. The slope of increase for PPolymer is different and 
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shows a steeper initial phase followed by an even more rapid middle phase and concluding 
with a slower terminal phase. The parameters from the fitted functions are listed below (Table 
5.4). 
Table 5.4. Parameters of fitted function of measured absorbance at 3525 cm-1 
wavelength. 
3525 cm -1 y0, a.u t1 (min) t2 (min) t3 (min) A1, a.u A2, a.u A3, a.u 
PPolymer 8.54E-6 253 9035 100000 1.6E-6 7.22E-6 7E-6 
NPolymer8 1.14E-5 178 14385 121143 5.29E-6 3.13E-6 6.41E-6 
NPolymer14 1.12E-5 191 12458 107102 6.79E-6 5.52E-6 5.72E-6 
NPolymer27 1.73E-5 315 7694 100000 5E-6 8E-6 3.48E-6 
 
 
Figure 5.30. Semi-log graph of absorbance at 3380 cm-1 as a function of aging time in 
atmosphere. The solid lines represent theoretical fits using functions with three 
exponential components. A – PPolymer, B – NPolymer8, C – NPolymer14, D – 
NPolymer27, E – All polymers combined. 
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The line at 3380 cm-1 represents contributions from both hydroxyl and NH groups (Figure 
5.30). The intensity of the lines for all the polymers increases with storage time in atmosphere. 
Overall the slope of this line is less sharp than that of the 3325 cm-1 line. The three phases of 
growth are subtler for the nitrogen doped polymers. In contrast PPolymer samples undergo a 
more rapid increase in intensity, with distinct slow, fast and slow phases. This is similar to what 
is seen for wavelength 3525 cm-1. The intensity correlates with nitrogen concentrations with 
the highest intensity seen with NPolymer27 samples. 
The parameters from the fitted functions are listed below (Table 5.5). 
Table 5.5. Parameters of fitted function of measured absorbance at 3380 cm-1 
wavelength. 
3380 cm -1 y0, a.u t1 (min) t2 (min) t3 (min) A1, a.u A2, a.u A3, a.u 
PPolymer 6.6E-6 31 7753 169537 4.69E-6 1.16E-5 5.73E-6 
NPolymer8 1.95E-5 42 4045 100000 3E-6 2.89E-6 4E-6 
NPolymer14 2.47E-5 135 6339 80000 4.95E-6 4.74e-6 3.7E-6 
NPolymer27 4.49E-5 251 5317 200000 9.22E-6 7.56E-6 5.13E-6 
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Figure 5.31. Semi-log graph of absorbance at 3255 cm-1 as a function of aging time in 
atmosphere. The solid lines represent theoretical fits using functions with three 
exponential components. A – PPolymer, B – NPolymer8, C – NPolymer14, D – 
NPolymer27, E – All polymers combined. 
The NH functional group accounts for the line at 3255 cm-1 (Figure 5.31). The line is analogous 
to that of the OH and NH line at 3380 cm-1. This is not surprising given the large contribution 
of NH functional groups to the absorbance at 3380 cm-1. The separation of the NPolymer27 
curve from that of the other polymers is very clear. This is explained by the incorporation of 
nitrogen into the polymer structure during the polymerization process. 
The parameters from the fitted functions are listed below (Table 5.6). 
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Table 5.6. Parameters of fitted function of measured absorbance at 3255 cm-1 
wavelength. 
3255 cm -1 y0, a.u t1 (min) t2 (min) t3 (min) A1, a.u A2, a.u A3, a.u 
PPolymer 1.26E-6 80 10884 200000 4.1E-6 7.92E-6 5E-6 
NPolymer8 1.05E-5 50 3000 91063 3.31E-6 2.30E-6 2.75E-6 
NPolymer14 1.63E-5 201 10622 193129 4.6E-6 4.16E-6 3.74E-6 
NPolymer27 4.34E-5 132 5000 300000 7.69E-6 9.06E-6 7.76E-6 
 
 
Figure 5.32. Semi-log graph of absorbance at 2945 cm-1 as a function of aging time in 
atmosphere. The solid lines represent theoretical fits using a function with three 
exponential components. A – PPolymer, B – NPolymer8, C – NPolymer14, D – 
NPolymer27, E – All polymers combined. 
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The absorbance line at 2945 cm-1 represents contributions from stretching vibrations of CH 
bonds in CH2, CH3 and CH configurations (Figure 5.32). The intensity of the vibrations 
increases sharply within the first day followed by slower changes towards 6 months. A negative 
correlation with increasing nitrogen concentration can be seen. A small decrease in the intensity 
occurs as nitrogen is introduced (NPolymer8), however with increasing nitrogen concentration 
the intensity decreases much more with the lowest level for NPolymer27. 
The parameters from the fitted functions are listed below (Table 5.7). 
Table 5.7. Parameters of fitted function of measured absorbance at 2945 cm-1 
wavelength. 
2945 cm -1 y0, a.u t1 (min) t2 (min) t3 (min) A1, a.u A2, a.u A3, a.u 
PPolymer 1.87E-5 88 7634 108352 3.72E-6 1.69E-6 2.22E-6 
NPolymer8 1.86E-5 228 16527 400000 1.78E-6 1E-6 2.07E-6 
NPolymer14 9E-6 111 6471 200000 1.91E-6 6.85E-7 1E-6 
NPolymer27 1.34E-6 280 7640 262444 1.82E-6 1E-6 2.77E-6 
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Figure 5.33. Semi-log graph of absorbance at 2888 cm-1 as a function of aging time in 
atmosphere. The solid lines represent theoretical fits using a function with three 
exponential components. A – PPolymer, B – NPolymer8, C – NPolymer14, D – 
NPolymer27, E – All polymers combined. 
The line at 2888 cm-1 represents an additional peak in the region of CH vibration (Figure 5.33). 
Similarities with the line at 2945 cm-1 with an initial sharp increase in the intensity of the 
absorbance followed by a more gradual change with time. A departure from this pattern is 
noted with the NPolymer27 samples, with a much slower increase in the first week followed 
by a sharper slope after this. A decrease in absorbance intensity is seen with increasing nitrogen 
concentration. 
The parameters from the fitted functions are listed below Table 5.8. 
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Table 5.8. Parameters of fitted function of measured absorbance at 2888 cm-1 
wavelength. 
2888 cm -1 y0, a.u t1 (min) t2 (min) t3 (min) A1, a.u A2, a.u A3, a.u 
PPolymer 1.54E-5 95 7969 100000 3.16E6 1.27E-6 1.5E-6 
NPolymer8 1.51E-5 130 5991 400000 1.48E-6 7.33E-7 1.64E-6 
NPolymer14 8.3E-6 331 3882 168794 2.56E-6 1.44E-7 1.5E-6 
NPolymer27 6.29E-6 152 20000 200000 1.27E-6 1.89E-6 1.67E-6 
 
 
Figure 5.34. Semi-log graph of absorbance at 2148 cm-1 as a function of aging time in 
atmosphere. The solid lines represent theoretical fits using a function with three 
exponential components. A –NPolymer8, B – NPolymer14, C – NPolymer27, D – All 
polymers combined. 
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The absorbance line at 2148 cm -1 is from vibrations from the nitrile or iso-nitrile functional 
groups (Figure 5.34). In contrast to other functional groups the intensity of this line decreases 
with time. A decay function with three exponential components was used to fit the experimental 
data. 
y = y0 + A1 e-t/t1 + A2 e-t/t2 + A3 e-t/t3 
A nitrile line could not be detected in PPolymer samples. As expected the intensity of the line 
is highest with NPolymer27 samples. This functional group is unstable in atmosphere and 
shows a decrease in intensity with time. The slope of the decline is greatest with NPolymer27 
samples. Despite the greater loss of this absorbance line, NPolymer27 samples still reach a 
steady state level much higher than NPolymer14 and NPolymer8 samples. 
The parameters from the fitted functions are listed below Table 5.9. 
Table 5.9. Parameters of fitted function of measured absorbance at 2148 cm-1 
wavelength. 
2148 cm -1 y0, a.u t1 (min) t2 (min) t3 (min) A1, a.u A2, a.u A3, a.u 
NPolymer8 8.39E-7 50000 5000 154 4.16E-7 4.5E-7 8.69E-7 
NPolymer14 4E-6 80000 20000 3000 1.64E-6 8E-7 2E-6 
NPolymer27 7.66E-6 89193 40000 6000 2.39E-6 2E-6 3E-6 
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Figure 5.35. Semi-log graph of absorbance at 1715 cm-1 as a function of aging time in 
atmosphere. The solid lines represent theoretical fits using a function with three 
exponential components. A – PPolymer, B – NPolymer8, C – NPolymer14, D – 
NPolymer27, E – All polymers combined. 
The absorbance line at 1715 cm -1 represents contributions from multiple functional groups 
including C = N, C = C and C = O (Figure 5.35). All polymer samples show time related 
increases in intensity with exposure to the atmosphere. The slope of the line becomes sharper 
after one day. NPolymer27 samples have the highest intensity of this line and the rate of 
increase is the fastest. The final intensity of PPolymer and NPolymer8 is similar. 
The parameters from the fitted functions are listed below (Table 5.10). 
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Table 5.10. Parameters of fitted function of measured absorbance at 1715 cm-1 
wavelength. 
1715 cm -1 y0, a.u t1 (min) t2 (min) t3 (min) A1, a.u A2, a.u A3, a.u 
PPolymer 4.8E-6 300 12987 8000 4.8E-6 5.76E-6 1.5E-5 
NPolymer8 5.15E-5 112 19729 137543 1.36E-6 7E-6 8.5E-6 
NPolymer14 6.23E-5 100 6916 100000 5E-7 1.91E-5 1.15E-5 
NPolymer27 1.19E-4 400 5999 119442 1E-6 2.06E-5 2.53E-5 
 
 
Figure 5.36. Semi-log graph of absorbance at 1375 cm-1 as a function of aging time in 
atmosphere. The solid lines represent theoretical fits using a function with three 
exponential components. A – PPolymer, B – NPolymer8, C – NPolymer14, D – 
NPolymer27, E – All polymers combined. 
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In contrast to the observations made for asymmetrical CH vibrations at 2945 cm -1, the intensity 
of symmetrical CH vibrations at 1375 cm -1 increases with higher nitrogen concentration 
(Figure 5.36). The slope of the increase is also highest with NPolymer27 samples. The 
intensity at 6 months for PPolymer and NPolymer8 samples approaches a similar value. 
The parameters from the fitted functions are listed below (Table 5.11). 
Table 5.11. Parameters of fitted function of measured absorbance at 1375 cm-1 
wavelength. 
1375 cm -1 y0, a.u t1 (min) t2 (min) t3 (min) A1, a.u A2, a.u A3, a.u 
PPolymer 1.06E-5 20 9239 100000 3.79E-6 5.7E-6 5.52E-6 
NPolymer8 2.12E-5 90 3284 421946 2.48E-6 2.82E-6 2.64E-6 
NPolymer14 2.97E-5 125 10000 479324 7.29E-6 4.23E-6 3E-6 
NPolymer27 5.21E-5 331 19930 500000 1.7E-5 1.58E-5 9E-6 
 
5.3.5 XPS curve fitting 
The Carbon 1s (C1s) spectra was assessed using XPS analysis. The spectra consist of 
contributions from multiple components representing various chemical functional groups and 
carbon in different bonding configurations [463]. Casa-XPS software was used for fitting of 
the components. Individual components were fitted using Gaussian-Lorentzian functions 
[471]. Fitting was initially attempted using 4 components (Figure 5.37) The component peak 
binding energy assignments were 284.5 eV, 285.5 eV, 286.2 eV and 287.4 eV, corresponding 
to C – C, C = N, C – N/CCN and C – O groups, respectively [472]. However, this failed to 
provide a suitable fit of the C1s spectra. Specifically, the fourth C – O component at 287.4 eV 
is poorly represented. 
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Figure 5.37. C1s spectra from XPS analysis fitted with 4 components. 
Using 5 components provided a better fit of the C1s spectra (Figure 5.38). The main carbon-
carbon bonding component was resolved into two to account for sp2 and sp3 bonding 
configurations [471]. The binding energy assignments and respective bonding configurations 
and chemical groups are shown below (Table 5.12) [470, 471]. 
 
Figure 5.38. C1s spectra from XPS analysis fitted with 5 components. 
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Table 5.12. Assignments of functional groups to binding energy. 
Component 1  284.4 ± 0.3 eV sp2 
Component 2 285.4 ± 0.3 eV sp3 
Component 3 286.4 ± 0.3 eV C – O, C = N, Nitriles 
Component 4 287.3 ± 0.3 eV C = O, C – N 
Component 5 288.6 ± 0.3 eV O – C = O 
 
What can be seen from these assignments is the considerable overlap of chemical functional 
groups for each component. Precise quantification of each group is therefore very difficult. A 
semi-quantitative appreciation of the changes with nitrogen concentration and time can be 
made however. 
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5.3.5.1 Curve fitting of PPolymer samples 
 
 
 
 
Figure 5.39. XPS spectra in the C1s region from PPolymer samples resolved into 5 
components. Top image: spectrum measured within 1 hour of deposition. Lower image: 
spectrum measured 2 months after deposition. Area under the curve for each 
component is expressed as a percentage of the area under the C1s curve. The fraction of 
carbon in the sp2 configuration is expressed as % of total carbon. 
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5.3.5.2 Curve fitting of NPolymer8 samples 
 
 
 
 
Figure 5.40. XPS spectra in the C1s region from NPolymer8 samples resolved into 5 
components. Top image: spectrum measured within 1 hour of deposition. Lower image: 
spectrum measured 2 months after deposition. Area under the curve for each 
component is expressed as a percentage of the area under the C1s curve. The fraction of 
carbon in the sp2 configuration is expressed as % of total carbon. 
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5.3.5.3 Curve fitting of NPolymer14 samples 
 
 
 
 
Figure 5.41. XPS spectra in the C1s region from NPolymer14 samples resolved into 5 
components. Top image: spectrum measured within 1 hour of deposition. Lower image: 
spectrum measured 2 months after deposition. Area under the curve for each 
component is expressed as a percentage of the area under the C1s curve. The fraction of 
carbon in the sp2 configuration is expressed as % of total carbon. 
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5.3.5.4 Curve fitting of NPolymer27 samples 
 
 
 
 
Figure 5.42. XPS spectra in the C1s region from NPolymer27 samples resolved into 5 
components. Top image: spectrum measured within 1 hour of deposition. Lower image: 
spectrum measured 2 months after deposition. Area under the curve for each 
component is expressed as a percentage of the area under the C1s curve. The fraction of 
carbon in the sp2 configuration is expressed as % of total carbon. 
Resolving the C1s spectra into 5 components allows broad trends in the carbon bonding 
configuration and chemistry, including changes with time, to be compared between plasma 
polymers of varying nitrogen concentration. Clear patterns in carbon bonding and functional 
groups can be seen with increasing nitrogen concentration. An increase of the sp
2
 fraction (sp
2
 
/ (sp
2
 + sp
3
)), from 61.4% to 70.6%, occurs with incorporation of nitrogen indicating increasing 
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graphitization of the carbon polymer. The percentage area under the curves (of the total area 
under the C1s curve) for each fitted component gives the relative content of the group of the 
chemical species at that binding energy. All of the chemical functional groups incorporated 
through atmospheric interactions can be seen to increase with nitrogen concentration. 
Noting that each component resolved in the XPS analysis represents a contribution from 
multiple chemical species and it is not possible to differentiate between them, FTIR spectra 
provides complimentary information. The XPS component at 286.4 eV which is seen to 
increase with time, is attributed to C – O, C = N and nitrile chemical species. Since FTIR 
analysis shows a degradation of nitrile species with time and a significant rise in C = N groups 
(amine, amide and imine groups) with aging, it can be deduced that C = N and to some extend 
the C – O group is responsible for the time related increases of the 286.4 eV component peak. 
The transition in shape (fresh vs aged samples) of the overall C1s spectrum is most obvious in 
NPolymer27 where a broadening of the high energy shoulder (>286eV) is observed. These 
time-related differences in C1s spectra shape are much subtler in samples with lower nitrogen 
content and are due to the relatively smaller increases of functional groups with aging. 
5.3.6 Elemental composition 
Using the XPS survey spectra (discussed in previous chapter) an appreciation of the elemental 
composition of the plasma polymers can be obtained. Carbon, nitrogen and oxygen are the 
predominant elements present. Nitrogen is seen in PPolymer samples despite an absence of this 
gas during the deposition process. Similarly, oxygen is seen across all polymers when oxygen 
was not introduced during polymerization. A potential explanation is small amounts of oxygen 
and nitrogen leaked from the atmosphere into the chamber. However, this is unlikely given the 
stability of the pressure in the plasma chamber. As noted by other authors the presence of these 
elements in the plasma polymers are predominantly a result of chemical reactions occurring 
after exposure to atmosphere [467, 473]. Comparison of fresh and aged samples (2 months) of 
nitrogen and oxygen normalized on carbon provide strong evidence for such post-deposition 
atmospheric reactions (Figure 5.43). 
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Figure 5.43. Top panel: Nitrogen / Carbon ratio (N/C) as a function of nitrogen gas 
flow. Lower panel: Oxygen / Carbon ratio (O/C) as a function of nitrogen gas flow. 
PPolymer (N2 gas flow = 0), NPolymer8 (N2 gas flow = 1), NPolymer14 (N2 gas flow = 
5), NPolymer27 (N2 gas flow = 10). 
The N/C ratio increases with nitrogen gas flow in an approximately linear fashion for both 
fresh and aged samples reflecting successful incorporation of nitrogen into the carbon polymer. 
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With aging an apparent loss in nitrogen is observed. A higher absolute loss is identified with 
NPolymer27 samples however the percentage loss (8.8%) is less than for PPolymer (11%). 
Oxygen rises considerably with aging with a percentage gain of 35.1% for PPolymer and 37.5% 
for NPolymer27. The immediate presence of oxygen functional moieties seen in the FTIR 
spectral analysis reveals the rapid uptake of oxygen in the plasma polymers. The amount of 
oxygen incorporated rises to a much lesser degree as nitrogen flow is increased and appears to 
reach a plateau. The XPS spectra reflects the oxygen concentration in the very thin (10 nm) 
surface layer, while FTIR spectra interrogates the concentration of oxygen containing groups 
in the bulk of the deposited film (100 nm or more). Taking into account that the surface layer 
is under direct influence of atmospheric oxygen, the immediate appearance of a high O1s signal 
in XPS spectra and the more delayed increase with storage time of the C = O line intensity in 
the FTIR spectra is then to be expected. 
5.3.7 Free radical measurements – electron spin resonance spectroscopy 
The ESR of fresh and aged PPolymer and NPolymer27 samples were obtained (Figure 5.44, 
and Figure 5.45). Fresh samples were measured within 3 hours of polymerization. A more 
immediate time point was not possible due to different physical locations of the ESR 
spectrometer and the plasma polymerization chamber. Aged samples were measured at 28 
days. All spectra are normalized to thickness of deposited spectra to allow comparison of 
relative free radical amount. 
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Figure 5.44. ESR spectra of PPolymer measured at two separate time points, within 3 
hours (fresh) and 28 days after deposition. Weak pitch standard spectra is shown as a 
comparison. Spectra are normalized to thickness of plasma polymer. 
 
Figure 5.45. ESR spectra of NPolymer27 measured at two separate time points, within 3 
hours (fresh) and 28 days after deposition. Weak pitch standard spectra is shown as a 
comparison. Spectra are normalized to thickness of plasma polymer. 
The ESR spectra of PPolymer and NPolymer27 samples were obtained by subtracting spin 
density signals of controls (glass capillaries treated with plasma without polymer deposition) 
from measured signals of polymerized samples. As a comparative standard weak pitch (Bruker) 
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which has a known free radical content and g factor was used. With time the intensity (positive 
and negative deflections) of both PPolymer (Figure 5.44) and NPolymer27 (Figure 5.45) 
samples can be seen to decrease. This represents a decay in free radical concentrations with 
aging. At each time point (fresh and day 28) the spectral intensity of NPolymer27 samples is 
greater than PPolymer. Furthermore, both fresh and aged NPolymer27 samples have higher 
intensity than the weak pitch standard. In contrast intensity of PPolymer remains consistently 
lower than weak pitch. Taken together, highly nitrogenized NPolymer27 has a higher free 
radical content than non-nitrogenized plasma polymers. 
An interesting observation of both NPolymer27 and PPolymer spectra is the asymmetry of 
positive and negative deflections. In comparison, weak pitch displays more symmetrical 
spectra. Asymmetry reflects the complex summation of different free radical species contained 
within the plasma polymers. In difference weak pitch contains a more homogenous population 
of free radicals as reflected by the symmetry of the spectra. With aging of plasma polymer 
samples, especially NPolymer27, the curves change in shape. This is likely secondary to 
changing contributions from different free radical species undergoing differential decay. 
5.4 Discussion 
The interaction between a biomaterial surface and the protein-cellular systems in vivo is 
determined by an interfacial layer of adsorbed plasma proteins [138]. The physio-chemical 
parameters of a biomaterial surface determine the composition, amount and conformation of 
the proteins bound. Plasma proteins in soluble natural conformation do not cause unwanted 
reactions in contrast to adsorbed and denatured versions of the same protein [474], indicating 
a transition from a biological favorable to a more hostile conformation once in contact with a 
surface. Modulating surface parameters using plasma treatment or plasma polymerization can 
tune the wettability, surface energy and surface chemical functionalities resulting in improved 
biocompatibility [453, 475-477]. Plasma modified and polymerized surfaces have been noted 
to undergo structural and chemical changes with exposure and aging in atmosphere [463, 467, 
478]. Broadly speaking these changes are highlighted by a decrease in surface energy and 
hydrophilicity [459, 468, 479] and accompanied by a significant increase in oxygen chemical 
moieties [463]. A free radical driven oxidation process has been proposed as the underlying 
mechanism for the incorporation of oxygen into the plasma polymer and the appearance of 
polar oxygen dominant species [463, 480]. The plasma polymer surface soon after deposition 
can be very physio-chemically different to the one after exposure to the atmosphere. Given the 
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pivotal importance of the surface parameters in determination of biocompatibility a detailed 
assessment of the time related changes with our plasma polymer was crucial. In general, our 
findings are in agreement with the literature with a decrease in wettability and surface energy, 
a growth in surface oxygen functionalities and decay in free radicals with time. The increase 
in polar functional groups as the polymer ages is contrary to the observed ‘hydrophobic 
recovery’ of the surface, as polar species are ‘water loving’ and tend to increase hydrophilicity. 
Indeed, a number of possible explanations for this phenomenon have been raised by different 
authors. Two main purported mechanisms are 1) Intrinsic reorientation or diffusion of the polar 
functional groups towards the bulk polymer and 2) Surface contamination by hydrophobic 
molecules from the atmosphere [481]. In this discussion we propose a free radical based 
mechanism for this paradoxical finding. 
5.4.1 Contact angle and surface energy 
The contact angle and surface energy provides a broad analysis of the physio-chemical 
characteristics of a surface and represents contributions from free radicals and chemical 
function groups [468, 482]. To probe the hydrophilicity of the deposited plasma polymers we 
employed established wetting techniques. The angle formed by a droplet of water on a surface 
is the most commonly utilized method for determination of surface hydrophilicity [483]. 
The classification of a surface as hydrophilic or hydrophobic is a rather arbitrary assignment 
based on the water contact angle. Using a cut off of 90° between hydrophilicity and 
hydrophobicity all deposited plasma polymers irrespective of nitrogen concentration had a 
contact angle of less than 90°, i.e. they were hydrophilic. There is a notable instability in the 
surface contact angle as evidenced by the decreased spreading of the water droplet on the 
polymer surface with aging. Plotting contact angle as function of time (Figure 5.11) reveals a 
number of important findings. 1) Recovery of hydrophobicity is most rapid in the first few 
hours in atmosphere and largely complete by the first day indicating the kinetics of the 
processes responsible for this loss of hydrophilicity are fastest during this time frame. 2) A 
ceiling or saturation effect is seen with the contact angle reaching a plateau by 30 days. 3) 
Nitrogen incorporation does not prevent the hydrophobic recovery but a concentration 
dependent effect is seen for the stable/saturated contact angle reached. Essentially nitrogen 
doping leads to more hydrophilic surfaces. The relative increase in contact angle from fresh to 
aged samples (30 day storage) is 1.33, 1.39, 1.42, and 1.52 fold for PPolymer, NPolymer8, 
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NPolymer14 and NPolymer27 respectively, therefore the relative loss of hydrophilicity is 
higher with increasing nitrogen. 
The surface energy is closely linked to the water contact angle. Not surprisingly similar time 
related kinetics are seen in which the greatest change occurs during the first day after polymer 
deposition (Figure 5.13). The higher the surface energy the easier it is for a surface to overcome 
the intermolecular interactions within the liquid. Water droplets on NPolymer27 samples (the 
highest surface energy) showed the greatest spread. Resolving surface energy into polar and 
dispersive components reveals the main contribution to the overall surface energy from aging 
is from the polar component. Moreover, when nitrogen is increased the polar component is 
seen to rise. In contrast both aging and nitrogen concentration has little effect on the dispersive 
component (Figure 5.14 and 5.15). 
The kinetics of the polar and dispersive components can be described using first order reactions 
with exponential functions [468]. A function using two exponential components provided 
adequate fitting of the experimental data. Two phases of kinetics are observed for polar and 
dispersive components, an initial faster decrease with time followed by a slower change. The 
exponential function permits the calculation of two theoretical time points, time = 0 
(immediately post deposition) and t = ∞ (infinite storage). 
Manipulating the equation 
y = y0 + A1 Exp (-t/t1) + A2 Exp (-t/t2) 
Time = 0 
y = y0 + A1 Exp (-0/t1) + A2 Exp (0/t2) 
= y0 + A1 Exp (0) + A2 Exp (0) 
= y0 + A1 x 1 + A2 x 1 
= y0 + A1 + A2 
Time = ∞ 
y = y0 + A1 Exp (-∞/t1) + A2 Exp (-∞/t2) 
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= y0 + A1 x 1/Exp (∞) + A2 x 1/Exp (∞) 
= y0 + A1 x 0 + A2 x 0 
= y0 
Using the parameters y0, A1 and A2 generated from the fitted functions (Figure 5.18 and 5.19) 
we can calculate the polar and dispersive components at these two time points. Total surface 
energy equals the summation of these two components. 
Time = 0 Polar component Dispersive component Surface Energy 
PPolymer 14.83 45.37 60.2 
NPolymer8 19.46 45.99 65.45 
NPolymer14 21.93 46.86 67.92 
NPolymer27 26.26 45.26 71.52 
 
Time = ∞ Polar component Dispersive component Surface Energy 
PPolymer 5.59 41.86 47.45 
NPolymer8 8.81 40.41 49.22 
NPolymer14 10.59 40.33 50.92 
NPolymer27 15.46 38.33 53.79 
 
The calculated surface energy for time zero gives a very high value from 60.2 to 71.52 mN/m 
(PPolymer to NPolymer27) and represents the theoretical measurements immediately after 
deposition without exposure to the atmosphere. Typical surface energies for polar organic 
polymers and substances are much lower (45-50mN/m) [466, 484]. Plasma deposited polymers 
are essentially carbon (organic) based and differ from traditional polymers in that they are 
highly cross-linked, branched and have a non-repeating unit structure [485]. In contrast 
inorganic materials and metals tend have higher surface energies due to the presence of free 
electrons [468]. A large reservoir of radicals is present in plasma polymers [419] due to 
energetic ion impacts breaking chemical bonds during deposition. These radicals, similar to the 
electron cloud in metals, are highly polar and make substantial contributions to the surface 
energy and polar component of the deposited plasma polymers [468]. 
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Extrapolating from the function for infinite storage time gives an indication of the stability of 
the film. The values for surface energy while decreasing between 21.2 – 25.1% with storage 
remain relatively high and are comparable to polar organic polymers. Moreover, the surface 
energy at infinite storage is not too dissimilar to experimental values at 30 days of aging, so 
we can assume that the surface by this time is largely stable. 
5.4.2 Chemical and structural changes of plasma polymers 
The surface chemistry and structure of the plasma polymers were interrogated with 
complimentary transmission FTIR and XPS investigations. The surface chemistry of the 
samples is unstable and evolves with exposure to atmosphere. While there is an ongoing change 
out to 6 months, in general the changes, mirroring those of the surface energy, are much slower 
after 1 month. If one feature dominates it is the increase in oxygen containing functional groups 
in the plasma polymers regardless of nitrogen concentration. Nitrogen incorporation does 
however influence this process, oxygen moieties are more prevalent and rise to greater levels 
with aging. As expected contributions from nitrogen species (-NH) in amine, imine and amide 
bonds and C = N bonds strongly influence the FTIR spectra in NPolymer14 and NPolymer27. 
Nitrile functionalities begin to emerge in NPolymer8 however these species are not 
thermodynamically favorable and with aging the intensity declines. Post deposition oxidation 
has been reported by a number of authors and is considered to be a radical driven process. 
Oxygen although technically absent during our polymerization process is clearly evident using 
XPS studies with the oxygen to carbon ratio increasing with aging. Oxygen therefore is 
incorporated into the polymer structure on exposure to the atmosphere. 
Ionic and electron bombardment, bond cleavage by UV radiation and diffusion of free radicals 
from the plasma generates a large reserve of radicals in the plasma polymer film [486]. Using 
ESR studies we documented the presence of radicals within the deposited plasma polymers. 
An interesting finding was a higher ESR spin density in NPolymer27 versus PPolymer samples 
indicating a role for nitrogen in modulating the concentration of free radicals. Hayashi et al, 
reported similar findings with nitrogen doping of amorphous carbon films in which higher 
nitrogen gas flow during polymer film formation resulted in greater ESR density [487]. Of note 
nitrogen incorporation into sp3 carbon structures have been shown to drive the formation of sp2 
carbon bonding [488]. Using XPS curve fitting of the main C1s spectra we resolved C – C 
bonding into sp2 and sp3 bonding configurations demonstrating an increase in the sp2 fraction 
of carbon from 61.4% to 70.6% with nitrogen incorporation. This increase is smaller than 
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reported by some authors [489, 490]. Our films however are predominantly graphitic (sp2 
bonding) to start with. The implications of a larger sp2 carbon fraction is that a higher number 
of carbons are in pi (π) bonds with electrons delocalized over the polymeric structure allowing 
greater movement and stabilization of radicals [487]. 
Oxygen diffusion from the atmosphere into the polymer results in rapid oxidative reactions 
with the radicals. The central agent in this process is the carbon-centered radical which under 
goes oxidation with peroxy radicals which in turn form hydroxyperoxides [467]. 
The reaction processes are detailed below.  denotes radical species. 
R + O2  R – O – O  (Reaction with Oxygen) 
R – O – O + RH  R – O – O – H + R(Formation of peroxide species) 
R – O – O + R  R – O – O – R 
R – O – O – R  R – O + O – R (Formation of alkoxy radicals) 
R – O + X R – COOH, R-COH, R – CO – R, R – OH (Formation of hydroxyl, carboxyl, 
aldehyde, ketone groups) 
X represents the range of chemical species required to create the products on the right 
side. 
(Adapted from Kondyurin et al [468]) 
The presence of oxidative reactions is evidenced by FTIR and XPS investigations showing 
elevated levels of oxygen species with aging. These reactions appear to proceed in three stages 
with different rates as shown in the fitted curves for each chemical species (Figures 5.29-5.36), 
the last phase is most consistent and shows a slowing of the reaction rates and flattening of the 
slope. Stages one and two are less uniform between species with the slopes for OH, NH and 
C=O species initially flatter followed by a steeper second phase, compared to what is seen with 
the CH species. 
Due to overlaps in the FTIR absorbance ranges and XPS binding energies for various chemical 
moieties we cannot precisely extract information regarding the bonding configuration of these 
oxygen species. For example, C = O groups can exist in amide, ketone, carboxyl, carbonyl and 
imide chemical structures. This is the same with NH, C – N and C = N nitrogenous groups 
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which similarly can exist in a variety of different configurations such as amines, amides and 
imides. The higher oxygen uptake seen in NPolymer14 and NPolymer27 samples is consistent 
with a radical mediated process in which higher levels of radicals result in more oxidative 
reactions and oxygen species, a finding also reported by Swaraj et al [467]. As the radicals 
participate in the oxidation reactions a reduction in their density in the polymer occurs. This is 
supported by our ESR studies done on PPolymer and NPolymer27 samples after 28 days of 
aging, showing a decay in the ESR spin. Other authors have reported similar declines in radical 
content with aging [485, 491]. 
Some additional remarks can be made in relation to the effect of nitrogen on surface chemistry. 
The CH peaks at 2945 and 2888 cm-1 (Figure 5.32-5.33) decrease with increasing nitrogen 
concentration, concurrently a broadening and increase in the 3255 cm-1 NH region is seen 
(Figure 5.31). This reflects a competitive binding process in which hydrogen atoms 
preferentially bind to nitrogen than to carbon atoms [492]. Furthermore, there is a tendency of 
nitrogen to form double bonds with carbon as evidenced by the prominence of the 1800-1500 
cm-1 region in NPolymer14 and NPoylmer27 samples. Triple bonded C ≡ N was present in high 
nitrogen samples (Figure 5.34) and with aging a loss of absorbance intensity in the 2148 cm-1 
line occurs. This is consistent with aging of polymerized ethylenediamine thin films and has 
been attributed to the hydrolysis of these groups to carboxyl and ammonia moieties [470]. 
The release of ammonia from the plasma polymer accounts for the loss of nitrogen as reflected 
in the decrease in the nitrogen to carbon ratio (Figure 5.43) with time. An additional reaction 
proposed by Swaraj et al [467] (see below) shows another hydrolysis reaction with release of 
ammonia. 
R – CH = NH + H2O  R – CH = O + NH3 
Differences in the oxidation reactions in nitrogen rich plasma polymers as compared to 
hydrocarbon dominant polymers have been raised by some investigators. Both Testrich et al 
and Truica-Marasescu et al [469, 470] used chemical derivatization reactions with 4-
trifluoromethylbenzaldehyde to ‘label’ primary amino groups and overcome the non-
specificity of XPS analysis. They found that oxidation reactions are centred around carbon in 
amino groups leading to a loss of these moieties and an elevation of amide and carboxyl groups. 
The proposed reaction scheme (below) by Gengenbach et al differs to some extend to the 
equations shown above, here peroxy radicals combine to form amides [463]. 
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The oxidative reactions further support a radical decay mechanism for hydrophobic recovery. 
The growth of polar species in the plasma polymers with aging is incongruent with our findings 
of decreasing surface energy and reduced polarity of the surface. This paradoxical observation 
has been explained by a reorientation of these polar groups away from the surface or diffusion 
into the bulk of the polymer [459, 481]. However, this seems improbable given the highly cross 
linked graphitic nature of our deposited polymers which would restrict the mobility of these 
groups [473]. The absence of narrow hydrocarbon peaks in the FTIR and the consistency of 
spectra despite varying atmospheric conditions soon after deposition discounts surface 
contamination with hydrophobic hydrocarbons as an explanation for aging. More likely the 
high surface energy of the deposited polymers is due to the large reservoir of radicals created 
during polymerization. With oxidative quenching of these radicals a decrease in surface energy 
is noted as a consequence. The surface energy after infinite storage shows our surface remains 
hydrophilic. The stable surface energy after aging and extinction of radicals reflects 
contributions from polar groups in the surface to its long-term hydrophilicity. 
5.5 Conclusion 
In this chapter a thorough physio-chemical examination of the plasma polymers provided 
insight into compositional changes with exposure to atmosphere. Indeed, our surface undergoes 
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changes after deposition characterized by a reduction in hydrophilicity and surface energy. 
Probing the surface with FTIR and XPS revealed a polymer landscape dominated by oxygen 
functional groups and oxygen incorporation accompanied by a decay of radicals. We found 
while slower chemical reactions persisted out to 6 months the transformation in the plasma 
polymer were largely complete after one month. This has important implications for clinical 
translational. We can expect a consistency of biological response 1 month after deposition. To 
achieve a balance between surface stability and usability we chose a one month time point to 
assess cellular and blood assays on plasma polymers. 
  
219 
Chapter 6: Biocompatibility of Nitrogenized Plasma Polymers: 
Thrombogenicity and Cell Interactions 
6.1 Introduction 
Low thrombogenicity and encouragement of endothelial adhesion and proliferation are 
important determinants of stent biocompatibility. Here we comprehensively examine the 
thrombogenicity and capacity of nitrogenized plasma polymers to support endothelial cells. 
Subsequently, the most biocompatible plasma polymer is translated using adapted 
polymerization methods on to coronary stents. 
Before a stent is expanded and deployed at the site of coronary artery stenosis it is exposed to 
cellular-protein systems in blood. Platelets and coagulation factors are the main components of 
the hemostatic pathway and in physiological conditions prevents uncontrolled hemorrhage. 
Inappropriate activation within the coronary vasculature can lead to thrombosis and sudden 
occlusion of blood flow. Initiation of thrombosis in response to a stent depends on two main 
factors: 1) The inherent thrombogenicity of the stent and; 2) Disruption of the endothelium 
with stent deployment, which compromises the integrity of the endothelial barrier, interrupts 
secretion of anti-thrombotic factors and exposes the pro-coagulant subendothelial matrix. 
Taking these factors into consideration a biocompatible platform which is innately 
thromboresistant and simultaneously encourages the recovery of the traumatized endothelium 
has the potential to ameliorate stent thrombosis. Moreover, endothelial cells can regulate 
vascular smooth muscle cell (VSMC) activity. Rapid restitution of the endothelium has been 
shown to attenuate intimal hyperplasia [493]. Limiting stent thrombosis in combination with 
pro-endothelialization capabilities was the main design goal of the nitrogenized plasma 
polymers. 
This chapter will explore in more detail the hemostatic system. Biomaterial thrombosis and in 
particular the role of fibrinogen (Fg) will be discussed, followed by a detailed in vitro study of 
nitrogenized plasma polymers focusing on thrombogenicity profile and the capacity to support 
endothelial cells. We conclude by adapting the polymerization process to three dimensional 
coronary stents. Given constraints on the maximal number of samples for some assays and the 
similarities in chemical and physical properties of PPolymer and NPolymer8, NPolymer8 
samples were not assessed.  
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6.1.1 The hemostatic system 
Haemostasis is initiated in response to injury to the vasculature. Conceptually haemostasis can 
be broadly divided into three phases: 1) platelet activation and aggregation (primary 
haemostasis); 2) stimulation of the coagulation pathway and; 3) fibrinolysis and 
anticoagulation [494]. 
Platelet activation is the central process in primary haemostasis leading to the formation of a 
platelet rich clot. An intact endothelium physically separates circulating platelets from the 
subendothelial matrix and through secretion of prostacyclin, nitric oxide (NO), tissue 
plasminogen activator and thrombomodulin [495] maintains an antithrombotic environment. 
Platelets are discoid shaped cellular fragments devoid of a cell nucleus with the capacity to 
adhere to sites of injury, release procoagulation factors from intracellular granules and 
aggregate to form a plug [496]. Following damage to the blood vessel, collagen (Cn) and Von 
Willebrand factor (vWF) in the subendothelium comes in contact with platelets (in particular 
the platelet GPIb-IX-V glycoprotein complex) [497], consequently platelets undergo initial 
activation and slow down over the injury site. α2β1 platelet surface integrin undergoes a change 
from low affinity to high affinity for Cn, reinforcing the tethering of moving platelets [498]. A 
phospholipase, protein kinase and calcium dependent intracellular activation cascade becomes 
activated leading to release of intragranular platelet agonists, ADP, ATP, serotonin and 
thromboxane which in turn further amplify platelet activation [499]. Central to formation of a 
hemostatic plug is the linking by Fg of adjacent platelets via the αIIbβ3 receptors. The αIIbβ3 
integrin on resting platelets have low affinity for Fg. Following stimulation by agonists a 
conformation change occurs engendering a high affinity state for Fg. Beyond linking platelets, 
Fg induces phospholipase C activation which in turn extends platelet activation [500]. This 
step has important implications for biomaterial thrombogenicity in which a non-physiological 
change in Fg conformation results in stimulation of resting platelets, a concept we will detail 
further in subsequent sections. 
The coagulation system, a complex cascade of tightly regulated proteolytic enzymes constitutes 
the second phase of haemostasis. Divided into the extrinsic and intrinsic pathways, the system’s 
ultimate end point is the conversion of Fg to fibrin, which combines with the platelet plug to 
form a robust hemostatic plug (Figure 6.1). 
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The extrinsic system is activated in response to vessel trauma and is the predominant 
physiological pathway. Exposure of tissue factor (TF) in the subendothelial space to circulating 
Factor VIIa forms the TF-Factor VIIa complex which activates Factor IX and Factor X. Factor 
Xa cleaves prothrombin to thrombin which in turn converts Fg to fibrin [495]. Platelets 
facilitate coagulation by providing a surface for positioning coagulation factors in close 
proximity, accelerating the generation of fibrin [500]. 
The intrinsic pathway (contact system) has limited contribution to haemostasis. Initiation is 
thought to occur following contact of Factor XII with negatively charged surfaces, leading to 
formation of Factor XIIa, and activation of kininogen, prekallikrein (subsequent reactions are 
detailed in Figure 6.1) and converge with the extrinsic pathway by way of Factor X activation 
[501]. 
Fibrinolysis is the third phase of haemostasis and acts as a counter-balance to the clotting 
system. Tissue plasminogen activator (t-PA) is an enzyme released by the endothelium in 
response to activation of the coagulation system. t-PA cleaves plasminogen to plasmin, which 
in turn breaks down fibrin [495]. 
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Figure 6.1. Schematic diagram of coagulation pathway. 
6.1.2 Fibrinogen – role in physiological and biomaterial thrombosis 
Fg plays a central role in physiological haemostasis and is implicated in biomaterial 
thrombosis. It is an abundant plasma protein with a concentration ranging from 1.5 to 4.0 g /L, 
behind albumin and immunoglobulins. Fg is approximately 340 kDa and structurally is a 
symmetrical dimer with hydrophobic outer and central domains connected via a pair of three α 
– helical coils (α, β and γ chains) [77] (Figure 6.2). 
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Figure 6.2. Structure of Fibrinogen. Adapted from Koh, Rodrigues and Venkatraman, 
2010 [502]. 
 
The final endpoint of the coagulation pathway involves the thrombin-mediated cleavage of N-
terminal peptides on α and β chains, converting Fg to fibrin [503]. Facilitation of platelet-to-
platelet aggregation is mediated via glycoprotein IIb/IIIa (GPIIb/IIIa) platelet receptors 
(Figure 6.3). Critically, the GPIIb/IIIa configuration on quiescent platelets has low affinity 
binding to Fg [504], preventing non-physiological activation and aggregation of platelets. 
Binding of Fg to GPIIb/IIIA in turn also leads to a conformation change in Fg with exposure 
of receptor binding sites [505]. A series of three pairs of platelet binding sites have been 
localized to position γ 400-411 on the D domains, RGDS motif of Aα chain 572-575 and the 
RGDF motif on the coiled coil regions 95-98 [502]. 
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Figure 6.3. Schematic diagram illustrating interaction of fibrinogen with platelet 
surface glycoprotein IIb/IIIa receptors. Inactive and active conformational states of 
GPIIb/IIIa receptor, increasing affinity for Fg binding (inset). Images adapted from 
[506]. 
Soluble Fg in plasma does not interact and activate platelets [507]. An important contribution 
of Fg to biomaterial thrombosis is the activation of otherwise quiescent platelets by surface 
immobilized Fg. Crucially, the interaction with platelets is independent of the need for pre-
activation of platelets or a favorable GP IIb/IIIa conformation [507]. Rapid adsorption of 
plasma proteins occurs immediately and forms an interfacial layer between the material surface 
and cells / protein systems in the plasma [508]. Fg, albumin and IgG are present in abundance 
in this layer, consistent with the high concentration of these proteins in plasma [402]. Surfaces 
pre-adsorbed with Fg were found to enhance platelet adhesion and activation [509]. Further 
implicating the central role of Fg in biomaterial thrombosis, when plasma is depleted of Fg, 
platelet adhesion was dramatically reduced. In contrast the selective depletion of vWF, 
vitronectin (Vn) and fibronectin (Fn) did not result in a significant change in platelet adhesion 
[510]. It appears the conformation of surface immobilized Fg is just as important in affecting 
platelet adhesion, in which changes to the secondary structure can expose platelet interactions 
sites [511]. 
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6.1.3 Assessment of Fibrinogen structure 
Antibody and spectroscopic methods have been applied to the study of Fg structure. Antibodies 
directed against anti-domain D and anti-domain E have been used to compare accessibility of 
these domains in biomaterial surface bound Fg [511]. Using this approach, the actual structural 
change of immobilized Fg cannot be directly determined. Alternatively, researchers have used 
antibodies directed against putative platelet binding sites, specifically gamma chain of the C-
terminus, RGDS and RGDF motifs of the alpha chain to assess exposure of these sites on Fg 
[512]. 
Spectroscopic approaches including Fourier transform infrared spectroscopy (FTIR), 
attenuated total reflection FTIR (ATR-FTIR) and circular dichroism have been employed to 
examine structural changes of Fg. A consistent finding among studies is the presence of three 
dominant secondary structures namely, α-helix, β – sheet and β – turns. Relative contributions 
from the secondary structures have been determined for Fg in native conformation. Some 
variations exist between investigators. α-helix is the main secondary structure in Fg ranging 
between 30 to 41% of the distribution of secondary structures. β – sheet ranges between 20 to 
33% with β – turns approximately 12 to 14% [77]. The secondary structures reside in the coil 
structures connecting the central and outer domains together. 
Infrared spectroscopic methods have exploited the amide spectra regions to determine the 
secondary structure of Fg. The peptide units of proteins give distinctive amide bands. The 
amide I band has an intense absorption signal typically found in the region of 1600 to 1700 cm-
1. Stretching vibrations of C = O functional groups and to a smaller extent C – N groups are 
responsible for the amide I band. The Amide I band is more sensitive to conformational changes 
and is typically used to determine protein secondary structures. Deconstructing amide I bands 
into components facilitates the analysis of the secondary structures of proteins [513]. 
6.1.4 Biomaterial thrombogenicity 
Biomaterial thrombogenicity is a complex process which involves multiple inter-related 
processes. Interaction between these processes and the biomaterial surface is in fact mediated 
by a layer of rapidly physisorbed plasma proteins. This protein layer develops almost 
instantaneously on the material surface upon contact with the plasma [514]. While the surface 
itself does not interact directly with biological systems it does determine the makeup and 
structural orientation of this layer [515]. As discussed above surface immobilized Fg can 
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undergo conformational changes which expose otherwise hidden platelet activation sites, 
initiating activation of resting platelet. The intrinsic and extrinsic coagulation pathway have 
both been implicated co-dependently in material thrombosis. TF can be activated by 
biomaterials which in turn trigger the extrinsic pathway and also FIX from the intrinsic 
pathway. It is thought the adsorption of contact phase proteins can also contribute to activation 
of the intrinsic system. Furthermore, negatively charged biomaterial surfaces may directly 
activate FXII [79]. Increasingly complement system activation has been implicated in 
biomaterial thrombosis through activation of the alternative pathway, a pathway which is 
physiologically activated by fungal and bacterial surfaces. This cascade leads to generation of 
protein messengers capable of stimulating white blood cells and VSMCs, inducing 
inflammation, which in turn stimulates platelets [79]. 
6.1.5 In vitro thrombogenicity assays 
In vitro thrombogenicity assays act as tests for predicting the in vivo response of the 
biomaterial. Blood coagulates quickly upon removal from the body. Anti-coagulation is 
required to prevent this process. Heparin is widely used as an in vivo anticoagulant during 
percutaneous coronary intervention (PCI), its use for in vitro assays provides a close 
approximation to clinical settings. Binding to anti-thrombin, heparin exerts its effect through 
potentiation of the enzymatic activity of anti-thrombin, accelerating the inactivation of 
coagulation enzymes IIa, Xa, IXa, XIa and XIIa and to a lesser degree also inhibit platelet 
activity through reducing the formation of platelet agonists [516, 517]. Using whole blood for 
in vitro thrombogenicity assays has the advantage of testing the thrombosis system in its 
entirety. While it does not isolate a particular part of the clotting system whole blood assays 
are more physiological as thrombotic cascades are closely inter-dependent. Endpoints 
measured include thrombus weight, visual analysis and microscopic imaging. 
Given the prominence of platelets in material and in particular, stent thrombosis [518] a variety 
of techniques have been employed to assess for platelet activity on biomaterials. Broadly 
speaking platelet assays have used isolated platelets or platelet rich plasma (PRP) to determine 
adhesion, aggregation and/or activation. Citrate-based anticoagulation such as sodium citrate 
and citric acid, sodium citrate and dextrose combination (ACD) have been favored over heparin 
for platelet handling [519, 520]. ACD has a more profound suppression of platelet activation 
than heparin and citrate [521]. Platelets are separated from red and white blood cells through 
centrifugation, a process where shear forces may activate platelets [522], highlighting the 
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importance of adequate suppression to prevent artificial activation of platelets. Quantification 
of platelet adhesion have employed radiolabelling and lactate dehydrogenase (LDH) release 
methods [69, 523]. Activation of platelets have been determined using morphological 
appearance of platelets on scanning electron microscope (SEM) imaging, ELISA detection of 
released soluble p-selectin (sP-selectin) and flow cytometry detection of sP-selectin 
configuration on platelet membranes [524, 525]. 
In vitro thrombogenicity assays can be performed using static or flow loop setups. Static assays 
involve the exposure of test substrates to whole blood or components without flow of the blood. 
Static testing does not account for shear force dependent activation of platelets in flow 
conditions. However, static testing systems are more simple to use and offer a quicker 
screening of biomaterial thrombogenicity [526]. 
In order to emulate flow conditions in blood vessels, in vitro flow models have been established 
for hemocompatibility testing of stent materials. Two popular models are the roller pump [527] 
and the modified Chandler loop [528]. Consisting of a close loop system the roller or peristaltic 
pump circulates blood through compression of the flexible tubing displacing the blood forward 
(Figure 6.4). A disadvantage of the roller pump system includes compression of the tubing 
which can lead to hemolysis of blood, resulting in artificial activation of thrombosis [529]. 
 
Figure 6.4. Schematic diagram of roller pump set up for flow model of thrombogenicity. 
Image adapted from Van Oeveren et al, 2012 [529]. 
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An alternative model free from deformation of the tubing system is the modified Chandler loop 
(Figure 6.5). Here a circular closed loop system is joined by an interconnector and filled with 
blood with some residual air. The loops are rotated with the test substrate placed in a fixed 
position. With each rotation the test substrate passes through the blood. 
In this chapter we explore the thrombogenicity of plasma polymers samples with varying 
nitrogen content, compared against medical grade 316L stainless steel (316L SS) widely used 
for coronary stents. 
 
Figure 6.5. Schematic representation of the modified chandler loop. Image adapted 
from Van Oeveren et al, 2012 [529]. 
6.1.6 Endothelialization 
Blood vessels are lined with a thin layer of cells known as the endothelium which plays a 
pivotal role in maintaining vascular homeostasis. A delicate balance between vasoconstriction 
and vascular relaxation is achieved through release of vasodilators NO and constricting factors 
including endothelin-1 and angiotensin. NO inhibits leukocyte and platelet activation and 
preserves VSMCs in a quiescent state [530]. Disturbance of vascular homeostasis predisposes 
to vessel thrombosis and unchecked VSMC migration and proliferation [531]. Acting as a 
semi-permeable barrier, a continuous and intact endothelial lining isolates the thrombogenic 
subendothelial matrix from platelets and the coagulation cascade [532]. 
PCI disrupts the endothelium through mechanical trauma from the guide wire, balloon 
expansion and stent implantation. Endothelialization is a repair process directed towards re-
establishing the integrity of this cell barrier. Initially it was thought this occurred solely through 
the migration and proliferation of nearby endothelium [533] however growing evidence have 
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implicated bone marrow mobilized endothelial progenitor cells (EPCs) playing a key role [534, 
535]. 
Failure of or delayed endothelial repopulation over injured areas and stent struts have direct 
clinical ramifications. From animal models the extent of neo-intima formation correlates with 
the degree of endothelial injury [536], with the rapid reconstitution of the endothelium reducing 
the amount of intimal hyperplasia [537]. In general, coronary stenting leads to more 
pronounced injury than balloon angioplasty alone [538]. Differences in the speed of 
endothelialization exist between bare metal stent (BMS) and drug eluting stent (DES) 
platforms. Typically, for BMS near complete endothelial recovery occurs by 3 months [400]. 
In contrast, DES in particular first generation systems, endothelialization is profoundly delayed 
[120]. This phenomenon has been attributed to inflammatory reactions to the polymers and 
cytotoxicity of the eluted drugs. The most notable clinical impact of poor endothelial 
repopulation is stent thrombosis [534]. 
Second generation DES evolved by reducing stent strut thickness and improving 
biocompatibility of the coated polymer leading to an improvement in endothelialization [121]. 
Reductions in the incidence of stent thrombosis reported with 2nd generation DES [539] 
supports the notion that encouraging endothelial healing translates to tangible clinical benefits. 
Somewhat sobering, results from the recently released DAPT study, a large trial powered to 
detect stent thrombosis reports an ongoing risk of stent thrombosis out to 30 months after stent 
implantation across a spectrum of stent platforms used in contemporary practice [129]. This 
provocative finding highlights the inadequate biocompatibility of current coronary stents. 
Functionalizing the stent surface with extracellular matrix (ECM) proteins has been one 
approach to promote endothelialization. ECM proteins help to maintain cellular integrity, 
govern physiological functions and engage with cell surface receptors for cell signalling and 
gene regulation [339]. Cell adhesion motifs on these proteins are involved in cell adhesion, 
spreading and proliferation [540]. Elastin is an abundant protein in elastic tissues and found in 
the elastic lamina of the media and internal elastic lamina of large elastic blood vessels [353]. 
Recombinant human tropoelastin (rhTE), the precursor of elastin, is a promising candidate for 
biomedical applications. rhTE is able to support endothelial cell adhesion, spreading and 
proliferation and when functionalized on to plasma polymerized surfaces maintains biological 
activity and importantly does not elicit thrombosis [281, 347]. 
230 
We explored the capacity of rhTE to enhance EPC function in chapter 2 and 3 of this thesis, 
finding a positive influence on EPC adhesion, spreading and proliferation mediated by integrin 
receptors. Functionalizing stent surfaces with rhTE has a number of limitations which can make 
clinical translation challenging. Firstly, the need to functionalize a stent surface with rhTE adds 
an additional complexity to the manufacturing process which may reduce the scalability of this 
approach. Furthermore, rhTE is susceptible to in vivo degradation by plasma proteases 
kallikrein and thrombin bringing into question the long term durability of its biological activity 
[357]. These considerations give impetus to the development of a biologically active surface 
coating for stents that is able to innately support endothelial function. In chapter 4 and 5 we 
developed and characterized a highly nitrogenized plasma polymer coating enriched with 
oxygen and nitrogen polar groups, abundant in free radicals, capable of covalently 
immobilizing proteins and hydrophilic in nature. In this chapter we investigate the capacity of 
these surfaces to support human coronary artery endothelial cells (HCAEC) and EPCs 
comparing against 316L SS with and without functionalization with rhTE. 
6.1.7 Mechanically stable coating platform 
Coronary stents are balloon expandable; in other words, they are crimped on to a balloon 
allowing for easier deliverability to the site of vessel stenosis. In situ the stent is deployed by 
inflation of the balloon and expansive deformation. Local stent deformation of up to 25% have 
been noted [541]. Non-erodible polymers on 1st and 2nd generation DES are coated using spray 
or dip coating technology [542]. Such methods bring into question the robustness of the coating 
under mechanical stress. Studies have shown that during stent expansion all DES coatings are 
susceptible to loss of integrity with cracking, peeling and delamination of the polymer (Figure 
6.6). In addition, micro fragments of polymer can be dislodged during expansion with the 
potential for embolization into the distal vessel [542]. 
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Figure 6.6. Optical microscopy of DES showing delamination of coated polymers after 
balloon expansion. Adapted from Puskas et al, 2013 [542]. 
These findings have been further supported by SEM examination of DES after balloon 
expansion showing exposure of bare metal beneath the polymer [125], a potential nidus of 
thrombus development. In this chapter the highly nitrogenized plasma polymers were coated 
on to precision laser cut medical grade stainless steel stents and expansive deformation was 
performed. Integrity of the coating was subsequently assessed. 
6.2 Methods and materials 
6.2.1 Plasma polymerization (polymer deposition) 
Plasma polymers of increasing nitrogen concentration were deposited in the purpose-built 
chamber. Conditions for deposition were consistent with that in chapter 4. For all studies 316L 
SS was used as substrate. Uncoated bare 316L SS samples were used as control. 316L SS were 
cleaned using acetone, 80% ethanol followed by distilled water and air dried under cover. 
6.2.2 Polymerization of stents 
Flat substrates were secured on to the substrate holder with two thin metal strips, ensuring 
adequate electric conducting contact with the negatively pulse biased electrode. The plasma 
polymerization process was adapted for coating laser cut 316L SS stents. For the three-
dimensional stent copper wire loops were fashioned to maintain continued contact with the 
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electrode while elevating the stent so all aspects of the surface was immersed in plasma. The 
setup can be seen in Figure 6.7. 
 
Figure 6.7. Photograph of modified polymerization setup for adaptation of coating to 
three dimensional stents. 
6.2.3 Thrombogenicity studies 
Plasma polymerized samples were systematically assessed for susceptibility to thrombosis in a 
range of in vitro assays. Uncoated bare 316L SS, a common metallic alloy used in the 
construction of coronary stents, was used as control. 
6.2.4 Blood preparation 
Blood was obtained from healthy non-smoking and non-medicated male volunteers with 
informed consent and in accordance with the Declaration of Helsinki. To prevent coagulation 
of whole blood or blood components, anticoagulants were used. During blood collection the 
first 5 ml of blood was collected with the tourniquet on and discarded in order to minimize 
hemolysis of blood components. Blood collected for experiments was taken with the tourniquet 
off and directly drawn into falcon tubes with anticoagulants and gently mixed three times. For 
whole blood experiments, heparin was used with the final concentration of heparinized blood 
at 0.5 U/ml. In isolated platelet studies PRP was used. ACD at a concentration of 9:1 v/v ratio 
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was used as the anticoagulant. Whole blood in ACD was centrifuged at 150 g for 20 min. The 
supernatant consisting of PRP was gently aspirated (Figure 6.8). 
 
Figure 6.8. Platelet rich plasma after centrifuging whole blood. 
6.2.5 Static blood assays 
6.2.5.1 Whole blood 
Thrombus formation (weight in mg) was assessed in static blood experiments. 
Triplicate samples of 316L SS and plasma polymerized samples (1.2 x 0.8 cm) were initially 
weighed prior to placement into 48 well tissue culture plastic (TCP). The wells were pre-
blocked with bovine serum albumin (BSA) 3% (w/v) for 1 hour at room temperature to prevent 
interaction of blood with the TCP. 2.5 ml of heparinized blood was gently pipetted onto the 
samples following which the samples were placed on a rocker in a 37°C room. Three time 
points were used 60 min, 120 min and 180 min. At the end of the incubation, excess blood was 
aspirated and samples gently washed in distilled water to remove non-adherent blood 
components. Samples were blot dried to remove excess water and then weighed before 
photography. 
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6.2.5.2 Scanning electron microscope 
SEM was used to provide high-resolution images of samples after static whole blood 
incubation. Samples for SEM were fixed using 2.5% glutaraldehyde for 1 hour at room 
temperature, post-fixed with osmium tetroxide 1% (v/v) and dehydrated in increasing 
concentrations of ethanol before drying with hexamethyldisilazane. After sputter coating with 
gold, the samples were imaged with a Zeiss EVO 50 scanning electron microscope. 
6.2.5.3 Platelet adhesion 
LDH is an intracellular enzyme which is liberated after cell lysis. Upon lysis of cells the 
released LDH can reduce nicotinamide adenine dinucleotide (NAD+) to NADH. NADH 
undergoes a reaction with tetrazolium dye leading to formation of a color substance. The 
intensity of color is proportional to the levels of LDH and in turn reflects the number of cells 
lysed. Using this approach quantification of cells can be achieved and has been used for 
ascertaining platelet adhesion [68]. A commercially available LDH assay kit was used (Sigma 
Aldrich). 
Samples in triplicates (1.2 x 0.8 cm) were placed in 48 well TCP which were pre-blocked with 
3% (v/w) (BSA) for 1 h to prevent non-specific platelet interaction. 500 µl of PRP was added 
to the samples. The plates were then placed on a rocker and incubated in a 37 °C room for 180 
min. Samples were then washed extensively with phosphate buffered saline (PBS) to remove 
non-adherent platelets and transferred to new wells. Adherent platelets on the samples were 
lysed by addition of 200 µl of cell lysis solution for 30 min at 37 °C, for liberation of 
intracellular LDH. 200 µl of LDH assay mixture was subsequently added to the wells and the 
reaction allowed to proceed for 15 min at 37°C. The reaction was stopped with 1M HCl and 
dual absorbance was measured at (490 nm and 690 nm) using a Biorad 680 microplate reader. 
6.2.5.4 Platelet activation 
Activated platelets release sP-selectin [543], this was detected using a sandwich ELISA kit 
(R&D Systems). 750 μl of PRP was added to each sample, placed in BSA blocked wells on a 
rocker for two time points 60 and180 min at 37°C, following which 100 µl of PRP was 
aspirated and added to the P-selectin ELISA kit as per manufacturer’s instructions. 
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6.2.6 Dynamic flow experiments 
6.2.6.1 Whole blood experiments 
Dynamic flow experiments were performed in a modified Chandler loop. Tygon tubing was 
cut to a length of 30 cm and fashioned into circular loops using a 3 cm silicon connector. 316L 
SS and plasma polymerized samples were cut into 1.2 x 0.6 cm pieces and weighed. The 
samples were positioned in the loops so that length of the sample is perpendicular to the flow 
of blood. A non-compliant 8.0 mm x 20 mm (Boston Scientific) peripheral vascular balloon 
(dilated to 18 atmospheres for 20 seconds) was used to push the samples to conform to the 
curvature of the loops, ensuring that turbulent flow due to poor apposition did not contribute 
to thrombus development. 2.5 ml of heparinized blood was gently injected into each loop. 
Triplicates were used for each test condition. The loops were placed over a rotating drum (34 
RPM) and placed at 37°C to simulate coronary artery flow (85 ml/min). At the end of 
progressively longer time points of 90 min, 120 min and 180 min the blood was poured out of 
each loop, with any developed clot weighed. Samples were carefully extracted and rinsed in 
PBS, blot dried, weighed and photographed. 
6.2.6.2 Platelet activation 
For platelet activation under dynamic flow conditions PRP was used in the Chandler loop. 
Chandler loops were fashioned as described above. Samples were cut to 1.2 x 1.2 cm, 
positioned using a balloon. 2 ml of PRP was placed into the loops and rotated for 180 min. 
Experiments were performed in triplicates. After incubation 100 µl of PRP was aspirated from 
each loop and used with the sP-selectin ELISA kit as per manufacturer’s instructions. 
6.2.7 Cell culture 
Human coronary artery endothelial cells (HCAEC) were harvested enzymatically from human 
coronary arteries (Cell applications, San Diego, Ca, USA) and outgrowth endothelial cells 
(OECs) were cultured as described in chapter 2. Cells were grown in a humidified 37°C 
incubator with 5% carbon dioxide. Fresh media was exchanged every 3 days and cells passaged 
when 80 – 90% confluent. For passaging the media was aspirated and cells washed once in 
warmed PBS. Trypsin/EDTA was added to the wells and left for 3 – 5 min in the incubator. 
The trypsin was quenched after the cells had been lifted using media containing 10% fetal 
bovine serum (FBS). The cell suspension was aspirated and placed into a falcon tube and 
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centrifuged for 5 min at 2000 RPM. The cell pellet was suspended in media and diluted to 
working concentrations after cell count. 
6.2.8 Cell adhesion to substrates 
For attachment studies, triplicate samples of 316L SS, plasma polymerized samples and rhTE 
pre-coated samples (0.8 x 0.6 cm) were placed in 48 well TCP. rhTE pre-coated 316L SS and 
plasma polymerized samples were incubated in 40 μg/ml concentration of rhTE (overnight at 
4°C), following which excess rhTE was aspirated and samples gently washed three times with 
PBS. HCAEC and OECs where lifted as described above and made to a concentration of 2 x 
105 cells /ml. Two conditions for attachment were used: 1) cells suspended in media without 
added FBS and; 2) cells suspended in media with 10% FBS. 500 µl of cells were added on to 
each sample/well and allowed to attach for 60 min in the incubator. At the end of 60 min excess 
cells were aspirated and non-adherent cells washed off gently with PBS (x3). Samples were 
fixed using 3.7% formaldehyde for 20 min and then stained with 0.1% (w/v) crystal violet for 
90 min. Excess dye was aspirated and samples washed three times with distilled water and 
transferred to new wells where the stained samples were solubilized with acetic acid 10% (v/v). 
100 µl from each well was aspirated and transferred to a 96 well plate and the absorbance was 
read at 580 nm. A standard curve generated using correlation with known number of cells and 
measured absorbance values was constructed to determine percentage of cells attached. 
Representative samples stained with crystal violet were allowed to air dry and imaged using 
reflective microscopy. 
6.2.9 Cell proliferation 
1 ml of 1 x 104 cells/ml (in media with 10% FBS) of HCAECs and OECs were added to each 
well and left to proliferate to 3 or 5 days. On day 3 media was changed. At the end of each time 
point the media was aspirated and non-viable cells were gently washed off using PBS washes. 
500 µl of 3.7% formaldehyde was used to fix the cells for 20 min. Crystal violet was used to 
quantify cell numbers on the samples using the technique described. Relative absorbance was 
used to quantify the amount of cells between the samples. 
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6.2.10 Fibrinogen studies 
6.2.10.1 Fibrinogen attachment kinetics 
Human Fg was made up to 1 mg / ml according to manufacturer’s instructions. In brief, Fg was 
solubilized in 0.85% (w/v) sodium chloride in a 37 °C water bath for 6 hours with gentle 
shaking. To reduce risk of degradation the Fg solution was used on the day of preparation. 
316L SS and plasma polymerized samples were cut into 2 x 6 cm strips and placed in 10 ml 
falcon tubes. The strips were fully submerged in Fg solution and incubated for 10, 60, 180, 
1440 and 2880 min at room temperature. At the end of each time point excess Fg solution was 
removed by incubating the sample in PBS solution for 30 min and then washed three times. 
Residual PBS was removed by washing three times with distilled water. Samples were allowed 
to air dry under cover overnight before measurement with the FTIR spectrometer the next day. 
In order to determine the amount of Fg bound to the surface the FTIR spectra were analyzed 
for amide I and II peaks at wavenumbers of 1650 and 1540 cm-1 (Figure 6.9), respectively. 
These peaks are associated with internal protein vibrations. The extinction coefficients were 
used to normalize the intensity of the amide II peak to the amide I peak. Protein concentration 
was calculated as an average of the intensities of amide I and normalized amide II peaks. 
 
Figure 6.9. FTIR spectra of 316L SS and plasma polymers. Amide I and amide II peaks 
are shown with arrows. 
238 
6.2.10.2 Covalent immobilization of fibrinogen to plasma polymerized samples 
316L SS and plasma polymer samples where cut into 2 x 6 cm strips and submerged in Fg 
solution overnight at room temperature. On the following day excess Fg was washed off using 
PBS and distilled water with samples air dried under cover. FTIR spectra of the samples were 
recorded and the concentration of Fg bound determined using the absorbance of the amide I 
and amide II peaks. To test for covalent attachment, protein bound samples were exposed to 
SDS and heated to 60 °C for 1 hour following which residual SDS was removed with extensive 
washing (distilled water) then air dried. The amide I and II peaks were measured and the post-
SDS concentrations determined. 
6.2.10.3 Determination of fibrinogen conformation 
Samples of 316L SS and plasma polymer were cut to similar size as above. Fg was made to a 
working concentration of 0.1mg/ml. Samples were exposed to Fg for 1 hour at room 
temperature. Washing and drying protocols were as described above. FTIR of the samples with 
high spectral resolution of 1 cm-1 were measured. The secondary structure of attached Fg 
proteins was determined by resolving the amide I peak into 8 peaks with each peak fitted using 
a Gaussian function. Fitting was performed with assistance from Dr Alexey Kondyurin at the 
School of Physics, University of Sydney. 
6.3 Results 
6.3.1 Static blood assays 
6.3.1.1 Whole blood 
The effect of nitrogen incorporation on thrombogenicity was assessed initially in static 
environments. A nitrogen dependent effect on thrombogenicity was seen, which become more 
apparent with increasing time of exposure in blood. After a 60 min incubation (Figure 6.10) 
the 316L SS samples were covered completely with thrombus, in contrast all plasma 
polymerized samples were free from thrombus. At this time point no discernible difference 
between the plasma polymerized samples can be seen. 
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Figure 6.10. Photograph of 316L SS and plasma Polymerized samples after 60 min in 
whole heparinized blood. 
The weight of the thrombus developed on the samples were 29.7 ± 1.2 mg, 3.1 ± 0.8 mg, 3.7 ± 
1.2 mg and1.3 ± 0.5 mg for 316L SS, PPolymer, NPolymer14 and NPolymer27, respectively 
(Figure 6.11). All plasma polymer samples displayed significantly lower thrombus weight (P 
< 0.0001) than the 316L SS sample. There was no appreciable difference between the plasma 
polymers with varying nitrogen concentration (P > 0.07). 
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Figure 6.11. Weight of thrombus on samples exposed to heparinized whole blood for 60 
min in 37°C. 
A time point of 60 min failed to demonstrate any difference between the plasma polymerized 
samples. We them extended exposure in blood to 120 min. Photographs of the samples are 
shown below (Figure 6.12). 316L SS demonstrated the highest level of thrombus formation. 
Interestingly we see partial thrombus accumulation on PPolymer and some development of clot 
on NPolymer14. NPolymer27 remained largely free from thrombus. This was also reflected in 
thrombus weight. 
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Figure 6.12. Photograph of 316L SS and Plasma Polymerized samples after 120 min in 
whole heparinized blood. 
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Figure 6.13. Weight of thrombus on samples exposed to heparinized whole blood for 120 
min at 37°C 
Thrombus weight after 120 min exposure to whole blood was 107.9 ± 6.6 mg, 32.4 ± 9.8 mg, 
5.3 ± 1.2 mg and 2.4 ± 1.4 mg, for 316L SS, PPolymer, NPolymer14 and NPolymer27, 
respectively (Figure 6.13). Consistent with the 60 min time point, 316L SS had the highest 
amount of thrombus development (P<0.0001). Among the plasma polymerized samples 
thrombus on PPolymer samples was statistically higher (P<0.002) while NPolymer14 and 
NPolymer27 were not different from each other (P = 0.93). 
A 120 min time point allowed the differentiation of the thrombogenicity potential of PPolymer 
from NPolymer14 and NPolymer27. The time point of the static blood assay was extended to 
180 min. Images of the samples are shown below (Figure 5.14). The build-up of thrombus on 
316L SS is clearly evident. In addition, both PPolymer and NPolymer14 developed increasing 
amounts of thrombus compared to samples at 120 min. Some thrombus is noted on the edges 
and corner of the NPolymer27 pieces however the majority of the surface remains free from 
clot. 
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Figure 6.14. Photograph of 316L SS and Plasma Polymerized samples after 180 min in 
whole heparinized blood. 
Samples were again weighed to quantify the amount of thrombus accumulated. As expected 
316L SS had the most clot of all the samples (210 ± 28.9 mg) followed by PPolymer (74.4 ± 
43.3), NPolymer14 (58.5 ± 38.7 mg) and NPolymer27 (4.5 ± 3.3 mg) (Figure 6.15). Consistent 
with earlier time points all plasma polymerized samples had significantly lower 
thrombogenicity than the 316L SS sample. A nitrogen dependent effect is observed with a 
reduction in thrombogenicity with increasing nitrogen content (P < 0.0001 for trend). 
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Figure 6.15. Weight of thrombus on samples exposed to heparinized whole blood for 180 
min in 37°C. 
6.3.1.2 Scanning electron microscopy 
The surfaces of the samples were closely examined using SEM at two time points of exposure 
to whole heparinized blood (60 min and 180 min). SEM images of samples at the 60 min time 
point showed (Figure 6.16) that the 316L SS sample was completely covered with a dense 
sheet of red cells, platelets and fibrin. The PPolymer surface was partially covered with cells. 
This was in contrast with photographic images showing limited clot thrombus on the surface 
suggesting that simple gross visualization fails to identify early thrombus development. 
NPolymer14 and NPolymer27 surfaces were only sparsely covered with platelets and red blood 
cells, with NPolymer27 showing the lowest number of cells. 
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Figure 6.16. SEM of 316L SS and plasma polymerized samples after a 60 min exposure 
to whole heparinized blood (x250 magnification). 
SEM images taken at the 180 min time point revealed (Figure 6.17) a build-up of thrombus on 
316L SS in agreement with the gross photographic images. Large clumps of platelets and red 
cells had developed on the surface of PPolymer samples. NPolymer14 samples remained free 
from thrombus aggregates however increased red cell and platelet presence was observed. 
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Resistance to clotting was demonstrated by NPolymer27 where an absence of clot is noted and 
a marginal increase in red cells and platelets from the 60 min time point is evident. 
 
Figure 6.17. Scanning electron microscopy of 316L SS and plasma polymerized samples 
after 180 min exposure to heparinized blood (x250 magnification). 
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6.3.1.3 Platelet attachment 
Platelet adhesion onto samples was measured using LDH release assays. In static blood under 
gentle rocking the surfaces were exposed to PRP for 180 min. The relative number of surface 
attached platelets is shown in Figure 6.18. 316L SS had the highest number of adherent 
platelets and a trend of reduced platelet adherence with increasing nitrogen concentration was 
noted. On NPolymer27, the number of platelets attached was dramatically less, with a 
58.2±4.8% (p<0.001) reduction compared to 316L SS. 
 
Figure 6.18. Platelet adhesion measured by LDH release. Number of platelets given as 
relative absorbance. 
6.3.1.4 Platelet activation 
Activated platelets express and up regulate the surface adhesion molecule P-selectin which can 
be cast off into the blood stream as sP-selectin. Measurement of sP-selectin levels can be a 
surrogate measure of surface P-selectin and in turn assess the degree of platelet activation. In 
static assays, samples were initially incubated in PRP for 60 min (Figure 6.19). sP-selectin 
levels were 20.2 ± 3.9 ng/ml, 5.1 ± 1.2 ng/ml, 4.4 ± 1.6 ng/ml and 2.1 ± 1.1 ng/ml for 316L SS, 
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PPolymer, NPolymer14 and NPpolymer27, respectively. sP-selectin levels for all plasma 
polymerized samples were significantly lower than 316L SS (P<0.0002). However, the 
duration of 60 min incubation was insufficient to differentiate the capacity for platelet 
activation between the samples with varying nitrogen concentration (P>0.4). 
 
Figure 6.19. sP-selectin levels in PRP after 60 min exposure to 316L SS and plasma 
polymerized samples. 
316L SS and plasma polymerized samples were subsequently incubated in PRP for 180 min 
(Figure 6.20). A stepwise reduction in sP-selectin levels is seen with rising nitrogen 
concentration in the plasma polymers. More specifically, sP-selectin levels were 67.3 ± 3.2 
ng/ml, 52.6 ± 1.3 ng/ml, 44.5 ± 1.5 ng/ml and 30.9 ± 1.2 ng/ml for 316L SS, PPolymer, 
NPolymer14 and NPolymer27, respectively. NPolymer27 had the lowest amount of sP-selectin 
released. Extending the time point to 180 min provided a better separation of the platelet 
activation potential of the plasma polymerized samples. 
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Figure 6.20. sP-selectin levels in PRP after 180 min exposure to 316L SS and plasma 
polymerized samples. 
6.3.2 Dynamic flow assays 
6.3.2.1 Whole blood 
To compliment static thrombogenicity tests, dynamic flow assays were performed. Blood flow 
is an important component of Virchow’s triad of thrombosis, in particular disruption to laminar 
flow. We approximated coronary arterial flow by using a rotating modified Chandler loop. At 
the end of the incubation with whole heparinized blood any thrombus developing both in the 
rotating column of blood and on the surface of samples was weighed. Each test condition was 
done in triplicate loops. 
316L SS, PPolymer, NPolymer14 and NPolymer27 samples were initially incubated for 120 
min in the Chandler loop. Photographic images of the samples are presented in Figure 6.21. 
316L SS pieces are covered with a thin layer of thrombus. The clot formed in each Chandler 
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loop is shown below the sample. Each of the 316L SS loops developed sizeable pieces of 
thrombus. PPolymer and NPolymer14 had similar levels of clot development, affecting mainly 
the edges of the samples. A small piece of thrombus is apparent in one loop only. At this time 
point, it can already be seen that NPolymer27 has an advantage in thrombogenicity with the 
surface free from thrombus and an absence of any clots in the loops. 
Quantification of thrombus formed gave results consistent with visual findings (Figure 6.22). 
Highest thrombus weight was found on 316L SS with 32.5 ± 1.9 mg followed by PPolymer 
and NPolymer14 with 13.8 ± 3.8 mg and 10.1 ± 5.1 mg respectively. NPolymer27 was the 
lowest with 1.4 ± 0.7 mg. All plasma polymerized samples had significantly lower thrombus 
compared to SS (P <0.06). PPolymer and NPolymer14 were non-significantly different from 
each other (P = 0.53), while NPolymer27 was significantly lower than both (P<0.04). 
 
Figure 6.21. Photographic images of SS, PPolymer, NPolymer14 and NPolymer27 after 
120 min exposure to heparinized whole blood in chandler loops. 
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Figure 6.22. Total thrombus weight developing on samples placed into a chandler loop 
for 120 min. 
The superiority of NPolymer27 samples was noted with a time point of 120 min. We extended 
the time to 180 min to evaluate if the benefit of high nitrogen is maintained. Photographic 
images of the samples are shown in Figure 6.23. As expected with prolongation of the clotting 
assay increased thrombus development did occur. 316L SS pieces showed a similar degree of 
thrombus formation to that at 120 min suggesting a ceiling effect in the amount of clot that can 
develop in the assay system. In contrast more advanced thrombosis is observed with PPolymer 
at 180 min, with a thin layer of thrombus on the surface and clot formation in all the loops, this 
was comparable to the thrombus burden seen on 316L SS. 
Extension for an additional 60 min also saw a progression in clotting on NPolymer14. Surfaces 
were coated with thrombus; however lesser thrombus was seen in the loops. The difference on 
NPolymer27 was significant, with the surface largely free from clot development. A small 
piece of thrombus was collected from a single loop. 
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Figure 6.23. Photographic images of 316L SS, PPolymer, NPolymer14 and NPolymer27 
after 180 min exposure to heparinized whole blood in chandler loops. 
Thrombus weight reflected similar findings as seen visually (Figure 6.24). Total thrombus 
weight developed on 316L SS and PPolymer were not significantly different from each other 
(36.3 ± 3.5 mg vs. 33.5 ± 1.9 mg, P = 0.7). An increase in thrombus on NPolymer14 to 15.4 ± 
3.4 mg is seen. Clotting on NPolymer27 remained remarkably low at 5.2 ± 3.4 mg, significantly 
lower than other plasma polymerized samples. A nitrogen dependent effect on thrombosis can 
be appreciated, with the P value for linear trend calculated at P = 0.0001. 
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Figure 6.24. Total thrombus weight developing on samples placed into a chandler loop 
for 180 min. 
6.3.2.2 Platelet activation in Chandler loop 
The sP-selectin level from platelets (PRP) exposed to samples in the Chandler loop was 
measured after 180 min of rotation. Having demonstrated in static and dynamic assays the 
thrombo-resistance advantage of highly nitrogenized NPolymer27 we compared the degree of 
platelet activation against 316L SS. For control, Chandler loops without any samples (loop 
only) were used. All test conditions were done in triplicates. sP-Selectin levels were 17.4 ± 1.6 
mg, 12.3 ± 1.4 mg and 13.3 ± mg, for 316L SS, NPolymer27 and loop only, respectively. This 
is graphically represented in Figure 6.25. NPolymer27 and loop only controls were non-
significantly different from each other, P = 0.63). NPolymer27 was significantly lower than 
316L SS (P = 0.007). 
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Figure 6.25. sP-selectin released from platelets after 180 min rotation in the chandler 
loop. 
6.3.3 Endothelialization on plasma polymers 
The capacity of biomaterial surfaces to support endothelial adhesion and proliferation is 
important in vascular healing following injury from stent deployment. Acceleration of 
endothelial recovery can facilitate coverage of stent struts and retard intimal hyperplasia. 
HCAEC were chosen to more closely approximate the cell type found in coronary arteries. 
Both adhesion and proliferation of HCAEC on the plasma polymers with varying nitrogen 
content was assessed. 
6.3.3.1 Human coronary artery endothelial cell attachment to plasma polymer samples 
HCAECs were allowed to attach to samples in cell media deficient in serum and in media 
supplemented with 10% FBS. Media deficient in serum is lacking in Vn, Fn and laminin which 
are important in mediating cell attachment [544]. While this culturing condition is not 
physiological it does grant the opportunity to assess the interaction of the surface itself with 
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the cells. Incorporation of serum in to the media mimics the in vivo environment when the 
plasma polymer surfaces are exposed to plasma. Proteins physisorbed from the added serum 
mediate cellular interactions. The composition and conformation of this layer of protein is 
determined by the physio-chemical properties of the plasma polymer surface. 
The percentage of cells attached to the plasma polymerized and 316L SS pieces were quantified 
using a standard curve correlating a known percentage of cells and the absorbance level using 
the crystal violet method as described in the method section. A linear trend line is drawn 
through the data points and an equation describing this line is used to facilitate the conversion 
of experimental data to percentage cell attached. A typical standard curve is shown in Figure 
6.26. 
 
Figure 6.26. Standard curve generated by correlating known cell numbers with 
measured absorbance. 
6.3.3.2 HCAEC attachment 
HCAEC attachment in serum-free media was further divided into two additional conditions, 1) 
samples only (Tropoelastin negative – Tropo -ve) 2) samples coated overnight with rhTE 
(Tropoelastin positive – Tropo +ve). 
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Figure 6.27 shows the percentage of HCAEC cells attached onto samples after 60 min of 
incubation. Black and blue bars correspond to attachment in serum-free media without rhTE 
and with rhTE binding, respectively. Without rhTE incubation, 316L SS had the lowest 
attachment at 50.9 ± 5.9%, while a correlation between nitrogen concentration in the plasma 
polymer and cell adhesion was observed. HCAEC adhesion was 69.2 ± 10.9%, 86.6 ± 10.8% 
and 106 ± 5.1%, for PPolymer, NPolymer14 and NPolymer27 respectively. NPolymer27 
samples increased cell adhesion by 2.08 ± 0.1 fold over 316L SS alone (P<0.0001). BSA-
coated NPolymer27 samples showed complete abolition of cell attachment confirming an 
absence of cell adhesive proteins on the sample surface. 
Incubation of rhTE on samples resulted in some interesting observations. rhTE attachment 
augmented HCAEC adhesion on 316L SS surfaces (blue bars) to 81.9 ± 10.4 %, this was a 37.8 
± 4.2% increase over 316L SS alone (P<0.0004). This enhancement of attachment is consistent 
with the 29.7 ± 4.4% rise seen on BSA blocked samples, which is attributable to the effect of 
rhTE alone. In contrast, rhTE did not uniformly facilitate the binding of HCAEC on plasma 
polymerized surfaces. HCAEC adhesion on PPolymer was 85.9 ± 6.7 %, an increase over 
PPolymer alone, however this was non-significantly different from rhTE free samples 
(P=0.06). 
For NPolymer14 and NPolymer27 surfaces a decrease in cellular adhesion of 24.9 ± 3.8% 
(P<0.01) and 20.1 ± 10.5% (P<0.0001) respectively, was noted. 
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Figure 6.27. HCAEC attachment to 316L SS and plasma polymerized sample in serum 
free media. Black bars - no rhTE pre-incubation on samples. Blue bars - rhTE pre-
incubation overnight on samples before attachment of HCAEC cells. 
Using serum free media, we assessed the interactions of the surface itself with HCAEC, 
ensuring that it supported adhesion and was not cytotoxic. We next explored HCAEC adhesion 
in a more physiological fashion in which serum containing cell adhesive proteins were added 
to supplement the media (Figure 6.28). Broadly speaking similar trends were noted for 
HCAEC adhesion compared to serum free media, in particular a nitrogen dependent effect on 
cell adhesion was observed. In the absence of rhTE pre-incubation attachment for 316L SS, 
PPolymer, NPolymer14, NPolymer27 and BSA was 39.2 ± 4.6%, 62.7 ± 3.5%, 72.7 ± 5.9, 90.4 
± 9.6% and 4.1 ± 1.7% respectively. NPolymer27 had the highest level of HCAEC attachment, 
a 2.3 ± 0.3 (P<0.0001) fold increase over that obtain with 316L SS. 
Pre-incubation with rhTE augmented cellular attachment for 316L SS increasing adhesion to 
71.6 ± 5.4%, a finding consistent with serum free assays. In spite of this HCAEC attachment 
was still less than seen for NPolymer27 without rhTE pre-incubation. A non-significant 
numerical increase in HCAEC adhesion on PPolymer was evident while in contrast a numerical 
decrease was seen on NPolymer14. A significant 18.6 ± 10.0 % reduction (P<0.01) for 
NPolymer27 was demonstrated, a finding also noted in the preceding attachment assay without 
serum supplementation. 
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Figure 6.28. HCAEC attachment to 316L SS and plasma polymerized sample in serum 
supplemented media. Black bars - no rhTE pre-incubation on samples. Blue bars - 
rhTE pre-incubation overnight on samples before attachment of HCAEC cells. 
Using reflective microscopy an appreciation of the cell morphology and semi-quantitative 
assessment of cell attachment can be made. Figure 6.29 shows representative HCAEC 
adhesion on 316L SS and plasma polymerized samples in serum supplemented media with and 
without precoated rhTE. Cellular coverage of the surface was lowest for 316L SS pieces. A 
progressive increase in the density of cells from PPolymer to NPolymer27 surfaces can be seen 
(top row of cell panel). On NPolymer27 almost the entire surface of the sample is covered by 
HCAECs. When rhTE is precoated onto the samples an enhancement for 316L SS surfaces is 
clear. In contrast, an inverse nitrogen dependent effect is identified with polymerized samples, 
with a reduction in cell adhesion for higher nitrogen levels (middle row of cell panel). Using a 
higher magnification cell morphology of HCAEC in serum supplemented media was 
investigated. Cells with larger cytoplasmic projections were considered to be more spread and 
established on the surface. Cells residing on 316L SS where noticeably less spread, with a large 
proportion found to be spindle shaped. In contrast, NPolymer27 encouraged HCAEC 
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spreading, with the majority of cells displaying a round shape with abundant cytoplasm (lower 
row of cell panel). 
 
Figure 6.29. Reflective microscopy of HCAEC attachment in serum supplemented 
media on 316L SS and plasma polymerized samples. A-H: images taken with x5 
magnification. I-L: images taken with x10 magnification. A-D: HCAEC attachment on 
surfaces not precoated with rhTE. E-H: HCAEC attachment on surfaces that were 
rhTE precoated overnight with rhTE 40 µg /ml. I-L: HCACE spreading (without rhTE 
pre-coating). 
6.3.3.3 Out growth endothelial cell adhesion 
Given similarities in HCAEC adhesion in serum free and serum supplemented media, adhesion 
of OECs on samples where explored in serum supplemented media. In general, the results 
mirrored that of HCAEC (Figure 6.30). This was not surprising as OEC and HCAEC are both 
cells from the endothelial lineage. In the absence of rhTE pre-coating, OEC attachment of 18.3 
± 3.4 % on 316L SS was the lowest of the surfaces. A marginal increase was observed for 
PPolymer to 22.5 ± 2.5 %, non-significant compared to 316L SS (P = 0.86). A trend of rising 
OEC attachment with higher nitrogen level is recognized, with 41.3 ± 6.3% and 67.8 ± 2.1% 
adhesion for NPolymer14 and NPolymer27 (P < 0.001 versus 316L SS), respectively. 
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Importantly on NPolymer27 there was a 3.7 ± 0.12 fold (P < 0.0001) increase of attachment 
over 316L SS. 
Pre-coating surfaces with rhTE augmented OEC attachment on 316L SS samples. A 2.6 ± 0.05 
fold increase for 316L SS alone, higher than that noted with HCAEC. In difference to HCAEC 
cells, rhTE significantly increased OEC adhesion on PPolymer samples, with a notable 2.1 ± 
0.5 fold rise (P<0.0001). Rising nitrogen levels reversed the effect of rhTE on cell binding. A 
numerically higher but non-significant difference (P = 0.63, rhTE vs rhTE free) was observed 
for NPolymer14 surfaces, while a 29.8% (P = 0.001) decrease in attachment was seen for 
NPolymer27. 
 
Figure 6.30. OEC attachment to SS and plasma polymerized samples in serum free 
media. Black bars - no rhTE pre-incubation on samples. Blue bars - rhTE 
preincubation overnight on samples before attachment of OEC cells. 
Reflective microscopy of OECs attached to various surfaces are shown in Figure 6.31. rhTE 
free surfaces (top row) show increased density of cells on the surface from left to right (316L 
SS, PPolymer, NPolymer14, NPolymer27). A reverse phenomenon (middle row) is observed 
with rhTE pre-incubation. OEC density rises on 316L SS with rhTE binding, in contrast the 
surface becomes sparser with increasing nitrogen levels. The lower row shows the OEC 
attached without rhTE pre-coating with higher (x 10) magnification. Cytoplasmic projection is 
better visualized, giving a semi quantitative impression of cell spreading. Cells on 316L SS are 
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more spindled shaped with less cytoplasm. PPolymer surfaces were similar to 316L SS. On 
NPolymer14 a higher number of cells have well established cytoplasm. OECs are well spread 
with extensive cytoplasm on NPolymer27 surfaces. Taken together NPolymer27 is a favorable 
surface for supporting OECS, not only increasing attachment but promoting cell spreading. 
 
Figure 6.31. Reflective microscope of OEC attachment in serum supplemented media on 
316L SS and plasma polymerized samples. A-H: images taken with x5 magnification. I-
L: images taken with x10 magnification. A-D: OEC attachment on surfaces not 
precoated with rhTE. E-H: OEC attachment on rhTE precoated overnight with rhTE 
40 µg /ml. I-L: OEC spreading without rhTE pre-coating. 
6.3.3.4 Cell proliferation 
NPolymer27 surfaces were shown to be superior to 316L SS and other polymerized samples 
for HCAEC and OEC adhesion. We next explored the capacity of NPolymer27 to support 
HCAEC and OEC proliferation compared to 316L SS. The concentration of cells added onto 
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the samples were deliberately less than that used for adhesion to prevent overcrowding of cells 
over the course of 5 days of growth. 
Growth of HCAEC cells on 316L SS and NPolymer27 at day 3 and day 5 is shown in Figure 
6.32 and expressed as relative absorbance. On day 3, proliferation on NPolymer27 was 
marginally higher than 316L SS, but this was not statistically significant (P = 0.7). By day 5 a 
clearer separation of the bars is evident. Proliferation on NPolymer27 was more robust, with a 
23.9 ± 1.3% increase over 316L SS (p<0.008). 
 
Figure 6.32. Proliferation of HCAEC on 316L SS and NPolymer27. Cells quantified 
using colorimetric method and expressed as absorbance. 
Representative reflective microscopy of HCAEC growth on 316L SS and NPolymer27 surfaces 
is shown in Figure 6.33. Patchy coverage of the samples is seen on day 3 for 316L SS and 
NPolymer27. On day 5 differences in cell density can be appreciated with a higher number of 
HCAEC on NPolymer27. 
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Figure 6.33. HCAEC proliferation on 316L SS and NPolymer27. 
Day 3 – Top row. Day 5 – Lower row. 
Proliferation of OECs on 316L SS and NPolymer27 is quantified in Figure 6.34. Across both 
day 3 and day 5, NPolymer27 demonstrated superior proliferation than 316L SS. A departure 
from HCAEC proliferation, significant differences in growth rates were apparent from day 3, 
where there was a 25.3 ± 10.7 % (P = 0.03) increase on NPolymer27 over 316L SS samples. 
The benefit of NPolymer27 is maintained out to day 5 with a 23.7 ± 6.8 % increase in 
proliferation over 316L SS (P = 0.01). Adhesion and proliferation assays consistently show 
across two endothelial lineages the advantage of nitrogen incorporation. 
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Figure 6.34. Proliferation of OECs on 316L SS and NPolymer27. Cells quantified using 
colorimetric method and expressed as absorbance. 
6.3.4 Fibrinogen studies 
6.3.4.1 Fibrinogen binding kinetics 
We explored the binding of Fg onto 316L SS and plasma polymerized samples in relation to 
time of exposure to Fg solution. Time points choosen were 10, 60, 180, 1440 and 2880 min. 
Shorter time points of 10 min were challenging given the number of samples that needed to be 
processed at the end of the time point while maintaining the same incubation times for each 
sample. Protein amount is expressed as absorbance intensity and correlated to time (Figure 
6.35). Within 10 min protein attachment has essentially reached a maximal point suggesting 
rapid physisorption. We see that extending time of incubation in Fg solution to 2 days (2880 
min), the amount of attached Fg does not change greatly. 
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Figure 6.35. Amount of Fg attached on to 316L SS and plasma polymerized samples as a 
function of time of incubation. Variations in the absorbance measured with time can be 
seen. This most likely reflects minor differences in washing and incubation conditions 
with each assay. 
We examined the difference in physisorption between 316L SS and plasma polymerized 
samples. Taking the longest incubation time (2880 min) we compare the amount of protein 
attached (Figure 6.36) on the samples. A number of trends can be deduced from this graph. 
When 316L SS is compared to plasma polymerized samples 316L SS had significantly more 
Fg attached, 20.1%, 33.04% and 40.75% increase over PPolymer, NPolymer14 and 
NPolymer27 respectively, P < 0.001. NPolymer27 had the lowest amount of Fg attached, 
significantly lower than PPolymer (P<0.01), although non-significant compared to 
NPolymer14 (P = 0.51). A trend towards lower Fg attachment with increasing nitrogen content 
in the sample is observed and is statistically significant (P <0.001) with good correlation, R2 = 
0.90. 
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Figure 6.36. Amount of Fg attached to 316L SS and plasma polymers after 2880 min of 
incubation in Fg solution. 
6.3.4.2 Robustness of fibrinogen attachment to plasma polymerized surfaces 
We previously demonstrated in Chapter 4 the capacity of plasma polymerized surfaces to bind 
rhTE in a tenacious fashion which was resistant to harsh SDS detergent washing, implicating 
a binding force greater than physisorption alone. Fg incubated onto 316L SS and plasma 
polymerized surfaces was exposed to SDS detergent following which the amount of Fg was 
quantified using the amide I vibration line intensity as measured by FTIR. It is notable from 
the graph below that again NPolymer27 surfaces have a significantly lower amount of Fg 
attached prior to SDS washing (Figure 6.37). After SDS washing a significant decrease in Fg 
amount on 316L SS is seen, with an 82.5% (P<0.001) decrease. PPolymer samples also 
displayed a significant but much smaller decrease in Fg amount of 22.9% (P = 0.03). On the 
other hand, both NPolymer14 and NPolymer27 had non-significant difference post SDS 
washing (P = 0.62 and P = 0.69, respectively). Taken together 316L SS had the lowest 
resistance to SDS washing. Plasma polymerized surfaces had much more robust Fg attachment 
in particular the highly nitrogenized samples. 
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Figure 6.37. Amount of Fg attached on surfaces before and after SDS washing, 
quantified using relative absorbance. Solid color bars indicate pre-SDS washing values, 
while diagonally striped bars represent post-SDS washing values. 
6.3.4.3 Conformation of surface bound fibrinogen 
Using deconvolution and subsequent Gaussian function fitting of the amide I FTIR spectra of Fg 
attached onto 316L SS and plasma polymer samples, we studied the conformational differences 
between Fg on the surfaces. These studies showed that conformational changes of surface 
bound Fg occur in minutes [77]. We chose a time point of 60 min to ensure the conformational 
changes had reached a steady state. 
The FTIR spectra of amide I was resolved into 8 to 9 components using the GRAMS program 
(Figure 6.38). Assignment of secondary structural positions were based on published data [77, 
545]. Dominant secondary structures present were β turns, α helices, random structures and β 
sheets at 1680 – 1670 cm-1, 1660 – 1650 cm-1, 1635 cm-1 and 1621 cm-1 wavelengths, 
respectively. 
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Figure 6.38. Amide I spectra of Fg on 316L SS and plasma polymer samples measured 
using FTIR. Spectra are resolved into component peaks. 
Taking the area under the curve for the individual components the relative contribution of each 
secondary structure was determined. The dominant secondary structure is the α helix which 
remains relatively consistent across 316L SS and the plasma polymers, ranging from 45.72% 
(316L SS) to 44.1% (NPolymer27) (Figure 6.39). Random structures undergo the greatest 
change from 316L SS to NPolymer27. Representing approximately 22.81% of secondary 
structures on 316L SS, this decreases to 17.7%, 17.1% and 15.1% on PPolymer, NPolymer17 
and NPolymer27, respectively. A corresponding increase in β turns is noted going from 16.14% 
on 316L SS to 18.27%, 17.82% and 21.9% on PPolymer, NPolymer17 and NPolymer27, 
respectively. Minor differences in β sheets are observed with a range of 6.8% to 7.3%. 
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Figure 6.39. Secondary structure of surface bound Fg on 316L SS and plasma polymer 
samples. 
Our findings were a departure from the reported native conformation of Fg. NPolymer27 with 
the lowest thrombogenicity showed the greatest difference from ‘native conformation’. A 
breakdown of secondary structures of Fg as reported from various authors and ourselves is 
summarized in the Table 6.1. One can see there is considerable variability of measured ‘native 
conformation’. This reflects different assay methodology and state of Fg (different buffer 
solutions) used. Manipulation of Fg in an in vitro environment may lead to unintended 
conformation changes. With this in mind we did not measure ‘native conformation’ but focused 
on differences between Fg conformations found on plasma polymer with varying nitrogen 
content. However, a general comparison can be made between our results and the reported 
native conformation. Fg undergoes a conformation change on 316L SS and all plasma polymer 
surfaces. A higher α-helix and β-turn is noted across all samples with the most profound 
difference being a decrease in β-sheet. Notably, despite a trend towards increasing β-turns with 
higher nitrogen content, thrombo-resistance is not compromised. One may surmise that rather 
than just maintaining native conformation a favorable conformational change in which platelet 
activation sites are rotated away from platelets may in fact promote hemocompatibility. Other 
authors have reported that certain Fg conformations in which platelet interaction domains are 
exposed are most susceptible to platelet activation [511]. 
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Table 6.1. Secondary structure of fibrinogen as reported in the literature compared to 
our own findings. 
 α-helix β-sheet β-turns Random Side chains Unassigned structures 
Soderquist and 
Walton [546] 
30-35% _ _ _ _ _ 
Azpiazu and 
Chapman [547] 
37% 30% 14% _ _ 16% 
Yongli et al 
[548] 
35.4% 20.8% 12.8% 31% _ _ 
Schwinte et al 
[549] 
35-37% 47% 19% _ _ _ 
Tunc et al [550] 41% 33% 13% 6% 7% _ 
Our findings  
316L SS 
 
45.7% 
 
7.3% 
 
16.1% 
 
22.8% 
 
_ 
 
_ 
PPolymer 43.5% 9.3% 18.3% 17.7% _ _ 
NPolymer14 45.5% 6% 17.8% 17.1% _ _ 
NPolymer27 44.1% 6.8% 21.9% 15.1% _ _ 
 
6.3.5 Integrity of NPolymer27 coating on stents 
Highly nitrogenized NPolymer27 was successfully translated onto laser cut 316L SS stents. 
Ensuring complete polymerization of both abluminal and adluminal aspects of the struts the 
stents were coated in a semi expanded configuration. In order to mimic clinical use, the coated 
stents were crimped onto a 3.0 mm semi-compliant balloon (for delivery into the coronary 
vessel) and expanded using an indeflator to 14 atmospheres (for deployment at a coronary 
lesion). Integrity of the polymer coating was examined under SEM (Figure 6.40). Despite 
mechanical stress the NPolymer27 coating remained homogenous without evidence of peeling, 
delamination, cracking or wrinkling. Higher magnification images (middle and right images) 
showed even at hinge points (which undergoes the most deformation) [551] the coating 
remained intact. 
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Figure 6.40. Scanning electron microscopy of NPolymer27 coated coronary stents after 
crimping and expansion. 
6.4 Discussion 
To date a truly biocompatible stent platform remains elusive. PCI has evolved from balloon 
angioplasty through BMS and now to the dominant contemporary platform, the DES. Use of 
drug elution has certainly reduced the incidence of stent restenosis at the cost of endothelial 
healing, resulting in heterogeneous and incomplete endothelial reconstitution, a factor strongly 
associated with stent thrombosis [124]. Through iterations of the coronary stent the material of 
choice remains metallic due to the benefits of radial strength, deformation characteristics and 
radio-opacity. Biodegradable coronary stents made from polylactide acid is a promising next 
generation platform which conceptually provides structural support and anti-restenosis drug 
elution for a finite period of time and then disintegrates to leave no residual foreign body. 
However, widespread adoption of this technology has not occurred in part due to limited 
clinical data supporting superior safety or efficacy over DES. Strut thickness of biodegradable 
stents (150-170 µm) [552] are substantially more than 2nd DES (80-90 µm) [553] due to the 
need to maintain radial strength. This can compromise deliverability of the stent and the thick 
struts can obstruct flow to branching vessels [203]. Furthermore, stent fracture is an inherent 
limitation of this platform as over dilatation can easily extend beyond the mechanical limits of 
these polymeric struts [554]. 
For the foreseeable future metallic alloys will remain the material of choice for coronary stents. 
The trade-off for the mechanical advantage of metals is thrombogenicity. To varying extents 
most metallic alloys are thrombogenic [555]. Stent surface contamination during 
manufacturing, heterogeneous metal oxide surface and metallic ion release are factors 
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implicated in metallic stent thrombogenicity [556]. The underlying metal struts can be exposed 
in DES after disruption of the polymer coating following expansion. Insufficient 
hemocompatibility is an issue with significant clinical impact. Stent thrombosis while 
infrequent is associated with disastrous patient outcomes [557]. Prolonged blood thinning using 
antiplatelet therapy often with multiple agents has reduced some of these risks but has increased 
bleeding events in patients who are generally middle age to elderly. Once thought to be 
attributable to DES only, very late stent thrombosis (> 1 year) appears to also plague BMS. 
Recently announced results from the large DAPT study found ongoing stent thrombosis in 
patients up to 30 months after receiving either BMS or DES [129]. This study highlights the 
suboptimal biocompatibility of metallic alloy stents. 
Our goal was to design a biocompatible coating technology that can be easily and rapidly 
adapted to current stent platforms. The deposition of carbon-based thin films from plasma 
including plasma polymerization has been used for many industrial purposes ranging from the 
coating of ocular contact lenses [558] and biomedical devices [559, 560] to optical [561] and 
automotive engines [562, 563]. Advantages of robust coating, geometrically independent 
conformative deposition and durability of the films [396] make this process particularly 
attractive for biomedical applications. Surface properties can be modulated with plasma 
polymerization to optimize biological response without impacting on the structural properties 
of the bulk material. Plasma polymers have been shown to reduce thrombogenicity [564, 565] 
and facilitate endothelial adhesion and growth [566, 567]. By varying the gases present during 
film deposition surface chemical properties can be tailored to improve material 
biocompatibility. Specifically, the incorporation of nitrogen and nitrogen functional groups in 
plasma polymers can enhance the adhesion of notochordal, monocyte and endothelial cells 
[411, 568, 569]. Potential benefits of nitrogenized plasma polymers on hemocompatibility have 
not been fully explored. 
We designed and built a dedicated plasma polymerization chamber. In chapter 4 we 
successfully created plasma polymers with nanometer thickness and optimized the deposition 
process to reliably produce polymers with graded nitrogen content. In chapter 5 we fully 
characterized these polymers using specialized techniques, finding key chemical parameters 
were fundamentally altered by and correlated with the amount of nitrogen. In contrast, we noted 
the physical characteristics of graphitic structure and smooth topography was largely 
unchanged with nitrogen. Here in this chapter we explored the biological features of the plasma 
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polymers with particular focus on in vitro assays relevant to stent biocompatibility. We 
assessed thrombogenicity of plasma activated thin films in both static contact conditions and 
dynamic flow loops with sheer stress. Samples were exposed initially to whole blood to 
approximate a more physiological system. We initially started with a time point of 60 min, 
finding poor hemocompatibility of medical grade 316L SS but with absence of thrombus 
development on plasma polymerized samples. However, no clear differences between 
polymerized samples were evident. Extending to more rigorous time points of 120 min and 
then 180 min we found a nitrogen-dependent effect on thrombus development in static blood 
assays. Replicating this with flow assays at similar time points we discovered that the observed 
nitrogen-dependent thrombogenicity of plasma polymers was preserved. Highly nitrogenized 
NPolymer27 samples had the lowest thrombogenicity. Typically, up to 120 min of whole blood 
exposure have been used for in vitro material testing [570]. To our knowledge 180 min 
represents one of the longest durations of testing and reflects the robustness of the anti-
thrombotic properties of nitrogen doped plasma polymers. Platelets have been implicated as 
one of the main mechanism of stent thrombosis. Looking at both platelet adhesion and 
activation, we found 316L SS and NPolymer27 had the highest and lowest degrees of platelet 
attachment and activation, respectively, further reinforcing the role of nitrogen in plasma 
polymer thrombogenicity. 
Detailed physio-chemical studies of the films in chapter 4 provided clues to the underlying 
mechanism of low thrombogenicity in nitrogenized plasma films. Topographical analysis using 
AFM demonstrated the thin coatings were smooth, a characteristic which was independent of 
nitrogen concentration. Materials with high surface roughness can induce more turbulent blood 
flow resulting in activation of coagulation and thrombosis [564]. Low grade activation of 
platelets exposed to high shear conditions in flow loops have been reported [571]. Chemical 
differences between the films were much more pronounced and correlated with nitrogen 
concentration. We found enrichment of the surface with polar nitrogenous functional groups 
and oxygen moieties with escalation of nitrogen doping. This was accompanied by an increase 
in surface energy and hydrophilicity (chapter 5). Separation of the surface energy into polar 
and dispersive components showed that the polar energy increased with nitrogen, reflecting the 
important contribution of polar functional groups to overall surface energy changes (chapter 
5). Hydrophilic surfaces are generally more hemocompatible, due to resistance to protein 
adsorption and retention of native protein conformation on the surface [572, 573]. 
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Studies of Fg adsorption on hydrophilic materials demonstrate a structural conformation that 
did not activate platelets [574]. However, it has been proposed rather than hydrophilicity alone, 
the overall surface interfacial tension is the more important factor in the prevention of 
denaturing of adsorbed plasma proteins [475]. In this model the driving force for protein 
conformational disruption is the blood-biomaterial interfacial tension, for which a lower value 
reduces this thermodynamic force. The higher surface polar energy of NPolymers27 films 
conceivably lowers the interfacial tension with blood. Furthermore, the potential of plasma 
polymer films to covalently immobilize a dense layer of native protein molecules directly from 
the blood upon contact is also likely to play a role in reducing the thrombogenicity. A confluent 
irreversibly immobilized layer of blood proteins in favorable conformations would shield the 
stent from the blood, preventing the adsorption of unfolded proteins and providing a biological 
cloak for the foreign material surface. 
Fg has been implicated as the main plasma protein mediating biomaterial induced platelet 
activation. In physiological conditions Fg is central to platelet activation and aggregation by 
linking adjacent platelets via the GPIIb/IIIa platelet surface proteins. When Fg is bound to a 
biomaterial, surface induced conformation changes can directly activate otherwise resting 
platelets. Both the quantity and the conformation of surface bound Fg impacts on the degree of 
platelet adhesion and activation [68]. We found a rapid adsorption of Fg onto all sample 
surfaces, consistent with reports from other authors [77]. Within 10 min the level of attachment 
had reached steady state. We then quantified the amount of Fg bound to each surface noting a 
nitrogen-dependent effect. As the nitrogen level increased the amount of Fg on the surfaces 
decreased, NPolymer27 showing the lowest level. Hydrophilic surfaces tends to bind less Fg 
which in turn results in a reduction in thrombogenicity [575]. NPolymer27 is the most 
hydrophilic of the plasma polymers. The use of high voltage negative pulse bias during our 
plasma polymerization process enhances energetic ion bombardment [576] of the developing 
plasma polymer. This in turn facilitates cross linking of the surface helping to retain 
hydrophilicity [577]. 
We then explored the tenacity of Fg absorption onto 316L SS and the plasma polymers. In 
Chapter 4 we found rhTE bound to the plasma polymers in a SDS resistant manner, despite 
aggressive incubation and washing protocols. It has been shown proteins adsorbed onto plasma 
immersion ion implantation (PIII) treated hydrophobic surfaces are highly resistant to removal 
when exposed to these protocols suggesting a more robust covalent form of attachment [389]. 
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Mirroring the results for rhTE we noted that Fg was covalently bound to plasma polymer 
surfaces as shown by the high retention of Fg after exposure to SDS. It has been proposed that 
covalent bonding develops between free radicals in the plasma polymers and exposed protein 
terminal groups [577]. The protein interfacial layer that physisorbs onto biomaterial surfaces 
is a changing and unstable layer. Known as the Vroman effect, competitive adsorption occurs 
when proteins with higher binding affinities but slower kinetics replace initially bound high 
mobility proteins making control of this protein layer difficult [578]. Conceivably, covalently 
tethered proteins help maintain a more consistent and stable interfacial layer to mediate 
cell/protein to biomaterial interactions. Furthermore, covalent anchoring may maintain proteins 
in more stable conformations. Potentially, a covalently immobilized stable layer of Fg can 
cloak the foreign material surface and prevent the exchange of thrombogenic proteins. 
Using the amide I spectra of Fg immobilized on 316L SS and plasma polymer surfaces we 
were able to deconstruct the spectra into components corresponding to the main secondary 
structures in Fg. We compared the secondary structural differences of Fg bound on 316L SS 
and the various plasma polymers. Intentionally the “native” conformation of Fg was not used 
as a comparator. Many authors have studied the native conformation of Fg in solution, typically 
dissolved in pH neutral PBS [547-549]. However, true native conformation should represent 
Fg in the in vivo environment. A reduction in thrombogenicity has been attributed to the 
closeness of the conformation of surface attached Fg to the native conformation of Fg. It has 
been proposed that a change in the structure of Fg can expose otherwise hidden platelet 
activating motifs [68]. More precisely as Koh et al have pointed out conformation changes per 
se does not necessarily activate platelets [502] as some configurations may actually hide 
platelet interaction motifs. In our samples we noted the main differences between 316L SS and 
NPolymer27 was a higher number of random chains and lower β-turns in 316L SS, indicating 
a conversion of the β-turns into random structures. Some authors have reported a loss of α-
helix structures with an increase in random chains [77]. The random chains are located 
predominantly in Bβ and γ chains. Increasing random chains suggests that there is more 
exposure of platelet interacting sites on 316L SS surfaces. In contrast NPolymer27 surfaces 
had the lowest level of random chains. 
The endothelium plays a vital role in haemostasis and modulation of VSMCs, a key contributor 
to stent restenosis [579, 580]. Accelerated endothelial regeneration over injured vasculature 
retards VSMC growth and ECM deposition [230], limiting intimal hyperplasia. Furthermore, 
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complete endothelialization ensures separation of the thrombogenic metallic stent struts from 
the blood stream. Repopulation of the endothelium arises from a combination of proliferation 
from surrounding endothelial cells and circulating EPCs recruited to the site of injury. Yin et 
al demonstrated that plasma polymers functionalized with covalent immobilized rhTE 
enhanced endothelial adhesion and proliferation over 316L SS [281]. In chapter 2, we 
demonstrated that rhTE supported OEC adhesion, spreading and proliferation. While rhTE is 
a promising candidate protein for biofunctionalization of vascular biomaterials the in vivo 
duration of biological activity is of concern. Enzymatic degradation of rhTE can occur through 
serine proteases [357]. Our goal was to design a plasma polymer platform that inherently 
improved endothelialization without dependence on rhTE biofunctionalization, thereby 
removing the concern of long term in vivo biological activity and simplifying the translational 
process. We used HCAEC cells to more closely emulate the endothelium of the coronary 
vasculature. Assays done with HCAEC prepared in media with and without supplemental 
serum yielded consistent results in adhesion assays. Without rhTE functionalization the plasma 
polymer surfaces demonstrated a higher level of HCAEC attachment that correlated with 
increasing nitrogen levels. Importantly, NPolymer27 showed a more than 2-fold increase in 
adhesion over 316L SS. When rhTE was immobilized onto the samples an expected increase 
in attachment was seen on 316L SS. However, the effect on polymerized surfaces was variable, 
with a modest increase in cell adhesion on PPolymer but a decrease on NPolymer14 and 
NPolymer27. The observed decrease in cell binding with rhTE functionalized NPolymer27 
may be due to the orientation of bound rhTE, where cell adhesive motifs are obscured. Bax et 
al reported differential endothelial cell adhesion to rhTE immobilized on 
polytetrafluoroethylene (PTFE) and PIII treated PTFE, with reduction of cell attachment on 
PIII treated PTFE attributed to an unfavorable rhTE orientation [581]. This however does not 
detract from the advantage that NPolymer27 has over 316L SS surfaces. Non-functionalized 
NPolymer27 supports HCAEC attachment above 316L SS with or without immobilized rhTE. 
Higher magnification reflective microscopy showed the morphology of attached HCAEC 
where a rise in nitrogen of the plasma polymer gave cells which were larger with expansive 
cytoplasmic projections indicating a more spread state [582]. On 316L SS surfaces HCAEC 
remained small and spindle shaped reflecting an unfavorable environment for cell adhesion 
[583]. 
Our discoveries for HCAEC typified the cellular effect of nitrogen incorporation in plasma 
polymers. We showed that OECs also displayed similar attachment behaviour to HCAEC. A 
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stepwise escalation of cell adhesion is noted with an elevation in nitrogen content without rhTE 
immobilization. NPolymer27 supported OEC adhesion well above 316L SS even with rhTE 
functionalization. Importantly, the superiority of NPolymer27 surface also translated into an 
improvement in proliferation of both HCAEC and OECs compared to 316L SS. 
Nitrogen doping of the plasma polymer surfaces created specific chemical and functional 
moieties which modulated cellular biology. NPolymer27 surfaces are rich in hydroxyl and 
amine groups which may be responsible for mediating cellular activity. Contribution of high 
surface concentrations of hydroxyl groups to cell adhesion have been reported by investigators 
[584]. Using self-assembling monomers Llopis-Hernandez et al, showed that increasing 
surface hydroxyl levels promotes a favorable conformation of adsorbed Fn which in turn 
positively modulates cellular adhesion [585]. Amine groups have also been implicated in the 
enhancement of cell attachment to surfaces. This has been attributed to the interaction between 
positively charged groups in amine and negatively charged groups on cells [482]. We showed 
that using controlled doping of nitrogen during the plasma polymerization process, surface 
chemistry can be tailored to specifically promote endothelialization. 
The mechanical and physical properties are a critical consideration for a coating applicable to 
vascular stents. Somewhat unique to stents, a low crimped profile ensures deliverability to 
narrowed segments of coronary vessels while expansive deformation is needed to deploy the 
stent in the vessel. Coatings in this case need to maintain strong substrate adhesion and 
withstand tensile and compressive forces. Polymers used for DES show inhomogeneity with 
susceptibility to peeling and delamination [125]. Low thrombogenicity and satisfactory cell 
adhesion has been reported for diamond like carbon (DLC) coatings [586, 587]. However, if 
the carbon structure is dominated by sp3 bonding state [588] high mechanical stress and 
interfacial tension with suboptimal substrate adhesion results [589]. ‘Graphitization’ by rising 
the sp2 carbon fraction results in softening of the DLC with a reduction in the internal stress 
and improved adhesion [590]. We demonstrated homogenous and robust coating of 
NPolymer27 films on 316L SS stents after mechanical deformation similar to what is expected 
for stent deployment. The raman spectra of our plasma polymer film (chapter 4) is dominated 
by a main G peak consistent with a graphitic structure, with carbon primarily in sp2 bonding 
configuration, interspersed with regions of sp3 bonded carbon. The ID/IG ratio of the intensities 
of the raman D and G peaks is inversely proportional to the size of the graphitic clusters [591]. 
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Numerically the ratio for NPolymer14 and NPolymer27 films were marginally higher however 
overall the graphitic architecture was preserved (chapter 4). 
6.5 Conclusion 
A truly biocompatible coronary stent platform remains elusive. Concerns of stent thrombosis, 
in stent restenosis (ISR) in high risk patients (diabetics) and bleeding complications from 
prolonged dual antiplatelet therapy (DAPT) persist in the clinical utilization of DES. DES 
suppress VSMC activity and endothelial recovery. Permanent DES polymer coatings can 
promote inflammation and further compromise vessel healing. Endothelial reconstitution after 
stenting is a critical part of the biocompatibility equation. We report a coating platform 
generated using plasma polymerization coupled with energetic ion bombardment. 
Nitrogenization of the films fundamentally altered the chemical makeup of the surface with 
increased hydrophilicity and enrichment with nitrogen and oxygen polar groups. Exceptionally 
low thrombogenicity and platelet activation was observed to correlate with nitrogen 
concentration. Highly nitrogenized NPolymer27 films inherently promoted HCAEC adhesion 
and proliferation. Crucially, the mechanical properties of NPolymer27 films were optimal for 
stent coating, with no discernible delamination following crimping and expansion. 
Nitrogenized plasma films exhibit very low thrombogenicity, encourage vascular endothelial 
cell activity and provide a mechanically stable coating platform for the enhancement of stent 
biocompatibility. 
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Chapter 7: General Discussion; Future Directions 
7.1 General discussion 
Coronary artery disease (CAD) remains a leading cause of morbidity and mortality in the 
world. Myocardial ischemia results from either a progressive or acute decrease in coronary 
blood flow secondary to either chronic atherosclerotic build up or plaque rupture with 
superimposed thrombus. Re-establishing normal coronary flow beyond the segment of 
obstruction is achieved through percutaneous coronary intervention (PCI) with insertion of 
coronary stents or bypass surgery. PCI is the main method of coronary revascularization, with 
stents being one of the most commonly implanted medical prostheses. Great strides have been 
made in stent technology with improvements in safety and efficacy. However, a truly 
biocompatible stent is currently unavailable and consequently, enhancing biocompatibility and 
biointegration remains a major goal. 
In this thesis we had two broad goals. The first, to examine the capacity of recombinant human 
tropoelastin (rhTE) to support endothelial progenitor cells (EPCs) with a detailed mechanistic 
study of the nature of this interaction. Earlier work identified tropoelastin as a promising non-
thrombogenic bio-regulatory protein which supported endothelial cell activity [258]. Our 
second aim was to develop a hemocompatible and pro-endothelial plasma enhanced stent 
coating with the ability to covalently bind biomolecules on to the surface, thereby creating a 
biocompatible and bio-functionally versatile platform. 
7.1.1 Isolation and characterization of outgrown endothelial progenitor cells with 
assessment of the interaction with recombinant human tropoelastin 
EPCs are thought to contribute to the process of endothelial repair. Debate exists in the field as 
to what cell type represents a true EPC. Increasingly, outgrowth endothelial progenitor cells 
(OEC) are being considered true EPCs based on the functional capacity to incorporate directly 
into regenerating endothelium [335]. Relevant to vascular applications, OECs have been shown 
in animal models to participate directly in endothelial regeneration following iatrogenic injury 
[314]. In this chapter we successfully isolated OECs by plating the mononuclear fraction of 
peripheral whole blood onto rat tail collagen-coated tissue culture plates. Appearing 1 – 3 
weeks after culturing, small clusters of cobblestone appearing cells were noted amongst smaller 
mononuclear cells. Using immunophenotyping we ascertained that the cells exhibited 
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endothelial characteristics of Ulex binding and AcLDL uptake. Crucially, flow cytometry 
revealed that the cells did not express hematopoietic markers, a key differentiator from early 
EPCs, which are hematopoietic in origin. Taken together, the isolated OECs were 
phenotypically consistent with descriptions in the literature [334]. 
Tropoelastin, the precursor to elastin, is a biomechanical protein with important cell regulatory 
roles. Elastin exhibits dual actions of supporting endothelial cell activity [592] and inhibition 
of vascular smooth muscle cells (VSMCs) [593], making tropoelastin a promising candidate 
for functionalization onto stent surfaces. We explored the interaction between the rhTE and 
OECs, finding a concentration dependent capacity to support adhesion and spreading, 
consistent across healthy donors. In addition, we discovered that rhTE is able to encourage 
OEC proliferation. In comparison to highly cell adhesive proteins, collagen and fibronectin, 
rhTE modestly supported OEC activity. However, the level of adhesion seen on rhTE is 
consistent with levels noted on other elastic fiber proteins [351]. To our knowledge, this is the 
first time a comprehensive study of the interaction between OECs and tropoelastin has been 
made. 
7.1.2 Outgrowth endothelial cells interact with tropoelastin via an integrin mediated 
mechanism with the binding region between N-terminal domains 10 and 18 
Having established that OECs can adhere, spread and proliferate on rhTE we sought to 
determine the mechanism for this interaction and the region on rhTE responsible for this. 
Addition of EDTA, a cation chelator led to a substantial reduction in OEC adhesion to 
tropoelastin hinting at an underlying integrin process in cell binding. Recovery of OEC 
adhesion to full levels was seen when the cation Mn2+ was reintroduced into the cell medium. 
This pattern of cation dependent cell adhesion is indicative of an integrin-mediated process. 
Both OEC adherence and spreading was decreased with exposure to anti - αVβ3 blocking 
antibody, marking the importance of this integrin in OEC interactions with tropoelastin. 
Human dermal fibroblast (HDF) and endothelial cell binding to tropoelastin has been well 
characterized. Discrepant findings have been reported in the literature, with the HDF adhesion 
motif located at the C-terminus [269] and in direct contrast the endothelial cell interaction was 
mediated by N-terminal domains N10 and N18 [357]. These findings indicate that tropoelastin 
has multiple cell binding sites that are cell type dependent. We found OECs had minimal 
attachment to the C-terminus discounting the relevance of this region for OEC binding. 
281 
Assessing adhesion to progressively truncated N-terminal domains we were able to narrow the 
site of OEC adhesion to a region between N10 and N18. Anti – αVβ3 blocking antibody 
significantly reduced OEC spreading to the N-terminal domains, a finding consistent with our 
results for full-length tropoelastin. 
7.1.3 Optimization of the plasma polymerization process and creation of nitrogenized 
plasma polymers 
For this thesis, a dedicated plasma polymerization chamber was built. Consistency and 
predictability of plasma polymer deposition was our primary focus in the early stages of 
development. We measured thickness (using ellipsometry) and density of chemical function 
groups (using infrared spectroscopy) to determine uniformity of deposition. The position of the 
gas inlet relative to the substrate holder strongly influenced the polymer thickness across the 
substrate. When the inlet was positioned above the substrate holder, the thickness was most 
uniform. 
By varying the amount of nitrogen delivered during plasma polymerization, the concentration 
of nitrogen within the plasma polymers could be modulated. Four different plasma polymers 
(PPolymer, NPolymer8, NPolymer14 and NPolymer28) were created, characterized by 
escalating levels of nitrogen as determined by X-ray photoelectron spectroscopy (XPS). 
Deposition curves (thickness versus time of plasma polymer deposition) were generated for 
each of the four conditions in order to make experimental samples with similar thickness. We 
characterized the plasma polymers using complementary techniques: raman spectroscopy, 
atomic force microscopy (AFM) and ellipsometry. In summary, we found the plasma polymer 
films were topographically smooth and contained nanoscale conjugated graphite-like 
clusters. The refractive index of the polymers was lower than observed for diamond-like carbon 
(DLC). While the main goal was to create a biocompatible plasma polymer coating we wanted 
to ensure that the capacity to covalently immobilize proteins was preserved. Using ELISA, 
retention of protein (rhTE) was significantly higher on plasma polymers than on control 
samples after exposure to extensive SDS wash, indicative of robust covalent attachment. 
7.1.4 Detailed study of the aging of plasma polymers 
Aging of plasma polymers from atmospheric exposure is a well-documented phenomenon 
[470]. Aging pertains to the chemical and physical changes in the plasma polymer with time. 
A free radical driven oxidation process leads to incorporation of oxygen into the plasma 
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polymer and the appearance of oxygen rich chemical functional groups [594]. Using XPS, 
fourier transform infrared spectroscopy (FTIR) and electron spin resonance (ESR) we 
examined the physio-chemical properties of the plasma polymers at different time points after 
removal from the plasma chamber. 
Consistent with reports in the literature [463] our plasma surface underwent aging. Most 
notable was a reduction of hydrophilicity and concurrent with this a decrease in surface energy. 
By day 30 the plasma polymers had reached a near stable point as evidenced by minimal 
changes in the measured contact angle. Despite the process of ‘hydrophobic recovery’ all 
polymers remained hydrophilic with the degree of wettability correlating with the nitrogen 
concentration. Probing with FTIR revealed detailed chemical changes with time. Dominating 
these changes were pronounced increases in oxygen rich moieties. Not surprisingly, nitrogen 
gas doping during polymerization increased nitrogen species (amine, imine and amide) and 
with aging more nitrogenized plasma polymers had higher levels of oxygen groups. The 
elemental composition of the plasma polymers was determined using XPS. We noted a rise in 
total oxygen levels between fresh and aged samples, in keeping with oxidative processes. 
Reactions with oxygen involves the formation of stable bonds from free radical reactions. ESR 
studies revealed a decrease in the intensity of radicals with aging. Using mathematical curve 
fitting procedures we were able to generate exponential curves to fit the kinetics of changes in 
surface energy and chemical functional groups. Taken together, our studies provide insight into 
the chemical and physical transformations in our plasma polymers. We witnessed a free radical 
driven oxidative process resulting in progressive incorporation of oxygen into the plasma 
polymer. We propose that loss of hydrophilicity is due to the removal of radicals as they are 
quenched by oxidation reactions. 
7.1.5 In vitro cell interaction and thrombogenicity assessment of nitrogenized plasma 
polymer 
In designing nitrogenized plasma polymers our objective was to create a biocompatible stent 
coating and retain the capacity to covalently bind biomolecules. The thrombogenicity of a 
coating platform has important clinical implications related to the risk of stent thrombosis and 
in turn the duration and degree of antiplatelet therapy. We started with heparinized whole blood 
under static conditions. After 60 min, all plasma polymer samples had markedly less surface 
thrombus development compared to 316L stainless steel (316L SS). Differences in thrombotic 
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tendency between plasma polymers could not be discerned. A nitrogen-dependent effect was 
however demonstrated after 180 min of exposure to whole blood. Clot development was 
significantly reduced with increasing nitrogen. These findings were mirrored in dynamic flow 
loop experiments, with NPolymer27 samples showing the lowest thrombogenicity. Moreover, 
both platelet adhesion and the level of soluble P-selectin (sP-selectin), a reflection of platelet 
activation, was the lowest on NPoymer27. Taken together, nitrogen modulates the 
thrombogenicity of plasma polymers. The smooth topography, hydrophilicity and high surface 
energy coupled with lower fibrinogen (Fg) adsorption and a potentially more favorable surface 
bound Fg conformation explains the lower thrombogenicity of NPolymer27. 
Deployment of coronary stents with expansion of rigid struts against the vessel wall causes 
injury and denudation of the endothelium. Rapid restoration of the endothelium re-establishes 
a natural barrier between the stent and the blood stream. Moreover, the endothelium regulates 
VSMC activity and maintains correct vasomotor tone. We observed a nitrogen-dependent 
increase in human coronary artery endothelial cell (HCAEC) adhesion, which was more than 
2-fold higher on NPolymer27 than on 316L SS. Unexpectedly, HCAEC attachment on 
NPolymer27 was greater than NPolymer27 functionalized with rhTE. In contrast, 
immobilization of rhTE on the lower nitrogen PPolymer led to a modest enhancement in 
HCAEC attachment. We propose this may be related to the orientation of rhTE on NPolymer27 
samples, with cell adhesive regions obscured. A similar phenomenon of reduced endothelial 
adhesion on rhTE bound to plasma immersion ion implantation (PIII) treated PTFE has been 
reported [344]. Mirroring these findings, adhesion of OECs onto NPolymer27 was more than 
3-fold higher than 316L SS. For both cell types, proliferation was greater on NPolymer27 than 
316L SS. These results indicate that highly nitrogenized plasma polymers can inherently 
enhance endothelial cell attachment and proliferation independent of the need for biomolecule 
functionalization. 
Having shown favorable in vitro biocompatibility of NPolymer27, we redesigned the plasma 
chamber substrate holder to polymerize coronary stents. Mechanical integrity of the coatings 
was tested by crimping and expansion of the stents under conditions similar to clinical 
deployment. Using scanning electron microscopy (SEM), the plasma polymer coatings were 
examined following mechanical distortion. Absence of peeling or disruption to the smooth 
coating was demonstrated. 
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7.2 Future directions 
The findings in this thesis have implications for future work in vascular medicine. We 
established that rhTE can support EPCs. Our findings complement the body of evidence 
supporting tropoelastin as a modulator of cell activity, in particular endothelial cells. Elastin 
has been shown to reduce VSMC migration and proliferation, an important function for 
attenuating intimal hyperplasia following coronary stenting. However, the capacity of 
tropoelastin to also suppress VSMCs is an area for further exploration. 
The use of tropoelastin to functionalize a biomaterial surface has one important caveat. In vivo, 
a number of serum proteases can degrade this protein, potentially shortening the duration of 
biological activity [347]. Point mutation variants of tropoelastin (R515A) are more resistant to 
proteases, however whether R515A retains the biological activity of tropoelastin remains to be 
examined. We isolated the site of OEC cell binding to a region between N-terminal domains 
10 and 18. The specific motif within this region still has not been identified. Creating shorter 
constructs from this region may help to isolate the binding motif. This has important 
ramifications beyond a more detailed mechanistic understanding of cell binding. N-terminal 
domains are more resistant to protease degradation, lacking in one or more of the protease 
recognition sites [357]. Identification of even shorter constructs will help to preserve the 
desired activity of full-length tropoelastin while extending the resistance to degradation. 
Highly nitrogenized plasma polymers were shown to both reduce thrombogenicity and 
enhanced endothelial and progenitor cell adhesion compared to 316L SS. Whether the promise 
of these in vitro results translates to in vivo will need to be examined in animal models. A 
porcine coronary stenting model could be used to assess acute stent thrombosis, 
endothelialization and intimal hyperplasia. We propose a more rapid and complete 
endothelialization on polymerized stents will reduce neo-intima development and restenosis. 
Our nitrogenized plasma polymers can covalently bind proteins. This provides the added option 
of functionalizing the stents with biomolecules such as tropoelastin and its derivatives or other 
candidate molecules. Ideal molecules would be non-thrombogenic and strongly inhibit 
VSMCs, giving additional bio-regulation to the surface. Furthermore, our coating platform is 
highly versatile and can be adapted to coat a range of blood contacting devices such as artificial 
heart valves, pacemaker leads and vascular conduits. 
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7.3 Conclusion 
In this thesis we explored two distinct but complementary streams of research with the goal of 
improving coronary stent biocompatibility. rhTE positively interacted with OECs, supporting 
adhesion, spreading and proliferation. This interaction was mediated by integrins, in particular 
αVβ3, with the binding motif not at the C-terminus but mapped to a region between N-terminal 
domains 10 and 18. Tropoelastin is a promising molecule for bio-functionalization of 
biomaterial surfaces. 
We created plasma polymers with increasing nitrogen content. In vitro thrombogenicity and 
cell studies found a nitrogen dependent effect on biocompatibility. Highly nitrogenized plasma 
polymers significantly reduced thrombus development compared to 316L SS. Moreover, both 
endothelial and progenitor cell adhesion and proliferation was enhanced on these surfaces. 
Interrogating these polymers with a range of detailed instruments we found an amorphous 
carbon structure with smooth topography, containing nanoscale conjugated graphite-like 
clusters. As nitrogen increased in these polymers they became enriched with oxygen containing 
species after exposure to air, likely due to free radical driven oxidation reactions. An increase 
in hydrophilicity and surface energy paralleled an elevation in nitrogen concentration. These 
polymers exhibited a dynamic quality, undergoing chemical changes with time of exposure to 
the atmosphere. Stability was largely reached by 30 days. Translation of plasma polymers onto 
coronary stents was successful with demonstration of a robust coating resistant to delamination 
upon mechanical deformation. Highly nitrogenized plasma polymers offer a promising 
biocompatible coating platform for coronary stents with the potential to be adapted to other 
vascular devices. Functionalization with biomolecules via covalent immobilization offers a 
versatile approach to further enhance bio-regulation of these polymer surfaces for a range of 
vascular applications. 
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